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Intestinal microbiota dysbiosis and modification of intestinal permeability leading 
to bacterial translocation, have been implicated in the development of numerous liver 
diseases or worsening of hepatic disorders, such as cirrhosis, portal hypertension, hepatic 
encephalopathy (HE) and acute-on-chronic-liver failure. There is strong evidence that the 
pathogenesis of cirrhosis and HE is linked to a dysbiotic gut microbiota and accumulation 
of microbial by-products, such as ammonia, indoles, oxindoles and endotoxins, which the 
liver fails to detoxify. Indeed, current main line clinical treatments target microbiota 
dysbiosis by decreasing numbers of pathogenic bacteria and reducing blood endotoxemia 
and ammonia levels. Despite the large amount of existing data, there is still a need to study 
in more detail the composition and the metabolic output of the gut microbiota and its cross-
talk with host physiological function in liver failure associated HE. 
Aim of this thesis was to investigate the microbiota effects of the main current 
therapies used in clinical practice to treat HE. Impact of a prebiotic (lactulose), a probiotic 
(VLS#3) and an antibiotic (rifaximin) to modulate the gut microbiotia of cirrhotic patients 
both in terms of composition and metabolic output was investigated using pH controlled 
anaerobic batch cultures. Combining high-throughput Illumina sequencing of V3-V4 16S 
rRNA region, Fluorescent In Situ Hybridization coupled with flow cytometry and GC-MS, 
changes in faecal microbiota composition and metabolic output were measured. Significant 
metabolic rather than microbial changes were observed. Short chain fatty acids (acetate, 
propionate and acetate) production was promoted over time by lactulose and lactulose plus 
VSL#3 treatment and this increase was accompanied by a concomitant reduction of 
ammonia level and an increase in bifidobacteria. Rifaximin and its combination with 
lactulose was able to strongly reduce Streptococcaceae abundance, a known hallmark of 
cirrhotic dysbiosis, and concomitantly increase of Bifidobacteriales. Moreover I 
investigated how the use of VSL#3 impacted on the microbiota of paediatric patients and 
young adults affected by portal vein hypertension and minimal HE. VSL#3 
supplementation resulted in a trend toward improved cognitive function and patients well-
being. A trend towards an increased relative abundance in Actinobacteria and a 
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concomitant decrease in Bacteroidetes, known to be overabundant in HE dysbiosis, was 
observed . The results suggested also a slight increase in Ruminococcus and 
Faecalibacterium abundance. Indeed the data suggest an amelioration of dysbiotic 
condition by VSL#3 that could evolve in a decreased severity of cirrhosis progression. 
However, as the current pilot study was limited by sample size, these observation await 
confirmation in an adequately powered clinical trial. 
In an effort to design more efficacious microbiota modulatory tools, I also 
characterized a Lactobacillus brevis strain isolated from an alpine traditional cheese for its 
potential as a next-generation probiotics thanks to its ability to produce and secrete high 
amounts of the neurotransmitter γ-aminobutyric acid (GABA). Lb. brevis FEM 1874 was 
able to efficiently convert glutamate to GABA by the increased expression of the GAD 
operon genes resulting in high GABA accumulation in the culture medium. Moreover, 
FEM 1874 proved resistant to acidic pH, pancreatic fluids and bile acids, good indicators 
for probiotic survival in the gastro-intestinal tract. FEM 1874 was also able to ferment 
prebiotic fibres indicating the potential of using a synbiotic formulation targeting the 
gut:brain axis.  
Overall, the research herein showed the potential of microbiota modulatory 
formulations to target the dysbiosis related to gut:liver:brain axis disruption in liver disease 
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 From birth humans establish a mutualistic relationship with their gut microbiota, 
the composite microbial population inhabiting the gastrointestinal tract (GIT). From 
metagenomic studies we now know, that this complex community differs substantially in 
composition between individuals and that it is modulated by age, genetic background, 
physiological state, microbial interaction, environmental factors and diet (1–6).  
Bacterial numbers within the gut microbiota reach a population of up to one 
hundred trillion organisms containing about 4 million distinct genes. Most of these genes 
encode proteins and enzymes which, even with functional redundancy, are capable of 
influencing the host physiology either directly or through interactions with and metabolism 
of human foods (7). The vast majority of these bacteria are strict anaerobes and 
fermentation is the main form of energy metabolism for the dominant microbiota 
phylotypes. Indeed, the gut microbiota may be considered an anaerobic bioreactor capable 
of synthesizing molecules that act directly on mammalian immune system, modify the 
human epigenome and regulate host metabolism (8–10). The gut microbiota uses both 
ingested dietary components (e.g. carbohydrates, proteins, and lipid) and host-derived 
components (including shed epithelial cells and mucus) to generate energy for their own 
cellular processes and growth and produce several metabolites which influence human 
health and metabolism. For instance, carbohydrate fermentation leads to the production of 
the short-chain fatty acids (SCFA) acetate, propionate and butyrate which contribute to 
normal large bowel function, immune regulation (11–16), regulation of food intake and 
intestinal physiology and motility (17) by regulating production of gut hormones or 
incretins (18), epigenetic effects through the histone deacetylase (HDAC) inhibitory 
activity of butyrate in particular and reducing gut wall permeability to improving tight 
junction control (19–21). Protein fermentation on the other hand, as well as producing 
some SCFA, also gives rise to phenolic metabolites and amines some of which may exert 
deleterious effects in the host. Gut microbiota and its metabolites have been also shown 
acting at the level of the enteric nervous system (ENS) (22). Moreover, it may impact also 
the central nervous system (CNS) and the human brain health by shaping different process. 
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The gut:brain axis 
The gut:brain axis includes the central nervous system (CNS), the neuroendocrine 
and neuroimmune systems, the sympathetic and parasympathetic arms of the autonomic 
nervous system (ANS), the enteric nervous system (ENS) and the gut microbiota (23,24). 
These components interact to form a complex bidirectional communication network 
whereby signals from the brain can influence the motor, sensory and secretory modalities 
of the gut and conversely, visceral messages from the gut can influence brain function 
(23,25). The data which most clearly indicates a direct influence of the gut microbiota on 
brain activity thus far has mainly derived from animal studies. However, the use of 
different laboratory animals indicate that there may be specific behavioural effects induced 
by specific microbiota in different mammals and the few clinical observations suggest that 
the influence of the gut microbiota on the gut:brain axis may also hold in humans (24). 
Indeed, there is an increasingly strong rationale implicating the gut microbiota in the 
development of the nervous system and in adverse early life influences on the gut:brain 
axis.  
Alterations in this bidirectional gut microbiota-brain seem to be implicated as a 
possible mechanism in the pathophysiology of several brain disorders including autism 
spectrum disorders (ASDs) (26,27), Parkinson’s disease (28), disorders of mood and 
depression (26,29), and chronic pain (30). However, the signalling mechanisms involved 
and how they relate to gut microbiota composition, community structure and metabolic 
output still remain to be determined. 
 
Hepatic Encephalopathy 
Altered metabolic, immune and hormonal homeostasis in advanced liver disease 
and cirrhosis may influence the onset of liver disease complications such as gut-based 
infections, multiorgan failure, chronic liver failure and hepatic encephalopathy (HE) (31). 
HE is considered a typical model of gut:liver:brain axis dysfunction, even though its 
pathogenesis is not well understood. Increasing evidence shows that alteration in gut 
microbiota and their metabolic by-products such as ammonia, indoles and/or oxindoles, a 
background of local and systemic inflammation, and bacterial translocation through leaky 
gut, may all drive the development of HE (32,33).  
Even if the pathophysiological basis of HE is multifactorial and complex, there is a 
general consensus that ammonia plays a pivotal role (34,35). Ammonia is a common end 
product of amino acid fermentation by the gut microbiota and although certain groups of 
bacteria (e.g. the clostridia) are commonly considered responsible for amino acid 
fermentation in the colon, we still do not fully understand ammonia metabolism by the gut 
microbiota and specifically, which species/genera are involved and under what conditions 
ammonia is produced. Over-representation of Streptococccaceae and Vellonellaceae, with 
a specific overabundance of Streptococcus salivarius, has been observed in HE and 
cirrhotic patients without cognitive impairments compared to healthy controls, leading to 
speculation that the possible involvement of this bacterial species in ammonia production 
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is due to its urease activity (36). However, ammonia production, as with production of 
other fermentation end products, is very unlikely to be the result of the metabolism of a 
single species, and more likely reflects fermentation profiles and end products, cross 
feeding, absorption and detoxification at the community level. Recent evidence of 
correlations between the gut microbiota, cognition and inflammatory cytokines in HE 
patients derive from next generation sequencing investigations. These investigations 
suggest some links between relative abundance of different gut bacteria and clinical 
processes affecting the pathogenesis of HE, as reviewed in depth in Chapter 1 of this 
thesis.  
 
The majority of the strategies used in the treatment of HE are primarily directed at 
the reducing or eliminating increased neurotoxic ammonia levels (37). Consequently, most 
of the therapies approved and utilized to date are based on modulation of the gut 
microbiota. Gut microbiota modulation may have efficacy in MHE and HE by various 
mechanisms including a decrease in counts of pathogenic bacteria, decreased bacterial 
urease activity and reduced ammonia absorption by decreasing luminal pH. The most 
common HE treatments used in clinical practice include prebiotics, antibiotics and 
probiotics (38,39) as discussed in Chapter 1. The first line of intervention in HE is the 
prebiotic lactulose (4-O-β-d-galactopyranosyl-d-fructose). However, the actual mechanism 
by which lactulose appears to work in HE is still not fully understood. Possible 
mechanisms seem to be related, in part, to alterations in gut microbiota, since lowering the 
colonic pH is linked to production of organic acids through bacterial fermentation. Lower 
pH and increased organic acids can inhibit urease-producing bacteria such as Klebsiella 
spp. and Proteus spp., facilitating the growth of acid resistant, non-urease-producing 
species, such as lactobacilli and bifidobacteria thus impacting on colonic ammonia 
production. Similarly, by providing a readily fermentable source of carbohydrate, lactulose 
switches off amino acid fermentation and thus ammonia production via this route. The 
non-absorbable antibiotic rifaximin, has been also shown to be effective in improving 
cognitive function in HE and is the most commonly used antibiotic to treat HE, especially 
in patients who do not respond to lactulose. Again the precise mechanism of action 
remains unclear (40). Probiotic treatment in patients with decompensated cirrhosis and HE 
has been shown to reduce serum ammonia levels and improve various neurocognitive tests 
and mental status (41). Commonly used as a second line intervention in HE, the probiotic 
VSL#3 (B. longum, B. infantis, B. breve, L. acidophilus, L. casei, L. delbrueckii ssp. 
bulgaricus, L. plantarum and St. salivarius ssp. thermophilus) has been demonstrated to be 
effective in preventing HE in patients with cirrhosis, to significantly reduce the level of 
arterial ammonia, small intestine bacterial overgrowth (SIBO) and orocaecal transit time 
together with increased psychometric HE scores, compared with placebo (42).  
However, due to the nature of these studies, i.e case/control studies and random 
controlled intervention trials, from the data available to date a clear association but not 
causation can be made between cognitive performance, HE and gut microbiota. Co-
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occurrence has been observed between certain microbial changes and improving 
symptoms. The use of in vitro fermentation systems inoculated with human faecal samples 
is widely accepted to simulate environmental conditions in the human large intestine (43). 
Indeed, its use provides an initial model to better understand the link between microbiota 
relative abundance, amino acid fermentation and ammonia production. In vitro systems 
could give insight on the fermentation profiles of the complex bacterial communities 
altered in HE giving insight on the mechanisms by which gut microbiota affects brain and 
liver function.  
In Chapter 2 of this thesis, an in vitro pH-controlled batch culture system has been 
used to study the effect of lactulose, rifaximin, VSL#3 and their combination on the gut 
microbiota population of cirrhotic patients. SCFA content and ammonia levels have also 
been correlated to the population structure analyzed by means of 16 rRNA sequencing.  
The effect of the probiotic VSL#3 on gut microbiota has also been studied in vivo 
in paediatric subjects affected by portal hypertension and MHE, a study carried out at the 
U.S.S.D Epatologia Gastroenterologia e Trapianti pediatrici, Azienda Ospedaliera 
Ospedali Riuniti di Bergamo. Data are presented in Chapter 3. 
 
Probiotic potential of γ-amminobutyric acid (GABA)-producing Lactobacillus 
brevis 
 As described in the previous section, in recent years much attention has been 
focused on the interaction between the intestinal microbiota, the gut, and the central 
nervous system (CNS) in the so called gut:brain axis (44–47). Indeed, gut microbiota 
modulation via probiotics represents a possible therapeutic strategy in ameliorating certain 
brain disorders and other systemic conditions. Bacteria commonly used as probiotics, 
especially bifidobacteria and lactobacilli, are able to produce a wide range of metabolites 
which may be involved in their probiotic potential. These metabolites include SCFA, 
vitamins B and K (48); bacteriocins (49), exopolysaccharides (50–52), which exert 
immunomodulatory function (50); conjugated linoleic acid (51–56) and also 
neurotransmitters like γ-amminobutyric acid (GABA) and serotonin. 
GABA is a non-protein amino acid widely distributed in nature which plays an 
important role in the mammalian central nervous system as the major inhibitory 
neurotransmitter (57). Moreover GABA is involved in physiological function and is 
involved in induction of hypotensive, diuretic and tranquilizing effects, but also in the 
regulation of different neurological disorders such as Parkinson’s disease, Alzheimer’s 
disease and Huntington’s chorea (58,59). Aside from CNS, GABA is present also in many 
organs such as the pancreas, pituitary, testes, gastrointestinal tract, ovaries, placenta, uterus 
and adrenal medulla (60). The potential probiotic strain Lb. rhamnosus (JB-1) was shown 
able to induce a direct effect on behavioural and physiological responses in a vagus nerve-
dependent manner (61). L. rhamnosus (JB-1) was able to modulate the expression of 
receptor implicated in anxiety behaviour and responses such as GABAAα2, GABAAα1, 
and GABAB1b (61), leading to the speculation that the changes induced by this probiotic 
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strain might provide an advantage toward stressful situations. Moreover, mimicking 
GABA molecules or increasing environmental GABA concentration in the brain was 
associated with a decreased cytokine production in macrophages (62,63). The cell 
signalling potential of GABA in immune cells may therefore also be of importance in 
terms of inflammatory processes not only in the gut but systemically. 
A number of different species of bifidobacteria and lactobacilli have been shown 
to produce GABA, in particular Lactobacillus subsp. isolated from fermented food (64), as 
shown by Siragusa et al. (65,66) with respect to Lb. paracasei, Lb. delbrueckii subsp. 
bulgaricus, Lc. lactis, Lb. plantarum, and Lb. brevis strains isolated from different Italian 
cheese varieties. Other GABA producing LABs have been isolated from tempeh, fruit 
juices and fermented dairy and soy products (Higuchi et al. 1997; Nomura et al. 1998; Hou 
et al. 2000; Aoki et al. 2003; Inoue et al. 2003; Siragusa et al. 2007; Chang et al. 2009; 
Kim et al. 2009; Lim et al. 2009). Wu and co-workers (67) reported the presence or 
absence of glutamate decarboxylase (gad) operons in the available genome sequences of 
Lb. brevis strains in 2016. 13 out of 14 published genomes have the intact gad operon. The 
amino acid sequences of GADs are highly conserved at the species level, where the genes 
encoding GADs are mainly distributed amongst Lactobacillus brevis, Lb. plantarum, Lb. 
fermentum, Lb. reuteri, Strrptococcus thermophilus, Lactococcus lactis subsp. cremoris, 
Lc. lactis subsp. lactis and some Bifidobacterium species. Most high GABA producing 
strains have been shown to belong to Lb. brevis and Lb. plantarum, even if species such as 
Lc. lactis, Str. thermophilus and Lb. bulgaricus isolated from milk environments also 
exhibit abilities to produce GABA in lower amounts (67). Also human intestinal 
Lactobacillus and Bifidobacterium isolates have been shown to produce GABA (68). In 
particular, Lb. brevis DPC6108 was able to significantly increase the GABA concentration 
of fermented faecal slurry, indicating that GABA biosynthesis could occur in vivo (68). Lb. 
brevis therefore, represents a promising starter for dairy fermentation to manufacture 
GABA-rich cultured dairy foods to be used in restoring or ameliorating conditions linked 
to an altered gut microbiota:(liver):brain axis.  
A probiotic strain is “a live organism which when administered in adequate 
amounts confer a health benefit on the host” (69). An effective probiotic will maintain 
sufficient viable microorganisms that can survive the host's digestive process, adapt to the 
resident microbiota - not displacing the native bacteria already present -  and produce a 
beneficial response in the host without pathogenic or toxic adverse effects. Indeed, a 
probiotic should resist the acidic environment of the stomach and the effects of bile in the 
duodenum (70). As already observed in Listeria monocytogenes, GAD activity in Lb. 
brevis may be critical for survival in acidic conditions and allows it to overcome the low 
pH stresses of fermented foods, gastric juice, volatile fatty acids in the GIT (75).  
Indeed, the ability to convert monosodium glutamate to GABA may be considered 
as a novel probiotic trait, because of the beneficial health effects of GABA and its 
protective action to acidic pH environment. 
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Chapter 4 of this thesis presents the data related to the characterization of Lb. 
brevis FEM 1874 strain isolated from traditional alpine cheese for its ability to accumulate 
high levels of GABA in the culture medium and for some phenotypic traits important for 
probiotics. This preliminary characterization indicates the potential of this strain as a next-
generation probiotic targeting the gut:brain axis, portal vein hypertension and systemic 
inflammation through GABA production. 
 
 
Aim and objectives 
 
The main hypothesis of the present thesis is if the modulation of the gut microbiota 
by using prebiotic, probiotic or antibiotic administration could benefit the gut:brain:axis.  
 
To address this point: 
- I reviewed the most recent literature about gut:brain:axis, with a special 
focus on cirrhosis and Hepatic Encephalopathy (Chapter 1); 
- I characterized the in vitro microbiota modification in terms of 
population dynamics and composition induced by lactulose, rifaximin 
and VSL#3 in the cirrhotic environment; data have been associated also 
to microbial metabolism (Chapter 2); 
- I characterized the in vivo microbiota modification in terms of 
population dynamics and composition induced by VSL#3 in paediatric 
and young adults affected by portal hypertention and minimal hepatic 
encephalopathy (Chapter 3); 
- I characterized the cheese isolated Lb. brevis strain FEM 1874 for its 
potential probiotic traits and for its ability to produce high amount of 
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Abstract 
Hepatic encephalopathy (HE) is a debilitating neuropsychiatric condition often 
associated to acute liver failure or advanced liver cirrhosis. Advanced liver diseases are 
characterized by a leaky gut and systemic inflammation. There is strong evidence that the 
pathogenesis of HE is linked to a dysbiotic gut microbiota and to the microbial by-
products, such as ammonia, indoles, oxindoles and endotoxins. Current main line clinical 
treatments target microbiota dysbiosis by decreasing the counts of pathogenic bacteria and 
reducing the endotoxemia. This review will focus on role of the gut microbiota and its 
metabolism in HE and advanced cirrhosis. It will present the different clinical trials testing 
the efficacy of prebiotics, probiotics and antibiotics used to treat HE and advanced 
cirrhosis through gut microbiota modulation. Despite the large amount of existing data, 
there is still a need to study in more detail the composition and the metabolic output of the 
gut microbiota and its cross-talk with the host as core factors in HE dysbiosis associated 
with liver failure. 
 
1.1 Introduction 
The human body is now considered a complex ecosystem within its own gut, 
harbouring thousands of different microbial species at different anatomical site and 
maintaining stable symbiotic or mutualistic relationships in health. From metagenomic 
studies in healthy subjects, we now know that substantial difference in gut microbial 
composition exists between individuals (1–3). In fact each individual has a unique gut 
microbiota which may be modulated by genetic background, physiological state, microbial 
interactions (e.g. phage), environmental factors and diet (4–6). There are more than 500 
species in the gut of each individual in different societies and the number of species 
(richness) increases with age (7). The gut microbiome can be considered as an anaerobic 
bioreactor able to synthesize molecules that act directly on the mammalian immune 
system, modify the human epigenome and regulate the host metabolism (8–10). Indeed the 
gut microbiota uses ingested dietary components (e.g. carbohydrates, proteins, and lipid) 
and host-derived components (including shed epithelial cells and mucus) to generate 
energy for their own cellular processes and for growth and also to produce several 
metabolites which influence human health and disease risk. Diet has an important role in 
shaping the gut microbiota and also the flux of metabolites and neurochemicals they 
produce. Certain fibres and prebiotics, like inulin, fructo-oligosaccharides and lactulose, 
promote the production of Short Chain Fatty Acids (SCFA) acetate, propionate and 
butyrate. Indeed, certain fibre/prebiotics are thought responsible for maintaining a 
butyrogenic gut microbiota characterised by increased relative abundance of 
Bifidobacterium and possibly butyrate producing bacteria, like Roseburia inulinivorans 
and Fecalibacterium prausnitzii (11–15) by acting as growth substrates. These bacteria 
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appear to be important members of the beneficial gut microbiota and induce beneficial host 
immune effects (16–21), improve mucosal integrity intestinal permeability (16,18,21,22), 
intestinal motility (23) and sensitivity (17,24). Some species also produce bioactive 
compounds other than SCFA, such as folate, serotonin, dopamine and γ-aminobutyric acid 
(GABA) (25,26). Species from the genera Lactobacillus, Bifidobacterium, Escherichia, 
Bacillus, Streptococcus and Enterococcus have all been described to produce 
neurotransmitters (27–31). Lactobacillus and Bifidobacterium species have also been 
shown to induce hypothalamic pituitary adrenal (HPA) hormones, like 
adrenoicorticotropin) and cortisol production (32). Indeed, the gut microbiota and its 
metabolites have also been shown to be involved in modulating the activity in the enteric 
nervous system (ENS) (33,34). Astonishingly, recent studies in animal models show that 
the gut microbiota influences and shapes the brain development and function. In fact, it 
appears that the gut microbiota may impact on the central nervous system (CNS) and brain 
health in different ways: i) by stimulating the innate (e.g. gut permeability) and adaptive 
immune system, ii) by producing neuroactive metabolites, iii) by producing hormones and 
neurotransmitters identical to those of human origin, iv) by directly stimulating the afferent 
neurons of the ENS sending signals to the brain via the vagus nerve.  
Alterations in the bidirectional communication between the brain and the gut 
microbiota have been implicated in the pathogenesis of well-known gut disorders such as 
irritable bowel syndrome (IBS) and related functional GIT disorders (35,36). They also 
seem to be implicated in the pathophysiology of several psychiatric conditions including 
autism spectrum disorders (ASDs) (27,37), Parkinson’s disease (38), disorders of mood 
and anxiety (27,39), and chronic pain (40). In most of these disorders a shift from the 
conventional symbiotic gut microbiota, to a dysbiotic condition, seems to represent the 
trigger for pathogenesis evolution, or at least it occurs with the onset of disease (41). Gut 
microbiota dysbiosis has also been linked to liver pathologies such as non-alcoholic fatty 
liver disease (NAFLD) (42), non-alcoholic steatohepatitis (NASH) (43), alcoholic liver 
diseases (ALD), cirrhosis and hepatic encephalopathy (HE) (44). In the last decades many 
studies have described the alteration of gut microbiota in liver cirrhosis. Mechanistically 
the break-down of the intestinal barrier by bacteria (or bacterial molecules) and their 
translocation into the liver, systemic circulation or lymphatic system, has been suggested 
to give rise to systemic inflammation and altered brain functions (45).  
Aim of this review is to describe how gut microbiota affects end-stage of liver 
disease, focusing on HE. Attention is also given to the main microbiota-targeted 
therapeutic approaches used to reverse the debilitating state, which characterizes HE. 
 
1.2 Gut microbiota:liver:brain axis: a matter of microbial ecology, metabolism 
and inflammation 
Although the gut microbiota clearly is altered in liver diseases, and has the 
potential to modulate physiological processes linked to liver disease, we still do not know 
which comes first, liver dysfunction or microbial dysbiosis. The gut liver-axis can be 
	 19 
defined as the set of anatomical and metabolic interactions between the gut and the liver. 
The liver receives more that 70% of blood from the gut through the portal vein and is 
continuously exposed to gut-derived bacteria, their components, including immune 
reactive molecules like lipopolysaccharide (LPS), and metabolites. Indeed, the liver has a 
fundamental physiological and crucial role in defence against gut-derived materials and 
xenobiotics which may be ingested with food (46,47). Moreover, the liver is rich in 
specific kinds of immune cells including natural killer (NK) cells, NK T cells, Kupffer 
cells and hepatic stellate cells, which are actively involved in maintaining a protective 
immune response and tolerance (e.g. resolution of inflammation), and in health, avoiding 
excessive reaction to exogenous antigens capable of inducing liver inflammation, 
autoimmune phenomena, fibrosis or carcinogenesis (48,49). In this context alteration of the 
gut:liver axis may evolve into dysbiosis of the conventional symbiotic microbiota which 
has in turn the potential to influence the aetiology of pre-cirrhotic and cirrhotic pathologies 
and systemic complications (42–44,50).  
 
1.2.1 Cirrhosis and the gut microbiota 
Cirrhosis is a pathological process by which the normal anatomical lobules of the 
liver are replaced by abnormal nodules separated by fibrous tissue (51). It represents the 
end result of various types of chronic liver disease. When decompensated e.g. the severe 
scarring of the liver has damaged and disrupted essential body functions, it drives the onset 
of the several complications like jaundice, variceal haemorrhage, ascites, or 
encephalopathy (52). When subjects reach the stage of cirrhosis, impairment of the gut-
liver axis leads to gut inflammation, systemic inflammation, and worsening of liver disease 
complications, such as HE, gut-based infections such as spontaneous bacterial peritonitis 
(SBP) and eventually the development of multi-organ failure, known as acute on chronic 
liver failure (ACLF) (53). Clinically the severity of cirrhosis is measured by two scoring 
systems, the Child-Turcotte-Pugh (CTP, which includes serum albumin, bilirubin, 
prothrombin time, HE, and ascites severity) and the Model for End-Stage Liver Disease 
(MELD, logarithmic score of bilirubin, creatinine, and the international normalized ratio -
INR- of the prothrombin time) (54,55).  
The “cirrhosis dysbiosis ratio” (CDR) has been introduced by Bajaj and coworkers 
as a quantitative index to describe microbiota alterations accompanying cirrhosis 
progression, where a low index indicates dysbiosis (50). It has been defined as the ratio of 
Ruminococcaceae, Lachnospiraceae and Clostridiales cluster XIV, to Enterobacteriaceae 
and Bacteroidaceae taxa based on previous observation of a reduced relative abundance of 
the former and relatively increased abundance of the latter in cirrhosis and HE (45,56,57). 
CDR encompasses a set of various cirrhotic stages, being highest in controls (2.05) 
followed by compensated (0.89), decompensated (0.66), and hospitalized cirrhotic subjects 
(0.32). Thus, the severity of liver disease per se negatively affects the composition of the 
microbiota, where MELD scores are associated with a relative decrease in Clostridiales 
XIV, Lachnospiraceae, Ruminococcaceae and Rikenellaceae, and a relative overgrowth of 
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potentially pathogenic taxa such as Staphylococcaceae, Enterococcaceae and 
Enterobacteriaceae. Moreover patients with lower concentration of faecal Clostridiales 
XIV, Lachnospiraceae and Ruminococcaceae bear higher levels of endotoxin, underlining 
an association between microbial composition and endotoxin-mediated inflammation 
derived from Gram negative LPS (50). In general the severity of cirrhosis may be a 
stronger determinant of microbial abundance as observed by Chen and coworkers in 
Chinese cirrhotic subjects compared to healthy people (58). Patients showed a reduced 
abundance of Bacteroidetes and Lachnospiraceae, whereas Proteobacteria, Fusobacterium 
spp., Enterobacteriaceae, Veillonellaceae and Streptococcaceae were all increased 
compared to healthy subjects (58). However, from the data available to date a clear 
association but not causation can be made between cognitive performance, cirrhosis 
severity and gut microbiota dysbiosis. 
 
1.2.2 Hepatic encephalopathy and the gut microbiota 
Effects of altered microbiota in advanced liver disease and cirrhosis may impact on 
brain functions resulting in hepatic encephalopathy (HE). HE is considered a typical model 
of gut:liver:brain axis disease, even though its pathogenesis is not well understood. 
Increasing evidence shows that alteration in gut microbiota and their by-products such as 
ammonia, indoles, and/or oxindoles, as well as a background of local and systemic 
inflammation and leaky gut drive HE development (59,60).  
HE is a spectrum of neurocognitive impairments and can be classified into three 
types, based on the nature of hepatic dysfunction: type A is associated with acute liver 
failure; type B occurs with portal-systemic shunting (bypass) without intrinsic liver 
disease; and type C develops in patients with cirrhosis (61). For more detail about 
definition and nomenclature in HE, please see the review from Dharel and Bajaj (54). 
Concerning type C HE, cirrhosis-related HE ranges from minimal (MHE), where patients 
are impaired on specialized cognitive tests, to overt HE (OHE), where patients experience 
mental status changes ranging from simple disorientation to coma. In the first case patients 
have difficulties in cognitive performance, psychomotor speed and visuo-motor 
coordination (62) resulting in reduced health-related quality of life, and increased 
progression to OHE. It has been shown that almost 80% of patients with chronic liver 
disease may have MHE with a fourfold higher risk of developing OHE (63). Indeed OHE 
is associated with decreased survival, risk of subsequent OHE episodes, and severely 
impacts on patient well-being (63,64). It can manifest as either episodic (when clinically 
overt symptoms develop over a short period of time) or persistent (continuous presence of 
symptoms) (65).  
HE patients present a different composition of the sigmoid colonic mucosal 
microbiota (45). Lower Roseburea and higher Enterococcus, Veillonella, Megasphaera 
and Burkholderia among sigmoid colonic mucosal microbiota were observed in HE group 
compared to controls. The authors found that the genera like Blautia, Fecalibacterium, 
Roseburia, and Dorea correlated with good cognition and decreased inflammatory 
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markers, while species Enterococcus and Streptococcus and genera including 
Burkholderiaceae, Veillonellaceae, Megaspheara, Rikenellaceae, Alistipes, 
Streptococcaceae, Alcaligenceae, Sutterella, Porphyromonadaceae, and Parabacteroides 
were associated with poor cognitive performance in patients with and without OHE. 
Specifically Alcaligenaceae are able to produce ammonia by degradation of urea, 
potentially explaining their association with poor cognitive function. Moreover, Bajaj and 
colleagues demonstrated that Enterobacteriaceae, Fusobacteriaceae, and Veillonellaceae 
were positively, and Ruminococcaceae negatively, related to inflammation (56). The 
correlation between the microbiota, cognition and inflammatory cytokines in HE patients 
show the critical need to deepen study the gut mucosa since several important processes in 
the pathogenesis of HE occur at the mucosal interface rather than in the lumen, such as 
translocation and interactions between the gut microbiota and the immune system (66).  
The influence of salivary microbiota on the distal gut was assessed by Bajaj and 
colleagues, considering microbial composition and function in cirrhotic patients with and 
without HE as well as the impact of cirrhosis in salivary defence and inflammation (67). 
Salivary microbiota analysis of cirrhotic subjects affected by HE showed an increase in 
Enterobacteriaceae with a concomitant reduction in Erysipelothricaceae with respect to 
no-HE patients and controls. Enterobacteriaceae was associated with functions related to 
endotoxin suggesting a role of oral microbiota toward the overall endotoxemia present in 
cirrhosis. Similar association have been noted before between oral microbiota as an 
inflammatory trigger of chronic low-grade systemic inflammation associated with 
metabolic disease and type 2 diabetes (68). Moreover in saliva a significantly higher 
relative abundance of Prevotellaceae, Fusobacteriaceae, and Enterococcaceae was 
observed in patients with cirrhosis, compared to controls. Correlation networks showed 
that cirrhotic salivary microbiota correlates well with a proinflammatory milieu, 
characterized by IL-1β and IL-6 production, and a consequent increase in secretory IgA 
(67). 
In a case study, a male HE patient (MELD score 10) was subjected to to an faecal 
microbiota transplantation (FMT) every week for five weeks from a universal stool donor 
(69). Improvement in attention, serum ammonia and quality of life were observed despite 
missing treatments and need of hospitalization during the study. Cognitive improvements 
were not associated with an increase in the relative abundance of Lachnospiraceae, 
suggesting that other microbial taxa and metabolic activities might be involved. Of note 
was the fact that despite the initial improvement, the beneficial effect of FMT did not 
persist after FMT was discontinued, suggesting a transient beneficial effects of FMT with 
heterologous microbiota did not colonize the new host or that a repeated therapy would be 
required to maintain response (69). However, more subjects should be analysed to support 
and validate this evidence. In another study magnetic resonance spectroscopy and diffusion 
tensor imaging have been used to define linkage between microbial modification and 
neuronal astrocytic dysfunction in cirrhotic patients with and without HE (70). Patients 
with HE had a higher abundance pattern of Staphylococcaceae, Enterococcaceae, 
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Porphyromonadaceae and Lactobacillaceae compared to controls and no-HE (70). Brain 
MR spectroscopy manifestations of ammonia were positively linked with families such as 
Streptococcacae, Enterobacteriaceae, Lactobacillaceae and Peptostreptococcaceae, while 
negatively correlated with Lachospiraceae, Ruminococcaeae and Clostridiales XIV. The 
latter taxa are predominant in healthy control studies and mediate several important 
benefits, such as production of SCFA and 7-α de-hydroxylation of bile acids in hosts 
(58,71). With the progression of cirrhosis, reduction in Lactobacillaceae and 
Peptostreptococcaceae parallels an increase in potentially harmful taxa such as 
Streptococcacae and Enterobacteriaceae (72). Cognitive dysfunction correlated also with 
an increase of Porphyromonadaceae (70), a bacterial group implicated in cognitive 
dysfunction, progression of fatty liver disease and in systemic and hepatic inflammation in 
animal studies (56,73,74). Interestingly, Ahluwalia and colleagues showed an increase in 
Lactobacillaceae in HE faecal samples, potentially as expansion of selected urease-
producing Firmicutes as already observed in humans and mouse cirrhosis models 
(72,75,76). 
 
1.3 Gut microbiota:brain axis in liver disease: mechanisms 
The higher risk of microbiota dysbiosis in cirrhotic patients, with subsequent 
clinical implications, is principally due to the variety of pathological interactions between 
the liver and the gastrointestinal tract. In particular the alteration in intestinal motility, the 
higher gastric pH and the reduced bile acid concentrations in the colon observed in patients 
affected by cirrhosis, may lead to a failure in the control of bacterial intestinal growth. 
Cirrhosis also impairs the homeostatic role of the liver in the systemic immune response. 
Damage to the reticulo-endothelial system compromises the immune surveillance function 
exerted by Kupffer cells and sinusoidal endothelial cells and the reduced hepatic synthesis 
of proteins, involved in innate immunity and pattern recognition, hinders the bactericidal 
ability of phagocytic cells (77,78). Monocyte spreading, chemotaxis and neutrophil activity 
are also significantly reduced in cirrhosis compared with controls (79,80). This in turn can 
lead to compromise the intestinal barrier and bacterial translocation, a higher risk of 
intestinal bacterial infections and increased risk of liver disease decompensation (81–87) 
 
1.3.1 Endotoxemia 
 A common symptom in cirrhosis is Small Intestinal Bacterial Overgrowth (SIBO), 
which leads to a qualitative and quantitative alteration in the microbiota composition in the 
upper gut (84,88–90). Defined as ≥ 105 total colony-forming units (CFUs) per milliliter of 
proximal jejunal aspirations, SIBO is present in 59% of cirrhotic patients and is correlated 
with the severity of liver disease. Indeed, SIBO, mostly induced by aerobic Gram-negative 
enteric organisms, like E. coli and Klebsiella pneumoniae (91–93), represents a risk factor 
for clinical decompensation (due to bacterial translocation and endotoxemia) of liver 
cirrhosis, favouring encephalopathy and SBP (88,94). 
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The intestinal mucosal surface has the secretory and anatomical means of 
preventing adhesion and translocation of microorganisms, and in health represent an 
efficacious barrier impeding bacteria entering the circulation. Structural 
changes/modifications, oxidative stress, and alteration in enterocyte function have been 
assessed in cirrhosis patients, as source of increases in intestinal permeability (IP) or 
leakiness (95–97). Leaky gut may lead to the passage of toxins, antigens, or bacteria into 
the body (98), and is suspected to play a pathogenic role in the development of chronic 
liver injury (99) as well as metabolic and immune derangement associated with many 
chronic debilitating diseases including obesity, type 2 diabetes and autoimmune 
manifestations (100,101). Bacterial translocation (BT) is the migration of viable 
microorganisms and microbial inflammatory products (LPS, lipoteichoic acid, bacterial 
DNA, peptidoglycans, and fragments) across the intestinal barrier from the intestinal 
lumen to mesenteric lymph nodes (MLNs) and other extra-intestinal organs or sites 
(102,103). Normally with a physiologically intact epithelium, endogenous bacteria 
translocate by an intracellular route through the epithelial lining cells and then travel via 
the lymph to the MLNs. When the epithelium is damaged bacteria translocate via the 
intercellular route between the epithelial cells directly to the blood and lymph nodes 
(104,105). Both the frequency and the clinical consequences of BT impact greatly on 
chronic disease (87).  
MLNs are normally sterile (105) but in cirrhosis may be subjected to translocation 
and replication of the endogenous gut microbiota, specially Enterobacteriaceae, 
Enterococcus spp and Proteus spp. (106). Translocated viable bacteria may induce 
“spontaneous” bacterial infections while the translocation of bacterial fragments may 
produce a pro-inflammatory state due to the release of cytokines and nitric oxide leading to 
endotoxemia. The rate and degree of BT depend on the severity of liver disease and the 
translocation of entire and viable bacteria to MLN is a characteristic of decompensated 
cirrhosis. Differently, the detection of bacterial DNA in the systemic circulation and/or in 
MLNs seems to be independent from the severity of liver disease as observed in mice (97). 
Together with modification in intestinal permeability and alterations of the local host 
immune system, bacterial overgrowth is probably a prerequisite for the development of 
BT. In rats it has been shown that bacteria which translocate to MLN are the same species 
involved in overgrowth of the intestinal lumen, although not all the bacteria present in 
large quantity are found in the MLN (90,107,108). In blood of cirrhotic patients, Moratalla 
and co-workers specifically identified bacterial DNA attributed to the bacterial species E. 
coli, S. aureus, K. pneuomoniae, P. vulgaris, P. mirabilis and Citrobacter freundii and 
associated bacterial DNA translocation with worse neurocognitive scores in the patients 
analysed (109). These species, especially E. coli, are those which most frequently cause 
infections and spontaneous bacteremia in cirrhotic patients (110). Inflammatory cytokines 
in fact contribute to the hyperdynamic circulation, portal hypertension (84), impaired liver 




Blood ammonia normally ranges between 35–60 µmol/l in the presence of a 
healthy liver. However, during liver disease, the reduced hepatic ammonia removal 
capability, increases two- to five fold the ammonia blood concentration with consequent 
increase of its levels in the brain and associated deleterious effects (113–115). Even if the 
pathophysiologic basis of HE is multifactorial and complex, there is a general consensus 
that ammonia plays a pivotal role (113,114).  
Ammonia is a by-product of nitrogen metabolism, mainly produced within the gut 
by the enterocytes deamination of glutamine by glutaminase in the small intestine and 
colon, but it is also produced upon microbial degradation of amines, amino acids, purines, 
and urea (116,117). Hydrolysis of urea (to carbamate and ammonia) is catalysed by the 
microbial enzyme urease, frequently produced by Gram negative Enterobacteriaceae, but 
also many anaerobes and Gram positive bacteria (118). Microbially produced ammonia 
may be absorbed across the mucosal epithelium by diffusion and transported into the 
hepatic portal circulation, where in a healthy liver it is removed through the urea cycle. 
Ammonia detoxification in the liver represents the main pathway by which ammonia 
homeostasis is maintained in the body, even if other organs like muscle, brain (astrocytes) 
and kidneys also contribute to ammonia metabolism. In the setting of liver failure however, 
ammonia escapes detoxification in the liver and enters the systemic circulation, inducing 
oxidative stress by generation of free radicals and leads to the nitrotyrosination of proteins 
in the brain (119–121). The neurotoxicity of ammonia is linked to its potential to modify 
pH, and membrane potential (113). It can also alter cellular functions like metabolism, 
neurotransmission, and can induce brain oedema and astrocyte swelling (120), which is a 
common feature of cirrhosis developing HE, found both in animal models (122,123) and in 
patients (124).  
The role of gut microbiota in the development of experimental neuroinflammation 
and hyperammonemia associated with cirrhosis, has been assessed using conventional 
mice and germ free (GF) mice (125). Significantly higher serum levels of the 
proinflammatory cytokines IL-1β and TNFα and ammonia were found in conventional 
cirrhotic mice compared to the other groups. Cirrhotic mice showed a significantly lower 
relative abundance of Lachnospiraceae, Ruminococcaceae, Clostridiales XIV, and 
Bifidobacteriaceae and higher Staphylococcaceae, Enterobacteriaceae, and 
Lactobacillaceae in large intestinal and caecal lining. Moreover, an increase in 
Enterobacteriaceae and Staphylococcaceae and Streptococcaceae was also observed in 
small intestinal border (125). Conventional cirrhotic mice also showed systemic 
inflammation, glial and microglial activation, and neuroinflammation associated with the 
microbial dysbiosis. The increase in the relative abundance of Lactobacillaceae in cirrhotic 
mice mirrored previous observations in HE patients (56). Over-representation of 
Streptococccaceae and Vellonellaceae, with a specific overabundance of Streptococcus 
salivarius, were observed in MHE and cirrhotic patients (even though without cognitive 
	 25 
impairments) compared to healthy controls, suggesting the possible involvement of this 
bacterial species in increasing the ammonia production due to its urease activity (126).  
However, while it has been consistently shown that patients with cirrhosis have 
higher circulating ammonia levels, the correlation between the arterial ammonia 
concentration and the clinical manifestation of HE has still to be confirmed (127) As such 
the tight mechanistic relationship between ammonia concentration and onset of HE 
remains to be fully established (128).  
There is a general agreement that infection is an important player in HE (127,129). 
Systemic inflammation participates to the propagation of cerebral consequences due to 
ammonia toxicity both in acute liver failure (130) and cirrhosis (131). A potential 
functional imbalance between a systemic inflammatory response and a compensatory anti-
inflammatory response may lead to multiorgan failure and death (132,133). In this context 
it has been shown that ammonia itself can induce neutrophil malfunction with excessive 
and inappropriate release of reactive oxygen species. This in turn leads to a consequent 
neutrophil failure to act against bacteria such as E. coli. This latter evidence could 
somehow support the effective relationship between ammonia and inflammation in the 
pathogenesis of HE (134).  
 
1.3.3 Bile Acids 
Composed of individual bile acid moieties, mucous, phospholipids and biliverdin, 
the main physiological roles of bile is the emulsification of fats, the release of fat-soluble 
vitamins and regulation of cholesterol metabolism in the small intestine (135). Moreover 
bile acids function also as systemic signalling molecules able to significantly alter host 
gene-expression profiles (136,137). They act as ligands to activate or repress host 
receptors, expressed locally on various intestinal epithelial cells and systematically, within 
a diverse range of organs (including both the liver and adipose tissue), such as farnesid X 
receptor (FXR), pregnane X receptor and vitamin D receptor (138). 
Bile acids (BAs) represent also one of the major selective pressures on the gut 
microbiota. BAs possess direct antimicrobial properties and can also modulate the gut 
microbiota through indirect activation of FXR-induced anti-microbial peptide synthesis in 
the small bowel (139). The gut microbiota is known to convert primary BAs 
chenodeoxycholic acid (CDCA) and cholic acid (CA) into secondary BAs lithocholic acid 
(LCA) and deoxycholic acid (DCA), respectively (140), more toxic to certain bacteria than 
primary BAs but also with altered signalling for mammalian BA receptors (141). 
It is known that a decrease in BA production is associated with a modulation of 
Lachnospiraceae, Ruminococcaceae, and Clostridiales Cluster XIV, which normally drive 
the SCFA production and strengthen the integrity of the gut barrier (142–144). In cirrhosis, 
reduction in gastric acid barrier has been shown to result in an increase of Gram-positive 
“oropharyngeal microbiota” (Streptococcus spp., Staphylococcus spp., Micrococcus spp., 
Lactobacillus spp., Neisseria spp., Veillonella spp., Stomatococcus spp., Gemella spp., 
Corynebacterium spp., Actinomyces spp., Fusobacterium spp.) in the stomach, duodenum 
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and proximal jejunum. Contemporarily with the reduction in small bowel motility, 
potentially due to the autonomic neuropathy (145) or comorbidities (diabetes, long term 
pharmacological therapies), the population density of normal colonic bacteria (including 
Enterobacteriaceae, Enterococcus spp., Pseudomonas spp. and Bacteroides spp.) tends to 
increase in the small intestine (89). Additionally, due to a reduced concentration of bile 
acids, an overgrowth of pathogenic and pro-inflammatory members of the microbiota 
including Porphyromonadaceae and Enterobacteriaceae has been observed (146). Patients 
with advanced cirrhosis have been shown to have a 5-fold decreased concentration of 
faecal BAs compared to controls, accompanied by a reduction in Blautia, 
Ruminococcaceae and the Clostridium cluster XIVa group, taxa containing a high 
proportion of 7-α-dehydroxylating bacteria (57). As the severity of cirrhosis progresses, 
less secondary BAs are formed with likely knock on implications both for gut microbiota 
community structure and physiological function regulated by BAs system like BA 
biosynthesis, cholesterol metabolism, glucose homeostasis and inflammation.  
 
1.4 Treating HE through microbiota modulation 
 The gut microbiota and its dysbiotic evolution in advanced liver disease is 
considered as the main actor, after liver failure, in HE onset. The majority of the strategies 
used to treat HE primarily target increased neurotoxic ammonia levels (147). 
Consequently, most of the therapies approved and used to date in clinical practice are 
based on modulation of the gut microbiota. Gut microbiota modulation may have efficacy 
in MHE and HE by various mechanisms including a decrease in counts of pathogenic 
bacteria, decreased bacterial urease activity and reduced ammonia production or absorption 
by decreasing luminal pH (58–61). The prebiotic non-absorbable disaccharide lactulose, 
non-absorbable antibiotics such as rifaximin and varying combinations of probiotics and 
synbiotics are the main therapies currently used in clinical practice. 
 
1.4.1 Lactulose 
Lactulose is a synthetic disaccharide, formed by the monosaccharaides lactose and 
galactose. It is considered a prebiotic, based on the definition: “prebiotic is a selectively 
fermented ingredient that allows specific changes, both in the composition and/or activity 
in the gastrointestinal microflora, that confer benefits” (148). An important characteristic 
of prebiotics, in fact, is that they are not absorbed and must mediate their activities in the 
gut or systematically only after fermentation by the gut microbiota. Together with other 
non-absorbable disaccharides, such as inulin, fructo-oligosaccharides (FOS) and galacto-
oligosaccharides (GOS), lactulose is able to stimulate the growth and activities of specific 
“good” bacteria in the gut, such as bifidobacteria (149–152). Indeed, lactulose could act on 
the intestinal production/absorption of ammonia through several potential mechanisms 
(153): i) catharsis or increase in intraluminal gas formation and osmolality as well as 
reduction in intraluminal pH and transit time; ii) bacterial uptake of ammonia, where 
lactulose promotes a bifidogenetic activity and SCFA are used as a preferred substrate by 
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the colonic bacteria with ammonia as the nitrogen source for protein synthesis (154,155); 
iii) inhibition of glutaminase activity, interfering with the intestinal uptake of glutamine 
and its subsequent metabolism to ammonia (156). 
Lactulose effect in improving quality of life and cognitive function in patients with 
HE has long being studied. In 2014, the European and American Associations for the 
Study of the Liver (EASL/AASLD) published a joint practice guideline in which they 
recommended lactulose as the treatment of choice for overt hepatic encephalopathy and for 
secondary prevention after an index event (157). Compared to placebo or no intervention, 
lactulose significantly reduced the risk of no improvement in neuropsychological tests and 
progression to OHE, reduced blood ammonia levels and improved health-related quality of 
life, even if no significant difference was observed in the mortality of patients with MHE 
(158). Lactulose has also been shown to be effective in the treatment of MHE in patients 
with extra hepatic portal vein obstruction (159) and to reduce arterial ammonia, 
inflammatory mediators (TNFα, IL-6, IL-18) and serum endotoxin (160). A recent meta-
analysis on a total of 38 randomized clinical trials involving 1828 participants provided 
moderate quality evidence that use of lactulose is associated with beneficial effects on 
hepatic encephalopathy in terms of mortality and serious adverse events when used to treat 
overt hepatic encephalopathy, minimal hepatic encephalopathy and to prevent hepatic 
encephalopathy (153). In a rat model of early HE, intragastrically administration of 
lactulose increased the number of new neurons in the hippocampal dentate gyrus 
promoting neuronal growth, showing that increased neuroplasticity may be linked to 
improved cognitive function (161). Moreover, lactulose also appear to exert a 
neuroprotective effect by elevating the number of GFAP-immunoreactive cells (161).  
Despite its effect on ammonia production and its clear amelioration of HE clinical 
symptoms, contrasting evidences link the effect of lactulose on HE and the changes in the 
gut microbiota. It has been observed that lactulose treatment in patients who developed HE 
leads to lower CDR and an increase in relative abundance of Enterobacteriaceae and 
Bacteroidaceae (72). Lactulose suspension determined a reduction of Faecalibacterium 
(162). This reduction was previously observed in patients with and without recurrent HE 
post-withdrawal (133).  
Furthermore it was demonstrated that lactulose treatment in MHE patients was 
able to significantly reduce the bacterial-DNA translocation rate, with consequent decrease 
in serum ammonia levels and an improvement in neurocognitive scores (109). 
Translocation of pathological bacterial antigens was present in up to one-third of MHE 
patients, whereas the use of lactulose significantly reduced this rate by up to 16%. This 
effect was also observed in a rat model of acute liver failure (163), suggesting that this 
disaccharide may inhibit BT (109) and reverse HE symptoms associated to gut microbiota 






Rifaximin is a nonsystemic structural analogue of rifamycin that inhibits the 
synthesis of bacterial RNA by binding to the β-subunit of bacterial DNA-dependent RNA 
polymerase (164,165). It effects a variety of intestinal aerobic and anaerobic bacteria 
(166,167). Less than 1% is absorbed after oral administration, resulting in greater 
concentration in the gastrointestinal tract and also presenting minimal side effects (168). At 
moderate and low doses it induces minimal effects on the normal gut microbiota. Higher 
doses, however, have been shown to initially suppress population of Enterococcus, E. coli, 
Lactobacillus spp., Bacteroides spp., Bifidobacterium spp. and Clostridium perfringens, 
which usually return to initial values after a wash-out period in patients with ulcerative 
colitis (169).  
In patients with cirrhosis and symptoms of HE, rifaximin has been shown to 
reduce serum ammonia and significantly improve neurological signs and symptoms of 
OHE, prevent episodes of HE and decrease the risk of hospitalization (170). It has also 
been shown to ameliorate acute HE (171). Rifaximin has been also used in randomised and 
open-label long-term studies both in the case of acute episodes and for the prevention of 
HE recurrence, including several studies showing beneficial effects on the neuropsychiatric 
and neuromotor abnormalities associated with cirrhosis (172–174). By analysing data from 
patients initially treated with placebo who crossed over to receive rifaximin during an 
open-label maintenance (OLM) study, Bajaj and colleagues (175) confirmed the efficacy 
of rifaximin in protecting against HE recurrence. 65% of patients who experienced an 
OHE episode during the placebo treatment in the randomised, controlled trial (RCT) were 
subsequently protected from a recurrent episode during the rifaximin therapy in the OLM 
study (175).  
Short-term treatment with rifaximin has been shown to effectively reduce blood 
ammonia level and improve psychometric test, with reduction in SIBO (176). Moreover 
rifaximin seemed to have direct effects on intestinal barrier function and the metabolome 
(177,178). A correlation network study between metabolic and microbial changes upon 
rifaximin treatment showed correlations amongst metabolic functions associated to 
Porphyromonadaceae, Bacteroidaceae and Enterobacteriaceae, cirrhosis, MHE and 
cognitive dysfunction (179). In contrast, modification in faecal microbiota composition 
were modest with respect to the changes observed in bacterial function. Rifaximin led to an 
increase of Eubacteriaceae and beneficial species linked with less oxidative stress and 
aromatic amino acid and nitrogen production. A concomitant reduction in the faecal 
Veillonellaceae content was also observed (179). Abundance of Veillonellaceae in faeces 
and colonic mucosa of cirrhotic patients were confirmed in other studies and correlate with 
the presence of HE and MHE (56,180). Veillonellaceae reduction could be explained by its 
symbiotic relationship with taxa such as Streptococcaceae, which are reduced by 
rifaximin. Indeed the main Streptococcaceae end-product of metabolism is lactate, the 
major fermentative substrate for Veillonellaceae.  
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Very recently, Kang and co-workers (172) considered different potential effects of 
rifaximin in GF mice humanized with faeces from MHE patients. Specifically they 
measured the effect of rifaximin on intestinal ammonia and amino-acid metabolism, 
intestinal barrier function, dysbiosis, and systemic inflammatory milieu. Their aim was to 
determine if these activities were dependent upon modulation of the gut microbiota (172). 
An increase in the relative abundance of the families Porphyromonadaceae and a decrease 
in Erysipelothriceae was observed in the rifaximin-treated humanized mouse group. 
Moreover, rifaximin profoundly reduced the elevated serum endotoxin after humanization. 
Concomitantly the addition of rifaximin significantly reduced BA deconjugation and 7α 
de-hydroxylation in the humanized mice, resulting in conjugated BAs, secondary BAs, and 
the secondary/primary BA ratio being significantly lower after rifaximin therapy (172). It 
also improved the systemic and intestinal inflammatory cytokines e.g. IL-6 and IL-8 and 
increased cecal amino acids related to the urea cycle in the humanized mice. Rifaximin 
was also able to act on intestinal ammonia generation in the absence of the intestinal 
microbiota, via suppression of small-bowel glutaminase (172).  
Overall, the studies to date available support a mode of action of rifaximin in 
ameliorating HE that involves modulation of bacterial metabolic function rather than 
reduction in overall or relative bacterial abundance. In a prospective randomized placebo 
study on 120 cirrhotic subjects, Sharma and co-workers investigated the synergistic effects 
of rifaximin and lactulose treatment on patients with OHE. The combined therapy was 
more effective than lactulose alone in complete resolution of HE (76% and 44% 
respectively). Furthermore rifaximin plus lactulose was able to reduce mortality after 
treatment and hospital stay compared to lactulose alone (Sharma et al., 2013). The impact 
of rifaximin plus lactulose treatment on the mucosal microbiota composition was also 
studied. The combination of the two significantly decreased the abundance of Roseburia, 
Blautia and Veillonellaceae and concomitantly increased Propionibacterium with respect 
to lactulose alone (Bajaj et al., 2012b). A previous similar study in 54 subjects with 
episodic HE revealed that the combination of lactulose and rifaximin was more effective in 
improving cognition and decreasing ammonia levels than either single treatment (181). 
These data reveal the potential of combined or synergistic strategies to improve treatment 
efficacies by acting at different physiological levels (182). 
 
1.4.3 VSL#3 
Probiotics represent an attractive therapeutic option among the potential treatment 
strategies in HE. As defined by the Food and Agriculture Organization and the World 
Health Organization, probiotics are “live microorganisms which when administered in 
adequate amounts confer a health benefit on the host” (183). Well tolerated even in 
cirrhotic patients (184), probiotics exert their efficacious effects by three suggested 
mechanisms: i) ammonia reduction in the portal blood (decreasing bacterial urease activity, 
intestinal permeability, ammonia absorption by lowering pH and improving nutritional 
status of the gut epithelium); ii) inflammation and oxidative stress reduction in the 
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hepatocytes; iii) reduced uptake of other toxins such as indoles, oxindoles, phenols and 
mercaptans (185–187). In general probiotics should possess specific traits such as 
resistance acidic pH, hydrochloric acid, and pancreatic juice; be able to tolerate stomach 
and duodenum conditions and gastric transport; and have the ability to stimulate the 
immune system thereby improving intestinal function by adhering to or colonizing the 
intestinal epithelium (188). The most utilized probiotics include strains of lactic acid 
producing bacilli (i.e. Lactobacillus and Bifidobacterium), nonpathogenic strains of E. coli 
(i.e. E. coli Nissle 1917), Clostridium butyricum, Streptococcus salivarius, nonpathogenic 
strain of yeast (i.e. Saccharomyces boulardii) and mixture of strains like VSL#3, which 
consists of a mixture of eight different probiotic strains - Streptococcus salivarius subp. 
thermophilus, Bifidobacterium breve, B. longum, B. infantis, Lactobacillus acidophilus, L. 
plantarum, L. paracasei, and L. bulgaricus (189,190). A meta-analysis on 9 intervention 
studies for a total of 120 subjects provided support for the efficacy of different probiotics - 
including among others VSL#3 (191,192) and Lb. rhamnosus GG (50)   in the 
improvement of MHE symptoms and prophylaxis of OHE (193). In general RCTs 
comparing probiotics with no intervention or placebo in patients with HE showed that 
probiotics appear to reduce plasma ammonia concentrations, endotoxemia levels and 
improve MHE compared to patients treated with placebo or no intervention (50,72,193–
196). In particular, Mittal and colleagues (197) reported reversal of MHE in 35% of 
patients treated with VSL#3 together with a decrease in arterial ammonia levels (197).  
VSL#3 has been used with promising results in various GI diseases including 
Crohn’s disease, IBS and ulcerative colitis (198–201). Feeding studies show a significant 
increase in faecal population of lactobacilli, bifidobacteria and S. thermophilus, without 
significant relative change in abundance of other bacterial group including faecal 
potentially pathogenic taxa like Bacteroides spp., coliforms, clostridia and enterococci 
(202). VSL#3 has been shown to have an effect in the inflammatory response, particularly 
inducing IL-10 in both human isolated lamina propria mononuclear cells and blood-
derived dendritic cells and inhibiting the generation of proinflammatory T helper (Th)-1 
cells via diminished levels of IL-12. This effect was suggested to derive specifically from 
the bifidobacteria species present in VSL#3 (203). Moreover this probiotic mixture appears 
to exert a beneficial effect on intestinal epithelial cells by reducing inflammation by 
inhibition of (NF)-κB activity and increasing heat shock protein (204) inducing expression 
of mucins (205), increasing transepithelial resistance upon pathogen challenge, stabilizing 
tight junction and reducing pathogen induced cell death (206). Available data suggest the 
protective effect of VSL#3 may be mediated by the DNA isolated from the bacteria rather 
than by their metabolic activity.  In fact, systemic and oral administration of VSL#3 DNA 
ameliorates inflammatory responses by inhibiting colonic IFNγ secretion in mouse colons 
or systemic release of TNFα in response to E. coli DNA infection (207,208). Of 
consequence, VSL#3 could act on diminishing the systemic inflammation observed in 
chronic liver diseases. VSL#3 contains also Bile Salt Hydrolase-active bacterial species of 
Lactobacillus and Bifidobacterium. In mice colonization of gut microbiota with VSL#3 
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increased BA deconjugation and faecal excretion. This process is associated with increased 
hepatic BA neosynthesis and biliary output via repression of the enterohepatic FXR/Fgf15 
axis (209). Indeed, VSL#3 treatment could restore the deficit in bile acid excretion seen in 
cirrhotic patients and limiting the overgrowth of pro-inflammatory members of the 
microbiota (57,146). Moreover, in a cirrhotic rat model, VSL#3 appeared to prevent 
endothelial dysfunction in the mesenteric artery (210) and reduce bacterial translocation, 
pro-inflammatory state and increase tight junction integrity (210–212), thus reducing the 
endotoxemia characterizing cirrhosis and HE diseases. 
In patients with cirrhosis and decompensated cirrhosis, VSL#3 treatment was 
associated with improved hepatic and systemic haemodynamics as well as portal 
hypertension (213–215) thus improving MHE symptoms. An open-labeled RCT study 
involving 160 patients investigated the preventive effects of probiotic intervention in 
patients with liver cirrhosis, who had not experienced OHE (216). Patients who received 
VSL#3 were less likely to develop OHE compared to patients with no intervention, 
indicating that the probiotic could be effective in preventing OHE (216). The results also 
indicated that VSL#3 treatment was effective in reducing SIBO (216). The use of VSL#3 
as secondary prophylaxis in HE was investigated also by Dhiman and colleagues in a RCT 
(192). Patients who had experienced and completely recovered from an episode of OHE 
where treated daily with VSL#3 for 6 months or a placebo. The VSL#3 treated group 
showed significant reduction in hospitalization over a 6-month period, a reduction in 
breakthrough episodes of encephalopathy, a reduction in inflammatory markers and an 
improvement in liver function (192). 
The efficacy of VSL#3 in ameliorating MHE symptoms has been compared to that 
of lactulose in a RCT trial performed on 120 MHE patients. Improvement in 
neuropsychiatric tests associated with a reduction in serum ammonia level was evidenced 
in the probiotic treated group compared to control and lactulose treated patients (217). 
Despite different evidence exist on the positive effects of VSL#3 administration in 
ameliorating HE symptoms as reduction of inflammation and ammonia levels, its effect in 
restoring the gut dysbiosis seen in HE remain to be elucidated. 
 
1.5 Conclusion 
 Given the emergent evidence that the gut microbiota plays a key role in human 
health and disease, there is currently great interest in manipulating its make up towards a 
potentially more beneficial composition or metabolic output (218–222). Restoring a 
compromised microbiota has been shown to ameliorate different disease symptoms and 
complications, including in severe advanced liver diseases such as cirrhosis and HE. 
Attempts have been made to increase beneficial bacterial groups such as Bifidobacterium 
and Lactobacillus that are perceived as exerting health-promoting properties as well as to 
be non-urease-producing bacteria (149,223,224). There is a substantial lack of information 
on changes and modulation of Bifidibacterium taxa during HE and during treatment of HE. 
Moreover despite a bifidogenetic activity of lactulose (152,225–231), most of the clinical 
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trials and studies about the use of disaccharide in HE have focused on the clinical 
outcomes such as cognition, metabolites and inflammation milieu (75,153,232) and few 
have focused on gut microbiota composition. The effect of a synbiotic preparation has 
been evaluated in a study involving 55 MHE patients receiving combination of probiotic 
(Pediacoccus pentoseceus 5-33:3, Leuconostoc mesenteroides 32-77:1, Lactobacillus 
paracasei subspecies paracasei 19 and Lb. plantarum 2592) and a fermentable fibre 
mixture (β-glucan, inulin, pectin, and resistant starch) (233). The authors reported a 
decrease in arterial ammonia level, endotoxemia, and reversal of MHE in 50% of patients 
upon symbiotic treatment. Cirrhotic patients with MHE were also found a significant 
faecal overgrowth of potentially pathogenic E. coli and Staphylococcus species. Symbiotic 
treatment significantly increased the faecal content of non-urease-producing lactobacilli at 
the expense of these other bacterial species. Such modulation of the gut microbiota was 
associated with a signiﬁcant reduction in blood ammonia levels and reversal of MHE in 
50% of patients (233). 
Up to now, the gut dysbiotic microbiota is considered the primary player for 
generating ammonia and intoxicating the host during a liver disease. Its modification in 
terms of microbial ecology and population structure has been until now considered as first 
line of intervention in HE. However, increasing evidence underlines that reducing the 
inflammatory burden in HE may be efficacious as well. Therefore, novel 
pharmacotherapeutic strategies targeting the evolution of bacterial translocation, 
endotoxemia and immune dysfunction should be taken into serious consideration. More 
studies are needed focusing the gut microbiota, using pre-, pro- or synbiotics 
administration, or selective gut decontamination with non-absorbable, non-toxic 
antibiotics, or faecal microbiota transplantation (179,233,234).  
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 Gut microorganisms may play a fundamental role in the pathogenesis and 
progression of liver disease and pathology. Alteration within microbiota composition and 
production of toxic compounds often coincide with liver pathology and may play an 
aetiological role. In particular, gut ammonia production from amino acid fermentation has 
been implicated in Hepatic Encephalopathy (HE), with a consequent strong impact on 
neuropsychiatric symptoms. Despite apparent clinical efficacy of prebiotics (lactulose), 
antibiotics (rifaximin) and probiotics (VSL#3) to ameliorate HE mental and cognitive 
status by reducing ammonia levels, little is known about the dynamics, interactions and 
responsible for metabolite production within the cirrhotic gut microbiota. We investigated 
how lactulose, rifaximin or VSL#3 effect gut microbial composition, ammonia and SCFA 
production using in vitro pH controlled batch cultures using faecal samples from 10 
cirrhotic patients. Changes in the microbiota structure were observed at different 
taxonomic levels under the different test, with a particularly large increase in bifidobacteria 
beneficial group in lactulose fermentation. Presence of the prebiotic was also associated 
with acetate, propionate and butyrate production, and reduced concentration of ammonia. 
Further investigations are needed to associate the metabolic activity to microbial 
population changes and cross-talk. However, the results emphasize the importance 
prebiotic fermentation in shifting metabolisms of the cirrhotic microbiota towards SCFA 
production while reducing ammonia level. 
 
2.1 Introduction 
Recent studies have described a fundamental role for gut microbiota in the 
pathogenesis of liver diseases such as alcoholic liver disease (ALD), non-alcoholic fatty 
liver disease (NAFLD) and liver cirrhosis as well as their complications such as hepatic 
encephalopathy (HE) (1). An alteration gut microbiota composition or dysbiosis is a 
characteristic of all these diseases. Small intestinal bacterial overgrowth, increased 
intestinal permeability, alteration in mucosal and systemic immunity, and production of 
toxic compounds are common disease characteristics related to the intestinal microbiota in 
liver disease (2). Mechanistically, higher gastric pH and reduced bile acid concentration in 
the colon of liver disease patients may lead to lack of control of intestinal microbiota and 
bacterial overgrowth. As a consequence break-down of the intestinal barrier may occur 
leading to bacteria (or bacterial components) translocating to the liver, systemic 
inflammation, and increasing the risk of liver disease decompensation and altered brain 
function (2–9). 
Microbiota analysis of patients affected by liver cirrhosis has shown decreased 
relative abundance of Bacteroidetes in favour of increased relative abundance of 
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Fusobacteria and Proteobacteria (11–14). In particular, increased Enterobacteriaceae, 
Streptococcaceae and Veillonellaceae abundance in cirrhotic patients has been reported 
compared with healthy subjects, whereas Lachnospiraceae, Ruminococcaceae, Blautia, 
Clostridium clusters XI and XIVab, lactic acid bacteria, Bifidobacterium and 
Faecalibacterium prausnitzii seem to be present at lower levels (10,11,13,15–18). Such a 
modification of the gut microbiota would be consistent with a shift away from 
carbohydrate or fibre fermentation and increased protein or aminoacid metabolism. 
Additionally, due to a reduced concentration of bile acids, an overgrowth of pathogenic 
and pro-inflammatory members of the microbiota including Porphyromonadaceae and 
Enterobacteriaceae has been observed (19). It is known that a decrease in bile acid 
production is associated with a modulation of bacterial taxa normally involved in short 
chain fatty acid (SCFA) production and strengthening the integrity of the gut barrier (20–
22). In these conditions, it is plausible that aberrant microbiota profiles could be 
deleterious to the intestinal mucosa, with consequent increase in systemic endotoxin (LPS) 
exposure due to the disruption of the epithelial tight junctions and imbalance of intestinal 
cell apoptosis (23). A compromised intestinal barrier can consequently lead to 
physiological effects such as hepatic and systemic inflammation and portal hypertension 
via immune activation (24,25). 
Modified homeostasis in advanced liver disease and cirrhosis may impact on brain 
function, with the consequent onset of HE. Considered as a typical example of 
gut:liver:brain axis disruption, HE is defined by a spectrum of neurocognitive impairments 
ranging from minimal (MHE) to overt HE (OHE) with a strong impact on health-related 
quality of life (26–28). HE is characterized by a complex pathogenesis, although ammonia 
and other gut microbiota by-products such as indoles, and/or oxindoles and unresolved 
systemic inflammation to play role in disease onset (29–32). Ammonia is primarily 
generated in the intestine mainly from the break-down of urea by urease of colonic bacteria 
and during amino acid fermentation in the colon (33–35). Normally ammonia is 
metabolized to urea in the liver but in presence of severe liver disease, it escapes hepatic 
detoxification and reaches systemic circulation and the brain, altering cellular functions, 
metabolism, neurotransmission, and inducing brain oedema and astrocyte swelling 
(31,32,36–39). To decrease the production and intestinal absorption of ammonia, current 
HE clinical treatment is mainly based on manipulating the gut microbiota using prebiotics, 
antibiotics and probiotics (40,41). The prebiotic lactulose (4-O-β-d-galactopyranosyl-d-
fructose) represents the first line intervention, as it lowers the colonic pH as result of 
production of SCFA by bacterial fermentation promoting a reduction of survival of urease-
producing bacteria such as Klebsiella spp. and Proteus spp., and facilitating the growth of 
acid resistant, non-urease-producing species, as lactobacilli and bifidobacteria. Similarly, 
by providing a readily fermentable source of carbohydrate, lactulose in effect switches off 
amino acid fermentation and thus ammonia production. Prebiotic or lactulose treatment 
reduces colonic ammonia production and absorption, but also facilitates the elimination of 
nitrogen compounds and ammonia via microbial biomass which is then excreted (42). The 
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non-absorbable antibiotic rifaximin, has also been used to improve cognitive function in 
HE and also to prevent the development of spontaneous bacterial peritonitis and 
endotoxemia (and portal hypertension) in minimal HE (43). It also improves 
hemodynamics in cirrhotics (44). Probiotics have been utilized as adjuvant therapies for 
liver diseases for their putative abilities to suppress pathogenic bacteria, improve intestinal 
barrier function, modulate the immune system, and reduce intestinal pain perception (45–
50). Moreover several probiotic studies in experimental animal models, and in a limited 
number of human studies in HE patients, have shown that probiotics may improve 
cognitive function and reduce stress and depression (51). Probiotic treatment in patients 
with decompensated cirrhosis and HE has been shown to reduce serum ammonia levels 
and endotoxemia and improve various neurocognitive tests and mental status 
(10,52,14,53–56). Commonly used as a second line intervention in HE, the probiotic 
VSL#3 (B. longum, B. infantis, B. breve, L. acidophilus, L. casei, L. delbrueckii ssp. 
bulgaricus, L. plantarum and Streptococcus salivarious ssp. thermophilus) has been 
demonstrated to be effective in preventing HE in patient with cirrhosis, to significantly 
reduce the level of arterial ammonia, small intestinal bacterial overgrowht and orocaecal 
transit time together with increased psychometric HE scores compared to placebo (57). 
Cirrhotic patients who received VSL#3 were less likely to develop overt HE indicating that 
the probiotic might be effective in preventing the worsening of the disease (58).  
Despite the effectiveness of these therapeutic approaches in ameliorating the 
clinical symptoms, a clear association between the positive effect on the brain and a 
modulation of gut microbiota is still missing. Thus, the aim of this study was to investigate 
the modulation of gut microbiota, in terms of microbial populations and metabolism, upon 
fermentation of lactulose, rifaximin and VSL#3 using in vitro anaerobic pH-controlled 
batch cultures inoculated with faecal microbiota of cirrhotic patients or healthy subjects. 
Gut microbiota phylogenetic composition was measured using 16S rRNA gene community 
sequencing (V3-V4 region, Illumina) and selected populations enumerated using FISH. 
Ammonia and SCFA production over 24 hours fermentation was used to assess the impact 
of lactulose, rifaximin and VSL#3 and their combination on gut microbiota metabolic 
output. 
 
2.2 Material and methods 
2.2.1 Reagents 
All media constituents were purchased from Oxoid Ltd. (Basingstoke, UK) and 
Sigma Aldrich (Milan, Italy), chemicals were purchased from Sigma Aldrich (Milan, 
Italy). VSL#3 (sachet boxes package) was kindly provided by Ferring (Milan, Italy). 
 
2.2.2 Patients enrollment  
We recruited 10 patients with clinical diagnosis of cirrhosis (median age 62, range 
55-69) and 3 healthy subjects (median age 61, range 60-63) to provide faecal samples as 
inoculum. All subjects of this study were under their habitual diet and no antibiotics, 
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probiotics or prebiotics have been taken in the 3 months prior the beginning of the 
intervention. The study was approved by the institutional review board of the APSS 
Ospedale Santa Chiara (Trento, Italy), and all enrolled subjects gave written informed 
consent in accordance with the sampling protocol approved by the local Ethical Committee 
(study ID 45175518, approval N.6/2013). The characteristics of the cirrhotic population is 
summarized in Table 1. 
 
Table 1. Characteristics of the cirrhotic population 
 All patients (n=10) 
Age [years; median (range)] 62 (55-59) 
Male [n(%)] 9 (90%) 
Child-Pugh  
  Child-Pugh A 9 (90%) 
  Child-Pugh B 1 (10%) 
MELD score [median (range)] 8 (7-14) 
Aetiology [n(%)]  
    Alcoholic cirrhosis 4 (40%) 
    Non Alcoholic Steatohepatitis, NASH 5 (50%) 
    Autoimmune cirrhosis 1 (10%)  
 
2.2.3 Faecal batch cultures 
 Faecal fermentations were conducted using the basal nutrient medium prepared as 
follow (per litre): 2 g Peptone (Oxoid), 2 g Yeast extract (Oxoid), 2 g NaHCO3 (Oxoid), 2 
ml Tween 80 (AppliChem) 0.5 g Bile Salts (Oxoid), 0.1 g NaCl (Fisher Scientific), 0.04 g 
K2HPO4 (BDH), 0.04 g KH2PO4 (BDH), 0.01 g MgSO4 7H20 (BDH), 0.01 g CaCl2 6H2O 
(Fluka), 2 ml Tween 80 (Sigma), 0.005 g Hemin (Sigma) dissolved in 1 ml of 1 M NaOH 
(Fisher Scientific), 10 µl Vitamin K (Sigma), 0.5 g L-Cysteine HCl (Sigma), and 1 ml of 
Resazurin (Sigma) (0.1 g/100ml). For each volunteer eight batch fermenters were run in 
parallel, filled with sterile pre-reduced PY broth and inoculated with 20 ml of 10% (w/v) 
faecal slurry up to a total volume of 200 ml. Slurries were prepared by homogenizing 
faeces in anoxic 1X PBS (pH 7.2). Anaerobic conditions were maintained by O2-free N2 
(15 ml/min) flow overnight. Temperature was held at 37°C using a circulating water bath, 
and pH was controlled between 6.8 and 7.2 using an automated pH FerMac 260 controller 
(Gloucester, England-GL208JH, United Kingdom), which added acid and alkali as 
required (0.5 M HCl and 0.5 M NaOH). One gram of VSL#3 sachets content (4.5x1011 live 
bacteria total), was suspended in 10 ml of anoxic PBS (pH 7.2) and cells microscopically 
counted with Petroff chamber. Inoculum was obtained by washing in anoxic PBS (pH 7.2) 
(centrifugation 4000 rpm for 7 min 3 times at 4°C each) before inoculation. The 
experimental conditions were as follows: vessel 1 contained only faecal inoculum 
(control); vessel 2 1% (w/v) lactulose; vessel 3 616 µg/ml of rifaximin; vessel 4 1% (w/v) 
lactulose and 616 µg/ml of rifaximin; vessel 5 VSL#3 (initial cell density 108cell/ml); 
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vessel 6 1% (w/v) lactulose and VSL#3 (initial cell density 108 cell/ml); vessel 7 616 
µg/ml of rifaximin and VSL#3 (initial cell density 108cell/ml); vessel 8, 1% (w/v) 
lactulose, VSL#3 (initial cell density 108 cell/ml) and 616 µg/ml rifaximin. Each 
fermentation was conducted once with faecal inoculum from each of the faecal donors (n = 
13). Batch cultures were run for 24 hours and samples obtained from each vessel at 0, 5, 
10, 24 h, were centrifuged at 18000 rcf, where the supernatants and pellets were stored at -
80 °C for metabolomics and metagenomics analysis respectively.  
 
2.2.4 DNA extraction, PCR amplification of the V3-V5 region of bacterial 16S rDNA  
 Total DNA extraction from faecal samples (250 mg, wet weight) was performed 
using the FastDNA™ SPIN Kit for Feces (MP Biomedicals, Santa Ana, CA, USA) 
following manufacturer’s instructions. DNA integrity and quality were checked on 1 % 
agarose gel TAE 1X and quantified with a NanoDrop® spectrophotometer. Samples were 
subjected to PCR amplification, Using the specific bacterial primer set 341F (5’ 
CCTACGGGNGGCWGCAG 3’) (59) and 806R (5’ GACTACNVGGGTWTCTAATCC 
3’) (60) with overhang Illumina adapters targeting a ~460 bp fragment of the 16S rRNA 
variable region V3-V4. PCR amplification of each sample, was carried out using 25 µl 
reactions with 0.2 µM of each primer. In particular 12.5 µl of 2x KAPA HiFi HotStart 
ReadyMix, 5 µl forward primer, 5 µl reverse primer, were used in combination with 2.5 µl 
of template DNA (5 ng/ul). All PCR amplification was carried out, using a GeneAmp PCR 
System 9700 (Thermo Fisher Scientific) and the following steps: melting step – 95°C for 3 
minutes (one cycle); annealing step – 95 °C for 30 seconds, 55 °C for 30 seconds, 72 °C 
for 30 seconds (25 cycles); extension step – 72 °C for 5 minutes (1 cycle). The PCR 
products were checked on 1.5 % agarose gel and cleaned from free primers and primer 
dimer, using the Agencourt AMPure XP system (Beckman Coulter, Brea, CA, USA), 
following the manufacturer’s instructions. Subsequently, dual indices and Illumina 
sequencing adapters Nextera XT Index Primer (Illumina), were attached by 7 cycles PCR 
(16S Metagenomic Sequencing Library Preparation, Illumina). The final libraries, after 
purification by the Agencourt AMPure XP system (Beckman), were analyzed on a 
Typestation 2200 platform (Agilent Technologies, Santa Clara, CA, USA) and quantified 
using the Quant-IT PicoGreen dsDNA assay kit (Thermo Fisher Scientific). Finally, all the 
libraries were pooled in an equimolar way, in a final amplicon library and analysed on the 
Typestation 2200 platform. Barcoded libraries were sequenced on an llumina® MiSeq 
(PE300) platform (MiSeq Control Software 2.0.5 and Real-Time Analysis software 
1.16.18). 
 
2.2.5 Metataxonomic data analysis  
 The sequences were assigned to samples, according to sample-specific barcodes. 
Raw data submission to European Nucleotide Archive is pending. Reads were processed 
using the QIIME pipeline (61), where open reference operational taxonomic unit (OTU) 
picking was performed using usearch (62). Alpha (within-sample richness) and beta-
	 50 
diversity (between-sample dissimilarity) estimates were computed using the phyloseq R 
package (63). Permutational MANOVA (PERMANOVA) was performed on the UniFrac 
distances and Bray-Curtis dissimilarity using the adonis function of the vegan R package 
with 999 permutations, and p-values were corrected using the Bonferroni correction. The 
non-parametric Wilcoxon rank-sum test was used for the comparison of relative 
abundances of microbial taxa between groups, and the resulting p-values were corrected 
for multiple testing controlling the false discovery rate (64) at all taxonomic levels taken 
into account. Starting from a table of OTUs, we obtained the final output from 
metagenome prediction as an annotated table of predicted gene family counts for each 
sample. All statistical analyses were performed using R (R: A language and environment 
for statistical computing, https://www.r-project.org/). 
 
2.2.6 Fluorescence In Situ Hybridization-Flow Cytometry (FISH-FCM)  
 Sample fixing and hybridization were performed as previously described (65,66). 
Genus-specific 16S rRNA gene oligonucleotide probes labelled with the fluorescent dye 
Cy5 (Sigma Aldrich, Italy) were utilized for selected bacterial group, the nucleic acid stain 
2-[N-(3-dimethylaminopropyl)-N-propylamino]-4-[2,3-dihydro-3-methyl-(benzo-1,3-
thiazol-2-yl)-methylidene]-1-phenyl-quinolinium - SYBR Green I - (Sigma Aldrich, Italy), 
for total cell counts. The probes used were as follows: Bif 164, specific for 
Bifidobacterium (67), Bac 303, specific for the Bacteroides and Prevotella group (68), 
Chis 150 for the Clostridium histolyticum subgroup (69), Lab 158 for Lactobacillus and 
Enterococcus (70), Fpra 655 for Fecalibacterium prausnitzii (71), Enterobac D for 
Enterobacteriaceae (72) and DSV 687 for Desulfovibrionales and Desulfomonales (73). 
Probes sequences and their respective hybridization temperatures were previously 
described (65). In 96 well plate, 10µl of fixed suspension was mixed into 190 µl of PBS 
(0.01 M phosphate buffer, 0.0027 M potassium chloride and 0.137 M sodium chloride, pH 
7.2) and centrifuged at 1700 rcf for 15 min at 4°C. After one wash in Tris–EDTA buffer 
(100 mM Tris– HCl, 50 mM EDTA, pH8) when requested, pellets were suspended in Tris–
EDTA buffer containing 1 mg/ml of lysozyme (Sigma Aldrich, Italy) and incubated for 10 
min at room temperature. Cells were washed in PBS (pH 7.2) to remove lysozyme and 
were suspended in the hybridization solution (900 mM NaCl, 20 mM Tris–HCl, pH 8.0, 
0.01% Sodium Dodecyl Sulfate, formamide as requested) containing 5ng/µl of specific 
probes, for a total volume of 55µl. The hybridization step was performed overnight at the 
appropriate labelled probe temperature. Following hybridization, a volume of 145µl of 
hybridization solution was added in each well, and cells were pelleted at 1700 rcf for 15 
min, at 4°C. Nonspecific binding of the probe was removed by incubating the bacterial cell 
suspension at 50°C for 20 minutes in 200 µl of a washing solution (64 mM NaCl, 20 mM 
Tris–HCl, pH 8.0). Cells were suspended in 50 µl of PBS (pH 7.2) containing 1X SYBR 
Green I and incubated at room temperature for 10 minutes. Following hybridization, a 
volume of 150 µl of PBS (pH 7.2) was added to each well, and cells were centrifuged at 
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1700 rcf for 15 minutes at 4°C. Final pellet was resuspended in 100 µl of PBS (pH 7.2) and 
subsequently analyzed.  
 
2.2.7 Data acquisition by flow cytometry (FCM)  
 The acquisition threshold was set in the side scatter channel using a Guava 
easyCyte 8T flow cytometer (Merck-Millipore, Italy). For each sample, a total of 10000 
events were acquired. Analyses were made using the inCyte software (Merck-Millipore, 
Italy). Cy5- positive cells have been enumerated on SYBR green gated cells. The 
proportion of positive cells was corrected by eliminating background fluorescence.  
 
2.2.8 Ammonia measurement 
 Ammonia concentration was spectrophotometric measured using a commercially 
available assay (Sigma Ammonia Assay Kit, Sigma-Aldrich, Milan, Italy), following the 
manufacturer instruction.  
 
2.2.9 SCFAs analysis 
 Upon defrosting, 1 ml batch culture samples were centrifuged at 13.000g for 5 
min. Supernatants were filtered using a 0.2-µm polycarbonate syringe filter and acidified 
by the addition of one volume of 6 M HCl to three volumes of sample. After 10 min 
incubation at room temperature, samples were centrifuged at 13.000g for 5 min. One 
volume of 10 mM 2-ethylbutyric acid was added to four volumes of sample as internal 
standard. Calibration was done using standard solutions of acetate, propionate, butyrate, 
isobutyrate, 2-methyl-butyrate (2-MeBut), valerate and isovalerate in acidified water (pH 
2). Standard solutions containing 50, 20, 10, 5, 1 and 0.5 mM of each external standard 
were used. Analysis was performed using a TRACE™ Ultra Gas Chromatograph (Thermo 
Scientific, Waltham, MA, USA) coupled to a TSQ Quantum GC mass spectrometric 
detector (Thermo Scientific, Waltham, MA, USA). SCFAs were separated using a Restek 
Stabilwax-DA (30 m×0.25 mm; 0.25-µm film thickness) (Restek corp., Bellafonte, PA, 
USA). The injected sample volume was 1 µl in split mode with a ratio of 10:1. The initial 
oven temperature was at 90 °C and maintained for 0.5 minutes and increased 20 
°C/minutes to 240 °C. The carrier gas helium was delivered at a flow rate of 1 ml min−1. 
The temperatures of the inlet, transfer line and electron impact (EI) ion source were set at 
280, 250 and 250 °C, respectively. The electron energy was 70 eV, and the mass spectral 
data was collected in a full scan mode (m/z 30–200).   
 
2.2.10 Statistical analysis 
 For ammonia, SCFA and FISH-FCM analysis, Kruskal Wallis test with post hoc 
comparison was used to compare differences between the effect of a particular treatment 
and the control (no treatment) at each specific time points or among the different 
treatments. The level of significance was set at p<0.05. For metagenomic data statistical 
analysis, please refer to paragraph 2.5. 
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2.3 Results  
2.3.1 Microbiota community structure with faecal inoculum taken from cirrhotic 
patients and healthy subjects 
 We used in vitro anaerobic pH-controlled faecal batch cultures to assess the 
dynamics and evolution of bacterial populations of cirrhotic patients (hereinafter termed 
CP) in response to different treatments. The effects of the administration of the prebiotic 
lactulose, the antibiotic rifaximin and the probiotic VSL#3 and their combinations were 
determined over 24 hours, sampling at four different time points: at time of inoculation 
(T0) and after 5 (T5), 10 (T10) and 24 hours (T24). In parallel the same treatments were 
performed on healthy faecal samples (hereinafter termed HS). We characterized bacterial 
microbiota community structure associated with the different treatments using high-
throughput sequencing of the V3-V4 region of the 16S rRNA gene.  
We first quantified the bacterial richness within each sample (alpha-diversity) of 
the two groups, CP and HS at baseline (T0). Three different alpha-diversity estimators 
were used, namely the observed number of OTUs, the Chao1 index and the Shannon 
entropy index. Since our patients cohorts included different aetiologies leading to cirrhosis 
we also determined those alpha-diversity estimators considering three different CP 
subgroups: NASH (n=5), alcoholic cirrhosis (ALC, n=4) and autoimmune cirrhosis (AI, 
n=1) to exclude differences intrinsic to the pathology in determining a diverse microbiota 
in the CP group. No statistically difference was observed between CP and HS microbiota 
nor CP subgroups and HS (Figure S1, Table S1). 
 To identify possible differences between the bacterial components of the faecal 
microbiota of CP subjects vs. HS, we calculated the beta-diversity using the Unweighted 
and Weighted UniFrac distances and the Bray-Curtis dissimilarity (Table S2). The 
Principal Coordinates Analysis (PCoA) based on these measures revealed that the gut 
microbiota of CP subjects was different with respect to HS, however, no statistically 
significant differences have been found between HS and the three different CP subgroups 
according to aetiologies (Table S2). We next analysed which taxa, at phylum, family and 
order levels, were differentially represented in CP vs. HS at the baseline (T0) (Figure 1 and 
Table A1, Appendix A). At the phylum level the most abundant taxa were: Firmicutes 
(median relative abundance, CP 55%, HS 55.9%), Bacteroidetes (CP 37.07%, HS 34.83%), 
Actinobacteria (CP 3.35%, HS 2.87%) and Proteobacteria (CP 1.41%, HS 1.68%). At the 
order level, Clostridiales (CP 39.09%, HS 41.21%) Bacteroidales (CP 37.14%, HS 
35.16%), Bifidobacteriales (CP 2.54%, HS 2.55%) and Lactobacillales (CP 17.94%, HS 
4.49%) were the most abudant. Moving to the family level, we found: Bacteroidaceae (CP 
25.74%, HS 27.43%), Lachnospiraceae (CP 19.05%, HS 18.3%), Ruminococcaceae (CP 
14.31%, HS 17.94%) and Streptococcaceae (CP 11.8%, HS 2,74%). Similar levels were 
present in the CP subgroups according to the aetiologies (Figure 1).  
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Figure 1. Representation of the most abundant bacterial phylum (A), order (B) and family (C) in 
Healthy subjects (HS), Cirrhotic patients (CP) and CP subgroups at the baseline. Median relative 
abundances expressed in percentage are presented. ALC, alcohol cirrhosis, AI, autoimmune 
cirrhosis, NASH, non-alcoholic steatohepatisis   
 
 Despite a trend towards an increase in Lactobacillales and Streptococcaceae in the 
CP, this observation was not supported statistically. However, we found that CP subjects 
presented a statistically significant higher abundance of Actinomycetales (mean relative 
abundance, CP 0.025%, HS 0.01%, p=0.04) and lower Desulfovibrionales (median relative 
abundance, CP 0.19%, HS 0.61%, p=0.03) and Desulfovibrionaceae (median relative 
abundance, CP 0.20%, HS 0.63%, p=0.009) compared to HS. We quantified the bacterial 
richness within each sample of the two groups CP and HS for each test fermentation at 
each time point. No statistically significant difference was observed comparing CP and HS 
microbiota during the different fermentations (Table A2, Appendix A). To identify 
possible differences between the bacterial components of the faecal microbiota of CP 
subjects vs. HS, we calculated the beta-diversity at the different time points. The Principal 
Coordinates Analysis (PCoA) based on these measures revealed that the gut microbiota of 




CP subjects was distinct from those of the HS at T24 but only when VSL#3 was associated 
with Lactulose (Unweighted UniFrac p = 0.05, Weighted UniFrac p ≤ 0.05, Bray-Curtis p 
≤ 0.05, PERMANOVA test) (Table A2, Appendix A). We next analyzed which taxa were 
differentially represented in CP vs. HS comparing them at the different time points for 
each fermentation condition. No statistically significant differences were observed when 
comparing the relative taxonomic abundances of CP and HS at the Phylum and Genus 
levels (Table A3-A18, Appendix A).  
 
2.3.2 Cirrhotic microbiota change over time with respect to healthy microbiota 
 To understand how the cirrhotic and healthy microbiota is modulated over time, 
alpha and beta-diversity indices were examined longitudinally, i.e for each condition tested 
from T0 to T24. No significant change in microbiota composition was obtained for HS 
(Table S3 and S4), while evidence of a time-associated microbial dynamics, both in terms 
of richness and diversity, was observed in CP especially in absence of any treatment 
(control, ctrl) and upon treatment with lactulose + rifaximin (LR), VSL#3 + rifaximin 
(VR) and VSL#3 + lactulose and rifaximin (VLR) (Figure 2A, 2B and 3A, 3B, Table S5 
and S6). These changes occurred at the later time points, mainly at T24, suggesting that at 
least ten hours are needed to observe a change in the microbiota upon probiotic, prebiotic 





Figure 2A. Measure of bacterial diversity. Alpha-diversity calculated on the number of observed 
OTUs, the Chao1 index and the Shannon entropy index, for CP subjects, overtime for each 
condition considered: ctrl (control), Lactulose, Lactulose+Rifaximin, Rifaximin. *p-value≤0.05, 
**p-value ≤0.01. The body of the box plot represents the first and third quartiles of the distribution 
and the median. The whiskers extend from the quartiles to the last datapoint within 1.5× IQR with 
































































































































Figure 2B. Measure of bacterial diversity. Alpha-diversity calculated on the number of observed 
OTUs, the Chao1 index and the Shannon entropy index, for CP subjects, overtime for each 
condition considered: VSL#3, VSL#3+Lactulose, VSL#3+Lactulose+Rifaximin, 
VSL#3+Rifaximin. *p-value≤0.05, **p-value ≤0.01. The body of the box plot represents the first 
and third quartiles of the distribution and the median. The whiskers extend from the quartiles to the 























































































































Figure 3A. PCoA plots of bacterial beta-diversity based on the Weighted UniFrac distance 
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Figure 3B. PCoA plots of bacterial beta-diversity based on the Weighted UniFrac distance 
according to treatments in CP subjects over time: VSL#3, VSL#3+Lactulose, 
VSL#3+Lactulose+Rifaximin, VSL#3+Rifaximin. 
 
 We next analysed the relative abundance over time at the order, family, and genus 
levels (Figure 4, Table 1 and 2, Tables A3-A18 in Appendix A). Several order and family 
taxa are affected by the treatment over time, changing mainly after 10 and 24 hours with 
respect to the baseline (Table 1). Analysis of taxa abundance at genus level showed that 
Bilophila abundance increased over the 24 hours of treatment with the prebiotic, the 
probiotic and the antibiotic alone or combination (VL) (Table 2). In the presence of 
VLS#3, we found also an increased abundance of Oscillospira, while 24 hour-lactulose 
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Figure 4. Representation of the most abundant bacterial phylum over time in CP (A) and HS (B) 
microbiota. Mean relative abundance expressed in percentage at the genus level are presented. 
Bacterial taxa with an abundance lower than 0.1 are included in the Others group. ctrl, Control; LR, 
Lactulose+Rifaximin; R, Rifaximin; V, VSL#3; VL, VSL#3+Lactulose; VLR, 

























Table 1. Bacterial order and family relative abundances (expressed in %) which were significantly 
different (corrected p < 0.05; Wilcoxon rank-sum test) between the different treatments along time 
(T0, T5, T10 T24) within the cirrhotic environment. 
 
 
Lactulose T0 (%) T24 (%)  
p-
value T5 (%) T24 (%) 
p-
value    














8 0.02    
Coriobacteriales 0.84±0.65 3.51±4.26 0.04 3.55±4.04 3.51±4.26 -    





0.05±0.11 0.028    
          
VSL#3 + Lactulose T0 (%) T24 (%) 
p-
value T10 (%) T24 (%) 
p-









0.03    
Coriobacteriales 0.78±0.40 1.39±1.44 0.13 2.33±2,46 1.39±1.44 0.03    
Erysipelotrichales 1.50±1.61 4.17±6.15 0.14 8.47±9.13 4.17±6.15 0.03    





-    
          
Rifaximin T0 (%) T24 (%) p-value T5 (%) T24 (%) 
p-






































6.69±8.05 0.018 6.64±9.4 6.69±8.05 - 
Desulfovribionaceae 0.25±0.25 5.45±3.10 - 0.96±0.82 5.45±3.10 0.049 2.84±1,62 5.45±3.10 0.04
2 
          
Lactulose + Rifaximin T0 (%) T24 (%) p-value T5 (%) T24 (%) 
p-



















Bifidobacteriales 2.57±2.2 5.64±12.37 0.004 2.89±3.06 
5.64±12.3
7 0.018 3,41±6.37 
5.64±12.3
7 0.04 
Clostridiales 39.22±12. 18.96±9.7 0.000 26.77±10. 18.96±9.7 0.005 31.89±19. 18.96±9.7 0.01
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Table 2. Bacterial genera relative abundances (%) which were significantly different (corrected p < 
0.05; Wilcoxon rank-sum test) between the different treatments along time (T0, T5, T10, T24) 
within the cirrhotic environment. 
 
Lactulose  T0 % T24 %  p-value 
Bilophila 0.11 ± 0.12  1.94  ± 1.38 0.03 
Blautia 5.34  ± 2.61 5.85 ± 4.89 0.01 
Faecalibacterium 4.46 ± 2.80 1.49 ± 1.51 0.01 
Odoribacter 0.25 ± 0.22 0.17 ± 0.10 0.01 
Parabacteroides 1.80 ± 1.69 2.90 ± 2.35 0.04 
Roseburia 1.97 ± 2.46 0.09 ± 0.12 0.01 
    
VSL#3 + Lactulose T0 % T24 % p-value 
Bilophila 0.22 ± 0.12 2.33 ± 1.27 0.02 
    
VSL#3 + Lactulose T5 % T24 % p-value 
Bilophila 0.21 ± 0.21 2.33 ± 1.27 0.01 
    
Rifaximin T0 % T24% p-value 
Bilophila 0.15 ± 0.10 8.35 ± 5.11 0.04 
    
VSL#3 T0 % T24% p-value 
Bilophila 0.12 ± 0.09 2.43 ± 1.49 0.04 




2.3.3 Cirrhotic microbiota respond differently to the different treatments  
 We next estimated for both CP and HS populations whether the different 
treatments affected the microbiota composition in a specific manner. We analysed the data 
in a cross-sectional manner, by comparing the different treatments ability to modulate the 
microbiota at each time point of the batch culture experiments. No differences among the 
treatments were observed in HS in terms of bacterial richness and diversity (Tables S25 
and S26). In CP microbiota alpha-diversity estimators showed some differences between 
the treatments after 24 hours (T24) (Figure 5, for the complete list of p-value, refer to 
Table S4). Also the beta-diversity analysis conducted at each time point evidenced 
differences in the CP microbiota composition at T10 (Bray-Curtis p = 0.027) and T24 
(Weighted UniFrac p = 0.002, Bray-Curtis p = 0.001) (Table S5). This indicated that the 





Figure 5. Measure of bacterial diversity at T24 within each test fermentation. Alpha-diversity 
calculated on the number of observed OTUs, the Chao1 index and the Shannon entropy index, for 
CP subjects, between the conditions considered.  *p-value≤0.05, **p-value ≤0.01. The body of the 
box plot represents the first and third quartiles of the distribution and the median. The whiskers 
extend from the quartiles to the last datapoint within 1.5× IQR with outliers beyond represented as 
dots. 
 
 Although the Bray-Curtis index found a different microbial composition at T10, no 
phylum, order, family or genus showed significant changes between one condition and 
another, suggesting that at T10 the treatments induced different alterations in the 
microbiota from different patients that are probably not consistent among subjects. 
Nevertheless at T24, rifaximin (R) and its combination with lactulose (LR) and both 
lactulose and VSL#3 (VLR) were able to reduce the relative abundance of some bacterial 
taxa, which were more abundant in the control, i.e absence of any treatment. In particular, 
we found differently represented: between ctrl and R, the order Coriobacteriales and 
Erysipelotrichales; the family Bacteroidaceae, Coriobacteriaceae, Erysipelotrichaceae, 




































































and Coprococcus; between ctrl and LR, the order Coriobacteriales and Erysipelotrichales; 
the family Bacteroidaceae, Coriobacteriaceae, Erysipelotrichaceae, Lachnospiraceae, and 
Veillonellaceae, as well as the genera Blautia Butyricimonas, Collinisella Coprococcus, 
and Odoribacter; between ctrl and VLR, the order Coriobacteriales and Erysipelotrichales; 
the family Coriobacteriaceae, Lachnospiraceae, and Veillonellaceae, as well as the genera 
Blautia, Collinisella, Coprococcus and Odoribacter (Table 3, Tables A3-A10 in Appendix 
A). 
 
Table 3. Bacterial taxa which relative abundances (expressed as percentage) were significantly 
different (p < 0.05; Wilcoxon rank-sum test) at T24 in the cirrhotic environment upon the different 
treatments. ctrl, no treatment; R, rifaximin; LR, lactulose + rifaximin; VLR, VSL#3 + lactulose + 
rifaximin.  
 
order ctrl (%) LR (%)  p-value 
Clostridiales 31.32±10.82  31.80±6.46  0.001 
Coriobacteriales 1.09±0.79  0.47±0.22 0.0003 
Erysipelotrichales 8,00±11.88 31.01±0.70 0.0002 
     
 ctrl (%) VLR (%)  p-value 
Clostridiales 31.32±10.82   21.80±3.71  0.026 
Coriobacteriales 1.09±0.79  0.26±0.09  0.007 
Erysipelotrichales 8.00±11.88  18.24±15.88  0.010 
     
 ctrl (%)  R (%)  p-value 
Clostridiales 31.32±10.82  32.17±13.17  0.013 
Coriobacteriales 1.09±0.79  0.78±0.44  0.0008 
Erysipelotrichales 8.00±11.88   30.55±3.89  0.013 
    
family ctrl (%)   LR (%)  p-value 
Bacteroidaceae  24.09 ± 9.84  8.83 ± 11.28  0.040 
Coriobacteriaceae  1.94 ± 1.67  0.28 ± 0.19  0.0003 
Erysipelotrichaceae  4.48 ± 7.80  40.19 ± 4.81  0.0001 
Lachnospiraceae  18.72 ± 4.71  6.50 ± 2.66  0.00004 
Porphyromonadaceae  1.87 ± 1.29  0.98 ± 2.93  0.031 
Rikenellaceae  1.68 ± 1.32  0.11 ± 0.13  0.043 
S24-7  0.67 ± 1.49  0.001 ± 0.003  0.0027 
Veillonellaceae  4.91 ± 3.93  0.58 ± 0.48  0.0003 
     
 ctrl (%)  VLR (%)  p-value 
Coriobacteriaceae  1.94 ± 1.67   0.70 ± 0.62  0.004 
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Lachnospiraceae  18.72 ± 4.71  10.26 ± 4.86  0.002 
Veillonellaceae  4.91 ± 3.93   1.68 ± 1.12  0.004 
     
 ctrl (%)  R (%)  p-value 
Coriobacteriaceae  1.94 ± 1.67  0.19 ± 0.19  0.0007 
Erysipelotrichaceae  4.48 ± 7.80  34.95 ± 19.26  0.013 
Lachnospiraceae  18.72 ± 4.71  6.02 ± 3.49  0.0004 
Veillonellaceae 4.91 ± 3.93   0.37 ± 0.35  0.004 
 
genera ctrl (%) LR (%)  p-value 
Blautia 4.69  ± 2.32 1.70  ± 1.26 0.004 
Butyricimonas 0.16 ± 0.21 0.018 ± 0.034 0.04 
Collinsella 2.04 ± 2.26 0.34 ± 2.38 0.0017 
Coproccoccus 4.30 ± 2.60 0.73 ± 0.55 0.0007 
Finegoldia 0.02 ± 0.02 0.00 ± 0.00 0.0341 
Odoribacter 0.19 ± 0.18 0.04 ± 0.06 0.004 
     
 ctrl (%) VLR (%)  p-value 
Blautia 4.69 ± 2.32 1.26 ± 0.99 0.03 
Collinsella 2.04 ± 2.26 0.18 ± 0.25 0.04 
Coproccoccus 4.30 ± 2.60 0.64 ± 0.57 0.002 
Odoribacter 0.19 ± 0.18 0.05 ± 0.07 0.004 
     
 ctrl (%) R (%)  p-value 
Collinsella 2.04 ± 2.86 0.49 ± 0.80 0.04 
Coproccoccus 4.3 ± 2.6 1.96  ± 2.59 0.002 
 
 We next looked at the most abundant genera considering both the time course and 
the potential effect of the treatments with respect to the control. The expression of the 
mean relative abundance as a log fold change, with respect to T0, allowed us to appreciate 
the genera impacted by the different fermentation condition (Figure S2). As already 
observed, over the 24 hours both control and the different treatments lead to an increase in 
Bilophila and a concomitant decrease of Roseburia, Lachnospira and Blautia. However, a 
specific pattern of modulation was also observed for other genera. Holdemania was 
increased only upon treatments containing rifaximin. As shown before, Collinisella 
appeared to decrease compared to the control when rifaximin and its combination with 
lactulose (LR) or VSL#3 (VLR) were fermented. Compared to control, Parabacteroides 
tended to decrease over time in the lactulose + rifaximin (LR) fermentation and by VSL#3 
and its combination with the prebiotic (VL) and the antibiotic (VR, VLR). Interestingly 
already at 5 hours of VLR treatment Veillonella seemed to be reduced with respect to the 
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control. Bifidobacterium tended to increase when lactulose alone or VL combination was 
administered. 
 
2.3.4 Modulation of bacterial composition after treatment  
 We used fluorescent in situ hybridization coupled with flow cytometry 
(FISH/FCM) to accurately enumerate different bacterial species and genera. In HS all the 
treatments, except lactulose, seem to have had little affect on microbial population levels, 
as shown by the lack of statistically significant variation amongst the treatments. Lactulose 
showed a small increase in bifidobacteria (data not shown). Differently, CP subjects 
responded dynamically to the different conditions tested (Figure 6A and B). For the 
majority of subjects, the use of lactulose or its association with the probiotic resulted in 
increased numbers of Bifidobacterium spp. especially at T10 and T24. A small but 
significant decrease in the population levels of Enterobacteria was also observed in 




Figure 6A. Bacteria cells enumeration through FISH/FCM, at times 0, 5, 10, and 24 (median-
max/min, N = 10) for CP subjects. *p-value≤0.05, **p-value ≤0.01, ***p-value ≤0.001, paired t-
test, treatment vs ctrl. ctrl, control; L, Lactulose R, rifaximin; LR, Lactulose + Rifaximin; V, 
VSL#3; VL, VSL#3+Lactulose; VR, VSL#3+Rifaximin; VLR, VSL#3 + lactulose + rifaximin. For 
the different FISH tested, percentage of positive cells were calculated on gated total bacterial cells. 
 











































































Figure 6B. Bacteria cells enumeration through FISH/FCM, at times 0, 5, 10, and 24 (median-
max/min, N = 10) for CP subjects. *p-value≤0.05, **p-value ≤0.01, ***p-value ≤0.001, paired t-
test, treatment vs ctrl. ctrl, control; L, Lactulose R, rifaximin; LR, Lactulose + Rifaximin; V, 
VSL#3; VL, VSL#3+Lactulose; VR, VSL#3+Rifaximin; VLR, VSL#3 + lactulose + rifaximin. For 
the different FISH tested, percentage of positive cells were calculated on gated total bacterial cells. 
 
2.3.5 Modulation of microbial ammonia production 
We next investigated if the cirrhotic microbiota modulation by lactulose, rifaximin 
and VSL#3 treatments induced modifications in the ammonia (NH3) concentrations 
produced by the microbiota (Table S9). As reported in Figure 7, absence of treatment 
showed an increase of the ammonia concentration in a time dependent manner, underlying 
how the absence of any treatment resulted in a prevalence of ammoniagenic metabolism or 
ammonia production probably from urea and protein present within the basal medium or 
inoculum. After microbiota modulatory treatment, NH3 was particularly reduced at T10, 
especially when lactulose was combined with rifaximin and VSL#3. Over 24 hours, NH3 
removal was retained when lactulose was combined with rifaximin. 
  




















































Figure 7. Ammonia level concentration assessed by colorimetric method on the batch culture 
fermentation supernatant, for each time point considered (median-max/min, N =10, in triplicates) in 
CP subjects. *p-value≤0.05, paired t-test, treatment vs ctrl. ctrl, control; L, Lactulose R, rifaximin; 
LR, Lactulose + Rifaximin; V, VSL#3; VL, VSL#3+Lactulose; VR, VSL#3+Rifaximin; VLR, 
VSL#3 + lactulose + rifaximin. 
 
2.3.6 Modulation of microbial SCFA production 
 Since SCFAs are important for colonic health and may act on neuronal physiology 
(74–76), we measured the faecal content of SCFAs in our samples by means of GC-MS 
(Table S10, Figure 8 and Figure S3). We observed that the different treatments induced 
different SCFA profiles. In general all the treatments determined an increase of SCFA 
during the 24 h-fermentation period. In particular, acetate content increased over time with 
respect to the control condition, particularly upon lactulose administration and when the 
prebiotic was associated with the VSL3 and/or rifaximin after 10 and 24 hours. With 
respect to the time 0, proprionate and butyrate increased when lactulose was administered 
alone or in combination with VSL#3. Isobutyrate and valerate tented to decrease 
significantly after 10 hours especially when rifaximin was in combination with lactulose 
and/or VSL#3 (Figure S3). No significant modification was observed for isovalerate/2-
metyl butyrate (Figure S3).  
 
2.4 Discussion 
 It is now well recognized that chronic liver diseases such as NAFLD, alcoholic 
steatohepatitis, NASH and cirrhosis and their extrahepatic complications such as HE, are 
characterized by gut microbiota dysbiosis, together with alterations in intestinal motility, 
increased gastric pH and reduced bile acid concentrations in the colon (77–79). Indeed, 
current clinical treatments are based on manipulation of the gut microbiota, with the 
principal aim of reducing the production and intestinal absorption of ammonia (41).  
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Figure 8. SFCA production at times 0, 5, 10, 24 for Acetate, Propionate and Butyrate (median-
max/min, N = 10) in CP subjects. *p-value≤0.05, **p-value ≤0.01, ***p-value ≤0.001, paired t-test, 
treatment vs ctrl. ctrl, control; L, Lactulose R, rifaximin; LR, Lactulose + Rifaximin; V, VSL#3; 
VL, VSL#3+Lactulose; VR, VSL#3+Rifaximin; VLR, VSL#3 + lactulose + rifaximin. 




















































































In this study, we made use of anaerobic pH controlled in vitro batch cultures of faecal 
microbiota from HS and CP to evaluate the modulatory effect of lactulose, VSL#3 and the 
antibiotic rifaximin. The study was conducted both cross-sectionally – comparing the 
microbiota response of cirrhotic patients and healthy subjects to treatments at the same 
time point – and longitudinally, observing the microbiota modulating effect of the pre-, 
pro- and antibiotic administration over time. Since it has been previously shown that the 
intestinal microenvironment of cirrhotic subjects without HE is closer to that of healthy 
subjects (18) it is not surprising that the analysis did not reveal a clear dysbiosis within the 
microbiota of our cirrhotic patients compared to the healthy subjects at baseline. A trend 
towards higher relative abundance in Streptococcaceae could be observed in cirrhotic 
patients in line with previous observations (17,80), although this difference was not 
statistically significant. Indeed, we found that CP presented a statistically significant higher 
abundance of Actinomycetales lower Desulfovibrionales and Desulfovibrionaceae 
compared to HS. The different aetiologies showed a similar profile, except autoimmune 
cirrhosis, although this may be due to the fact that there was only one autoimmune CP 
donor albeit with multiple technical replicates (n = 8). When we moved to specifically 
characterize the effects of the prebiotic, the probiotic and the antibiotic on the cirrhotic 
faecal microbiota, we observed a significant increase in the relative abundance of the 
genus Bilophila. Bilophila is an intestinal bile resistant pathobiont belonging to the 
Proteobacteria phylum, which is highly represented in NAFLD with respect to healthy 
group (81,82). However, its overgrowth was potentially due to the bile salt concentration 
present in the media used for the batch cultures. Increased relative abundance of Bilophila 
was also observed in the control fermentation in which no probiotic, prebiotic or antibiotic 
was added (Figure S2). Moreover, we observed, independently by the treatment, an 
increase over time of Erysipelotrichaceae. This bacterial family has been shown to be 
abundant in choline deficiency-induced fatty liver disease (83), which causes multiple 
organ dysfunctions. Choline is an important component of our diet, and recently, it was 
found that choline and phospatidylcholine are converted by the intestinal microbiota to 
trimethylamine, which is further metabolized to proatherogenic trimethylamine-N-oxide, 
linking diet and microbiota to cardiovascular disease (84,85). It seems that the different 
treatments herein used have no effect in reducing the abundance of this taxa within the 
cirrhotic environment.  
Consistent with previous reports the most abundant genera retrieved from the CP 
microbiota in this study were Roseburia, Blautia, Fecalibacterium, Bifidobacterium, 
Streptococcus, Sutterella, Ruminococcus, Parabacteroides and Lachnospira (3,10,86,87). 
Data showed that the prebiotic, probiotic not antibiotic and their combinations did not 
change the overall composition of the CP microbiota, but did seem to provide minimal 
changes on microbiota. In general, however, the different treatments appeared to promote a 
small reduction of Bacteroidales (Figure 3, Table 3). Increased Bacteroidaceae has been 
shown as an hallmark of dysbiosis of liver disease (14). 
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 Beyond its bactericidal/bacteriostatic, immuno-modulating and anti-inflammatory 
activities, a little is known about rifaximin interaction with the gut microbiota (88–92), 
despite its effect in reducing the risk of HE recurrence and hospitalization rate (93–99). In 
a previous study rifaximin was shown to induce only a moderate change in the faecal 
microbiota in HE patients, with a modest reduction of Veillonellaceae abundance and an 
increase in Eubacteraceae (43). In our study, after the 24 hours fermentation, rifaximin or 
its association with lactulose or lactulose plus VSL#3 significantly decreased the 
abundance of Clostridiales, Lachnospiraceae, Vellonellaceae and at genus level, Blautia 
abundance in agreement with a previous study on the mucosal microbiota composition of 
HE patients supplemented with rifaximin plus lactulose (3). Moreover, rifaximin alone and 
in combination with lactulose was able to significantly reduce Streptococcaceae relative 
abundance and concomitantly increase Fusobacteriaceae and Bifidobacteriales (Table 3). 
As mentioned before, Streptococcaceae were found overabundant in cirrhotic and MHE 
patients (17) and associated with poor cognitive performance (3). Furthermore, in response 
to rifaximin we observed a decrease of Collinsella with respect to the control (Table 4). 
Collinsella has been recently shown, together with other Firmicutes, such as 
Faecalibacterium, and Coprobacillus o be highly represented in mice with NAFLD 
induced by a high fat diet (100). Indeed, its reduction might be positive in reversing this 
disease.  
 The use of VSL#3 in the treatment of HE to date has given contradictory results. In 
one study, VSL#3 was used to treat cirrhotic patients in a randomized controlled trial and 
proved effective in preventing  HE (11). However, in a second double-blind placebo-
controlled study, its supplementation did not show beneficial effects on portal hypertension 
or decreased hepatic synthetic function (101). Furthermore, a direct link between the 
ability of VSL#3 to modulate the gut microbiota and amelioration of chronic liver diseases 
is still missing. Here, we showed that VSL#3 supplementation resulted in an increase in 
the relative abundance of Oscillospira bacteria after 24 hours of batch culture 
fermentation. Little is known about the role of this bacterial genus within the intestinal 
tract. However, Oscillospira was found positively associated with leanness (102) and 
reduced in paediatric NASH patients (103). Moreover, a recent study found Oscillospira 
enriched in rats with a lower risk to develop NAFLD (104). 
 Lactulose has been proven to reduce colonic pH by production of SCFA upon 
bacterial fermentation, to induce an environment that is both hostile to the survival of 
urease-producing gut bacteria and facilitates the growth of acid resistant, non-urease-
producing species, such as lactobacilli and bifidobacteria. Moreover, the acidification of 
colonic environment reduces the absorption of ammonia by nonionic diffusion (42). The 
16S rRNA community sequencing revealed the ability of lactulose to modulate the gut 
microbiota in synergy with rifaximin. Moreover, bacterial enumeration by FISH/FCM 
indicated that the use of lactulose with or without the probiotic VSL#3 induced an increase 
in bifidobacteria that could account for the concomitant reduction of ammonia levels. From 
a nutritional point of view, an increased in bifidobacteria has been suggested to enhance 
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immunity, produce vitamins (folate, B complex), inhibit potential pathogens (105–108) 
and produce SCFAs. SCFAs, important modulators of host health acting as neuroactive 
peptides (109), are able to enter the blood and pass the blood brain barrier (110), have anti-
inflammatory effects (111) and modulate epigenetic regulation of gene expression (110). 
SCFA production may also be associated with reduced pH and consequent growth 
inhibition of pathogenic bacteria. Our results indicate that lactulose, alone or in 
combination with the probiotic VSL#3 leads to an increase in the SCFA production. 
Butyrate and acetate are involved in liver lipogenesis and may be involved in regulating 
fatty acid oxidation and glycogen storage. Propionate acts in the liver as a precursors for de 
novo gluconeogenesis. Butyrate increase and butyrate-producing bacteria have been 
suggested to be important in preventing NAFLD and cirrhosis progression (112). 
Moreover, it was shown that an oral supplementation of sodium butyrate protects mice 
from inflammation in the liver and consequent cirrhosis development (113).  
 To summarize, we observed that a prebiotic (lactulose), probiotic (VSL#3) and 
antibiotic (rifaximin) or their combination, commonly used to treat cirrhosis and HE in 
clinical practice induce different changes within the gut microbiota of CP under simulated 
colonic conditions. Although at the community structural level little change was observed, 
lactulose induced a statistically significant increase in relative abundance and absolute 
numbers of bifidobacteria. However, significant changes were observed from different 
treatment at the metabolic level. Lactulose, or lactulose combined with antibiotic or 
antibiotic plus probiotic, consistently lowered ammonia production and increased 
production of SCFA. This shift in metabolite production is indicative of carbohydrate 
fermentation that could also significantly increased consumption or conversion of 
ammonia and other nitrogenous compounds in bacterial biomass. In either case, reduced 
ammonia concentrations and increased concentration of SCFA are consistent with 
improved gut health and reduced risk of HE.  
Several directions of research are opened by this study: on the one hand future 
investigations should assess the molecular pathways that are involved in the modulation of 
gut microbiota and its metabolic reprogramming and on the other hand translational studies 
should assess the clinical potential of these in vitro observation. Moreover, a deep analysis 
of patients’ response to treatment could identify the microbiota profile of responders and 
non responders helping in defining personalized therapies. 
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Figure S1. Measure of bacterial diversity. Alpha-diversity calculated on the number of observed 
OTUs, the Chao1 index and the Shannon entropy index, for CPvs.HS and also respect etiology at 
T0. The body of the box plot represents the first and third quartiles of the distribution and the 
median. The whiskers extend from the quartiles to the last datapoint within 1.5× IQR with outliers 


















































































Figure S2. Log fold change trend for the main genera in CP. Data are represented as mean relative 




































































































































































Figure S3. SFCA production at times 0, 5, 10 and 24 for Isobutyrate, 2-methyl butyl isovalerate and 
Valerate. (median-max/min, N = 10). *p-value≤0.05, **p-value ≤0.01, ***p-value ≤0.001, paired t-
test, treatment vs ctrl. ctrl, control; L, Lactulose R, rifaximin; LR, Lactulose + Rifaximin; V, 
VSL#3; VL, VSL#3+Lactulose; VR, VSL#3+Rifaximin; VLR, VSL#3 + lactulose + rifaximin. 

























































Table S1. Measure of bacterial diversity. Alpha-diversity calculated on the number of observed 
OTUs, the Chao1 index and the Shannon entropy index, for Healthy subjects (HS), Cirrhotic 
patients (CP) and  CP subgroups according to the aetiologies s at the baseline. ALC, alcohol 
cirrhosis, AI, autoimmune cirrhosis, NASH, non-alcoholic stehatosis. 
 
Populations (T0) Metric p-value 
CP vs. HS Observed 0.1437 
 Chao1 0.1709 
 Shannon 0,8440 
HS vs. Ai Observed 0.3457 
 Chao1 0.2873 
 Shannon 0.3205 
HS vs. ALC Observed 0.3457 
 Chao1 0.4229 
 Shannon 0.8502 
HS vs. NASH Observed 0.3457 
 Chao1 0.3200 
 Shannon 0.6897 
Ai vs. ALC Observed 0.3457 
 Chao1 0.2873 
 Shannon 0.2266 
 Ai vs. NASH Observed 0.3457 
 Chao1 0.2873 
 Shannon 0.0681 
ALC vs. NASH Observed 0.7168 
 Chao1 0.6874 
 Shannon 0.6897 
 
 
Table S2. Permutational multivariate analysis of variance (PERMANOVA) tests of the bacterial gut 
microbiota on the unweighted and weighted UniFrac distances and the Bray-Curtis dissimilarity, for 
for Healthy subjects (HS), Cirrhotic patients (CP) and CP subgroups according to the aetiologies s 
at the baseline.  
 
Populations (T0) Metric F R2 p-value 
CP vs. HS Unweighted UniFrac 31.938 0,03036 0,035 
 Weighted UniFrac 14.251 0,01378 0,008 
 Bray-Curtis 26.416 0,02524 0,001 
	 81 
Health status Unweighted UniFrac 0.6254 0.04361 0.896 
 Weighted UniFrac 0.87729 0.06012 0.999 
 Bray-Curtis 0.84347 0.05794 0.881 
 
 
Table S3. Measure of bacterial diversity. Alpha-diversity calculated on the number of observed 
OTUs, the Chao1 index and the Shannon entropy index, for HS subjects, overtime for for each 
condition considered. No statistically significant differences have been found. ctrl, Control; LR, 
Lactulose+Rifaximin; R, Rifaximin; V, VSL#3; VL, VSL#3+Lactulose; VLR, 
VSL#3+Lactulose+Rifaximin; VR, VSL#3+Rifaximin 
 
 	 Time point vs time point 
 	 T0vsT5 T0vsT10 T0vsT24 T5vsT10 T5vsT24 T10vsT24 
Treatment Metric p-value* p-value p-value p-value p-value p-value 
ctrl Observed 1 1 1 1 1 1 
 Chao1 1 1 1 1 1 1 
 Shannon 1 1 1 1 1 1 
L Observed 0.8 0.8 1 0.84 0.84 0.8 
 Chao1 1 0.8 1 1 0.8 0.8 
 Shannon 0.4 0.4 1 0.48 0.4 0.48 
R Observed 1 1 1 1 1 1 
 Chao1 0.7 0.7 0.7 0.7 0.6 0.7 
 Shannon 1 1 1 1 0.6 0.6 
LR Observed 1 0.8 1 0.8 0.8 1 
 Chao1 0.84 0.8 0.84 0.8 0.8 1 
 Shannon 1 0.3 0.3 0.4 0.6 1 
V Observed 0.8 1 1 0.8 1 0.8 
 Chao1 1 1 1 1 1 1 
 Shannon 0.6 0.6 0.6 1 1 0.6 
VL Observed 1 1 1 1 1 1 
 Chao1 1 1 0.8 1 0.8 0.8 
 Shannon 0.7 0.48 0.4 0.48 0.3 0.3 
VR Observed 0.7 0.7 0.7 0.7 0.7 0.7 
 Chao1 1 1 1 1 1 1 
 Shannon 1 1 1 1 1 1 
VLR Observed 1 0.8 0.8 0.8 1 1 
 Chao1 1 0.84 0.84 0.84 0.84 0.84 
 Shannon 1 1 1 1 1 1 





Table S4. Permutational multivariate analysis of variance (PERMANOVA) tests of the bacterial gut 
microbiota on the unweighted and weighted UniFrac distances and the Bray-Curtis dissimilarity, for 
HS subjects, overtime for for each condition considered. No statistically significant differences have 
been found. ctrl, Control; LR, Lactulose+Rifaximin; R, Rifaximin; V, VSL#3; VL, 
VSL#3+Lactulose; VLR, VSL#3+Lactulose+Rifaximin; VR, VSL#3+Rifaximin 
 
Treatment Metric F R2 p-value* 
ctrl Unweighted UniFrac 1 0.2200 0.611 
 Weighted UniFrac 1 0.2603 0.821 
 Bray-Curtis 0.86992 0.2459 0.739 
L Unweighted UniFrac 10083 0.2743 0.488 
 Weighted UniFrac 0.98807 0.2703 0.527 
 Bray-Curtis 11.612 0.3033 0.2 
LR Unweighted UniFrac 0.72497 0.2137 0.857 
 Weighted UniFrac 0.94057 0.2607 0.738 
 Bray-Curtis 1 0.2328 0.807 
R Unweighted UniFrac 16.351 0.3801 0.153 
 Weighted UniFrac 1 0.2681 0.52 
 Bray-Curtis 11.797 0.3067 0.267 
V Unweighted UniFrac 16.753 0.3858 0.127 
 Weighted UniFrac 1 0.2615 0.796 
 Bray-Curtis 10.118 0.2750 0.46 
VL Unweighted UniFrac 11.375 0.2990 0.333 
 Weighted UniFrac 1 0.2504 0.901 
 Bray-Curtis 1 0.2686 0.506 
VR Unweighted UniFrac 1 0.2353 0.52 
 Weighted UniFrac 1 0.2424 0.99 
 Bray-Curtis 1 0.1947 0.973 
VLR Unweighted UniFrac 10858 0.2893 0.378 
 Weighted UniFrac 0.94017 0.2606 0.715 
 Bray-Curtis 1 0.2137 0.802 




Table S5. Measure of bacterial diversity. Alpha-diversity calculated on the number of observed 
OTUs, the Chao1 index and the Shannon entropy index, for CP subjects, overtime for each 
condition considered. Significant differences are reported in italic. ctrl, Control; LR, 
Lactulose+Rifaximin; R, Rifaximin; V, VSL#3; VL, VSL#3+Lactulose; VLR, 
VSL#3+Lactulose+Rifaximin; VR, VSL#3+Rifaximin 
 
  Time point vs time point 
  T0vsT5 T0vsT10 T0vsT24 T5vsT10 T5vsT24 T10vsT24 
Treatment Metric p-value* p-value p-value p-value p-value p-value 
ctrl Observed 0.4359 0.0006 0.0006 0.0030 0.0058 0.4232 
 Chao1 0.7394 0.0012 0.0030 0.0030 0.0220 0.2611 
 Shannon 0.9705 0.3806 0.9551 0.3806 0.9551 0.3806 
L Observed 0.7054 0.5290 0.5290 0.5290 0.7054 0.5290 
 Chao1 0.7219 0.7219 0.7394 0.7219 0.7394 0.7219 
 Shannon 0.6346 0.4294 0.9118 0.6346 0.4351 0.4294 
R Observed 0.6842 0.3712 0.0881 0.6346 0.3712 0.2258 
 Chao1 0.7394 0.7394 0.0690 0.7394 0.4949 0.2258 
 Shannon 0.4198 0.5230 0.2102 0.9705 0.2102 0.2102 
LR Observed 0.2855 0.1278 0.0035 0.5204 0.1127 0.4132 
 Chao1 0.2460 0.3263 0.0102 0.6842 0.0339 0.3688 
 Shannon 0.1784 0.3358 0.0011 0.6305 0.0173 0.2427 
V Observed 0.6945 0.6945 0.6945 0.6945 1.0000 0.6945 
 Chao1 0.7566 0.7566 0.7566 0.7566 0.9705 0.7566 
 Shannon 0.5775 0.2460 0.6842 0.4198 0.2460 0.2460 
VL Observed 0.1049 0.1049 0.1049 0.9705 0.9705 0.9705 
 Chao1 0.0865 0.0865 0.0865 0.9705 0.9705 0.9705 
 Shannon 0.3146 0.3310 0.3310 0.5775 0.5290 0.8534 
VR Observed 0.6842 0.1890 0.3310 0.1890 0.4198 0.5394 
 Chao1 0.4813 0.0945 0.0019 0.3358 0.0045 0.0465 
 Shannon 0.7394 0.5230 0.0032 0.5230 0.0019 0.0371 
VLR Observed 0.1718 0.0532 0.0019 0.4359 0.0022 0.0294 
 Chao1 0.7959 0.0864 0.2863 0.0864 0.3263 0.7959 
 Shannon 0.8534 0.8534 0.8534 0.8534 0.8534 0.8534 




Table S6. Permutational multivariate analysis of variance (PERMANOVA) tests of the bacterial gut 
microbiota on the unweighted and weighted UniFrac distances and the Bray-Curtis dissimilarity, for 
CP subjects, overtime for for each condition considered. Significant differences are reported in 
italic. ctrl, Control; LR, Lactulose+Rifaximin; R, Rifaximin; V, VSL#3; VL, VSL#3+Lactulose; 
VLR, VSL#3+Lactulose+Rifaximin; VR, VSL#3+Rifaximin 
 
Treatment Metric F R2 p-value* 
ctrl Unweighted UniFrac 1 0.0647 0.569 
 Weighted UniFrac 10835 0.0822 0.11 
 Bray-Curtis 1.604 0.1179 0.006 
L Unweighted UniFrac 0.6035 0.0478 0.847 
 Weighted UniFrac 0.9742 0.0759 0.589 
 Bray-Curtis 11.486 0.0873 0.206 
R Unweighted UniFrac 0.5995 0.0475 0.811 
 Weighted UniFrac 0.9971 0.0767 0.469 
 Bray-Curtis 12.248 0.0926 0.126 
LR Unweighted UniFrac 17.325 0.1261 0.1 
 Weighted UniFrac 12.642 0.0953 0.001 
 Bray-Curtis 23.195 0.1619 0.002 
V Unweighted UniFrac 13.939 0.1040 0.156 
 Weighted UniFrac 10.461 0.0801 0.265 
 Bray-Curtis 13.392 0.1003 0.053 
VL Unweighted UniFrac 16.076 0.1181 0.12 
 Weighted UniFrac 10.931 0.0834 0.071 
 Bray-Curtis 12.101 0.0916 0.144 
VR Unweighted UniFrac 1 0.0441 0.889 
 Weighted UniFrac 1.238 0.0935 0.003 
 Bray-Curtis 1.908 0.1371 0.001 
VLR Unweighted UniFrac 0.6122 0.0485 0.784 
 Weighted UniFrac 0.9952 0.0765 0.489 
 Bray-Curtis 11.052 0.0843 0.261 




Table S7. Measure of bacterial diversity. Alpha-diversity calculated on the number of observed 
OTUs, the Chao1 index and the Shannon entropy index, for CP subjects, between considered 
treatments. Significant values are reported in italic. ctrl, Control; LR, Lactulose+Rifaximin; R, 
Rifaximin; V, VSL#3; VL, VSL#3+Lactulose; VLR, VSL#3+Lactulose+Rifaximin; VR, 
VSL#3+Rifaximin 
 
 	 Time point 
 	 T0 T5 T10 T24 
Treatment vs treatment Metric p-value* p-value p-value p-value 
ctrl vs L Observed 0.9579 0.8095 0.8466 0.6474 
 Chao1 0.9808 0.6245 0.8626 0.5224 
 Shannon 0.9456 0.9872 0.9705 0.8914 
ctrl vs R Observed 0.9579 0.9337 0.2180 0.9456 
 Chao1 0.9808 0.9558 0.1916 0.6170 
 Shannon 0.9456 0.9872 0.7337 0.1505 
ctrl vs LR Observed 0.9579 0.8095 0.8626 0.2911 
 Chao1 0.9808 0.6245 0.7596 0.0738 
 Shannon 0.9456 0.6769 0.9292 0.0014 
ctrl vs V Observed 0.9579 0.8095 0.9456 10 
 Chao1 0.9808 0.9558 0.9705 0.8254 
 Shannon 0.9456 0.9872 0.9003 0.9705 
ctrl vs VL Observed 0.9579 0.8095 0.4305 0.6474 
 Chao1 0.9808 0.6888 0.5010 0.6170 
 Shannon 0.9456 0.6769 0.9705 0.8025 
ctrl vs VR Observed 0.9579 0.8095 0.8626 0.9456 
 Chao1 0.9808 0.6245 0.8626 0.6170 
 Shannon 0.9456 0.6769 0.8710 0.5188 
ctrl vs VLR Observed 0.9579 0.8095 0.8229 0.0291 
 Chao1 0.9808 0.6245 0.7596 0.0292 
 Shannon 0.8326 0.6769 0.9705 0.0014 
ctrl vs R Observed 0.9579 0.9337 0.6092 0.6474 
 Chao1 0.9808 0.9558 0.7596 0.5512 
 Shannon 0.9456 0.6769 0.7337 0.0932 
L vs LR Observed 0.9579 0.9337 0.8626 0.0843 
 Chao1 0.9808 0.9558 0.8626 0.0689 
 Shannon 0.9456 0.9872 0.9705 0.0027 
L vs V Observed 1 1 0.8626 0.7404 
 Chao1 1 0.9558 0.8626 0.6170 
 Shannon 0.9456 10 0.7337 0.9705 
L vs VL Observed 1 1 0.6092 0.9286 
 Chao1 1 0.9558 0.6769 0.6170 
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 Shannon 0.9456 1 0.9705 0.6114 
L vs VR Observed 1 1 0.8626 0.6474 
 Chao1 1 0.9705 0.8626 0.3310 
 Shannon 0.9456 1 0.7337 0.6738 
L vs VLR Observed 0.9858 0.9337 0.8626 0.0136 
 Chao1 1 0.9558 0.9191 0.0292 
 Shannon 0.8703 1 0.9705 0.0014 
R vs LR Observed 1 0.9337 0.2180 0.3082 
 Chao1 1 0.9558 0.5010 0.1052 
 Shannon 0.9456 0.6769 0.7337 0.0014 
R vs V Observed 0.9579 0.9337 0.4205 0.9456 
 Chao1 0.9808 0.9558 0.4906 0.9118 
 Shannon 0.9456 0.9872 0.7337 0.5188 
R vs VL Observed 0.9579 0.9337 0.2422 0.6780 
 Chao1 1 0.9558 0.2482 0.6170 
 Shannon 0.9456 0.6769 0.7337 0.4061 
R vs VR Observed 0.9579 0.9337 0.2180 0.9286 
 Chao1 0.9808 0.9558 0.2482 0.6170 
 Shannon 0.9456 0.6769 0.7337 0.9705 
R vs VLR Observed 0.9579 0.9337 0.2180 0.0291 
 Chao1 0.9808 0.9558 0.2482 0.0383 
 Shannon 0.8326 0.6769 0.7337 0.0027 
LR vs V Observed 0.9579 10 0.9456 0.4333 
 Chao1 0.9808 0.9558 0.8626 0.1370 
 Shannon 0.9456 0.9872 0.7337 0.0020 
LR vs VL Observed 0.9579 0.9337 0.8626 0.1989 
 Chao1 1 0.9558 0.9705 0.1052 
 Shannon 0.8703 	 0.9705 0.0066 
LR vs VR Observed 0.9579 0.9337 0.8626 0.6474 
 Chao1 0.9808 0.9558 0.8626 0.2608 
 Shannon 0.9456 1 0.9705 0.0027 
LR vs VLR Observed 0.9579 0.9337 1 0.1578 
 Chao1 0.9808 0.9558 0.8626 0.2426 
 Shannon 0.8703 1 0.9579 0.8914 
V vs VL Observed 0.9579 1 0.8018 0.9286 
 Chao1 0.9808 0.9558 0.7596 0.8254 
 Shannon 0.9456 1 0.7337 0.7051 
V vs VR Observed 1 0.9337 0.9456 0.9286 
 Chao1 1 0.9558 0.8914 0.6482 
 Shannon 0.9705 1 0.7337 0.6738 
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V vs VLR Observed 	 0.9337 0.8626 0.0291 
 Chao1 1 0.9705 0.8626 0.0363 
 Shannon 0.9456 1 0.7337 0.0018 
VL vs VR Observed 0.9579 1 0.3512 0.7404 
 Chao1 0.9808 0.9558 0.4214 0.6170 
 Shannon 0.9456 1 0.7337 0.8914 
VL vs VLR Observed 0.9579 0.9337 0.8626 0.0291 
 Chao1 0.9808 0.9558 0.8626 0.0364 
 Shannon 0.4113 1 0.8710 0.0027 
VR vs VLR Observed 1 0.9337 0.8626 0.0319 
 Chao1 1 0.9705 0.8626 0.0536 
 Shannon 0.8703 1 0.7337 0.0027 
*FDR corrected p-values 
 
 
Table S8. Permutational multivariate analysis of variance (PERMANOVA) tests of the bacterial gut 
microbiota on the unweighted and weighted UniFrac distances and the Bray-Curtis dissimilarity, for 
CP subjects, between the considered treatments. Significant valies are reported in italic. ctrl, 
Control; LR, Lactulose+Rifaximin; R, Rifaximin; V, VSL#3; VL, VSL#3+Lactulose; VLR, 
VSL#3+Lactulose+Rifaximin; VR, VSL#3+Rifaximin 
 
Time point Metric F R2 p-value* 
T0 Unweighted UniFrac 0 0.04422 0.981 
 Weighted UniFrac 0.87846 0.07869 0.995 
 Bray-Curtis 1 0.07683 0.841 
T5 Unweighted UniFrac 0.5284 0.04886 0.961 
 Weighted UniFrac 0.9216 0.08223 0.974 
 Bray-Curtis 0.87487 0.07839 0.827 
T10 Unweighted UniFrac 0.7031 0.06398 0.843 
 Weighted UniFrac 10.158 0.08988 0.33 
 Bray-Curtis 12.745 0.11025 0.027 
T24 Unweighted UniFrac 1.063 0.09367 0.389 
 Weighted UniFrac 1.185 0.10331 0.002 
 Bray-Curtis 17.686 0.14672 0.001 




Table S9. Ammonia level in CP batch cultures. Values are presented as median values (µg/ml). ctrl, 
control; LR, Lactulose+Rifaximin; R, Rifaximin; V, VSL#3; VL, VSL#3+Lactulose; VLR, 
VSL#3+Lactulose+Rifaximin; VR, VSL#3+Rifaximin	
 Time points 
Treatment 0 5 10 24 
ctrl 14.58 79.84 113.26 139.06 
L 19.90 74.92 65.59 104.62 
L+R 23.32 81.99 71.17 73.10 
R 22.08 82.43 82.10 126.27 
V 18.37 122.88 78.93 149.52 
V+L 20.04 64.72 59.62 108.67 
V+L+R 16.11 83.09 57.50** 59.95 
V+R 24.49 100.47 88.70* 140.70 
 
 
Table S10. SCFA content in CP batch cultures. The different SCFAs are presented as median 
values (µmol/g). ctrl, Control; LR, Lactulose+Rifaximin; R, Rifaximin; V, VSL#3; VL, 



















ctrl 0 2.53  0.56 0.11 0.41 0.03 0.03 3.68  
	
5 15.38 2.01 0.12 1.45 0.08 0.39 19.44 
	
10 20.54 2.37 0.17 2.05 0.16 1.08 26.37 
	
24 21.08 3.07 0.30 2.62 0.45 1.45 28.97 
L 0 2.72 0.52 0.11 0.38 0.03 0.03 3.79 
	
5 38.50 3.48 0.13 3.36 0.08 0.29 45.83 
	
10 45.97 5.10 0.18 5.66 0.11 0.73 57.76 
	
24 45.04 5.83 0.39 6.16 0.33 1.36 59.11 
L+R 0 2.79 0.47 0.11 0.36 0.03 0.03 3.79 
	
5 14.72 1.42 0.11 1.33 0.06 0.14 17.78 
	
10 28.30 1.79 0.12 2.18 0.06 0.23 32.69 
	
24 32.70 2.46 0.14 3.94 0.08 0.35 39.67 
R 0 2.61 0.49 0.11 0.38 0.03 0.04 3.66 
	
5 7.50 1.16 0.11 0.88 0.06 0.13 9.83 
	
10 13.29 1.53 0.12 1.57 0.07 0.24 16.82 
	
24 17.67 2.13 0.15 2.34 0.10 0.43 22.81 
V 0 2.21 0.48 0.11 0.37 0.03 0.03 3.23 
	
5 14.37 1.82 0.12 1.28 0.07 0.27 17.94 
	
10 19.21 2.26 0.17 1.97 0.15 0.68 24.45 
	
24 19.97 2.90 0.35 2.62 0.53 1.34 27.72 
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V+L 0 2.50 0.50 0.11 0.37 0.03 0.03 3.53 
	
5 36.50 3.14 0.12 2.93 0.07 0.19 42.94 
	
10 47.90 5.01 0.16 5.70 0.10 0.48 59.35 
	
24 44.93 6.25 0.38 6.29 0.31 1.27 59.44 
V+L+R 0 2.45 0.46 0.11 0.36 0.03 0.03 3.43 
	
5 14.29 1.35 0.11 1.15 0.05 0.14 17.08 
	
10 25.98 1.78 0.11 2.13 0.06 0.21 30.27 
	
24 33.07 2.75 0.14 3.78 0.10 0.33 40.18 
V+R 0 2.28 0.46 0.11 0.39 0.03 0.03 3.31 
	
5 5.94 1.05 0.12 0.84 0.05 0.13 8.14 
	
10 11.81 1.53 0.12 1.53 0.06 0.24 15.28 
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Many liver and vascular diseases cause portal hypertension in children, which may 
give rise to severe and life-threatening complications, including hepatic encephalopathy. 
The effective prevention and management of portal hypertension and its complications, 
therefore, are important goals for improving the quality of life of affected children. 
Restoration and modulation of intestinal microbiota using probiotics has potential in 
treating symptoms associated with acute liver diseases and chronic liver failure. We 
assessed the efficacy of the probiotic VSL#3 in modulating the gut microbiota and 
reducing the severity of portal vein hypertension and Minimal Hepatic Encephalopathy in 
paediatric and young adult patients with liver disease. We performed a double-blind trial 
by assigning randomly patients to groups given the probiotic preparation or placebo daily 
for 3 months. Fecal samples were collected at the beginning of the experiment and after the 
treatment and 16S rRNA gene metataxonomic analysis was performed. VSL#3 
supplementation resulted in a trend toward improved cognitive function but not change in 
the gut microbiota was observed. High inter-individual variation in gut microbiota was 
observed. The study was confounded by the low study sample size and the different 
underlying aetiologies of the portal vein hypertension patients. Thus, a larger study with a 
more potent stratification for different underlying liver disease is needed to prove the link 
between gut microbiota changes in terms of community structure and metabolism and the 
efficacy of VSL#3 in ameliorating the disease condition. 
 
3.1 Introduction 
The intestinal microbiota plays an important role in health and disease. Alteration 
in its healthy homeostasis, dysbiosis and modification of intestinal permeability leading to 
bacterial translocation may result in the development of numerous liver disorders or 
worsening of hepatic disorders, such as cirrhosis, portal hypertension, hepatic 
encephalopathy (HE) and acute-on-chronic-liver failure (1,2). Antibiotics appear to 
effectively reduce the impact of these complications of liver diseases mainly through their 
effect on intestinal microbiota (1,2). However, due to the increasing drug resistance, 
alternatives to antibiotics are now considered for the prevention of bacterial translocation 
and its consequences (3). Such alternatives include prebiotics and probiotics which 
effectively modulate the ecology of the gut microbiota (4–6).  
Generally defined as “live microorganisms that produce a beneficial effect to the 
host when administered in an adequate amount (7)”, interest towards probiotics has grown 
in recent years, partly because their administration is safe, inexpensive and they represent a 
noninvasive approach to prevent and treat a variety of diseases, including hepatic disorders 
(3,8). In the context of liver diseases, some evidence supports probiotic efficacy for (i) 
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changing gut metabolism; (ii) reducing ammonia in the portal blood (decreasing bacterial 
urease activity, intestinal permeability, ammonia absorption by lowering pH and 
improving nutritional status of gut epithelium); (iii) reducing hepatic inflammation and 
oxidative stress; (iv) reducing the absorption of other toxins such as indoles, oxindoles, 
phenols and mercaptans (9–11).  
Several studies in animal models of non-alcoholic fatty liver disease (NAFLD) 
have reported beneficial effects of certain probiotics on liver damage, such as reduction in 
hepatic total fatty acid content and liver inflammation as well as an improvement in 
hepatic insulin resistance (9–11). However, most studies evaluating probiotics in 
experimental models of cirrhosis and portal hypertension gave contrasting results. No 
benefits on intestinal microbiota or bacterial translocation have been observed 
with Lactobacillus rhamnosus GG (12) and Lactobacillus johnsonii La1 (13), or with 
Lactobacillus acidophilus and Lactobacillus rhamosus GG in rats with portal vein ligation 
(14). Nevertheless, several human intervention studies, mainly in the field of HE, have 
provided supportive evidence for the efficacy of certain probiotics in the improvement of 
Minimal HE (MHE), in the prevention of HE recurrence and prophylaxis of Overt HE 
(OHE). In these studies the probiotics appeared to be acting by reducing plasma ammonia 
concentrations and endotoxemia levels (15–20) and improving cognitive function as 
measured by neuropsychiatric tests (21). Use of Escherichia coli Nissle strain was also 
reported to result in improvement in liver function, as measured by Child- Pugh score, and 
also reducing blood endotoxin levels (22). Patients with cirrhosis and minimal HE treated 
for 1 month with a probiotic combination (Pediococcus pentoseceus 5–33:3, Leuconostoc 
mesenteroides 32–77:1, Lactobacillus paracasei spp. paracasei 19 and Lb. 
plantarum 2592) administered with a fermentable fiber, significantly increased the fecal 
content of non-urease-producing lactobacilli with a decrease in Escherichia coli fecal 
concentrations, decrease in blood endotoxemia, and an improvement in liver function and 
cognitive tests (23).  
The most studied probiotic in treating chronic liver diseases and their complication 
is VSL#3. VSL#3 is a multispecies probiotic containing 8 bacterial strains, Lb. paracasei, 
Lb. plantarum, Lb. acidophilus, Lb. delbrueckii spp. bulgaricus, Bifidobacterium longum, 
B. breve, B. infantis and Streptococcus salivarius spp. thermophilus (24).  This mixture has 
been observed to decrease fibrosis in an experimental model of non-alcoholic 
steatohepatitis in mice (25), to prevent endothelial dysfunction in the mesenteric artery 
(26) and to reduce bacterial translocation, pro-inflammatory state and increase tight 
junctions and intestinal integrity in cirrhotic rats (26–29) . In patients with different liver 
diseases VSL#3 has been shown to improve liver function tests, pro-inflammatory 
cytokines and oxidative damage (29). Cirrhotic and decompensated cirrhotic subjects 
benefit of VSL#3 treatment due to the associated improvement in hepatic and systemic 
haemodynamics as well as in portal hypertension (30–32). Moreover, preventive effects of 
probiotic intervention in patients with liver cirrhosis, who had not experienced OHE, 
showed that VSL#3 may be useful in the prevention of HE and in the treatment of minimal 
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HE (33,34). As these trials concluded the bulk of evidence favours the use of certain 
probiotics for ameliorating MHE disease symptoms by modulation of gut microbiota 
metabolism and ammonia levels (35). To note, the potentiality of probiotics 
supplementation, namely Lb. rhamnosus strain GG (36) and VSL#3 (37), vs. placebo, to 
improve  transaminase level and reduce plasma LPS level has been evidenced also in 
paediatric patients with pre-cirrhotic biopsy-proved NAFLD state.  
In paediatric age, acute liver diseases and chronic liver diseases - from NAFLD to 
portal hypertension to acute liver failure - represents an increasing issue, where diagnosis 
and management are a challenge. Cases of hepatic encephalopathy are increasing (38,39). 
However, there is little data associating probiotic use with improvements in portal vein 
hypertension or HE and what data does exist, has been generated from studies in adults. 
Children with primary extrahepatic portal vein thrombosis have portal-systemic shunting, 
which may lead to disturbed neurocognitive function similar to portal-systemic 
encephalopathy (PSE) and MHE seen with chronic liver disease and cirrhosis in adults. 
Bacterial translocation plays a role in increasing portal pressure by exacerbating the 
hyperdynamic circulatory state and increasing hepatic vascular resistance. Moreover the 
induced portal circulation shunt leads to reduced blood circulation in the liver and 
consequently passage of gut-derived un-detoxified compounds in the main circulation, 
including ammonia, the principal toxic molecules involved in triggering HE onset (40). 
Previously, a 6-week administration of VSL#3 resulted in reductions of the hepatic 
vascular resistance, as well as in the improvement of systemic haemodynamics (30,41). 
Data in this area are conflicting. Two studies in adult patients with compensated or 
decompensated cirrhosis utilizing VSL#3 for 2 months did not reduce hepatic venous 
pressure gradient and no changes in gut microbiota were observed as measured by terminal 
restriction fragment length polymorphism (TRFLP). However the authors did report 
reductions in plasma endotoxemia and inflammatory cytokines (31,42).  
Here, we present a pilot intervention study in paediatric and young adults afflicted 
by portal vein hypertension and manifesting symptoms of MHE. Intervention was with 
VSL#3 or placebo for 3 months. 16S rRNA sequencing has been performed on faecal 
samples before and after the treatment. Data were correlated with cognitive function 
improvement measured by neuropsychiatric tests. The overall aim was to study the effect 
of VSL#3 in ameliorating impaired cognitive function and patients quality of life by 
modulating the gut microbiota and reducing the ammonia level. 
 
3.2 Material and Methods 
3.2.1 Patients enrollment and intervention study 
The clinical trial (ClinicalTrials.gov Identifier: NCT01798329) expected the 
enrolment of 50 patients with clinical diagnosis of prehepatic portal hypertension and 
developing Minimal Hepatic Encephalopathy. During the duration of the study we were 
able to recruite 18 patients (median age 10, range 4-18). In particular subjects were 
affected by portal vein hypertension [cavernome portal hypertension (n=2), portal 
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thrombosis (n=3), congenital hepatic fibrosis (n=1), biliary atresia (n=10) and sclerosis 
cholangitis (n=1)]. All subjects of this study were under a Mediterranean-based diet and no 
antibiotics, probiotics or prebiotics have been taken in the 3 months prior the beginning of 
the intervention. The study was approved by the institutional review board of the A. O. 
Ospedali Papa Giovanni XXIII (Bergamo, Italy), and all enrolled subjects or tutors gave 
written informed consent in accordance with the sampling protocol approved.  
We performed a double-blind trial by assigning, randomly, patients to groups 
given the probiotic preparation (n=9) or placebo (n=9) for 3 months.	The probiotic group 
received an oral therapy with 1 sachets per day VSL#3 containing 4.5x1011 colony forming 
units of bacteria per sachet (VSL#3; Ferring, Milan, Italy). VSL#3 contains eight different 
strains of bacteria: Streptococcus salivarius subspecies thermophilus, Bifidobacterium 
longum, Bifidobacterium breve, Bifidobacterium infantis, Lactobacillus acidophilus, 
Lactobacillus plantarum, Lactobacillus casei and Lactobacillus delbrueckii subspecies 
bulgaricus (24). There were 4 drop-outs, one in the probiotic group and three in the 
placebo group. An overview of the trial is illustrated in Figure 1. 
 
3.2.2 Baseline and follow-up protocol 
Baseline examination of the patients comprised a physical examination, peripheral 
blood measures and abdominal ultrasonography as well neuropsychiatric tests. After the 3 
months, patients were subjected to a physical examination, and new neuropsychiatric tests. 




Figure 1. Flow chart showing the overview of the study 
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3.2.3 DNA extraction, PCR amplification of the V3-V5 region of bacterial 16S rDNA  
Total DNA extraction from faecal samples (250 mg, wet weight) was performed 
using the FastDNA™ SPIN Kit for Feces (MP Biomedicals, Santa Ana, CA, USA) 
following manufacturer’s instructions. DNA integrity and quality were checked on 1 % 
agarose gel TAE 1X and quantified with Quant-IT PicoGreen dsDNA assay kit (Thermo 
Fisher Scientific). Samples were subjected to PCR amplification, Using the specific 
bacterial primer set 341F (5’ CCTACGGGNGGCWGCAG 3’) (43) and 806R (5’ 
GACTACNVGGGTWTCTAATCC 3’) (44) with overhang Illumina adapters targeting a 
~460 bp fragment of the 16S rRNA variable region V3-V4. PCR amplification of each 
sample, was carried out using 25 µl reactions with 0.2 µM of each primer. In particular 
12.5 µl of 2x KAPA HiFi HotStart ReadyMix, 5 µl forward primer, 5 µl reverse primer, 
were used in combination with 2.5 µl of template DNA (5 ng/ul). All PCR amplification 
was carried out, using a GeneAmp PCR System 9700 (Thermo Fisher Scientific) and the 
following steps: melting step – 95°C for 3 minutes (one cycle); annealing step – 95 °C for 
30 seconds, 55 °C for 30 seconds, 72 °C for 30 seconds (25 cycles); extension step – 72 °C 
for 5 minutes (1 cycle). The PCR products were checked on 1.5 % agarose gel and cleaned 
from free primers and primer dimer, using the Agencourt AMPure XP system (Beckman 
Coulter, Brea, CA, USA), following the manufacturer’s instructions. Subsequently, dual 
indices and Illumina sequencing adapters Nextera XT Index Primer (Illumina), were 
attached by 7 cycles PCR (16S Metagenomic Sequencing Library Preparation, Illumina). 
The final libraries, after purification by the Agencourt AMPure XP system (Beckman), 
were analyzed on a Typestation 2200 platform (Agilent Technologies, Santa Clara, CA, 
USA) and quantified using the Quant-IT PicoGreen dsDNA assay kit (Thermo Fisher 
Scientific). Finally, all the libraries were pooled in an equimolar way, in a final amplicon 
library and analyzed on the Typestation 2200 platform. Barcoded libraries were sequenced 
on an llumina® MiSeq (PE300) platform (MiSeq Control Software 2.0.5 and Real-Time 
Analysis software 1.16.18). 
 
3.2.4 Metagenomic data analysis  
 The sequences were assigned to samples, according to sample-specific barcodes. 
This allowed collecting the FASTQ formatted files. Raw data will be submitted to 
European Nucleotide Archive before publication. Reads were processed using the QIIME 
pipeline (45), where open reference operational taxonomic unit (OTU) picking was 
performed in using usearch61 (46). Alpha (within-sample richness) and beta-diversity 
(between-sample dissimilarity) estimates were computed using the phyloseq R package 
(47). Permutational MANOVA (PERMANOVA) was performed on the UniFrac distances 
and Bray-Curtis dissimilarity using the adonis function of the vegan R package with 999 
permutations, and p-values were corrected using the Bonferroni correction. The non-
parametric Wilcoxon rank-sum test was used for the comparison of relative abundances of 
microbial taxa between groups, and the resulting p-values were corrected for multiple 
testing controlling the false discovery rate (48) at all taxonomic levels taken into account. 
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Starting from a table of OTUs, we obtained the final output from metagenome prediction 
as an annotated table of predicted gene family counts for each sample. All statistical 




3.3.1 Characteristic of study population 
 Eighteen patients fulfilling inclusion criteria were recruited for the study between 
March 2013 and April 2016. All patients underwent the baseline evaluation and were 
randomly assigned to the VSL#3 (1 sachet /daily) or placebo groups. Four patients 
discontinued the treatment for personal reasons. Therefore the final study population 
comprised 14 patients (VSL#3, n=8; placebo, n=6) (Figure 1). The characteristics of these 
patients at baseline are shown in Table 1. The data reported are only for the intent-to-treat 
population. 
Psycometric tests, including visual motor intergration (VMI) test, to evaluate memory, 
neuromotor function and attention were measured at baseline and after 3 months of VSL#3 
or placebo. 
 Blood ammonia levels prior and post treatment are shown in Table 2. We found 
that there were no significant differences between the treated and placebo groups. 























Table 1. Baseline characteristics of the final study population 
 
 
Table 2. Blood ammonia levels (µmol/l) before (A) and after (B) VSL#3/placebo treatment 
 Median value range Mean ± SD 
Placebo A 26 15-119 37 ± 36.7 
Placebo B 28 11-108 38 ± 36.7 
VSL#3 A 32 18-96 38.6 ± 23.8 
VSL#3 B 34 19-76 39.5 ± 18.4 
 
VSL#3 group Placebo group All patients (n=14) 
Age [years; median (range)] 10 (6-14) 10 (4-18) 10 (4-18) 
Aetiology [n(%)]   
 
  Cavernome portal hypertension 1 (12.40%) 1 (16.66%) 2 (14.28%) 
  Portal thrombosis  3 (50%) 3 (21.42%) 
  Congenital hepatic fibrosis  1 (16.66%) 1 (7.14%) 
  Biliary atresia 6 (75.00%) 1 (16.66%) 7 (49.98%) 
  Sclerosis cholangitis 1 (12.50%)  1 (7.14%) 
Varices [n(%)]   
 
  No 5 (62.50%) 5 (35.70%) 8 (57.12%) 
  Small 1 (12.50%) 2 (14.28%) 3 (21.42%) 
  Large 2 (25.00%) 1 (7.14%) 3 (21.42%) 
Haemoglobin level [g/dl, median (range)] 13.0 (12.5-14.3) 11.7 (10.3-13.3) 12.75 (10.3-14.3) 
White cell count, per mm3 [median (range)] 3.24 (2.22-3.75) 3.58 (1.51-8.02) 3.25 (2.24-8.02) 
Platelet count, per mm3 [median (range)] 92.1 (44-131) 69 (40-198) 71 (26-198) 
Serum bilirubin level [g/dl, median (range)] 1.11 (0.4-2.8) 0.74 (0.4-1.2) 0.95 (0.4-2.8) 
International normalized ratio [median (range)] 1.18 (0.93-1.29) 1.28 (1.1-1.42) 1.24 (0.93-1.4) 
Serum abumin level [median (range)] 4198 (3740-4480) 4489 (4428-4676) 4293 (3489-4676) 
Alanine aminotransferase ALT [IU/l, median (range)] 56.9 (18-185) 24.5 (22-144) 53.5 (20-185) 
Aspartate aminotransferase AST [IU/l, median 
(range)] 
51.5 (22-143) 30.5 (19-210) 48.5 (19-210) 
Gamma-glutamyl transferase GGT [IU/l, median 
(range)] 
152.4 (23-502) 22.5 (6-330) 53.5 (6-502) 




Table 3. Blood parameters at the end of the study 
 VSL#3 group Placebo group 
Haemoglobin level [g/dl, median (range)] 12.3 (11.7-13.9) 11.8 (9.7-13.5) 
White cell count, per mm3 [median (range)] 2.76 (1.62-4.07) 4.26 (1.27-9.32) 
Platelet count, per mm3 [median (range)] 84 (36-139) 72 (60-246) 
Serum bilirubin level [g/dl, median (range)] 0.9 (0.4-2.4) 0.7 (0.4-1.4) 
International normalized ratio [median (range)] 1.22 (0.91-1.36) 1.38 (1.0-1.48) 
Serum abumin level [median (range)] 4233 (3961-4425) 4420 (3677-4778) 
Alanine aminotransferase ALT [IU/l, median (range)] 55 (23-232) 23.5 (17-192) 
Aspartate aminotransferase AST [IU/l, median (range)] 66 (27-149) 33.5 (17-205) 
Gamma-glutamyl transferase GGT [IU/l, median (range)] 55 (18-197) 20.5 (5-300) 
Alkaline phosphatase ALP [IU/l, median (range)] 271 (46-560) 177 (85-907) 
 
 
3.3.2 Determination of the effects of probiotic VLS#3 supplementation on gut 
microbiota 
Faecal samples were collected at the beginning of the experiment before 
intervention and after the treatment. The bacterial gut microbiota was profiled using 
Illumina high-throughput sequencing of the V3-V4 region of the 16S rRNA gene. Bacterial 
richness within each sample (α-diversity) of the 4 groups, VSL#3 and placebo groups, both 
before (A) and after the treatment (B) was calculated. Three different alpha-diversity 
estimators were used, namely the observed number of OTUs, the Chao1 index and the 
Shannon entropy index. The bacterial gut microbiota of subjects did not change 
significantly upon treatment with either VSL#3 or placebo (Figure 2 and Table A1, 
Appendix B).  
 To identify possible differences between the bacterial components of the gut 
microbiota of the VSL#3 treated patients compared to the placebo, we calculated the beta-
diversity of the samples using the unweighted and weighted UniFrac distances and the 
Bray-Curtis dissimilarity. The Principal Coordinates Analysis (PCoA) based on these 
measures (Figure 3 and Figure S1) revealed that the gut microbiota of probiotic treated 
patients was not distinct from those of the control group (Table 4). 
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Figure 2. Measure of bacterial diversity. Alpha-diversity calculated on the number of observed 
OTUs, the Chao1 index and the Shannon entropy index. No statistically significant differences have 
been found. The body of the box plot represents the first and third quartiles of the distribution, and 
the median. The whiskers extend from the quartiles to the last datapoint within 1.5× IQR, with 
outliers beyond represented as dots.	Placebo A, placebo at baseline; placebo B, placebo at 3 months; 
VSL#3 A, VSL#3 at baseline; VSL#3 B, VSL#3 at 3 months. 
 
However, the analysis of β-diversity among VSL#3 treated patients and placebo 
groups after the 3 month-therapy revealed significant differences (VSL#3 B vs placebo B, 
p=0.036, PERMANOVA, Figure 2 and Table 4). Surprisingly no significant difference was 
detected when comparing the gut microbiota of patients before and after VSL#3 treatment 
(Figure S1 and Table 4). To identify the taxa that were differentially represented in the 
VSL#3 group and placebo subjects, we compared the relative abundances between these 










































Figure 3. PCoA plots of bacterial beta-diversity based on the Weighted UniFrac distance according 
to groups of treatments (left) and groups of treatments after the 3 month-therapy (right).  Placebo A, 
placebo at baseline; placebo B, placebo at 3 months; VSL#3 A, VSL#3 at baseline; VSL#3 B, 
VSL#3 at 3 months. 
 
 
Table 4. Permutational multivariate analysis of variance (PERMANOVA) tests of the bacterial gut 
microbiota on the 
unweighted and weighted UniFrac distances and the Bray-Curtis dissimilarity according to 
individuals’ treatments (VSL#3 or placebo) 	
 Metric F R2 p value* 
Treatments  Unweighted UniFrac 1055 0.11651 0.405 
 Weighted UniFrac 1.247 0.13485 0.087 
 Bray-Curtis 10.133 0.11243 0.43 
Placebo A** vs. Placebo B Unweighted UniFrac 0.32351 0.03134 0.917 
 Weighted UniFrac 0.58886 0.05561 0.964 
 Bray-Curtis 0.62049 0.05842 0.864 
VSL#3 A vs. VSL3 B Unweighted UniFrac 0.14861 0.0105 0.969 
 Weighted UniFrac 0.40156 0.02788 0.998 
 Bray-Curtis 0.20371 0.01434 0.997 
VSL#3 B vs Placebo B Unweighted UniFrac 1.7823 0.12932 0.081 
 Weighted UniFrac 1.6989 0.12402 0.036 
 Bray-Curtis 1.408 0.10501 0.075 
*Bonferroni corrected p-values 
**Placebo A, placebo at baseline; placebo B, placebo at 3 months; VSL#3 A, VSL#3 at baseline; VSL#3 B, VSL#3 
at 3 months. 
 
The analysis did not show any statistically significant increase or decrease in the relative 
abundance of any phylum, genera or OTU in the VSL#3 treated group compared to 
placebo or between the groups before treatment. However, there was a trend towards an 





































Weighted Unifrac PCoA Placebo B vs. VSL#3 B
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compared to the baseline (VSL#3 A) (Figure 4). In the same group, a trend towards 
decreased Bacteroides relative abundance was observed, as well as a slight increase of 




Figure 4. Relative abundance of microbial taxa at phylum (A) and genus (B) level. Only taxa with 
abundance > 0.001 are depicted. Placebo A, placebo at baseline; placebo B, placebo at 3 months; 
VSL#3 A, VSL#3 at baseline; VSL#3 B, VSL#3 at 3 months. 
 
To investigate better the absence of any significant changes in terms of bacterial 
abundance after the VSL#3 treatment, we calculated the β-diversity of the subjects prior 
oral supplementation of VSL#3 or placebo. The unweighted UniFrac distance revealed that 
the two groups were different at the baseline (Figure 5A and Table 4). We then calculated 
the β-diversity of the subjects according to the different aetiologies (Figure 5B and Figure 
S2). The indices revealed that the patients distributed accordingly to their aetiology.  
 
3.4 Discussion 
 Many liver and vascular diseases cause portal vein hypertension in children. Portal 
vein hypertension may give rise to severe and life-threatening complications, including 
haemorrhaging from oesophageal varices, ascites, hepatopulmonary syndrome, 
portopulmonary hypertension and HE. The effective prevention and management of portal 
hypertension and its complications, therefore, are important goals for improving health 














































































Figure 5. PCoA plots of bacterial beta-diversity. (A) Unweighted UniFrac distance calculated 
according to groups of treatments at the baseline. Placebo A, placebo at baseline; VSL#3 A, VSL#3 




Table 4. Permutational multivariate analysis of variance (PERMANOVA) tests of the bacterial gut 






















































unweighted and weighted UniFrac distances and the Bray-Curtis dissimilarity. Placebo A, placebo 
at baseline; VSL#3 A, VSL#3 at baseline 	
 Metric F R2 p value* 
VSL3 A vs Placebo A** Unweighted UniFrac 1.3029 0.09794 0.281 
 Weighted UniFrac 1.5699 0.11569 0.04 
 Bray-Curtis 1.2323 0.09313 0.158 
*Bonferroni corrected p-values 
**Placebo A, placebo at baseline; VSL#3 A, VSL#3 at baseline 
 
 
As portal hypertension worsens, it is associated with a reduced ability of the liver to 
detoxify compounds such as ammonia absorbed from the gut. This in turn can lead to the 
onset of Minimal HE (MHE) (49,50), the mildest form of the spectrum of HE, the 
neurocognitive impairment in cirrhosis and/or portosystemic shunting (51). MHE impairs 
daily functioning, attention, speed of information processing, motor abilities, work 
capability, coordination and learning ability (51,52). The prevalence of MHE in adults with 
chronic liver disease ranges from 30-84% (53). It also predisposes to the development of 
overt HE, increased falls and increased mortality. This results in impaired quality of life 
and its early detection and treatment are mandatory. Two studies in 30 and 67 chronic liver 
disease children found MHE in 57% and 50.6 % cases, respectively (38,39). Improvement 
of cognitive function remains the main goal of the MHE treatment. Most of the available 
MHE therapies concentrate on reducing the serum ammonia levels by decreasing its 
production in the intestine and increasing its elimination. Prebiotics (34,54–56), antibiotics 
(16,57,58), L-ornithine L-aspartate (59), branched aminoacids (60), probiotics and 
synbiotics (23) as well as a low protein diet have all been shown to improve psychometric 
performance and quality of life.  
The efficacy of probiotics in the treatment of liver disease and HE has been largely 
investigated in adults (10). In several human intervention studies in adults affected by HE 
provided probiotics have been linked to the amelioration of MHE symptoms (21–23,29,30) 
and the prevention of manifesting OHE (33,34). Despite the suspicion that probiotic effects 
on disease may be related to modulation of gut metabolism and consequent reduction in 
blood ammonia levels and endotoxemia (9–11), a clear association between modulation of 
the gut microbiota and amelioration of clinical conditions is still missing. Contrasting 
results directly linking the dysbiosis and the improvement of cognitive function in HE 
therapies have also been observed in response to other clinical therapies such as lactulose 
or rifaximin (61–65). This suggest the potential activity of these therapeutically approaches 
through changes gut bacterial function or metabolism, rather than microbiota composition. 
Here, we studied the gut microbiota modulating effect of a 3-month oral 
administration of the probiotic mixture VSL#3 in paediatric and young adult subjects 
affected by portal hypertension manifesting with MHE. VSL#3 treatment did not promote 
a decrease in blood ammonia levels nor a significant change in the relative abundances of 
specific bacterial taxa. Our pilot intervention study suffer from the small number of 
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subjects recruited (14 out of 50 expected) and potential of the different underlying 
pathological causes of portal vein hypertension to influence baseline variation in gut 
microbiota composition. In fact, we did observe distinct microbiota profiles for the 
different underlying pathologies.  Indeed, 7 out of 14 subjects were affected by biliary 
atresia and 6 out of those 7 were randomly included in the VSL#3 treatment groups. This 
aspect might therefore increase variation greatly and lower our ability to effectively 
measure the microbiota modulation of VSL#3. Liver disease results in qualitative 
(dysbiosis) and quantitative (bacterial overgrowth) changes of the intestinal microbiota, as 
recently indicated also for primary sclerosing cholangitis (66), one of the underlying 
pathologies present in our study. Similarly, it has been shown that the gut microbiota 
differed with respect to the pathological aetiology of liver disease (67,68). Hepatitis-B-
virus related cirrhosis and primary biliary cirrhosis bear a different duodenal mucosa 
microbiota, characterized by a different abundance of Neisseria and Gemella (69). We are 
now assessing if the different aetiologies leading to portal intervention could account by 
themselves for distinct and diverse bacterial communities between patients. However, the 3 
month-supplementation of VLS#3 did show a trend towards the increase in Actinobacteria 
and a concomitant decrease in Bacteroidetes. The results suggested also a mild decrease in 
Bacteroides relative abundance, as well as a slight increase of Ruminococcus and 
Faecalibacterium. Ruminococcus has been previously associated to secondary bile acids 
production and decrease in severity of cirrhosis progression (70) while Faecalibacterium 
abundance has been shown to be increased by lactulose treatments (71,72). To better 
address the potential of using the probiotic VSL#3 in the treatment of portal hypertension 
and HE in children a larger study with a more potent stratification for different underlying 
liver disease is therefore needed. However, according to previous studies (36,73,74), the 50 
patients we initially planned to enroll for the study will be sufficient to observe microbiota 
changes as well as changes in the plasma ammonia or transaminase levels. 
Thus, the investigation should not only to be restricted to the relative abundance of 
particular species but should also evaluate any changes in the gut microbiota metabolism, 
i.e the production of Short Chain Fatty Acids (SCFAs), which have been shown to be 
important for colonic health and may act on neuronal physiology (75–77). Indeed, 16S 
rRNA profiling flanked by a metabolomic approach would allow a better understanding of 
the link between microbiota modulation and disease symptoms. 
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Figure S1. Measures of bacterial diversity. PCoA plots of bacterial beta-diversity based on 
Unweighted and Weighted UniFrac distances and the Bray-Curtis dissimilarity analyzed according 























































































































































































































































































































































































































































































































































































































































































































































































Figure S2. Measures of bacterial diversity. PCoA plots of bacterial beta-diversity based on 
Unweighted and Weighted UniFrac distances and the Bray-Curtis dissimilarity analyzed according 





























































































































































Probiotic characterization of high GABA producing strain 
Lactobacillus brevis FEM 1874  
 
Andrea Mancini, Elena Franciosi, Ilaria Carafa, Kieran M. Tuohy* 
 
Department of Food Quality and Nutrition, Research and Innovation Centre, Fondazione 
Edmund Mach, 38010 San Michele all’Adige, Trento, Italy 
 





KMT conceived the idea 
AM performed GABA level determination, DNA extraction and GAD operon 
characterization, RNA extraction and gene expression, pH and ox-bile resistant tests, 
measuring bacterial growth rate on different carbon sources, analysed the data and wrote 
the manuscript 
EF, IC isolated the strain, performed the antibiotic resistance test and pancreatic fluids 
resistance test 










probiotic, Lactobacillus brevis, oxbile, γ-aminobutyric acid, GABA, GAD genes 
 
Abstract 
γ-Aminobutyric acid (GABA) has strong potential for the food and pharmaceutical 
industries as a bioactive compound, with increasing evidence of its effects on the gut-brain 
axis. Different lactic acid bacteria are capable of producing GABA particularly strains of 
Lactobacillus brevis. In this study we characterized a Lb. brevis isolated from traditional 
alpine cheese for its ability to accumulate high levels of GABA in the culture medium and 
for other phenotypic traits important for probiotics. Lb. brevis FEM 1874 converted 
monosodium glutamate to GABA more efficiently compared to the type strain Lb. brevis 
DSM 20054, resulting in high amount of GABA. This ability seemed to be related to the 
higher transcriptional activation of the gene encoding for the glutamate (gad) 
decarboxylase antiporter (gadC) and regulator (gadR). Lb. brevis FEM 1874 performed 
well in vitro under the stress conditions mimicking the gastro-intestinal tract passage, 
being resistant to acid pH (pH 2.5) and growing on pancreatic fluid and 0.3% ox-bile. 
Compared to the type strain FEM 1874 expressed more efficiently the glutamate 
decarboxylase operon and was also able to produce high amount of GABA compared to 
the type strain These preliminary studies indicate that this strain holds promise as a starter 
for GABA-rich dairy fermented foods as well as a promising probiotic microorganism with 
potential to modulate the gut(microbiota):brain axis, portal vein hypertension and systemic 
inflammation through GABA production. 
 
4.1 Introduction 
γ-Aminobutyric acid (GABA) is a natural non-proteinogenic amino acid widely 
found in animals, plants and microorganisms (1–4). It represents the major inhibitory 
neurotransmitter of the vertebrate central nervous system (5), where it modulates the 
general excitability of neurons (6,7). GABA is involved in the regulation of cardiovascular 
conditions such as blood pressure and heart rate and in the sensation of pain and anxiety 
(8), moreover it controls different activity such as growth hormone secretion (9), protective 
effect against glycerol induced acute renal failure in rats (10) and anti-proliferative activity 
on colon carcinoma cells (11). GABA possesses several physiological functions such as 
improving brain function, antianxiety effects, tranquilizer effects, boosting fertility, 
diuretic effects, anti-diabetic effects and treatment of epilepsy (7,12). Alteration of the 
GABA system can lead to anxiety and depression (13,14). Aside from central nervous 
system, GABA is present also in many organs such as the pancreas, pituitary, testes, 
gastrointestinal tract, ovaries, placenta, uterus and adrenal medulla (15). Also immune cells 
may also produce GABA expressing GABA-A ion channels, GABA transporters and the 
GABA-B receptor (16). Indeed GABA is able to activate GABA-A ion channel in T cells 
and macrophages (17–19) and its application resulted in decreased cytokine secretion and 
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T cells proliferation (18–20). Moreover recent evidence support the potential of GABA 
derived from the gut to act as neuroactive molecule in the context of the gut-brain axis - 
the complex communication system established between the gut microbiota and the 
(central and peripheral) nervous systems (21,22).  
 Indeed, GABA is currently being investigated as a bioactive compound by both 
the food and pharmaceutical industries (1,4,23–25) and a several number of placebo 
controlled studies reported have been carried out to study the effects of an oral 
administration of GABA (26–31). A strong effort has been made in the formulation of 
GABA enriched foods especially fermented foods, including dairy products, soybean, 
kimchi and juice products, which could be used as potential GABA-delivery vehicles (32–
37). Cheese is one great source of GABA, where GABA is produced during cheese 
ripening (38–40). One approach may therefore be to increase GABA levels in humans by 
consuming GABA-enriched food products. Isolation of GABA producing strains from 
diverse fermented food and from the human gut is providing considerable natural 
biotechnological solutions for the design of new GABA-rich fermented foods and for the 
selection of next generation, efficacious, probiotic strains (25,40–42).  
As defined by the Food and Agriculture Organization and the World Health 
Organization, probiotics are “live microorganisms which when administered in adequate 
amounts confer a health benefit on the host”. Other definitions advanced through the years 
have been restrictive by specification of mechanisms, site of action, delivery format (e.g. 
food) or host (43). To accumulate in the intestinal tract, probiotics must first survive the 
various conditions specific to the digestive system, such as low pH in the stomach and the 
presence of bile acids in the intestines: these represent the most important properties of a 
probiotic (44). Particularly bile secreted into the duodenal section of the small intestine is 
known to reduce the viability of probiotics, and the ability to tolerate bile is one of the 
requisite characteristics of successful probiotics (45,46). Probiotics have been shown to 
exert a wide range of effects, such as enhancing immune function (43,47–50), improving 
metabolic disorders (51–54) and being effective against pathogens, such as Clostridium 
difficile (55). Probiotic efficacious have been shown to be species and even strain 
dependent since different bacterial strain can affect host via diverse modes of action (56–
58). Of consequence, probiotics targeted toward unique outcomes and functionalities are 
now be demanded as next generation probiotics (NGP) and put through rigorous and 
properly designed human intervention studies.	A large number of potential novel probiotic 
candidates are being isolated from the dominant members of the adult microbiota as well 
as from traditional fermented food, as potential next-generation probiotics (59).  
Probiotic intervention targeting the microbiota-gut-brain axis to modulate behavior 
has recently been reported. The probiotic Bifidobacterium longum (Bl NCC3001) has been 
shown to normalize behavior and CNS biochemistry (60,61) in mice with mild colitis, an 
effect also mediated though the vagus nerve (61,62). By contrast, Lactobacillus rhamnosus 
NCC4007 (LGG) was not able to improve anxiety-like behavior (60). However, another 
strain of Lb. rhamnosus, namely Lr JB-1, was able to induce a direct effect on behavioural 
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and physiological responses in a vagus nerve-dependent manner (21). Lb. rhamnosus JB-1 
promoted an anxiolytic–antidepressant-like effect through alterations in the expression of 
GABA receptors, such as GABAAα2, GABAAα1, and GABAB1b (21). Indeed, GABA 
receptors targeting represents a goal for improving brain function. Identification of bacteria 
able to produce high GABA levels and bearing features of a probiotic is a viable approach 
for designing efficacious next generation probiotics targeting the gut:brain axis. 
GABA is the end product of the α-decarboxylation of glutamic acid by lactic acid 
bacteria (LAB) and several GABA-producing LAB species isolated from traditional 
fermented food and beverages have been reported. These include Lactobacillus paracasei 
(25) (40,63), Lb. buchneri (6,37,64), Lactococcus lactis (39,40), Lb. delbrueckii subsp. 
bulgaricus (40), Lb. plantarum (40) and Lb. brevis (37,40,42,65–67). Cheese represents a 
rich source of LAB with potential GABA producing properties (38–40). The results of 
these findings offer potential alternatives to take advantage of GABA's health benefits 
through GABA-enriched cheeses. In this work, we characterized an isolate from 
“Nostrano-cheese”, typical of the Trentino province (north, alpine area) in Italy, Lb. brevis 
FEM 1874, for its ability to produce GABA and for some characteristics considered 
important for a probiotic strain (68,69). The high GABA producing Lb. brevis FEM 1874 
strain possesses a Generally Regarded As Safe (GRAS) status – as a Lactobacillus - and is 
able to survive gastrointestinal (GI) tract conditions, which makes it a good candidate as a 
starter ingredient for functional food and potential of next generation probiotic with 
specific mode of action based around its GABA producing capability and modulation of 
the gut:brain axis. 
 
 
4.2 Material and methods 
4.2.1 Reagents 
All media constituents were purchased from Oxoid Ltd. (Basingstoke, UK) and 
Sigma Aldrich (Milan, Italy), chemicals were purchased from Sigma Aldrich (Milan, 
Italy). VSL#3 (sachets) were kindly provided by Ferring (Milan, Italy). 
 
4.2.2 Bacterial strains, culture medium and growth conditions  
The stock culture collection of Lb. brevis FEM 1874 and DSM 20054 were 
maintained at -80°C in 20% v/v glycerol. Bacteria cells were propagated twice in MRS 
broth (Oxoid Ltd., Basingstoke, UK) by incubation at 37°C for 16 h before each 
experiments. VSL#3 powder was washed three times with PBS, counted and used the 
appropriate concentration for the different assays. 
 
4.2.3 𝛾-Aminobutyric Acid (GABA) production and quantification 
Glutamate decarboxylase (GAD) activity of Lb. brevis FEM 1874 and the 
production of GABA were measured as reported by Nomura et al. (70). Briefly, Lb. brevis 
FEM 1874 and DSM 20054 were grown in MRS for 24 h at 37°C temperature, VSL#3 was 
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washed three times with sterile 1X PBS (pH 7.4). Cell cultures were then centrifuged 
(8600 rcf for 15 min at 4°C), washed twice with sterile PBS, and suspended in sterile 
0.85% w/v NaCl solution in order to achieve the A620 nm value of 2.5. 100 µL of cell 
suspension was then mixed with 900 𝜇L of 50mM sodium acetate buffer (pH 4.7) 
containing 7.0 mM L-glutamate and 0.1 mM pyridoxal phosphate. The reaction mixture 
was incubated for 24 h at 37°C and filtered through a 0.22 µm pore size filter (Minisart, 
Sartorius Stedim Biotech, Goettingen, Germany). The sample, diluted 10 times with 
sodium tetraborate 0.1 M (pH adjusted to 10.5) and added to glycine, as internal standard 
to a final concentration of 10 mg/L, was stored at −20°C before the analysis. L-Glutamic 
acid, glycine, and GABA were quantified as o-phthalaldehyde (OPA) adducts. The 
detection limit for GABA was estimated at 0.025 mg/L (3 times the standard deviation of 
the GABA contents measured repeating 10 times the analysis of a sample at unquantifiable 
content). 
 
4.2.4 GAD genes sequencing  
From Lb. brevis FEM 1874 overnight broth culture DNA was extracted with 
QIAamp DNA Blood Mini Kit (QIAGEN, Milan, Italy) following the manufacturer 
protocol. PCR amplification for the GABA genetic locus (gadR, gadA, gadC and gadB), 
were performed by using of specific primers (see Supplementary Table S1). PCR reactions 
were carried out in a 2720 Applied Biosystems Thermal Cycler (Applied Biosystems, 
Foster City, CA, USA). Amplified products were subsequently purified using the Promega 
PCR and Gel Clean Up system kit according to the manufacturer’s instructions (Promega 
Corporation, Milan, Italy). Sequencing was carried out by Sequencing Platform Unit, 
Fondazione Edmund Mach (San Michele a/A, Trento, Italy). The identifications were 
refined by BLAST (1 www.ncbi.nlm.nih.gov/BLAST) and Clustal Omega 
(www.ebi.ac.uk/Tools/msa/clustalo/) alignment of the GAD DNA sequences to the 
reference genome. The sequence of gadR, gadA, gadC and gadB loci were deposited in 
GenBank database. Data submission is pending.  
 
4.2.5 GAD genes expression 
Lb. brevis FEM 1874 and DSM 20054 were inoculated in MRS in presence of 30 
mg/ml of monosodium glutamate for 12 hours. Total RNA was extracted from cultures at 
0, 3, 7 and 12 hours using TriZol® (LifeTechnologies, Monza, Italy), according to the 
manufacturer's instructions. The sample was reverse transcribed using SensiFAST cDNA 
Synthesis Kit (BioLine AUROGENE s.r.l., Rome, Italy) and cDNA products were 
amplified in the presence of the specific primers for gadR, gadA, gadB and gadC as well as 
for the housekeeping gene tuf1 (see Supplementary Table S2). The conditions were chosen 
so that none of the RNAs analysed reached a plateau at the end of the amplification 
protocol, i.e. they were in the exponential phase of amplification. Each set of reactions 
always included a no-sample negative control. The PCR products were loaded onto 
Ethidium Bromide-stained, 1% agarose gels. A 1 Kbp DNA ladder molecular weight 
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marker (Life Technologies, Monza, Italy) was run on every gel to confirm expected 
molecular weight of the amplification product. After images acquisition, quantification of 
the bands was performed using ImageJ software (71). Band intensity was expressed as 
relative absorbance units. The ratio between the sample RNA to be determined and the 
housekeeping reference gene tuf1 was calculated to normalize for initial variations in 
sample concentration and as a control for reaction efficiency. Mean and standard deviation 
of all experiments performed were calculated after normalization to tuf1. The experiment 
was performed in triplicate. 
 
4.2.6 Tolerance to pH, oxbile and pancreatic fluid 
Effect of low pH was studied by the method of Tsai et al. (72). Briefly, one 
millilitre of culture containing about 109 CFU/ml of LAB was transferred into 9 ml 
phosphate-buffered saline (PBS). The pH was adjusted to 2.0, 2.5 and 3.2 using 0.1 N HCl 
and cells incubated at 37°C for 3 h. Control was performed at pH 7.2. After incubation, 
serial dilution plating on MRS agar were performed to determine viable bacterial counts. 
Plates were incubated anaerobically at 37°C for 48 h and acid tolerance was estimated by 
comparing the viable LAB bacteria counts in MRS agar for surviving cells. Data are 
presented as log(CFU/ml) ± standard deviation. Five independent experiments were 
performed. 
Tolerance for bile acids was performed on LAB cells exposed to low pH. After the 
3 h treatment described above, cells were centrifuged (5000g, 5 min), washed with PBS 
(pH 7.2) and then grown in 9 ml MRS broth with and without 0.3% (w/v) Oxgall bile 
(Sigma Aldrich, Milan, Italy) for 3, 12 and 24 h. Bile tolerance was estimated by 
comparing the viable LAB bacteria count in MRS with and without bile salt. Data are 
presented as log(CFU/ml) ± standard deviation. Three independent experiments were 
performed. 
Tolerance for pancreatic fluid was tested by inoculating actively growing bacteria 
(10% v/v inoculum size) to the test medium [150 mM NaHCO3	and 1.9 mg/ml pancreatin 
(Sigma, USA); pH 8.0]. The cultures were kept for 3 h in a shaking water bath (Certomat 
WR, B. Braun, Melsungen, Germany) at 37°C. Survival of LAB strains was examined by 
plating on MRS agar after 0, and 3 h of incubation. Data are presented as log(CFU/ml) ± 
standard deviation. Three independent experiments were performed. 
 
4.2.7 Growth on different carbon substrates 
Lb. brevis FEM 1874 growth rate to different carbon substrates was monitored by 
supplementation of PY (0. 2% w/v Peptone, 0.05% w/v Bacto Yeast Extract, 3% w/v 
NaCl, 0.5% w/v MgCl2 x 6H2O, 0.0005% w/v CaCl2 x 2H2O, 0.0005% w/v Na2MoO4 x 
7H2O, 0.0004% w/v CuCl2 x 2H2O, 0.0006% w/v FeCl3 x 6H2O) broth with 1% of glucose, 
fructose, lactate, lactulose, inulin and arabinogalactan. Optical density has been measured 
spectrophotometrically at 650 nm over 24 hours. Specific growth rate has been calculated 
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using the formula Nt = N0 eµt, where: Nt was the OD at 24 hours; N0, the OD at time 0; µ, 
the specific growth rate and t, the time passed (24 h). 
 
4.2.8 Antibiotic susceptibility test  
Antibiotic resistance to ampicillin, vancomycin, gentamicin, erythromycin, 
clindamycin, and tetracycline was assessed using the strip test M.I.C.Evaluator (Oxoid 
Ltd., Basingstoke, UK) following the manufacturer’s instruction. The strips consist of a 
gradient of stabilised antimicrobial covering 15 doubling dilutions. M.I.C.E. strips were 
used on a pre-inoculated agar plate, with formation of defined concentration gradient in the 
area around it. Minimum Inhibitory Concentration (MIC) was determined at the border of 
growth inhibition around the strip. Values were compared to the guidelines for facultative 
heterofermentative lactobacilli as indicated in the “Guidance on the assessment of bacterial 
susceptibility to antimicrobials of human and veterinary importance” by the European 
Food Safety Authority (EFSA) (73). 
 
4.2.9 Statistics 
Paired t-test was used to compare differences between the effect of a particular 
stress condition and the control, or between different gene level expression. The level of 
significance was set at p<0.05. 
 
4.3 Results  
4.3.1 Lactobacillus brevis FEM 1874 GABA production  
GABA is produced primarily from the irreversible α-decarboxylation of L-
glutamate by the enzyme glutamate decarboxylase (GAD) (Cotter and Hill, 2003). In the 
intracellular glutamate decarboxylase (GAD) system, glutamate is imported into cells by 
the GABA antiporter, decarboxylated by intracellular GAD to produce GABA and 
subsequently GABA is exported from the cells via the antiporter (74–76). In Lc. lactis the 
GAD gene (gadA) and the glutamate/GABA antiporter gene (gadC) are part of an operon, 
positively regulated by the gadR protein (encoded by gadR) which recognises glutamate 
and induces gene expression (75).  
Our previous study identified several cheese isolates capable of producing GABA (38). 
Starting from this preliminary information, we focused on Lb. brevis FEM 1874. Firstly, 
the GABA production rate of Lb. brevis FEM 1874 was compared to that of the type strain 
Lb. brevis DSM 20054 and the well-known probiotic mixture VSL#3 (77). VSL#3 is 
currently used as second line of intervention in prophylaxis of diseases affecting the 
gut:brain axis, such as liver and inflammatory bowel diseases (78–81). As reported in 
Table 1, after incubation at 37°C for 24 h, FEM 1874 was able to produce considerable 





Table 1. GABA level production 
 GABA (mg/L) 
FEM 1874 262.06 ± 15.42 
DSM 20054 78.27 ± 18.61* 
VSL#3 9.39 ± 0.21$ 
*p<0.00001, FEM 1874  vs DSM 20054, 
$ p<0.00001, FEM 1874  vs VSL#3 
 
Two different GAD encoding genes have been characterized in different Lb. brevis 
stains, namely gadA and gadB (39–41,63). gadA is located adjacent to and downstream of 
the glutamate/GABA antiporter gene (gadC), commonly referred as gadCA. They form an 
operon with the operon regulator gadR, being immediately upstream of gadCA. gadB is 
located separately from the other gad genes (74). By the use of fourteen sets of primers 
based on the nucleotidic sequence of the reference strain ATCC367, the FEM 1874 operon 
and gadB sequences were amplified confirming the presence of each genetic locus 
involved in the GABA production within FEM 1874 strain. The gene sequences shared 
high similarity with the ATCC367 strain, revealing the absence of any polymorphisms in 
the operon system or in the antiporter, which could account for this strain ability to 
produce the high amount of GABA. We thus asked whether this high ability was related to 
an increase in gene expression of such genes in the presence of glutamate. The 
semiquantitative expression analysis of gad genes showed a different expression profile in 
Lb. brevis FEM 1874 and DSM 20054 genes, both in presence or absence of the operon 
inducer glutamate (Figure 1). While gadA and gadB genes are repressed in absence of 
glutamate, the presence of glutamate induced their expression in both strains. gadA and 
gadB were up-regulated to a greater degree by FEM 1874 than in the type strain (gadA, 
p<0.05; gadB, p<0.01). Interestingly, at 7 h of growth, FEM 1874 strain induced an higher 
expression of gadC gene (relative expression = 2.17±0.11, p<0.01), encoding for the 
antiporter in response to glutamate and of gadR, the gene encoding for the GAD operon 
regulator (relative expression = 1.96±0.05, p<0.01), which was down regulated in DSM 




Figure 1. Expression levels of gad genes in response to 30mg/ml of monosodium glutamate. Semi-
quantitative PCR has been used to assess the transcription level of the gad genes in FEM 1874 and 
DSM 20054 as described in Material and Methods section. Data are presented as fold increase with 
respect to the reference gene tuf1 (mean ± sd, N=3). *p<0.05, **p<0.01, paired t-test, FEM 1874 
relative expression vs DSM 20054 relative expression. 
 
4.3.2 Lb. brevis FEM 1874 resists to simulated gastrointestinal conditions 
One of the characteristics required for being a probiotic is the ability to survive the 
gastrointestinal (GI) physiochemical environment. Therefore we measured the Lb. brevis 
FEM 1874 tolerance to acid pH, bile and pancreatic fluid, mimicking the acidic and 
liptolytic environment present along the GI tract. L. brevis FEM 1874 was more resistant 
to acid pH than the type strain DSM 20054, being able to survive to 3 hours exposure at 
pH 2.5 and 3.2, but not to pH 2.0 (Table 2).  
We next explored the resistance of our isolate to bile acid (Table 3). FEM 1874 
cells that survived pH 2.5 (3 h) acid treatment were cultured in MRS broth in the presence 
or absence of 0.3% Oxbile. Lb. brevis FEM 1874 cells were able to resist to bile salts, even 
with a fitness reduction over time, as shown by the cell number decline (Table 3). 
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Table 2. Analysis of acid tolerance (pH 2.0, 2.5 and 3.2) for L. brevis FEM 1874 
strain 0 h pH 7.2, 3 h pH 3.2, 3 h pH 2.5, 3h pH 2, 3h 
FEM 1874 9.64 ± 0.40a 9.09 ± 0.21 8.85 ± 0.64 7.75 ± 0.74 nd 
DSM 20054 9.87 ± 0.70 8.61 ± 0.22 8.43 ± 0.37 n.d n.d 
aBacterial counts are converted to log CFU/ml. 
 
Table 3. Effect of bile salts on FEM 1874 after low pH treatment 
Time (h) 0 3 12 24 
MRS 5.38 ± 0.79b 4.16 ± 0.45 6.29 ± 0.51 8.55 ± 0.37 
MRS + oxbilea 5.78 ± 1.13 2.03 ± 1.3* 2.3 ± 1.41** 3.12 ± 1.55*** 
aMRS + oxbile means MRS broth with 0.3% Oxgall. 
bBacteria counts are converted to log CFU/ml.;  
*p < 0.05, **p < 0.01, ***p < 0.001, paired t-test, oxbile vs none. 
 
FEM 1874 cells surviving the pH 2.5 acid treatment grew at rate comparable to the 
not pH-treated cells when transferred into MRS broth (Table 3). Moreover, incubation of 
FEM 1874 strain in growth medium containing pancreatic fluid had no effect on its 
viability and fitness (Table 4). The type strain DSM 20054 behaved in a similar manner 
and not statistically significant differences were observed between the survival of both 
strain in pancreatic fluid (Table 4).  
 
Table 4. Resistance of FEM 1874 to pancreatic fluid 
Time (h) 0 3 
FEM 1874 7.84 ± 0.56a 7.92 ± 0.45 
DSM 20054 8.11 ± 1.13 7.90 ± 0.51 
a Bacterial counts are converted to log CFU/ml. 
 
4.3.3 Growth rates on different carbon substrates  
The specific grow rate of FEM 1874 was measured on commercial sugars and 
prebiotics, including inulin, lactulose and the dietary fibre arabinogalactan. Growth curves 
over time revealed that FEM 1874 is able to utilize all the carbon sources tested even 
though at different extents (Figure 2).  
 Growth rates between time 0 and 24 h have been calculated for each substrate as 
indicated in Material and Methods section (Table 5). The results indicate a preference of 
Lb. brevis FEM 1874 for glucose, fructose and arabinogalactan. No significant differences 
have been observed between growth rates in lactose and lactulose as well as among those 




Figure 2. Fitness of FEM 1874 on different carbohydrates to be used as carbon sources. Growth 
curves on PY broth plus1 % w/v sugar have been determined over 24 h by means of optical density 
(OD) spectrophotometrically measures at 650 nm. Data are presented as mean ± sd (N=3). PY, 
Peptone Yeast; Arab-Gal, arabinogalactan  
 
 
Table 5. Growth rates of FEM 1874 in different carbon substrates. *p-values, paired t-test, one sugar vs 
others; significant p-values are indicated in italics  
 
 
4.3.4 Antibiotic susceptibility testing 
Regarding the safety assurance of probiotic organisms in food, FAO/ WHO 
guidelines (2002) suggest testing probiotic strains for antibiotic resistance. Primary testing 
of the antibiotic resistance patterns of Lb. brevis FEM 1874 strain was carried out by the E-
strip method, following manufacturer’s instruction. According to the sensitivity guidelines 
provided by EFSA (73), FEM 1874 was interpreted to be sensitive to ampicillin while 
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lactulose 0.034 ± 0.0005 
 
0.023 0.004 0.148 0.012 0.004 
inulin 0.025 ± 0.0008 0.023 
 
0.0002 0.004 0.0002 0.001 
glucose 0.052 ± 0.0014 0.004 0.0002 
 
0.001 0.0008 0.070 
lactose 0.036 ± 0.0022 0.148 0.004 0.001 
 
0.003 0.009 
fructose 0.042 ± 0.0026 0.012 0.0002 0.0008 0.003 
 
0.052 




resistant to gentamicin, erythromycin, clindamycin, and vancomycin, with MICs being 
two, four, two and one times more the indicated cut off values (Table 6). 
 
 
Table 6. Resistance of FEM 1874 to various antimicrobial agents 
 CA VA DA TE AM ER 
cut off value (mg/ml)* 4 nr 1 8 4 1 
MIC (mg/ml) 8 1 2 8 1 4 
*Microbiological cut-off values as indicated by EFSA; CA, Gentamycin; VA, Vancomycin; DA, Clindamycin; TE, 
Tetracycline; AM, Ampicillin; ER, Erythromycin 
 
 
4.4 Discussion  
Beside the technological relevance of LAB in cheese production, there is a strong 
research interest to identify and characterize dairy strains with potential probiotic activities 
(82,83). The identification of strains with specific mode of action or biochemical trait 
capable of mediating specific host physiological responses represents the basis of a rational 
scientific selection of next generation probiotic strains designed to mediate specific health 
effects in the host. Targets will include microbiota-impacted physiological functions 
extending beyond the gut.  
In the recent years, particular attention has been paid to high 𝛾-aminobutyric acid 
(GABA) producing LAB strains (84) particularly from fermented food, including cheese 
(38,40) and fresh unpasteurized milk (85) or by strains isolated from the human intestinal 
tract (86). From a technological point of view, GABA in cheese may have a direct effect in 
the formation of holes thanks to the increased decarboxylase activity and consequent gas 
formation (87,88). This may sometimes be an unwanted phenotype depending on the type 
of cheese being produced. From a health perspective GABA has several well-characterized 
physiological functions in humans and other mammals. Moreover there is strong evidence 
that GABA derived from the gut can act as a neuroactive molecule in the context of the 
gut-brain axis (21,22).  
In previous work, we isolated 276 strains from a specific raw cow milk “Nostrano-
cheese”, typical of the Trentino province (north, alpine area) in Italy. 71% bacterial strains 
were able to produce GABA (38). Upon investigation of GABA production, we found that 
one of these isolates, named L. brevis FEM 1874 possessed high glutamate decarboxylase 
(GAD) activity compared to the type strain DSM 20054 and the known probiotic mixture 
VSL#3 (89). As in Listeria monocytogenes, GAD activity in Lb. brevis may be critical for 
survival in acidic conditions and allows it to overcome the low pH stresses of fermented 
foods, gastric juice, volatile fatty acids in the GIT (90). The high GABA production from 
Lb. brevis has been confirmed by several individual studies on various Lb. brevis strains 
(91). GABA production represents therefore an important protection mechanism for these 
strains under acidic environments.  
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Two GAD-encoding genes, named gadA and gadB are present in Lb. brevis 
(74,91). The phylogenetic distance between gadA and the other GADs gene in Lb. 
plantarum, Lc. lactis, Lb. reuteri and Lb. fermentum suggests the occurrence of an 
independent evolution in Lb. brevis (91), and only gadA gene is present in the gad operon 
in Lb. brevis. gadB is located distantly from the gad operon. The high GABA production 
by Lb. brevis FEM 1874 appears not to be due to mutation in these genes as we identified 
the presence of the intact gad operon at the genomic level. In general the bacterial GAD 
system includes i) a glutamate uptake by a specific transporter followed by ii) the removal 
of an intracellular proton during glutamate decarboxylation and iii) GABA export from the 
cell via an antiporter. This leads to an increase in the cytoplasmic pH (by the removal of 
hydrogen ions) and also slightly increasing the extracellular pH (by the exchange of 
extracellular glutamate for GABA) (90). Interestingly, compared to the type strain DSM 
20054, Lb. brevis FEM 1874 induces a higher expression of both gadA and gadB genes 
over time, accompanied by an increased level of gadC, the gene encoding for the antiporter 
and gadR, encoding for the positive operon regulator. Indeed, the higher activation of the 
GAD system observed could account for the high GABA production. 
The physiological activity of GABA makes it an interesting bioactive molecule 
which has already been used as a food supplement in pure form (92). In recent years 
researchers have reported a number of placebo controlled studies in which GABA was 
administered as a food or oral supplement to healthy participants (26–31). GABA have 
been shown to be rapidly absorbed with the half-life of 5 h in a human intervention study 
where twelve healthy subjects were subjected to oral administration of 2 g GABA once or 
2 g GABA three times/day for 7 days (31). A recent study has shown that the ingestion of 
800 mg synthetic GABA enhanced the ability of prioritized planned actions (30). 10 gr of 
chocolate enriched with 28 mg GABA (27), a beverage containing 50 mg GABA (28), or 
100 mg encapsulated GABA (29) were reported to reduce psychological fatigue and 
psychological stress after completion of an arithmetic task. To reach those doses, one 
would have to eat more than 2 kg of uncooked spinach, a vegetable rich in GABA (93). A 
pioneering study in patients with mild hypertension reported that daily intake of fermented 
milk containing 10-12 mg/100 mL of GABA could significantly lower blood pressure 
within 2 weeks (35). In these terms fermented milk enriched in GABA produced by Lb. 
brevis FEM 1874 may have commercial potential as a health-oriented dairy product as well 
as any direct probiotic effect of the high GABA producing strain.  
To be considered a possible probiotic the bacterial strain, in addition to being a 
GRAS organism, should be able to survive within the human GI tract and therein mediate a 
specific health related activity in the right environment (68,69). Testing for tolerance of 
low pH, bile acids and pancreatic fluids have often been considered as good indicators for 
survival through the GI tract. In this study, Lb. brevis FEM 1874 strain performed well in 
the in vitro tests, and survival through the stomach is likely. In addition, previous studies 
have shown that food matrix plays an important role in probiotic survival of gastric pH 
(94,95) and cheeses in particular appears to effectively protect probiotics from low pH 
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encountered in the stomach (96,97). However, survival under in vivo conditions in human 
subjects should be tested.  
Lb. brevis FEM 1874 was able to ferment and growth on several carbon sources 
including arabinogalactan, Arabinogalactan is a non-starch polysaccharide found in coffee 
beans, soybeans, broad beans, larch, tamarack, and cereals (98). Differently to what 
occurred with fructo-oligosaccharides, arabinogalactan acts as a prebiotic for the distal 
colon microbiota (99). Its oral administration has been reported to increase Lactobacillus 
spp. (100). Due to its saccharolytic function, short chain fatty acid production and 
ammonia level reduction (101) arabinogalactan could be used in the treatment of  diseases 
characterized by ammonia build-up in the liver such as cirrhosis, chronic liver diseases and 
portal systemic encephalopathy. The potential action of arabinogalactan on the 
gut:brain:liver axis and the GABA producing capability of FEM 1874 suggest the 
possibility of using a combination of both in synbiotic formulation. 
Lactic acid bacteria are intrinsically resistant to many antibiotics (102–109). In 
many cases resistances are not, however, transmissible, and the species are also sensitive to 
many clinically used antibiotics even in the case of a lactic acid bacteria- associated 
opportunistic infection. Among 187 isolates from 55 European probiotic products showed 
that 79% of the isolates were resistant against kanamycin and 65% of the isolates were 
vancomycin resistant. Remaining resistances were in the order of tetracycline (26%), 
penicillin G (23%), erythromycin (16%) and chloramphenicol (11%). Overall, 68.4% of 
the isolates showed resistance against multiple antibiotics including intrinsic resistance 
(110). The antimicrobial susceptibility tests indicated that Lb. brevis FEM 1874 was 
sensitive to ampicillin and mildly resistant toward gentamycin, clindamycin, erythromycin 
and vancomycin. To note that a Lb. brevis strain isolated from human GIT (103) has been 
shown to be resistant to higher level of vancomycin (256 mg/ml) and clindamycin (32 
mg/ml) than Lb. brevis FEM 1874. Furthermore, the probiotic L. brevis KB290 MICs of 
tetracycline, and vancomycin were four, and eight times, respectively, higher than the 
breakpoint MICs suggested by the European Scientific Committee on Animal Nutrition, 
and the MIC of tetracycline was eight times the MIC suggested by the European Scientific 
Panel on Additives and Products or Substances Used in Animal Feed (109). The main 
concern amongst LAB is the resistance to vancomycin, within the genus Enterococcus 
where the resistance has been shown to be transferable (111). Vancomycin resistance is 
generally considered as an intrinsic property in lactobacilli, however, being described in 
several isolates from fermented food, diary and GIT (69,103–105,107–109) and this 
resistance also has been described in the widely used probiotic strain Lb. rhamnosus GG 
(108), where it has been described as not transferable. Therefore no particular safety 
concern is associated with this intrinsic type of resistance. Of course, we will investigate if 
the antibiotic resistances of FEM 1874 are intrinsic and we will perform plasmid curing of 
FEM 1874 to eliminate plasmid-associated antibiotic resistance, if any. 
Even though in vivo investigations are needed, altogether these preliminary results 
showed that the Lb. brevis GABA producing FEM 1874 strain represents a promising 
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starter for manufacturing GABA-rich cultured dairy foods to be used as functional food as 
well as a promising next generation probiotic in the context of the gut(microbiota):brain 
axis. Tests on GABA level availability in FEM 1874 dairy products are ongoing.  Overall 
our data indicate the importance of studying and preserving the traditional raw milk cheese 
microbiome. Traditional cheeses represent an important source of microbial biodiversity 
where new LAB strains with potential health promoting properties can be isolated.  
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Table S1. List of utilized primers for gad genes locus amplification. 
	
Primer name Primer sequence PCR product size 
(bp)/target gene 
gadR2-F 3’- AAACGGCTAGTTTTGGAAAGC -5’ 
408bp/gadR gadR2-R 3’- AACGACCAAAGCCGGATTTT -5’ 
gadR3-F 3’- AGAACTAAGGAAAGGCTGGGG -5’ 
218bp/gadR 
gadR3-R 3’- TAACTAGCCAGCCAGTTGTCG -5’ 
gadR4-F 3’- TCGATCTGATTGTGGAACGA -5’ 
208bp/gadR 
gadR4-R 3’- TCTAATAACATGGCCAATTGC -5’ 
gadR/intra_F 3’- CAGAGTCTGAAGCAGGCATGT -5’ 
549bp/intergenic region 
gadR/intra_R 3’- AATGCCGCAAAACCGTAAAC -5’ 
gadA4-F 3’- ACCACGCAAATGGAACCACAA -5’ 
894bp/gadA 
gadA4-R 3’- CTTCAATGACACCTTCCGAA -5’ 
gadA7-F 3’- CTTTGTGGTCATGCTCGTTTT -5’ 
576bp/gadA 
gadA7-R 3’- CAGTTGAGGTCCCAATGAAA -5’ 
gadA8-F 3’- TTTACCCGCAGAAATGCGAT -5’ 
711bp/gadA 
gadA8-R 3’- ATGGTTCCGTGATAGTGCCG -5’ 
gadIntra/gadA_F 3’- ATCCGTTGCCTCAAAACACA -5’ 
394bp/intergenic region 
gadIntra/gadA_R 3’- CGATAGTGTTCCACCAATTGA -5’ 
gad/anti1-F 3’- GATTGCCCAATGGTGTTTCA -5’ 
545bp/gadC 
gad/anti1-R   3’- TCCCATATTTATTGGCCTTAGAG -5’ 
gad/anti2-F 3’- TCCCAAATTGAAACCGCTGT -5’ 
737bp/gadC 
gad/anti2-R 3’- ACCGGCAAAAGCCAAGATAA -5’ 
gad/anti4-F 3’- TTTACGCCTATGGGGCCTT -5’ 
674bp/gadC 
gad/anti4-R 3’- GGTTTCTTTTTCCAACGCCT -5’ 
gadB4-F 3’- CGGTTATCAAGTTTGTTGGG -5’ 
458bp/gadB 
gadB4-R 3’- AGGCACTGTGGGAGAAGTTGAT -5’ 
gadB6-F 3’- ATCTTACTCCGGTCCCTTTGA -5’ 
662bp/gadB 
gadB6-R 3’- GGTTGATGGGCAGTTAAGTCA -5’ 
gadB7-F 3’- TAATCTGGCGTGACCAACA -5’ 696bp/gadB 
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gadB7-R 3’- CAATGATGGTAAACGCCGAA -5’ 
	
 
Table S2. List of utilized primers for gad genes expression analysis in presence of 30 
mg/ml of MSG. 
 
Primer name Primer sequence PCR product size 
(bp)/target gene 
gadA_RT2-F 3’- GCCAATTAATGGTGACCAAGT -5’ 
110bp/gadA 
gadA_RT2-R 3’- CGGAGCCTGTGTACGTAATG -5’ 
gadB_RT2-F 3’- GTCCTTGAATGTCGATCACG -5’ 
126bp/gadB 
gadB_RT2-R 3’- CGCTCTACAACGGCATCTAA -5’ 
gad/anti_RT-F 3’- AAGATTGCCCAATGGTGTTT -5’ 
147bp/gadC 
gad/anti_RT-R 3’- ACTCCCATTCCAACTCGATG -5’ 
gad/R_RT1-F 3’- CCCATGCTTATTCGGAATTT -5’ 
111bp/gadR 
gadR_RT1-R 3’- CATTGCGGAAATGTAACTGC -5’ 
Lb_tuf2-F 3’- GCCGCTCAAATGGACGGTGC -5’ 
230bp/tuf1 











 There are many potential mechanisms by which gut microbiota can influence 
human (patho)physiology. Indeed recent fascinating evidence has emerged on the deep 
interconnections between the host central nervous system, brain health and gut microbiota. 
Alterations in the gut:brain axis have been implicated in the pathogenesis of gut disorders 
such as irritable bowel syndrome and related functional gastro intestinal disorders and also 
in several psychiatric conditions including autism spectrum disorders, depression and 
chronic pain. In most of these disorders a shift from the healthy symbiotic gut microbiota 
to a dysbiotic condition is repeated and seems to represent the turning point in the 
evolution of pathogenesis or at least the onset of these diseases. Dysbiotic microbiota has 
also been reported in liver diseases and their complications such as hepatic encephalopathy 
(HE). This debilitating complication of liver failure may be considered as a clear example 
of how an altered gut microbiota homeostatis can influence physiological function outside 
the intestine with implication for host health at the systems level. 
The studies presented in this thesis uses a multilevel approach to study i) the 
microbial dynamics and metabolic activity of the liver disease microbiota, upon 
modulation by prebiotic, antibiotic and probiotic; ii) the impact of the probiotic VSL#3 on 
the gut microbiota of children with HE in double blind, randomized pilot scale dietary 
intervention run by the U.S.S.D Epatologia Gastroenterologia e Trapianti pediatrici 
(Ospedale di Bergamo); iii) initial probiotic strain characterization of Lactobacillus brevis 
FEM 1874 strain, selected as a putative next generation probiotic capable of impacting on 




Measuring cirrhotic microbiota modulation by prebiotic, antibiotic and 
probiotic treatment using in vitro faecal batch cultures 
	 136 
Gut microbiota alteration represents a key factor in cirrhosis progression and 
appear to be related to neuropsychiatric complications. In particular, microbial dysbiosis 
and gut ammonia production by microbial activities are the main factors implicated in HE 
development. Most of the available HE therapies concentrate on reducing serum ammonia 
levels by decreasing its production in the intestine and increasing its elimination. Despite 
apparent clinical efficacy of prebiotics, antibiotics and probiotics to ameliorate mental and 
cognitive status in HE by reducing ammonia levels, little is known about the dynamics, 
interactions and bacteria, responsible for metabolite production within the cirrhotic gut 
microbiota. Moreover, data on ammonia levels are usually related to circulating levels and 
not based on ammonia concentrations within the colonic environment. Here, I investigated 
how cirrhotic microbiota is modulated by lactulose, rifaximin and VSL#3, treatments 
currently used in clinical practice in the treatment of HE. I used in vitro pH controlled 
batch cultures using faecal samples from 10 cirrhotic patients to evaluate changes in the 
microbiota structure, short fatty acid production and ammonia concentration. Data from 
this in vitro approach showed how the microbial environment characteristic of cirrhosis 
can be modulated dynamically at both the community structural and metabolic levels. 
Although lactulose, VSL#3, rifaximin and their mixtures all appeared to modulate the 
cirrhotic microbiota to some degree changing relative abundance of certain bacterial taxa, 
their major impact appeared to be at the metabolic level.  
Across the 24 hour of fermentation, data showed that at least 10 hours are needed 
to induce the most appreciable changes. In particular, few changes have been observed at 
the population structural level, where rifaximin fermentation leads to the larger modulation 
in terms of taxa relative abundance. After the 24 hours fermentation, rifaximin or its 
association with lactulose or lactulose plus VSL#3 significantly decreased the abundance 
of Clostriadiales, Lachnospiraceae, Vellonellaceae and at genus level, Blautia abundance 
in agreement with a previous study on the mucosal microbiota composition of HE patients 
supplemented with rifaximin plus lactulose. Moreover, rifaximin alone and in combination 
with lactulose was able to strongly reduce Streptococcaceae relative abundance which 
were previously associated to poor cognitive performance in HE patients. Furthermore, in 
response to rifaximin we observed a decrease of Collinsella, which was found overabudant 
in mice with NAFLD induced by a high fat diet. I observed a particularly large increase in 
bifidobacteria beneficial group in lactulose fermentation. Presence of the prebiotic was 
also associated with acetate, propionate and butyrate production, and reduced 
concentration of ammonia. This shift in metabolite production is indicative of carbohydrate 
fermentation that could also significantly increased consumption or conversion of 
ammonia and other nitrogenous compounds in bacterial biomass. In either case, reduced 
ammonia concentrations and increased concentration of SCFA are consistent with 
improved gut health and reduced risk of HE.  
Previously, human intervention studies have usually only shown a clear association 
between cognitive performance, liver disease, gut microbiota and ammonia increase and 
not causation. Co-occurance was observed between certain microbial changes and 
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improving symptoms. Although in vitro batch cultures provide a technically simple way of 
studying complex biological systems, here, they helped to correlate ecological niches and 
metabolic activities with particular phylogenetic groups amongst the gut microbiota of 
cirrhotic patients. The results emphasize the importance of prebiotic in shifting 
fermentation patterns of the cirrhotic microbiota towards SCFA production while reducing 
ammonia level and also the possible synergistic effects of lactulose, VSL#3 and rifaximin 
in lowering colonic ammonia accumulation and possibly HE symptomatology. However, 




Effect of VSL#3 treatment in paediatric patients and young adults affected by 
Minimal Hepatic Encephalopathy from portal hypertension: a pilot 
intervention study 
Many liver and vascular diseases cause portal vein hypertension in children. Portal 
vein hypertension may give rise to severe and life-threatening complications, including 
haemorrhaging from oesophageal varices, ascites, hepatopulmonary syndrome, 
portopulmonary hypertension and HE. The effective prevention and management of portal 
hypertension and its complications, therefore, are important goals for improving health 
related outcomes and quality of life in affected children. Prebiotics, antibiotics, L-ornithine 
L-aspartate, branched aminoacids, probiotics and synbiotics as well as a low protein diet 
have all been shown to improve psychometric performance and quality of life in this 
disease group.  
Generally defined as “life microorganisms that produce a beneficial effect to the 
host when administered in an adequate amount”, probiotics have been shown to be 
effective in amelioration of liver disease conditions by (i) changing gut metabolism; (ii) 
reducing ammonia in the portal blood (decreasing bacterial urease activity, intestinal 
permeability, ammonia absorption by lowering pH and improving nutritional status of the 
gut epithelium); (iii) reducing hepatic inflammation and oxidative stress; (iv) reducing the 
absorption of other toxins such as indoles, oxindoles, phenols and mercaptans. However, 
despite their potential, most studies evaluating probiotics in experimental models of 
cirrhosis and portal hypertension have given conflicting results. Nevertheless, several 
human intervention studies, mainly in the field of HE, have provided supportive evidence 
for the efficacy of certain probiotics in the improvement of Minimal HE (MHE), in the 
prevention of HE recurrence and prophylaxis of Overt HE.  
Here, I presented a pilot intervention study in paediatric and young adults affected 
by portal vein hypertension and manifesting with symptoms of MHE 
(https://clinicaltrials.gov/ct2/show/NCT01798329). Intervention was with VSL#3 or 
placebo for 3 months. The study was initially powered at 25 patients per group but because 
of difficulties in recruiting patients meeting the inclusion and exclusion criteria the 
	 138 
responsible clinicians were only able to provide faecal samples from 8 patients in the 
VSL#3 treated group and 6 patients in the placebo group. I performed 16S rRNA 
sequencing on faecal samples before and after the treatment from patients involved in this 
pilot study. The overall aim was to study the effect of VSL#3 in ameliorating cognitive 
function and patients quality of life by modulating the gut microbiota and reducing the 
ammonia level. Despite the small sample size VSL#3 supplementation resulted in a trend 
towards improved cognitive function but not a significant change in the gut microbiota nor 
a decrease in blood ammonia levels. Even though not statistically significant a trend 
towards an increased relative abundance in Actinobacteria and a concomitant decrease in 
Bacteroidetes was evident from the 16S rRNA profiling data. The results suggested also a 
mild decrease in Bacteroides relative abundance, as well as a slight increase of 
Ruminococcus and Faecalibacterium. Ruminococcus has been previously associated with 
secondary bile acid production and decreased severity of cirrhosis progression.  
This pilot intervention study suffered from the small number of subjects recruited 
(14 out of 50 expected) and potential of the different underlying pathological causes of 
portal vein hypertension to influence baseline variation in gut microbiota composition. 
Moreover, VSL#3 might induce different alterations in the microbiota from different 
patients that are probably not consistent between subjects, due to their intrinsic difference 
in microbiota composition. A larger study with a more potent stratification for different 
underlying liver disease is needed to prove the link between gut microbiota changes in 
terms of community structure and metabolism and the efficacy of VSL#3 in ameliorating 
the disease condition. However, according to previous studies in adults, the 50 patients we 
initially planned to enrol might be sufficient to observe microbiota changes as well as 
changes in the plasma ammonia or transaminase levels. 
Conflicting results directly linking the dysbiosis and the improvement of cognitive 
function in HE therapies have also been observed in response to other clinical therapies 
such as lactulose or rifaximin. Moreover, also my previous investigation using in vitro 
faecal batch cultures showed only modest changes of bacterial community structure upon 
VSL#3 fermentation. This suggests that further investigations should not be restricted to 
measuring the relative abundance of particular bacterial taxa but should also evaluate any 
changes in the gut microbiota metabolism. Indeed, 16S rRNA profiling flanked by a 
metabolomic approach would allow better understanding of the link between microbiota 
modulation and disease symptoms.  
 
 
Probiotic characterization of high GABA producing strain Lactobacillus brevis 
FEM 1874 
Probiotic interventions targeting the microbiota-gut-brain axis to modulate 
behavior have recently been reported. Lb. rhamnosus JB-1 promoted an anxiolytic–
antidepressant-like effect through alterations in the expression of GABA receptors, such as 
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such as GABAAα2, GABAAα1, and GABAB1b. Indeed, GABA receptors targeting 
represents a goal for improving brain function. Identification of bacteria able to produce 
high GABA levels and bearing features of a probiotic is a viable approach for designing 
efficacious next generation probiotics targeting the gut:brain axis. A previous study of our 
group isolated 276 strains from a specific raw cow milk “Nostrano-cheese”, typical of the 
Trentino province (north, alpine area) in Italy. 71% bacterial strains were able to produce 
GABA. Among those, Lb. brevis FEM 1874 possessed the highest glutamate 
decarboxylase (GAD) activity compared to the type strain. We therefore sought to 
characterize its potential as a novel next generation probiotic. Indeed the identification of 
strains with specific mode of action or biochemical trait capable of mediating specific host 
physiological responses, represents the basis of a rational scientific selection of next 
generation probiotic strains designed to mediate specific health effects in the host. Targets 
will include microbiota-impacted physiological functions extending beyond the gut.  
Lb. brevis FEM 1874 accumulated high levels of GABA in the culture medium 
thanks to a higher transcriptional GAD activity compared to the type strain. FEM 1874 was 
able to efficiently convert glutamate to GABA by the increased expression of the operon 
regulator (gadR) and the (gadC) antiporter encoding genes. Testing for tolerance of low 
pH, bile acids and pancreatic fluids have often been considered as good indicators for 
survival through the GI tract. In this study, Lb. brevis FEM 1874 strain proved resistant to 
low pH, bile acids and pancreatic fluids thus suggesting its survival through the stomach is 
likely. However, survival under in vivo conditions in human subjects should be tested.  
There are some concerns about the ability of free GABA in reaching the brain and 
cross the brain barrier. However, the physiological activity of GABA makes it an 
interesting bioactive molecule which has already been used as a food supplement in pure 
form. GABA was shown to reduce blood pressure and heart rate and anxiety as well as to 
have anti-proliferative activity on colon carcinoma cells. Moreover GABA 
supplementation resulted in inflammation relief by decreasing cytokine secretion and T 
cells proliferation. In these terms fermented milk enriched in GABA produced by Lb. 
brevis FEM 1874 may have commercial potential as a health-oriented dairy product as well 
as any direct probiotic effect of the high GABA producing strain. Tests on GABA level 
availability in FEM 1874 dairy products are ongoing. My data showed that Lb. brevis FEM 
1874 was able to ferment and growth on arabinogalactan which oral administration has 
been reported to increase Lactobacillus spp., to promote short chain fatty acid production 
and ammonia level reduction. The potential action of arabinogalactan on the gut:brain:liver 
axis and the GABA producing capability of FEM 1874 suggest the possibility of using a 
combination of both in synbiotic formulation. 
Overall, this preliminary characterization indicates the potential of FEM 1874 as a 
next-generation probiotic targeting disruptions occurring in the gut(microbiota):brain axis, 
as in the case of advanced liver disease and liver failure as well as systemic inflammation 
through GABA production. 
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To conclude, this thesis work showed the efficacious of prebiotic, probiotic and 
antibiotic in targeting the dysbiosis related to gut:liver:brain axis disruption, as in the case 
of cirrhosis and HE. The major changes occurred at the metabolic level with a reduction in 
ammonia accumulation and production of SCFA, especially when a synbiotic formulation 
is used. Of consequence this restored metabolic make up will account for ameliorating 
clinical symptoms and quality of life of cirrhotic and HE patients. The research moved also 
a step forward by identifying a Lb. brevis strain capable of producing and secreting high 
amount of GABA. Lb. brevis FEM 1874 might be a promising probiotic or a starter for 
dairy fermentation to manufacture GABA-rich cultured dairy foods to be used in restoring 










































Supplementary Tables Chapter 2 
 
Table A1. Mean relative abundance (%) ± standard deviation (SD) of bacterial taxa at phylum order 
and family levels in Healthy subjects (HS), Cirrhotic patients (CP) and CP subgroups at the 
baseline. ALC, alcohol cirrhosis; AI, autoimmune cirrhosis; NASH, non-alcoholic stehatosis. 
 
 Health status 
Phylum HS 
mean ± sd 
CP 
mean ± sd 
ALC 
mean ± sd 
AI 
mean ± sd 
NASH 
mean ± sd 
Actinobacteria 6.281 8.433 4.202 3.389 3.858 2.579 3.645 2.644 4.741 4.030 
Bacteroidetes 31.33 12.64 34.19 10.58 34.22 10.41 39.83 9.60 34.27 11.00 
Chloroflexi 0.000 0.000 0.000 0.001 0.000 0.002 0.000 0.000 0.000 0.000 
Cyanobacteria 0.007 0.011 0.016 0.039 0.005 0.009 0.058 0.079 0.017 0.041 
Euryarchaeota 0.014 0.042 0.007 0.028 0.005 0.017 0.000 0.000 0.015 0.035 
Firmicutes 56.753 12.584 56.405 9.089 56.754 8.810 54.357 9.163 57.082 9.520 
Fusobacteria 0.031 0.095 0.060 0.172 0.057 0.162 0.000 0.000 0.067 0.196 
Lentisphaerae 0.004 0.009 0.004 0.009 0.003 0.007 0.007 0.013 0.003 0.010 
Proteobacteria 4.786 6.458 3.375 6.095 4.246 7.036 1.258 0.439 2.942 5.765 
Synergistetes 0.000 0.002 0.003 0.015 0.001 0.007 0.000 0.000 0.007 0.020 
Tenericutes 0.006 0.019 0.010 0.027 0.016 0.035 0.000 0.000 0.005 0.022 
TM7 0.000 0.000 0.002 0.005 0.003 0.006 0.005 0.005 0.001 0.002 
Verrucomicrobia 0.013 0.020 0.039 0.103 0.026 0.043 0.017 0.016 0.072 0.137 
Other 0.774 0.332 0.776 0.285 0.798 0.296 0.815 0.391 0.772 0.260 
 
 Health status 
Order HS 
mean ± sd 
CP 
mean ± sd 
ALC 
mean ± sd 
AI 
mean ± sd 
NASH 
mean ± sd 
Actinomycetales 0.01 0.01 0.025 0.023 0.027 0.022 0.024 0.020 0.022 0.024 
Aeromonadales 0.00 0.00 0.001 0.004 0.001 0.004 0.00 0.00 0.001 0.004 
Anaerolineales 0.00 0.00 0.000 0.001 0.000 0.002 0.00 0.00 0.000 0.000 
Bacillales 0.00 0.00 0.001 0.004 0.002 0.005 0.00 0.00 0.001 0.002 
Bacteroidales 31.5 12.7 34.87 10.66 34.49 10.50 38.6 9.65 34.50 11.09 
Bifidobacteriales 4.09 6.11 3.535 3.410 3.133 2.624 2.60 2.39 4.031 4.061 
Burkholderiales 1.10 1.17 0.911 0.423 0.819 0.317 0.76 0.22 1.013 0.502 
Campylobacterales 0.00 0.00 0.006 0.014 0.009 0.015 0.00 0.00 0.004 0.014 
Cardiobacteriales 0.00 0.00 0.000 0.002 0.001 0.002 0.00 0.00 0.000 0.002 
Clostridiales 40.69 10.9 39.25 12.39 38.70 14.55 48.9 10.3 37.97 10.13 
Coriobacteriales 2.22 6.07 0.734 0.519 0.731 0.538 0.83 0.35 0.718 0.538 
CW040 0.00 0.00 0.000 0.003 0.001 0.004 0.00 0.00 0.000 0.000 
Desulfovibrionales 0.60 0.58 0.199 0.182 0.132 0.103 0.42 0.25 0.214 0.188 
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Enterobacteriales 3.08 5.44 2.160 6.009 3.199 6.931 0.09 0.05 1.678 5.661 
Erysipelotrichales 7.80 13.7 1.417 1.157 1.241 1.228 0.88 0.37 1.657 1.150 
Flavobacteriales 0.00 0.00 0.000 0.001 0.000 0.000 0.00 0.00 0.000 0.002 
Fusobacteriales 0.03 0.09 0.058 0.174 0.057 0.163 0.00 0.00 0.068 0.198 
Gemellales 0.00 0.00 0.008 0.016 0.006 0.012 0.00 0.01 0.010 0.019 
I025 0.00 0.00 0.000 0.001 0.000 0.000 0.00 0.00 0.000 0.000 
Lactobacillales 8.68 8.79 16.54 14.77 17.249 16.864 6.605 8.830 17.742 13.339 
Methanobacteriales 0.014 0.042 0.009 0.028 0.005 0.018 0.000 0.000 0.015 0.035 
ML615J-28 0.004 0.017 0.006 0.022 0.012 0.029 0.000 0.000 0.003 0.016 
Neisseriales 0.000 0.000 0.000 0.002 0.001 0.002 0.000 0.000 0.000 0.002 
Pasteurellales 0.011 0.022 0.068 0.166 0.102 0.202 0.009 0.011 0.051 0.143 
Pseudomonadales 0.000 0.002 0.000 0.003 0.001 0.004 0.000 0.000 0.000 0.000 
RF32 0.011 0.018 0.009 0.020 0.016 0.025 0.004 0.008 0.004 0.013 
RF39 0.003 0.005 0.003 0.009 0.004 0.011 0.000 0.000 0.003 0.009 
Rhizobiales 0.002 0.004 0.002 0.004 0.002 0.004 0.001 0.004 0.001 0.004 
SHA-98 0.000 0.002 0.002 0.006 0.003 0.009 0.001 0.004 0.001 0.004 
Streptophyta 0.000 0.000 0.000 0.003 0.000 0.000 0.000 0.000 0.001 0.004 
Synergistales 0.000 0.002 0.004 0.015 0.001 0.007 0.000 0.000 0.007 0.020 
Turicibacterales 0.030 0.068 0.044 0.090 0.012 0.053 0.056 0.073 0.069 0.109 
Verrucomicrobiales 0.013 0.020 0.048 0.104 0.026 0.043 0.014 0.016 0.072 0.138 
Victivallales 0.004 0.009 0.004 0.009 0.003 0.007 0.010 0.013 0.003 0.010 
YS2 0.005 0.010 0.015 0.040 0.005 0.010 0.050 0.080 0.017 0.043 
 
 Health status 
Family CP 
mean ± sd 
HS 
mean ± sd 
ALC 
mean ± sd 
AI 
mean ± sd 
NASH 
mean ± sd 
Actinomycetaceae 0.017 0.020 0.010 0.01 0.020 0.019 0.015 0.015 0.015 0.015 
Aerococcaceae 0.001 0.003 0.000 0.00 0.001 0.001 0.000 0.000 0.001 0.001 
Alcaligenaceae 0.944 0.443 1.141 1.19 0.847 0.837 0.821 0.824 0.987 0.974 
Bacteroidaceae 25.70 12.28 25.95 11.8 28.39 28.40 27.64 27.85 23.42 23.73 
Bifidobacteriaceae 3.675 3.539 4.237 6.25 3.234 3.253 2.839 2.871 4.128 3.869 
Burkholderiaceae 0.000 0.002 0.000 0.00 0.001 0.000 0.000 0.000 0.000 0.000 
Campylobacteraceae 0.002 0.006 0.000 0.00 0.004 0.003 0.002 0.002 0.001 0.001 
Carnobacteriaceae 0.012 0.019 0.006 0.01 0.007 0.007 0.011 0.012 0.015 0.016 
Christensenellaceae 0.059 0.157 0.077 0.15 0.101 0.104 0.114 0.103 0.036 0.037 
Clostridiaceae 0.684 0.901 0.808 1.12 0.433 0.416 0.506 0.520 0.910 0.843 
Coriobacteriaceae 0.769 0.550 2.283 6.15 0.766 0.785 0.940 0.948 0.703 0.717 
Corynebacteriaceae 0.001 0.004 0.000 0.00 0.002 0.002 0.001 0.001 0.000 0.000 
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Dehalobacteriaceae 0.003 0.008 0.001 0.07 0.005 0.005 0.005 0.005 0.002 0.002 
Desulfovibrionaceae 0.209 0.195 0.630 0.59 0.138 0.142 0.226 0.229 0.226 0.219 
Dethiosulfovibrionac
eae 0.004 0.016 0.000 0.07 0.001 0.001 0.001 0.001 0.004 0.004 
Enterobacteriaceae 2.205 6.124 3.155 5.55 3.265 2.728 1.230 1.261 1.937 1.992 
Enterococcaceae 0.300 0.663 0.644 2.00 0.522 0.497 0.461 0.469 0.198 0.203 
Erysipelotrichaceae 1.481 1.234 7.976 13.9 1.298 1.270 1.311 1.337 1.670 1.702 
Eubacteriaceae 0.002 0.005 0.001 0.00 0.002 0.002 0.002 0.002 0.001 0.001 
Fusobacteriaceae 0.058 0.176 0.031 0.09 0.058 0.060 0.005 0.005 0.083 0.085 
Gemellaceae 0.008 0.016 0.001 0.00 0.006 0.005 0.005 0.005 0.012 0.012 
Helicobacteraceae 0.004 0.014 0.001 0.00 0.006 0.006 0.006 0.006 0.004 0.004 
Lachnospiraceae 17.96 5.659 17.51 6.69 17.72 17.67 20.55 20.45 17.28 17.51 
Lactobacillaceae 4.084 4.586 1.375 1.61 3.575 3.685 2.206 2.198 4.877 4.791 
Leuconostocaceae 0.014 0.034 0.021 0.04 0.022 0.022 0.022 0.022 0.006 0.006 
Methanobacteriaceae 0.010 0.029 0.015 0.04 0.005 0.005 0.005 0.005 0.009 0.009 
Microbacteriaceae 0.000 0.000 0.000 0.00 0.000 0.000 0.000 0.000 0.000 0.000 
Micrococcaceae 0.007 0.012 0.000 0.00 0.006 0.006 0.008 0.008 0.007 0.007 
Neisseriaceae 0.000 0.002 0.000 0.00 0.001 0.001 0.000 0.000 0.000 0.000 
Oxalobacteraceae 0.001 0.004 0.000 0.00 0.001 0.001 0.001 0.001 0.001 0.001 
Pasteurellaceae 0.070 0.169 0.011 0.02 0.105 0.087 0.046 0.047 0.055 0.056 
Peptococcaceae 0.016 0.079 0.038 0.11 0.022 0.023 0.025 0.026 0.017 0.017 
Peptostreptococcace
ae 0.014 0.021 0.014 0.03 0.011 0.011 0.006 0.007 0.018 0.017 
Phyllobacteriaceae 0.002 0.004 0.002 0.00 0.002 0.002 0.002 0.002 0.002 0.002 
Porphyromonadacea
e 1.219 1.073 1.534 1.06 1.162 1.199 1.508 1.520 1.178 1.215 
Prevotellaceae 5.500 11.45
4 
1.372 2.15 2.651 2.730 3.891 4.012 7.460 7.692 
Propionibacteriaceae 0.000 0.002 0.000 0.00 0.000 0.000 0.000 0.000 0.000 0.000 
Pseudomonadaceae 0.000 0.003 0.000 0.00 0.001 0.001 0.001 0.001 0.000 0.000 





















0.897 2.961 1.597 3.81 1.187 1.224 2.068 2.132 0.181 0.187 
Staphylococcaceae 0.001 0.003 0.000 0.00 0.001 0.001 0.001 0.001 0.001 0.001 
Streptococcaceae 12.58 12.51 6.944 7.71 13.46 13.76 8.909 8.558 13.14 12.55 
Succinivibrionaceae 0.001 0.004 0.000 0.00 0.001 0.001 0.000 0.000 0.001 0.001 
Turicibacteraceae 0.047 0.096 0.032 0.07 0.013 0.013 0.025 0.026 0.077 0.072 
Veillonellaceae 2.151 1.275 1.880 1.29 1.840 1.793 1.726 1.756 2.422 2.460 
Verrucomicrobiaceae 0.050 0.108 0.014 0.02 0.027 0.028 0.031 0.032 0.049 0.050 
Victivallaceae 0.004 0.010 0.004 0.01 0.003 0.003 0.006 0.006 0.004 0.004 
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[Barnesiellaceae] 0.334 0.358 0.349 0.40 0.307 0.312 0.381 0.389 0.287 0.296 
[Cerasicoccaceae] 0.000 0.001 0.000 0.00 0.000 0.000 0.000 0.000 0.000 0.000 
[Mogibacteriaceae] 0.084 0.106 0.172 0.23 0.105 0.108 0.126 0.124 0.070 0.072 
[Odoribacteraceae] 0.311 0.237 0.399 0.26 0.357 0.365 0.438 0.431 0.246 0.252 
[Paraprevotellaceae] 0.818 1.492 0.311 0.70 0.235 0.243 0.520 0.536 1.228 1.266 




Table A2. Permutational multivariate analysis of variance (PERMANOVA) tests of the bacterial 
microbiota on the unweighted and weighted UniFrac distances and the Bray-Curtis dissimilarity 
according to treatments and time points. ctrl, Control; LR, Lactulose+Rifaximin; R, Rifaximin; V, 
VSL#3; VL, VSL#3+Lactulose; VLR, VSL#3+Lactulose+Rifaximin; VR, VSL#3+Rifaximin 
 
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table A3. Mean relative abundance (%) ± standard deviation (sd) of bacterial taxa at the phylum, 
order, family and genus levels in Cirrhotic patients (CP) at the baseline, over time. 
 Time point 
Phylum T0 mean ± sd 
T5 
mean ± sd 
T10 
mean ± sd 
T24 
mean ± sd 
Actinobacteria 3.792 4.069 4.621 5.688 5.862 6.929 8.679 11.110 
Bacteroidetes 36.543 9.436 32.665 8.634 22.225 16.252 31.624 6.892 
Cyanobacteria 0.013 0.026 0.003 0.007 0.001 0.003 0.004 0.010 
Euryarchaeota 0.016 0.051 0.012 0.038 0.021 0.045 0.045 0.099 
Firmicutes 55.723 7.797 47.189 9.678 59.511 21.146 49.622 7.471 
Fusobacteria 0.052 0.162 2.081 4.323 1.406 2.920 0.669 1.634 
Lentisphaerae 0.006 0.013 0.004 0.009 0.004 0.008 0.006 0.016 
Proteobacteria 3.779 6.367 13.351 7.327 10.900 10.947 9.305 7.771 
Synergistetes 0.005 0.016 0.008 0.025 0.005 0.016 0.005 0.016 
Tenericutes 0.012 0.038 0.002 0.004 0.000 0.000 0.000 0.000 
TM7 0.003 0.007 0.000 0.000 0.000 0.000 0.000 0.000 
Verrucomicrobia 0.055 0.127 0.063 0.142 0.065 0.148 0.039 0.084 
 
 Time point 
Order T0 mean ± sd 
T5 
mean ± sd 
T10 
mean ± sd 
T24 
mean ± sd 
Actinomycetales 0.028 0.022 0.018 0.016 0.008 0.008 0.006 0.010 
Aeromonadales 0.000 0.000 0.001 0.003 0.000 0.000 0.001 0.003 
Bacillales 0.001 0.003 0.000 0.000 0.001 0.003 0.001 0.003 
Bacteroidales 36.543 9.435 32.668 8.635 22.226 16.252 31.626 6.892 
Bifidobacteriales 3.020 4.053 3.722 5.947 4.525 6.947 6.813 9.922 
Burkholderiales 1.123 0.460 3.010 1.534 2.101 1.552 1.836 0.838 
Campylobacterales 0.006 0.011 0.003 0.005 0.006 0.013 0.002 0.006 
Cardiobacteriales 0.002 0.004 0.000 0.000 0.000 0.000 0.000 0.000 
Clostridiales 47.312 11.954 37.297 9.075 30.803 13.628 39.549 8.067 
Coriobacteriales 0.745 0.499 0.881 0.458 1.329 2.300 1.860 1.573 
CW040 0.002 0.006 0.000 0.000 0.000 0.000 0.000 0.000 
Desulfovibrionales 0.225 0.215 0.836 0.488 1.049 0.968 1.472 1.051 
Enterobacteriales 2.320 6.207 9.430 8.144 7.675 9.564 5.967 6.836 
Erysipelotrichales 1.307 0.883 2.853 4.021 24.279 29.884 4.310 7.531 
Fusobacteriales 0.052 0.162 2.081 4.323 1.406 2.920 0.670 1.634 
Gemellales 0.013 0.024 0.005 0.007 0.002 0.004 0.001 0.003 
Lactobacillales 7.030 8.137 6.959 7.065 4.399 4.668 5.753 4.708 
Methanobacteriales 0.016 0.051 0.012 0.038 0.021 0.045 0.045 0.099 
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ML615J-28 0.009 0.029 0.000 0.000 0.000 0.000 0.000 0.000 
Neisseriales 0.000 0.000 0.003 0.010 0.003 0.007 0.000 0.000 
Pasteurellales 0.089 0.200 0.059 0.106 0.059 0.124 0.018 0.037 
Pseudomonadales 0.000 0.000 0.001 0.003 0.000 0.000 0.001 0.003 
RF32 0.015 0.026 0.004 0.013 0.004 0.013 0.001 0.003 
RF39 0.003 0.010 0.002 0.004 0.000 0.000 0.000 0.000 
Rhizobiales 0.000 0.000 0.000 0.000 0.002 0.004 0.002 0.004 
SHA-98 0.003 0.010 0.000 0.000 0.000 0.000 0.000 0.000 
Sphingobacteriales 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Sphingomonadales 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Streptophyta 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Synergistales 0.005 0.016 0.008 0.025 0.005 0.016 0.005 0.016 
Turicibacterales 0.057 0.115 0.077 0.179 0.028 0.040 0.011 0.018 
Verrucomicrobiales 0.055 0.127 0.062 0.139 0.065 0.148 0.039 0.084 
Victivallales 0.006 0.013 0.004 0.009 0.004 0.008 0.006 0.016 
YS2 0.013 0.026 0.003 0.007 0.001 0.003 0.004 0.010 
 
 Time point 
Family T0 mean ± sd 
T5 
mean ± sd 
T10 
mean ± sd 
T24 
mean ± sd 
[Barnesiellaceae] 0.383 0.392 0.457 0.435 0.281 0.429 0.523 0.535 
[Mogibacteriaceae] 0.086 0.112 0.074 0.122 0.077 0.143 0.207 0.328 
[Odoribacteraceae] 0.352 0.238 0.294 0.158 0.151 0.122 0.260 0.165 
[Paraprevotellaceae] 0.924 1.822 0.305 0.434 0.573 1.353 0.142 0.260 
[Tissierellaceae] 0.002 0.004 0.008 0.013 0.013 0.022 0.021 0.044 
Actinomycetaceae 0.026 0.025 0.016 0.014 0.007 0.007 0.005 0.010 
Aerococcaceae 0.001 0.003 0.000 0.000 0.000 0.000 0.000 0.000 
Alcaligenaceae 1.172 0.479 3.083 1.541 2.133 1.564 1.904 0.850 
Bacteroidaceae 28.14 12.63 26.87 11.30 19.89 15.61 24.09 9.845 
Bifidobacteriaceae 3.183 4.313 3.805 6.028 4.575 6.997 7.120 10.324 
Burkholderiaceae 0.001 0.003 0.000 0.000 0.000 0.000 0.000 0.000 
Campylobacteraceae 0.004 0.010 0.003 0.005 0.006 0.013 0.002 0.007 
Cardiobacteriaceae 0.002 0.004 0.000 0.000 0.000 0.000 0.000 0.000 
Carnobacteriaceae 0.018 0.015 0.007 0.009 0.002 0.006 0.002 0.004 
Christensenellaceae 0.068 0.179 0.015 0.014 0.015 0.020 0.045 0.048 
Clostridiaceae 0.838 1.225 1.975 4.013 1.082 2.033 0.402 0.439 
Comamonadaceae 0.000 0.000 0.000 0.000 0.002 0.004 0.000 0.000 
Coriobacteriaceae 0.781 0.522 0.909 0.469 1.346 2.308 1.947 1.678 
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Corynebacteriaceae 0.000 0.000 0.001 0.003 0.001 0.003 0.000 0.000 
Dehalobacteriaceae 0.005 0.011 0.000 0.000 0.000 0.000 0.000 0.000 
Desulfovibrionaceae 0.239 0.234 0.863 0.499 1.082 1.024 1.526 1.081 
Dethiosulfovibrionaceae 0.005 0.017 0.008 0.026 0.005 0.016 0.005 0.017 
Enterobacteriaceae 2.385 6.363 9.830 8.562 7.843 9.681 6.208 7.077 
Enterococcaceae 0.442 0.841 0.305 0.699 0.295 0.602 1.007 2.281 
Erysipelotrichaceae 1.361 0.911 2.922 4.067 24.510 30.176 4.485 7.806 
Eubacteriaceae 0.003 0.007 0.001 0.003 0.004 0.007 0.003 0.007 
Fusobacteriaceae 0.053 0.164 2.097 4.354 1.416 2.941 0.674 1.645 
Gemellaceae 0.013 0.024 0.005 0.007 0.002 0.004 0.001 0.003 
Helicobacteraceae 0.002 0.007 0.000 0.000 0.000 0.000 0.000 0.000 
Lachnospiraceae 22.403 5.215 13.390 3.862 12.961 8.161 18.720 4.718 
Lactobacillaceae 2.740 4.885 2.424 3.665 1.890 3.021 1.246 2.215 
Leuconostocaceae 0.023 0.043 0.003 0.010 0.008 0.023 0.012 0.032 
Methanobacteriaceae 0.017 0.053 0.012 0.039 0.021 0.046 0.047 0.103 
Micrococcaceae 0.003 0.007 0.002 0.007 0.000 0.000 0.001 0.003 
Moraxellaceae 0.000 0.000 0.000 0.000 0.000 0.000 0.001 0.003 
Neisseriaceae 0.000 0.000 0.003 0.010 0.003 0.007 0.000 0.000 
Oxalobacteraceae 0.001 0.003 0.000 0.000 0.001 0.003 0.000 0.000 
Pasteurellaceae 0.091 0.205 0.060 0.108 0.060 0.127 0.019 0.038 
Peptococcaceae 0.001 0.003 0.004 0.007 0.021 0.068 0.032 0.098 
Peptostreptococcaceae 0.013 0.017 0.095 0.219 0.020 0.033 0.015 0.032 
Phyllobacteriaceae 0.000 0.000 0.000 0.000 0.002 0.004 0.002 0.004 
Planococcaceae 0.001 0.003 0.000 0.000 0.000 0.000 0.000 0.000 
Porphyromonadaceae 1.079 0.923 1.416 1.363 0.636 0.706 1.873 1.292 
Prevotellaceae 5.400 12.134 3.315 9.746 0.433 1.005 3.342 6.626 
Pseudomonadaceae 0.000 0.000 0.001 0.003 0.000 0.000 0.000 0.000 
Rikenellaceae 1.584 1.752 0.920 0.804 0.731 1.051 1.685 1.326 
Ruminococcaceae 19.689 8.136 14.726 11.386 11.002 10.720 13.084 6.129 
S24-7 0.092 0.236 0.109 0.215 0.038 0.063 0.673 1.498 
Staphylococcaceae 0.000 0.000 0.000 0.000 0.001 0.003 0.001 0.003 
Streptococcaceae 3.987 3.900 4.386 5.042 2.234 2.618 3.683 4.432 
Succinivibrionaceae 0.000 0.000 0.001 0.003 0.000 0.000 0.001 0.003 
Turicibacteraceae 0.061 0.123 0.079 0.181 0.029 0.041 0.012 0.020 
Veillonellaceae 2.257 1.066 5.123 4.190 4.523 5.240 4.916 3.933 
Verrucomicrobiaceae 0.058 0.132 0.064 0.142 0.066 0.150 0.041 0.089 
Victivallaceae 0.006 0.014 0.004 0.009 0.004 0.009 0.007 0.017 
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 Time point 
Genus T0 mean ± sd 
T5 
mean ± sd 
T10 
mean ± sd 
T24 
mean ± sd 
[Eubacterium] 0.418 0.863 0.814 1.352 4.158 5.669 2.526 4.891 
[Prevotella] 0.810 2.133 0.125 0.397 0.005 0.009 0.100 0.276 
[Ruminococcus] 1.322 0.791 0.851 0.603 0.819 0.698 0.900 0.773 
Acidaminococcus 0.405 0.671 0.211 0.355 0.143 0.328 0.772 1.535 
Actinobacillus 0.005 0.013 0.000 0.000 0.000 0.000 0.000 0.000 
Actinomyces 0.037 0.034 0.020 0.015 0.010 0.009 0.009 0.018 
Adlercreutzia 0.052 0.096 0.020 0.042 0.044 0.125 0.034 0.098 
Aggregatibacter 0.002 0.006 0.001 0.004 0.000 0.000 0.000 0.000 
Akkermansia 0.081 0.183 0.099 0.231 0.121 0.303 0.051 0.108 
Anaerococcus 0.000 0.000 0.001 0.004 0.001 0.004 0.002 0.008 
Anaerofustis 0.003 0.009 0.002 0.006 0.001 0.004 0.000 0.000 
Anaerostipes 0.169 0.127 0.054 0.060 0.054 0.050 0.040 0.043 
Anaerotruncus 0.004 0.014 0.005 0.010 0.008 0.026 0.029 0.049 
Atopobium 0.002 0.006 0.005 0.008 0.002 0.008 0.002 0.006 
Bacteroides 39.13 16.422 38.538 16.194 29.537 18.463 34.616 14.670 
Bifidobacterium 4.560 6.057 5.711 8.951 10.338 16.508 9.350 12.643 
Bilophila 0.156 0.109 0.862 0.727 1.711 1.365 1.948 1.385 
Blautia 6.665 2.501 3.932 1.502 4.527 2.741 4.698 2.313 
Bulleidia 0.020 0.057 0.021 0.062 0.158 0.499 0.042 0.133 
Butyricimonas 0.109 0.126 0.098 0.114 0.076 0.093 0.167 0.215 
Campylobacter 0.007 0.019 0.005 0.007 0.010 0.023 0.004 0.012 
Cardiobacterium 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Catenibacterium 0.070 0.220 0.079 0.243 5.863 18.514 1.234 3.894 
cc_115 0.009 0.018 0.016 0.034 0.033 0.059 0.006 0.010 
Christensenella 0.002 0.005 0.002 0.005 0.000 0.000 0.004 0.007 
Citrobacter 0.015 0.032 0.868 2.702 1.104 2.454 0.940 2.513 
Clostridium 0.104 0.118 1.641 4.756 1.721 4.698 0.183 0.311 
Clostridium 0.000 0.000 0.000 0.000 0.011 0.034 0.000 0.000 
Collinsella 0.618 0.690 0.651 0.484 1.296 2.716 2.044 2.266 
Coprobacillus 0.014 0.023 0.036 0.078 0.125 0.253 0.004 0.006 
Coprococcus 5.411 3.727 2.976 1.660 4.505 4.272 4.306 2.603 
Corynebacterium 0.000 0.000 0.001 0.004 0.001 0.004 0.000 0.000 
Dehalobacterium 0.007 0.016 0.000 0.000 0.000 0.000 0.000 0.000 
Delftia 0.000 0.000 0.000 0.000 0.001 0.004 0.000 0.000 
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Desulfovibrio 0.167 0.348 0.347 0.606 0.286 0.590 0.156 0.351 
Dialister 0.361 0.449 0.748 1.397 0.717 1.260 0.662 1.138 
Dorea 1.145 0.702 1.613 1.358 2.214 2.518 2.514 2.359 
Eggerthella 0.092 0.146 0.143 0.252 0.182 0.357 0.323 0.609 
Eikenella 0.000 0.000 0.006 0.018 0.005 0.012 0.000 0.000 
Enterobacter 0.004 0.011 0.004 0.012 0.000 0.000 0.000 0.000 
Enterococcus 0.684 1.346 0.487 1.239 0.482 1.070 1.344 2.910 
Epulopiscium 0.004 0.012 0.007 0.013 0.009 0.023 0.008 0.013 
Erwinia 0.000 0.000 0.000 0.000 0.000 0.000 0.002 0.006 
Escherichia 0.076 0.237 0.320 0.330 0.334 0.532 0.239 0.306 
Facklamia 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Faecalibacterium 4.941 2.837 3.566 4.216 2.246 3.241 1.103 0.732 
Finegoldia 0.002 0.006 0.005 0.010 0.003 0.008 0.018 0.029 
Fusobacterium 0.065 0.199 2.385 4.921 1.623 3.318 0.848 2.017 
Gemella 0.001 0.004 0.002 0.006 0.000 0.000 0.000 0.000 
Granulicatella 0.017 0.018 0.005 0.008 0.002 0.007 0.001 0.004 
Haemophilus 0.150 0.374 0.095 0.190 0.093 0.204 0.032 0.069 
Helicobacter 0.003 0.010 0.000 0.000 0.000 0.000 0.000 0.000 
Holdemania 0.020 0.031 0.021 0.030 0.023 0.041 0.020 0.024 
Klebsiella 0.046 0.144 0.085 0.251 0.082 0.251 0.068 0.134 
Lachnobacterium 0.140 0.262 0.005 0.016 0.014 0.030 0.021 0.044 
Lachnospira 1.852 1.107 0.949 0.984 0.512 0.607 0.382 0.513 
Lactobacillus 3.273 5.698 2.979 4.539 2.369 3.504 1.467 2.606 
Lactococcus 0.018 0.043 0.012 0.023 0.012 0.021 0.000 0.000 
Lautropia 0.002 0.006 0.000 0.000 0.000 0.000 0.000 0.000 
Leuconostoc 0.014 0.033 0.000 0.000 0.001 0.004 0.003 0.005 
Luteolibacter 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Megamonas 0.059 0.188 0.312 0.658 0.609 1.301 0.204 0.646 
Megasphaera 0.083 0.258 1.860 3.900 1.507 3.813 1.690 3.727 
Mesorhizobium 0.000 0.000 0.000 0.000 0.004 0.008 0.003 0.005 
Methanobrevibacter 0.023 0.073 0.021 0.065 0.042 0.092 0.063 0.139 
Mogibacterium 0.000 0.000 0.002 0.007 0.002 0.005 0.000 0.000 
Morganella 0.004 0.012 0.094 0.299 0.083 0.254 0.011 0.033 
Moryella 0.003 0.007 0.000 0.000 0.000 0.000 0.000 0.000 
Odoribacter 0.373 0.278 0.329 0.281 0.172 0.183 0.198 0.183 
Oribacterium 0.005 0.011 0.000 0.000 0.000 0.000 0.000 0.000 
Oscillospira 0.985 0.686 1.962 1.216 2.382 2.145 3.080 2.463 
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Other 0.000 0.000 0.001 0.005 0.008 0.025 0.000 0.000 
Parabacteroides 1.460 1.279 2.063 2.277 0.977 0.943 2.653 1.922 
Paraprevotella 0.376 0.694 0.290 0.564 0.981 2.410 0.083 0.110 
Pediococcus 0.002 0.008 0.001 0.004 0.000 0.000 0.000 0.000 
Peptococcus 0.000 0.000 0.001 0.004 0.038 0.120 0.044 0.138 
Peptoniphilus 0.001 0.004 0.004 0.007 0.018 0.026 0.008 0.020 
Peptostreptococcus 0.004 0.012 0.010 0.019 0.018 0.034 0.015 0.036 
Phascolarctobacterium 1.214 1.327 2.232 1.921 1.588 1.512 2.261 2.031 
Porphyromonas 0.001 0.004 0.000 0.000 0.000 0.000 0.001 0.004 
Prevotella 6.480 14.281 4.270 12.273 0.711 1.758 4.384 7.935 
Providencia 0.000 0.000 0.000 0.000 0.000 0.000 0.001 0.004 
PSB-M-3 0.001 0.004 0.001 0.004 0.000 0.000 0.000 0.000 
Pseudoramibacter_Eubacterium 0.001 0.004 0.000 0.000 0.004 0.009 0.005 0.010 
Pyramidobacter 0.007 0.023 0.014 0.043 0.011 0.034 0.006 0.021 
Roseburia 2.022 2.590 0.636 1.430 0.172 0.351 0.089 0.099 
Rothia 0.004 0.009 0.003 0.008 0.000 0.000 0.001 0.004 
Ruminococcus 5.521 5.319 2.729 2.912 2.005 1.981 3.234 2.649 
Scardovia 0.002 0.005 0.003 0.008 0.001 0.004 0.000 0.000 
Selenomonas 0.005 0.013 0.002 0.006 0.005 0.012 0.000 0.000 
Serratia 0.008 0.021 0.035 0.080 0.215 0.608 0.017 0.054 
Slackia 0.054 0.075 0.035 0.071 0.039 0.065 0.033 0.037 
SMB53 0.051 0.089 0.065 0.099 0.060 0.091 0.013 0.022 
Staphylococcus 0.000 0.000 0.000 0.000 0.002 0.006 0.001 0.004 
Streptococcus 5.282 4.656 5.777 6.769 5.515 9.886 4.743 5.552 
Sutterella 1.612 0.698 4.249 2.038 3.520 3.432 2.629 1.191 
Tetragenococcus 0.000 0.000 0.002 0.006 0.000 0.000 0.000 0.000 
Trabulsiella 0.002 0.006 0.000 0.000 0.004 0.009 0.003 0.006 
Turicibacter 0.085 0.172 0.115 0.260 0.102 0.180 0.018 0.031 




Table A4. Mean relative abundance (%) ± standard deviation (SD) of bacterial taxa at the phylum, 
order, family and genus levels in Cirrhotic patients (CP) upon lactulose treatment, over time. 
 
 Time point 
Phylum T0 mean ± sd 
T5 
mean ± sd 
T10 
mean ± sd 
T24 
mean ± sd 
Actinobacteria 5.385 4.034 17.046 17.075 18.106 18.620 13.574 15.219 
Bacteroidetes 32.846 8.510 28.490 11.340 26.338 8.481 29.369 12.084 
Cyanobacteria 0.005 0.011 0.014 0.031 0.001 0.003 0.002 0.004 
Euryarchaeota 0.018 0.034 0.002 0.006 0.007 0.016 0.051 0.112 
Firmicutes 57.534 8.794 47.434 11.446 46.761 13.440 46.205 16.369 
Fusobacteria 0.071 0.216 0.660 2.061 1.599 3.849 0.839 2.153 
Lentisphaerae 0.004 0.010 0.003 0.010 0.003 0.007 0.012 0.038 
Proteobacteria 3.804 6.999 6.300 5.480 7.156 7.264 9.845 6.653 
Synergistetes 0.014 0.033 0.001 0.003 0.006 0.019 0.010 0.028 
Tenericutes 0.009 0.025 0.000 0.000 0.001 0.003 0.001 0.003 
TM7 0.004 0.007 0.000 0.000 0.000 0.000 0.000 0.000 
Verrucomicrobia 0.066 0.154 0.050 0.132 0.022 0.066 0.091 0.156 
	
 Time point 
Order T0 mean ± sd 
T5 
mean ± sd 
T10 
mean ± sd 
T24 
mean ± sd 
Actinomycetales 0.025 0.029 0.006 0.011 0.008 0.016 0.010 0.025 
Bacteroidales 32.925 8.524 28.490 11.340 26.338 8.481 29.371 12.086 
Bifidobacteriales 4.528 4.029 13.480 17.163 15.345 17.678 10.049 14.994 
Burkholderiales 1.047 0.542 1.539 0.681 1.671 0.652 2.758 2.100 
Campylobacterales 0.002 0.006 0.001 0.003 0.000 0.000 0.004 0.007 
Clostridiales 41.801 13.263 37.226 14.083 28.996 15.070 33.855 10.972 
Coriobacteriales 0.846 0.654 3.560 4.049 2.754 3.710 3.515 4.268 
Desulfovibrionales 0.202 0.203 0.211 0.158 0.653 0.640 1.628 1.291 
Enterobacteriales 2.491 6.892 4.531 5.201 4.829 6.717 5.444 5.651 
Erysipelotrichales 1.588 1.001 5.070 4.976 12.896 18.766 4.233 6.171 
Fusobacteriales 0.072 0.216 0.660 2.061 1.599 3.849 0.839 2.153 
Gemellales 0.006 0.013 0.001 0.003 0.000 0.000 0.001 0.003 
I025 0.001 0.003 0.000 0.000 0.000 0.000 0.000 0.000 
Lactobacillales 14.217 15.395 5.127 4.340 4.854 4.636 8.111 9.281 
Methanobacteriales 0.018 0.034 0.002 0.006 0.007 0.016 0.051 0.112 
ML615J-28 0.006 0.019 0.000 0.000 0.001 0.003 0.000 0.000 
Neisseriales 0.001 0.003 0.002 0.006 0.000 0.000 0.004 0.013 
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Pasteurellales 0.065 0.161 0.014 0.031 0.002 0.004 0.004 0.007 
RF32 0.002 0.004 0.002 0.006 0.000 0.000 0.000 0.000 
RF39 0.003 0.007 0.000 0.000 0.000 0.000 0.001 0.003 
Rhizobiales 0.001 0.003 0.000 0.000 0.001 0.003 0.000 0.000 
SHA-98 0.001 0.003 0.000 0.000 0.001 0.003 0.001 0.003 
Streptophyta 0.002 0.006 0.000 0.000 0.000 0.000 0.000 0.000 
Synergistales 0.014 0.033 0.001 0.003 0.006 0.019 0.010 0.028 
Turicibacterales 0.062 0.135 0.010 0.022 0.014 0.030 0.005 0.011 
Verrucomicrobiales 0.066 0.154 0.050 0.132 0.022 0.066 0.091 0.156 
Victivallales 0.004 0.010 0.003 0.010 0.003 0.007 0.012 0.038 
YS2 0.002 0.006 0.014 0.031 0.001 0.003 0.002 0.004 
	
 Time point 
Family T0 mean ± sd 
T5 
mean ± sd 
T10 
mean ± sd 
T24 
mean ± sd 
[Barnesiellaceae] 0.386 0.452 0.230 0.296 0.219 0.297 0.445 0.701 
[Mogibacteriaceae] 0.111 0.161 0.051 0.081 0.156 0.300 0.154 0.256 
[Odoribacteraceae] 0.273 0.225 0.108 0.071 0.124 0.162 0.249 0.190 
[Paraprevotellaceae] 0.496 0.583 0.428 0.838 0.207 0.193 0.182 0.270 
[Tissierellaceae] 0.003 0.007 0.003 0.005 0.001 0.003 0.009 0.014 
Actinomycetaceae 0.019 0.024 0.006 0.011 0.008 0.017 0.004 0.010 
Aerococcaceae 0.001 0.003 0.000 0.000 0.000 0.000 0.000 0.000 
Alcaligenaceae 1.090 0.575 1.579 0.679 1.726 0.685 2.825 2.118 
Anaerolinaceae 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Bacteroidaceae 24.876 10.438 22.383 11.771 16.506 10.170 22.343 11.965 
Bifidobacteriaceae 4.765 4.288 13.954 17.397 15.803 18.007 10.357 15.221 
Burkholderiaceae 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Campylobacteraceae 0.002 0.007 0.000 0.000 0.000 0.000 0.004 0.007 
Carnobacteriaceae 0.005 0.010 0.002 0.004 0.003 0.005 0.007 0.012 
Christensenellaceae 0.089 0.242 0.020 0.046 0.049 0.121 0.034 0.056 
Clostridiaceae 0.997 1.296 0.399 0.471 0.400 0.449 0.377 0.383 
Comamonadaceae 0.000 0.000 0.001 0.003 0.001 0.003 0.001 0.003 
Coriobacteriaceae 0.885 0.688 3.726 4.262 2.913 3.964 3.658 4.420 
Dehalobacteriaceae 0.008 0.012 0.001 0.003 0.002 0.005 0.001 0.003 
Desulfovibrionaceae 0.212 0.211 0.219 0.163 0.691 0.694 1.668 1.310 
Dethiosulfovibrionaceae 0.015 0.034 0.001 0.003 0.007 0.021 0.011 0.031 
Enterobacteriaceae 2.555 7.050 4.614 5.200 5.020 6.944 5.550 5.694 
Enterococcaceae 0.145 0.308 2.296 3.322 0.878 2.081 0.755 1.610 
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Erysipelotrichaceae 1.656 1.042 5.185 5.095 13.058 18.782 4.408 6.544 
Eubacteriaceae 0.002 0.004 0.001 0.003 0.004 0.010 0.016 0.036 
Flavobacteriaceae 0.001 0.003 0.000 0.000 0.000 0.000 0.000 0.000 
Fusobacteriaceae 0.072 0.218 0.662 2.070 1.603 3.856 0.843 2.162 
Gemellaceae 0.006 0.013 0.001 0.003 0.000 0.000 0.001 0.003 
Helicobacteraceae 0.000 0.000 0.001 0.003 0.000 0.000 0.000 0.000 
Lachnospiraceae 18.798 5.537 20.577 8.585 12.635 7.575 15.332 7.445 
Lactobacillaceae 3.462 4.721 1.528 2.730 1.695 2.406 3.962 7.306 
Leuconostocaceae 0.002 0.004 0.006 0.016 0.004 0.013 0.012 0.017 
Methanobacteriaceae 0.019 0.035 0.002 0.007 0.007 0.018 0.055 0.121 
Micrococcaceae 0.007 0.014 0.000 0.000 0.000 0.000 0.005 0.016 
Neisseriaceae 0.001 0.003 0.002 0.007 0.000 0.000 0.004 0.013 
Oxalobacteraceae 0.002 0.007 0.000 0.000 0.001 0.003 0.001 0.003 
Pasteurellaceae 0.066 0.165 0.014 0.032 0.002 0.004 0.004 0.007 
Peptococcaceae 0.037 0.113 0.002 0.007 0.062 0.190 0.264 0.834 
Peptostreptococcaceae 0.017 0.021 0.009 0.016 0.003 0.007 0.014 0.035 
Phyllobacteriaceae 0.001 0.003 0.000 0.000 0.001 0.003 0.000 0.000 
Porphyromonadaceae 1.400 1.303 0.888 0.852 1.155 0.895 2.262 1.776 
Prevotellaceae 4.138 11.677 4.585 11.388 7.512 12.720 2.306 4.420 
Propionibacteriaceae 0.000 0.000 0.000 0.000 0.000 0.000 0.001 0.003 
Rikenellaceae 1.426 1.308 0.631 0.676 0.849 1.268 1.078 1.152 
Ruminococcaceae 17.331 7.199 11.772 6.492 10.662 6.958 11.485 6.970 
S24-7 1.198 3.762 0.062 0.161 0.503 1.431 1.105 2.888 
Streptococcaceae 11.139 13.787 1.379 1.225 2.403 3.047 3.540 3.989 
Turicibacteraceae 0.066 0.143 0.011 0.024 0.015 0.032 0.005 0.011 
Veillonellaceae 2.200 1.166 2.602 1.941 3.085 3.291 4.555 2.330 
Verrucomicrobiaceae 0.069 0.160 0.054 0.144 0.024 0.072 0.095 0.163 
Victivallaceae 0.004 0.010 0.003 0.010 0.003 0.007 0.013 0.040 
	
 Time point 
Genus T0 mean ± sd 
T5 
mean ± sd 
T10 
mean ± sd 
T24 
mean ± sd 
[Eubacterium] 0.679 1.257 1.544 2.982 5.163 6.649 3.316 5.608 
[Prevotella] 0.213 0.484 0.473 1.239 0.194 0.292 0.107 0.231 
[Ruminococcus] 1.111 0.752 1.596 1.523 0.681 0.753 1.341 1.672 
Acidaminococcus 0.412 0.703 0.162 0.227 0.205 0.374 0.954 1.854 
Actinobacillus 0.004 0.013 0.003 0.008 0.000 0.000 0.000 0.000 
Actinomyces 0.027 0.036 0.007 0.013 0.013 0.029 0.005 0.013 
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Adlercreutzia 0.029 0.052 0.036 0.066 0.079 0.167 0.033 0.066 
Aggregatibacter 0.002 0.006 0.003 0.010 0.000 0.000 0.000 0.000 
Akkermansia 0.090 0.216 0.067 0.175 0.029 0.086 0.123 0.207 
Anaerococcus 0.000 0.000 0.001 0.004 0.000 0.000 0.000 0.000 
Anaerofustis 0.003 0.006 0.001 0.005 0.007 0.017 0.000 0.000 
Anaerostipes 0.204 0.118 0.124 0.168 0.082 0.130 0.121 0.201 
Anaerotruncus 0.004 0.007 0.007 0.017 0.017 0.033 0.016 0.029 
Atopobium 0.001 0.005 0.001 0.004 0.002 0.006 0.000 0.000 
Bacteroides 34.22 15.44 30.18 15.41 23.38 13.34 28.40 15.20 
Bifidobacterium 6.390 5.784 19.00 23.987 20.783 24.435 13.032 19.095 
Bilophila 0.118 0.129 0.253 0.221 0.924 0.890 2.104 1.724 
Blautia 5.344 2.615 7.394 4.549 4.470 2.751 5.859 4.897 
Bulleidia 0.010 0.030 0.035 0.110 0.077 0.163 0.105 0.225 
Butyricimonas 0.108 0.163 0.036 0.065 0.030 0.061 0.138 0.207 
Campylobacter 0.004 0.013 0.000 0.000 0.000 0.000 0.005 0.009 
Catenibacterium 0.080 0.253 0.734 2.321 1.770 3.733 1.035 2.487 
cc_115 0.008 0.011 0.003 0.008 0.001 0.004 0.003 0.006 
Christensenella 0.001 0.004 0.001 0.004 0.004 0.008 0.008 0.014 
Chryseobacterium 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Citrobacter 0.001 0.004 0.208 0.642 0.027 0.073 0.934 2.885 
Clostridium 0.099 0.192 0.243 0.590 0.238 0.392 0.263 0.375 
Clostridium 0.000 0.000 0.000 0.000 0.000 0.000 0.001 0.004 
Clostridium 0.000 0.000 0.000 0.000 0.002 0.007 0.001 0.004 
Collinsella 0.690 0.814 4.405 5.216 3.310 5.020 3.908 5.246 
Coprobacillus 0.011 0.024 0.004 0.007 0.011 0.018 0.005 0.009 
Coprococcus 4.789 2.741 5.495 3.289 3.455 3.099 2.776 2.232 
Dehalobacterium 0.011 0.015 0.001 0.005 0.003 0.007 0.001 0.004 
Delftia 0.000 0.000 0.001 0.004 0.000 0.000 0.000 0.000 
Desulfovibrio 0.154 0.272 0.033 0.086 0.128 0.326 0.068 0.183 
Dialister 0.506 0.657 0.286 0.538 0.349 0.564 0.511 0.826 
Dorea 1.012 0.650 1.283 0.844 1.344 1.471 2.227 2.194 
Eggerthella 0.066 0.130 0.053 0.058 0.039 0.045 0.121 0.196 
Eikenella 0.002 0.006 0.003 0.010 0.000 0.000 0.005 0.016 
Enterobacter 0.002 0.008 0.000 0.000 0.001 0.004 0.009 0.020 
Enterococcus 0.239 0.593 2.321 3.649 0.608 1.161 0.478 0.737 
Epulopiscium 0.004 0.013 0.002 0.005 0.002 0.006 0.000 0.000 
Escherichia 0.089 0.267 0.138 0.165 0.212 0.346 0.146 0.124 
Faecalibacterium 4.464 2.806 2.645 2.548 1.973 1.418 1.495 1.517 
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Finegoldia 0.000 0.000 0.003 0.006 0.002 0.007 0.009 0.015 
Flavobacterium 0.001 0.004 0.000 0.000 0.000 0.000 0.000 0.000 
Fusobacterium 0.091 0.267 0.807 2.516 2.216 4.764 0.953 2.400 
Gemella 0.000 0.000 0.002 0.005 0.000 0.000 0.000 0.000 
Granulicatella 0.005 0.012 0.003 0.006 0.004 0.006 0.007 0.014 
Haemophilus 0.113 0.303 0.015 0.037 0.002 0.005 0.005 0.009 
Helicobacter 0.000 0.000 0.001 0.005 0.000 0.000 0.000 0.000 
Holdemania 0.019 0.046 0.019 0.022 0.016 0.022 0.034 0.050 
Klebsiella 0.055 0.174 0.052 0.111 0.075 0.157 0.212 0.426 
Lachnobacterium 0.077 0.128 0.059 0.095 0.012 0.033 0.024 0.046 
Lachnospira 1.538 0.959 0.353 0.386 0.381 0.599 0.387 0.461 
Lactobacillus 4.002 5.422 1.840 3.234 1.984 2.780 5.020 9.686 
Lactococcus 0.009 0.028 0.009 0.027 0.001 0.004 0.005 0.014 
Leuconostoc 0.003 0.006 0.001 0.005 0.007 0.023 0.010 0.016 
Megamonas 0.068 0.209 0.337 1.065 0.574 1.804 0.213 0.673 
Megasphaera 0.074 0.233 0.314 0.978 0.321 0.927 0.494 1.295 
Mesorhizobium 0.001 0.005 0.000 0.000 0.002 0.005 0.000 0.000 
Methanobrevibacter 0.024 0.046 0.003 0.008 0.009 0.021 0.070 0.152 
Mogibacterium 0.000 0.000 0.001 0.004 0.000 0.000 0.000 0.000 
Morganella 0.000 0.000 0.032 0.101 0.000 0.000 0.050 0.155 
Odoribacter 0.255 0.222 0.111 0.074 0.155 0.226 0.180 0.109 
Oribacterium 0.001 0.004 0.001 0.005 0.001 0.004 0.000 0.000 
Oscillospira 0.925 0.816 0.902 0.794 1.823 2.772 2.638 2.563 
Other 0.001 0.004 0.000 0.000 0.000 0.000 0.001 0.004 
Parabacteroides 1.802 1.690 1.222 1.317 1.579 1.319 2.904 2.353 
Paraprevotella 0.400 0.611 0.148 0.233 0.093 0.143 0.115 0.152 
Parvimonas 0.003 0.006 0.000 0.000 0.000 0.000 0.000 0.000 
Pediococcus 0.000 0.000 0.000 0.000 0.001 0.004 0.000 0.000 
Peptococcus 0.046 0.145 0.000 0.000 0.073 0.230 0.350 1.106 
Peptoniphilus 0.001 0.005 0.000 0.000 0.000 0.000 0.003 0.005 
Peptostreptococcus 0.005 0.016 0.006 0.016 0.002 0.007 0.011 0.036 
Phascolarctobacterium 1.029 1.049 1.572 1.448 2.190 1.139 2.972 1.429 
Prevotella 4.806 13.383 5.794 13.597 10.361 16.396 2.830 5.322 
Proteus 0.000 0.000 0.000 0.000 0.000 0.000 0.004 0.009 
PSB-M-3 0.000 0.000 0.000 0.000 0.001 0.004 0.000 0.000 
Pseudoramibacter_Eubacterium 0.000 0.000 0.000 0.000 0.000 0.000 0.021 0.045 
Pyramidobacter 0.019 0.046 0.001 0.004 0.008 0.025 0.013 0.038 
Ralstonia 0.003 0.009 0.000 0.000 0.000 0.000 0.001 0.004 
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Roseburia 1.971 2.460 0.205 0.243 0.114 0.132 0.095 0.126 
Rothia 0.010 0.018 0.000 0.000 0.000 0.000 0.007 0.022 
Ruminococcus 5.070 5.394 2.706 2.461 2.352 3.101 2.000 1.924 
Scardovia 0.002 0.008 0.001 0.004 0.004 0.008 0.006 0.017 
Selenomonas 0.004 0.013 0.000 0.000 0.000 0.000 0.000 0.000 
Serratia 0.001 0.005 0.019 0.060 0.006 0.015 0.048 0.118 
Slackia 0.072 0.094 0.049 0.085 0.071 0.148 0.071 0.094 
SMB53 0.077 0.128 0.012 0.019 0.014 0.042 0.007 0.009 
Streptococcus 13.725 15.471 1.782 1.447 3.209 4.275 4.512 5.064 
Sutterella 1.484 0.844 2.097 0.894 2.428 1.115 3.553 2.717 
Tetragenococcus 0.002 0.006 0.000 0.000 0.000 0.000 0.000 0.000 
Trabulsiella 0.000 0.000 0.000 0.000 0.000 0.000 0.001 0.004 
Turicibacter 0.091 0.198 0.014 0.030 0.022 0.048 0.007 0.015 





Table A5. Mean relative abundance (%) ± standard deviation (SD) of bacterial taxa at the phylum, 
order, family and genus levels in Cirrhotic patients (CP) upon lactulose + rifaximin treatment, over 
time. 
	
 Time point 
Phylum T0 mean ± sd 
T5 
mean ± sd 
T10 
mean ± sd 
T24 
mean ± sd 
Actinobacteria 3.543 2.553 3.517 3.034 4.627 8.084 5.936 12.394 
Bacteroidetes 35.960 9.493 29.348 8.662 24.193 14.894 10.069 12.907 
Cyanobacteria 0.003 0.007 0.009 0.019 0.000 0.000 0.000 0.000 
Euryarchaeota 0.010 0.022 0.016 0.035 0.020 0.042 0.104 0.328 
Firmicutes 58.915 9.264 49.089 13.323 53.334 8.056 67.743 12.884 
Fusobacteria 0.137 0.293 2.372 7.461 3.322 10.496 0.623 1.970 
Lentisphaerae 0.007 0.016 0.001 0.003 0.009 0.015 0.005 0.013 
Proteobacteria 1.384 0.891 15.605 17.349 14.392 14.318 15.447 12.697 
Synergistetes 0.002 0.006 0.003 0.010 0.005 0.016 0.019 0.061 
Tenericutes 0.011 0.024 0.005 0.013 0.000 0.000 0.000 0.000 
TM7 0.001 0.003 0.000 0.000 0.001 0.003 0.001 0.003 




 Time point 
Order T0  mean ± sd 
T5  
mean ± sd 
T10 
mean ± sd 
T24 
mean ± sd 
Actinomycetales 0.027 0.032 0.023 0.029 0.006 0.010 0.008 0.010 
Aeromonadales 0.002 0.006 0.000 0.000 0.000 0.000 0.000 0.000 
Bacillales 0.000 0.000 0.000 0.000 0.001 0.003 0.001 0.003 
Bacteroidales 35.961 9.493 29.349 8.660 24.193 14.895 10.068 12.908 
Bifidobacteriales 2.576 2.204 2.896 3.063 3.413 6.371 5.642 12.351 
Burkholderiales 0.765 0.471 1.660 1.553 1.949 1.602 3.725 2.723 
Campylobacterales 0.002 0.004 0.001 0.003 0.008 0.015 0.023 0.047 
Clostridiales 39.225 12.383 26.775 10.279 31.892 16.949 18.961 9.775 
Coriobacteriales 0.940 0.595 0.597 0.444 1.208 1.779 0.286 0.189 
Desulfovibrionales 0.177 0.194 0.576 0.465 0.967 0.775 1.495 0.500 
Enterobacteriales 0.408 0.722 13.325 16.767 11.448 14.170 10.196 12.871 
Erysipelotrichales 1.884 1.533 8.345 8.312 18.600 19.868 43.828 10.653 
Fusobacteriales 0.137 0.293 2.372 7.461 3.322 10.496 0.623 1.970 
Gemellales 0.004 0.010 0.002 0.006 0.000 0.000 0.001 0.003 
Lactobacillales 17.764 13.203 13.949 13.671 2.823 4.826 4.939 5.455 
Methanobacteriales 0.010 0.022 0.016 0.035 0.020 0.042 0.104 0.328 
ML615J-28 0.007 0.022 0.001 0.003 0.000 0.000 0.000 0.000 
Pasteurellales 0.022 0.040 0.027 0.058 0.016 0.028 0.002 0.004 
Pseudomonadales 0.000 0.000 0.000 0.000 0.000 0.000 0.001 0.003 
RF32 0.006 0.019 0.009 0.017 0.003 0.010 0.000 0.000 
RF39 0.004 0.013 0.004 0.010 0.000 0.000 0.000 0.000 
Rhizobiales 0.002 0.004 0.001 0.003 0.000 0.000 0.001 0.003 
SHA-98 0.005 0.013 0.000 0.000 0.000 0.000 0.000 0.000 
Sphingobacteriales 0.000 0.000 0.000 0.000 0.000 0.000 0.001 0.003 
Sphingomonadales 0.000 0.000 0.000 0.000 0.000 0.000 0.002 0.004 
Synergistales 0.002 0.006 0.003 0.010 0.005 0.016 0.019 0.061 
Turicibacterales 0.034 0.060 0.022 0.039 0.019 0.047 0.014 0.025 
Verrucomicrobiales 0.027 0.073 0.035 0.101 0.098 0.302 0.053 0.169 
Victivallales 0.007 0.016 0.001 0.003 0.009 0.015 0.005 0.013 
YS2 0.002 0.006 0.009 0.019 0.000 0.000 0.000 0.000 
	
 Time point 
Family T0 mean ± sd 
T5 
mean ± sd 
T10 
mean ± sd 
T24 
mean ± sd 
[Barnesiellaceae] 0.271 0.281 0.211 0.217 0.369 0.383 0.053 0.070 
[Mogibacteriaceae] 0.120 0.117 0.093 0.145 0.146 0.195 0.022 0.032 
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[Odoribacteraceae] 0.301 0.291 0.298 0.254 0.220 0.231 0.026 0.036 
[Paraprevotellaceae] 0.619 0.553 0.737 1.186 0.346 0.462 0.071 0.166 
[Tissierellaceae] 0.003 0.005 0.004 0.010 0.005 0.010 0.113 0.341 
Actinomycetaceae 0.018 0.022 0.014 0.015 0.003 0.007 0.005 0.007 
Aerococcaceae 0.000 0.000 0.001 0.003 0.000 0.000 0.000 0.000 
Alcaligenaceae 0.787 0.477 1.681 1.560 2.022 1.661 3.762 2.760 
Bacillaceae 0.000 0.000 0.000 0.000 0.000 0.000 0.001 0.003 
Bacteroidaceae 24.461 15.092 21.171 8.326 18.445 12.977 8.832 11.287 
Bifidobacteriaceae 2.701 2.287 2.946 3.079 3.631 6.911 5.677 12.430 
Burkholderiaceae 0.001 0.003 0.000 0.000 0.000 0.000 0.000 0.000 
Campylobacteraceae 0.002 0.004 0.001 0.003 0.008 0.015 0.023 0.047 
Carnobacteriaceae 0.007 0.012 0.003 0.007 0.000 0.000 0.002 0.004 
Christensenellaceae 0.085 0.180 0.066 0.169 0.027 0.044 0.029 0.060 
Clostridiaceae 0.541 0.470 0.803 1.386 0.403 0.429 0.305 0.595 
Comamonadaceae 0.000 0.000 0.000 0.000 0.002 0.004 0.000 0.000 
Coriobacteriaceae 0.990 0.637 0.618 0.468 1.281 1.929 0.289 0.190 
Corynebacteriaceae 0.003 0.007 0.000 0.000 0.000 0.000 0.001 0.003 
Dehalobacteriaceae 0.002 0.004 0.003 0.007 0.000 0.000 0.000 0.000 
Desulfovibrionaceae 0.187 0.207 0.590 0.473 0.999 0.806 1.507 0.504 
Dethiosulfovibrionaceae 0.002 0.007 0.003 0.010 0.005 0.017 0.019 0.061 
Enterobacteriaceae 0.420 0.741 13.642 17.004 11.671 14.251 10.262 12.922 
Enterococcaceae 0.030 0.056 0.473 1.182 0.387 0.747 1.474 3.435 
Erysipelotrichaceae 1.986 1.654 8.509 8.407 18.793 19.947 44.193 10.813 
Eubacteriaceae 0.002 0.007 0.001 0.003 0.001 0.003 0.002 0.004 
Flavobacteriaceae 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Fusobacteriaceae 0.138 0.297 2.388 7.511 3.337 10.546 0.626 1.981 
Gemellaceae 0.004 0.010 0.002 0.006 0.000 0.000 0.001 0.003 
Helicobacteraceae 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Lachnospiraceae 17.772 5.108 9.167 3.891 14.067 8.298 6.505 2.665 
Lactobacillaceae 5.132 5.330 3.266 4.733 1.360 3.296 2.484 4.163 
Leptotrichiaceae 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Leuconostocaceae 0.006 0.020 0.013 0.027 0.008 0.017 0.010 0.029 
Methanobacteriaceae 0.010 0.023 0.017 0.036 0.021 0.044 0.104 0.330 
Microbacteriaceae 0.000 0.000 0.000 0.000 0.001 0.003 0.000 0.000 
Micrococcaceae 0.007 0.012 0.009 0.026 0.002 0.004 0.002 0.004 
Moraxellaceae 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Neisseriaceae 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
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Nocardioidaceae 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Oxalobacteraceae 0.000 0.000 0.001 0.003 0.000 0.000 0.000 0.000 
Pasteurellaceae 0.023 0.041 0.028 0.058 0.016 0.029 0.002 0.004 
Peptococcaceae 0.037 0.110 0.040 0.122 0.200 0.628 0.000 0.000 
Peptostreptococcaceae 0.019 0.026 0.111 0.316 0.011 0.021 0.083 0.259 
Phyllobacteriaceae 0.002 0.005 0.001 0.003 0.000 0.000 0.001 0.003 
Planococcaceae 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Porphyromonadaceae 1.503 1.180 1.282 1.328 1.692 2.224 0.990 2.933 
Prevotellaceae 7.315 14.486 5.278 10.025 2.992 8.371 0.027 0.051 
Pseudomonadaceae 0.000 0.000 0.000 0.000 0.000 0.000 0.001 0.003 
Rikenellaceae 1.383 1.738 1.004 1.191 0.934 0.940 0.112 0.134 
Ruminococcaceae 15.692 7.355 12.427 7.188 13.248 8.888 10.729 10.081 
S24-7 1.372 4.087 0.128 0.268 0.013 0.040 0.001 0.003 
Sphingobacteriaceae 0.000 0.000 0.000 0.000 0.000 0.000 0.001 0.003 
Sphingomonadaceae 0.000 0.000 0.000 0.000 0.000 0.000 0.002 0.004 
Staphylococcaceae 0.000 0.000 0.000 0.000 0.001 0.003 0.000 0.000 
Streptococcaceae 13.197 11.147 10.476 11.826 1.113 1.762 0.992 1.272 
Succinivibrionaceae 0.002 0.006 0.000 0.000 0.000 0.000 0.000 0.000 
Synergistaceae 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Turicibacteraceae 0.037 0.065 0.023 0.041 0.020 0.050 0.014 0.026 
Veillonellaceae 2.774 1.637 2.432 1.456 2.085 1.849 0.582 0.482 
Verrucomicrobiaceae 0.028 0.075 0.036 0.103 0.103 0.317 0.054 0.170 
Victivallaceae 0.007 0.017 0.001 0.003 0.010 0.016 0.005 0.013 
	
 Time point 
Genus T0 mean ± sd 
T5 
mean ± sd 
T10 
mean ± sd 
T24 
mean ± sd 
[Eubacterium] 1.512 1.841 2.757 2.585 4.049 5.858 7.996 8.866 
[Prevotella] 0.326 0.586 0.539 1.318 0.196 0.478 0.000 0.000 
[Ruminococcus] 0.892 0.491 1.067 1.196 2.777 3.410 1.753 2.984 
Acidaminococcus 0.098 0.250 0.166 0.383 0.734 1.360 0.014 0.036 
Actinobacillus 0.000 0.000 0.003 0.011 0.000 0.000 0.000 0.000 
Actinomyces 0.021 0.026 0.025 0.032 0.005 0.010 0.009 0.013 
Adlercreutzia 0.032 0.066 0.028 0.055 0.048 0.079 0.037 0.097 
Aggregatibacter 0.001 0.004 0.000 0.000 0.000 0.000 0.000 0.000 
Akkermansia 0.034 0.087 0.043 0.119 0.142 0.434 0.089 0.281 
Anaerococcus 0.002 0.005 0.002 0.008 0.005 0.013 0.007 0.024 
Anaerofustis 0.003 0.009 0.002 0.005 0.000 0.000 0.003 0.010 
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Anaerostipes 0.197 0.159 0.075 0.108 0.096 0.099 0.027 0.038 
Anaerotruncus 0.007 0.014 0.006 0.010 0.013 0.019 0.002 0.005 
Atopobium 0.001 0.004 0.003 0.011 0.000 0.000 0.001 0.005 
Bacillus 0.000 0.000 0.000 0.000 0.000 0.000 0.001 0.004 
Bacteroides 31.40 18.79 33.23 14.26 30.16 18.818 17.700 22.120 
Bifidobacterium 3.543 3.156 4.908 5.496 6.103 9.221 11.478 20.580 
Bilophila 0.142 0.122 0.774 0.636 1.762 1.581 3.055 1.681 
Blautia 5.669 2.814 3.772 2.076 5.254 4.099 1.701 1.264 
Bulleidia 0.030 0.075 0.018 0.057 0.032 0.102 0.308 0.624 
Burkholderia 0.001 0.004 0.000 0.000 0.000 0.000 0.000 0.000 
Butyricimonas 0.153 0.253 0.144 0.168 0.130 0.235 0.019 0.035 
Campylobacter 0.002 0.005 0.002 0.006 0.029 0.066 0.068 0.169 
Catenibacterium 0.158 0.333 0.122 0.382 0.091 0.289 10.428 21.961 
cc_115 0.040 0.107 0.003 0.008 0.006 0.010 0.029 0.061 
Christensenella 0.003 0.006 0.005 0.016 0.000 0.000 0.006 0.014 
Citrobacter 0.015 0.026 3.087 9.740 5.398 16.98 6.189 15.91 
Clostridium 0.030 0.032 0.837 2.339 0.168 0.233 0.487 1.314 
Clostridium 0.000 0.000 0.000 0.000 0.015 0.028 0.009 0.024 
Collinsella 0.720 0.696 0.462 0.475 1.384 2.356 0.349 0.390 
Coprobacillus 0.013 0.026 0.058 0.126 0.061 0.177 0.095 0.167 
Coprococcus 4.274 2.759 1.942 1.418 3.916 3.127 0.737 0.558 
Corynebacterium 0.004 0.008 0.000 0.000 0.000 0.000 0.003 0.010 
Cryocola 0.000 0.000 0.000 0.000 0.003 0.008 0.000 0.000 
Dehalobacterium 0.003 0.006 0.004 0.010 0.000 0.000 0.000 0.000 
Desulfovibrio 0.094 0.221 0.062 0.175 0.192 0.406 0.390 0.866 
Dialister 0.795 1.113 0.951 1.231 0.590 0.851 0.348 0.719 
Dorea 0.845 0.628 0.701 0.631 3.590 4.348 2.723 5.326 
Eggerthella 0.006 0.012 0.056 0.156 0.017 0.031 0.020 0.046 
Enterobacter 0.005 0.011 0.002 0.008 0.004 0.009 0.002 0.008 
Enterococcus 0.034 0.078 0.366 0.681 1.241 2.931 3.842 8.386 
Epulopiscium 0.001 0.004 0.006 0.012 0.007 0.018 0.004 0.011 
Erwinia 0.000 0.000 0.002 0.006 0.003 0.008 0.009 0.018 
Escherichia 0.003 0.006 0.674 1.138 0.536 1.038 0.319 0.497 
Faecalibacterium 4.100 2.850 2.841 1.358 2.282 1.684 0.553 0.861 
Finegoldia 0.000 0.000 0.001 0.004 0.000 0.000 0.000 0.000 
Fusobacterium 0.163 0.350 2.864 8.987 4.422 13.96 0.926 2.928 
Gemella 0.001 0.004 0.000 0.000 0.000 0.000 0.000 0.000 
Granulicatella 0.008 0.014 0.006 0.013 0.000 0.000 0.003 0.006 
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Haemophilus 0.025 0.047 0.071 0.183 0.053 0.128 0.005 0.012 
Holdemania 0.011 0.016 0.061 0.178 0.059 0.121 0.057 0.066 
Klebsiella 0.090 0.192 0.097 0.298 0.095 0.275 0.082 0.142 
Lachnobacterium 0.072 0.131 0.015 0.029 0.068 0.122 0.062 0.163 
Lachnospira 1.612 1.191 0.478 0.374 0.782 1.175 0.428 0.550 
Lactobacillus 5.888 6.035 3.853 5.406 1.829 4.278 3.169 4.878 
Lactococcus 0.019 0.040 0.040 0.115 0.023 0.072 0.067 0.120 
Leuconostoc 0.009 0.028 0.007 0.016 0.009 0.027 0.002 0.007 
Megamonas 0.124 0.265 0.034 0.108 0.009 0.030 0.009 0.028 
Megasphaera 0.199 0.414 0.112 0.327 0.016 0.047 0.013 0.038 
Mesorhizobium 0.003 0.006 0.002 0.006 0.000 0.000 0.002 0.008 
Methanobrevibacter 0.013 0.027 0.020 0.042 0.028 0.059 0.173 0.546 
Mogibacterium 0.001 0.004 0.002 0.006 0.000 0.000 0.003 0.009 
Morganella 0.000 0.000 0.014 0.045 0.064 0.143 0.742 2.146 
Novosphingobium 0.000 0.000 0.000 0.000 0.000 0.000 0.003 0.010 
Odoribacter 0.242 0.243 0.293 0.302 0.210 0.201 0.042 0.063 
Oscillospira 0.977 0.630 2.429 2.484 3.301 2.721 5.942 4.643 
Other 0.001 0.004 0.000 0.000 0.000 0.000 0.000 0.000 
p-75-a5 0.003 0.010 0.000 0.000 0.000 0.000 0.000 0.000 
Parabacteroides 1.966 1.596 1.716 1.896 2.292 2.859 1.497 4.325 
Paraprevotella 0.395 0.510 0.330 0.494 0.259 0.447 0.108 0.249 
Parvimonas 0.001 0.004 0.000 0.000 0.000 0.000 0.000 0.000 
Pediococcus 0.004 0.010 0.002 0.006 0.001 0.004 0.001 0.005 
Pedobacter 0.000 0.000 0.000 0.000 0.000 0.000 0.001 0.004 
Peptococcus 0.045 0.142 0.049 0.150 0.253 0.801 0.000 0.000 
Peptoniphilus 0.000 0.000 0.002 0.005 0.002 0.005 0.325 1.026 
Peptostreptococcus 0.010 0.021 0.012 0.028 0.004 0.013 0.121 0.384 
Phascolarctobacterium 1.568 1.446 1.710 2.292 1.312 1.633 0.799 1.434 
Porphyromonas 0.003 0.006 0.000 0.000 0.000 0.000 0.000 0.000 
Prevotella 8.381 16.467 6.324 11.618 3.893 10.895 0.032 0.060 
Proteus 0.000 0.000 0.007 0.015 0.009 0.017 0.001 0.004 
PSB-M-3 0.002 0.008 0.001 0.004 0.000 0.000 0.006 0.019 
Pseudomonas 0.000 0.000 0.000 0.000 0.000 0.000 0.002 0.008 
Pseudoramibacter_Eubacterium 0.000 0.000 0.000 0.000 0.005 0.016 0.002 0.008 
Pyramidobacter 0.002 0.008 0.004 0.011 0.007 0.023 0.032 0.101 
Roseburia 1.065 1.665 0.324 0.556 0.155 0.187 0.030 0.039 
Rothia 0.009 0.014 0.013 0.031 0.003 0.006 0.002 0.005 
Ruminococcus 4.128 5.422 2.494 3.061 3.682 4.200 1.913 2.842 
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Scardovia 0.002 0.005 0.001 0.004 0.000 0.000 0.001 0.004 
Selenomonas 0.001 0.004 0.005 0.011 0.000 0.000 0.000 0.000 
Serratia 0.001 0.004 0.032 0.089 0.045 0.118 1.637 4.898 
Slackia 0.066 0.066 0.041 0.057 0.046 0.083 0.018 0.038 
SMB53 0.060 0.092 0.017 0.029 0.045 0.115 0.020 0.046 
Sphingomonas 0.000 0.000 0.000 0.000 0.000 0.000 0.002 0.008 
Staphylococcus 0.000 0.000 0.000 0.000 0.002 0.005 0.000 0.000 
Streptococcus 15.998 13.280 13.230 13.193 1.830 2.369 1.443 1.483 
Sutterella 0.964 0.567 2.691 2.868 3.594 3.245 9.319 9.396 
Trabulsiella 0.000 0.000 0.002 0.006 0.013 0.040 0.014 0.025 
Turicibacter 0.048 0.086 0.039 0.072 0.048 0.132 0.044 0.091 
Veillonella 0.605 0.780 0.805 1.648 0.490 1.003 0.086 0.097 
WAL_1855D 0.001 0.004 0.000 0.000 0.000 0.000 0.000 0.000 
	
 
Table A6. Mean relative abundance (%) ± standard deviation (SD) of bacterial taxa at the phylum, 
order, family and genus levels in Cirrhotic patients (CP) upon rifaximin treatment, over time. 
 
 Time point 
Phylum T0 mean ± sd 
T5 
mean ± sd 
T10 
mean ± sd 
T24 
mean ± sd 
Actinobacteria 3.841 2.0358 4.061 2.194 5.214 8.320 7.346 11.129 
Bacteroidetes 28.270 13.964 29.423 13.302 30.533 9.574 22.972 11.063 
Cyanobacteria 0.170 0.371 0.011 0.025 0.003 0.010 0.001 0.003 
Euryarchaeota 0.000 0.000 0.029 0.065 0.016 0.051 0.000 0.000 
Firmicutes 60.962 13.577 56.297 11.252 47.851 11.959 40.278 9.138 
Fusobacteria 0.826 2.339 3.406 10.720 2.021 5.288 4.151 10.169 
Lentisphaerae 0.026 0.083 0.005 0.009 0.005 0.011 0.007 0.013 
Proteobacteria 5.984 1.269 6.489 6.230 14.243 12.079 25.226 17.077 
Synergistetes 0.013 0.042 0.009 0.019 0.006 0.019 0.000 0.000 
Tenericutes 0.052 0.126 0.006 0.013 0.000 0.000 0.002 0.004 
TM7 0.013 0.041 0.001 0.003 0.000 0.000 0.001 0.003 
Verrucomicrobia 0.314 0.530 0.262 0.563 0.108 0.293 0.015 0.027 
 
 Time point 
Order T0 mean ± sd 
T5 
mean ± sd 
T10 
mean ± sd 
T24 
mean ± sd 
Actinomycetales 0.025 0.023 0.025 0.026 0.042 0.042 0.014 0.017 
	 165 
Aeromonadales 0.002 0.006 0.001 0.003 0.001 0.003 0.000 0.000 
Bacillales 0.000 0.000 0.003 0.007 0.002 0.006 0.000 0.000 
Bacteroidales 37.133 10.740 29.426 13.304 30.535 9.574 22.973 11.062 
Bifidobacteriales 2.840 3.106 3.185 2.079 4.615 8.463 6.647 10.657 
Burkholderiales 0.955 0.392 1.790 1.441 2.802 1.869 2.414 2.227 
Campylobacterales 0.005 0.013 0.003 0.007 0.013 0.021 0.004 0.013 
Cardiobacteriales 0.001 0.003 0.000 0.000 0.000 0.000 0.000 0.000 
Clostridiales 39.563 11.209 36.302 15.786 37.649 12.612 30.142 11.038 
Coriobacteriales 0.628 0.405 0.851 0.463 0.557 0.305 0.685 0.604 
Desulfovibrionales 0.246 0.231 0.925 0.785 2.769 1.574 5.354 3.092 
Enterobacteriales 3.295 9.391 3.740 6.168 8.616 12.745 17.433 15.577 
Erysipelotrichales 1.461 1.186 4.828 4.334 3.482 4.843 3.382 3.717 
Fusobacteriales 0.064 0.180 3.406 10.720 2.021 5.289 4.151 10.169 
Gemellales 0.011 0.021 0.002 0.004 0.003 0.005 0.003 0.007 
Lactobacillales 13.576 13.137 15.102 16.834 6.646 9.241 6.693 8.058 
Methanobacteriales 0.000 0.000 0.029 0.066 0.016 0.051 0.000 0.000 
Pasteurellales 0.088 0.240 0.015 0.031 0.021 0.060 0.019 0.038 
Pseudomonadales 0.000 0.000 0.000 0.000 0.003 0.005 0.000 0.000 
RF32 0.006 0.013 0.001 0.003 0.010 0.020 0.000 0.000 
RF39 0.004 0.010 0.006 0.013 0.000 0.000 0.002 0.004 
Rhizobiales 0.002 0.004 0.007 0.008 0.001 0.003 0.002 0.004 
SHA-98 0.000 0.000 0.000 0.000 0.001 0.003 0.000 0.000 
Streptophyta 0.000 0.000 0.001 0.003 0.000 0.000 0.000 0.000 
Synergistales 0.001 0.003 0.009 0.019 0.006 0.019 0.000 0.000 
Turicibacterales 0.054 0.079 0.065 0.114 0.070 0.142 0.060 0.106 
Verrucomicrobiales 0.024 0.041 0.262 0.563 0.108 0.293 0.015 0.027 
Victivallales 0.002 0.006 0.005 0.009 0.005 0.011 0.007 0.013 
YS2 0.013 0.029 0.010 0.026 0.003 0.010 0.001 0.003 
 
 Time point 
Family T0 mean ± sd 
T5 
mean ± sd 
T10 
mean ± sd 
T24 
mean ± sd 
[Barnesiellaceae] 0.357 0.388 0.409 0.516 0.396 0.488 0.290 0.476 
[Mogibacteriaceae] 0.058 0.050 0.109 0.108 0.093 0.171 0.041 0.052 
[Odoribacteraceae] 0.295 0.226 0.330 0.237 0.300 0.252 0.161 0.098 
[Paraprevotellaceae] 0.775 1.848 0.914 1.422 0.712 1.128 0.045 0.098 
[Tissierellaceae] 0.001 0.003 0.001 0.003 0.011 0.029 0.007 0.016 
Actinomycetaceae 0.016 0.023 0.020 0.018 0.032 0.033 0.013 0.018 
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Aerococcaceae 0.000 0.000 0.000 0.000 0.001 0.003 0.000 0.000 
Alcaligenaceae 0.990 0.408 1.863 1.555 2.875 1.970 2.465 2.275 
Bacteroidaceae 27.693 12.747 20.738 11.382 23.854 10.607 19.027 8.758 
Bifidobacteriaceae 2.964 3.227 3.298 2.142 4.700 8.569 6.808 10.990 
Campylobacteraceae 0.001 0.003 0.002 0.004 0.010 0.020 0.004 0.013 
Cardiobacteriaceae 0.001 0.003 0.000 0.000 0.000 0.000 0.000 0.000 
Carnobacteriaceae 0.016 0.020 0.009 0.013 0.007 0.007 0.009 0.014 
Christensenellaceae 0.025 0.043 0.058 0.106 0.075 0.204 0.016 0.026 
Clostridiaceae 0.800 0.811 0.604 0.693 1.996 4.875 1.089 2.093 
Comamonadaceae 0.000 0.000 0.000 0.000 0.001 0.003 0.000 0.000 
Coriobacteriaceae 0.660 0.431 0.885 0.483 0.573 0.316 0.705 0.625 
Corynebacteriaceae 0.002 0.004 0.001 0.003 0.001 0.003 0.000 0.000 
Dehalobacteriaceae 0.000 0.000 0.001 0.003 0.001 0.003 0.000 0.000 
Desulfovibrionaceae 0.260 0.252 0.964 0.822 2.844 1.624 5.451 3.110 
Dethiosulfovibrionaceae 0.001 0.003 0.009 0.020 0.006 0.020 0.000 0.000 
Enterobacteriaceae 3.355 9.544 3.821 6.192 8.772 12.915 17.728 15.709 
Enterococcaceae 0.330 0.763 0.258 0.667 0.419 0.690 1.063 2.341 
Erysipelotrichaceae 1.526 1.258 4.950 4.396 3.548 4.910 3.446 3.776 
Eubacteriaceae 0.001 0.003 0.000 0.000 0.001 0.003 0.003 0.007 
Fusobacteriaceae 0.064 0.182 3.443 10.838 2.045 5.355 4.185 10.236 
Gemellaceae 0.011 0.021 0.002 0.004 0.003 0.005 0.003 0.007 
Helicobacteraceae 0.004 0.013 0.001 0.003 0.003 0.010 0.000 0.000 
Lachnospiraceae 18.092 5.049 13.739 5.529 12.185 4.047 10.266 4.862 
Lactobacillaceae 3.582 4.908 3.511 4.922 3.007 6.293 0.814 1.295 
Leuconostocaceae 0.005 0.013 0.004 0.010 0.032 0.077 0.004 0.013 
Methanobacteriaceae 0.000 0.000 0.030 0.067 0.017 0.052 0.000 0.000 
Micrococcaceae 0.008 0.011 0.005 0.010 0.009 0.017 0.001 0.003 
Moraxellaceae 0.000 0.000 0.000 0.000 0.003 0.005 0.000 0.000 
Nocardioidaceae 0.000 0.000 0.000 0.000 0.001 0.003 0.000 0.000 
Oxalobacteraceae 0.001 0.003 0.003 0.007 0.003 0.007 0.002 0.004 
Pasteurellaceae 0.090 0.244 0.015 0.031 0.021 0.061 0.020 0.039 
Peptococcaceae 0.002 0.007 0.000 0.000 0.004 0.014 0.003 0.007 
Peptostreptococcaceae 0.013 0.015 0.020 0.029 0.011 0.017 0.010 0.033 
Phyllobacteriaceae 0.002 0.005 0.007 0.009 0.001 0.003 0.002 0.004 
Porphyromonadaceae 1.100 0.891 1.439 1.278 1.045 0.885 1.463 1.829 
Prevotellaceae 5.982 12.495 4.746 10.366 3.376 7.310 0.028 0.063 
Rikenellaceae 0.925 0.879 1.712 1.357 1.468 1.702 1.844 3.546 
Ruminococcaceae 15.898 7.378 17.815 10.973 20.260 11.406 15.699 11.460 
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S24-7 1.412 3.691 0.133 0.236 0.068 0.135 0.611 1.037 
Staphylococcaceae 0.000 0.000 0.003 0.007 0.002 0.007 0.000 0.000 
Streptococcaceae 10.101 10.662 11.645 14.804 3.271 3.787 4.899 7.040 
Succinivibrionaceae 0.002 0.006 0.001 0.003 0.001 0.003 0.000 0.000 
Synergistaceae 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Turicibacteraceae 0.058 0.084 0.069 0.122 0.073 0.146 0.062 0.111 
Veillonellaceae 2.493 1.339 2.136 1.553 1.744 1.146 1.689 1.130 
Verrucomicrobiaceae 0.025 0.043 0.270 0.579 0.110 0.300 0.015 0.028 
Victivallaceae 0.002 0.007 0.005 0.009 0.005 0.012 0.007 0.014 
 
 Time point 
Genus T0 mean ± sd 
T5 
mean ± sd 
T10 
mean ± sd 
T24 
mean ± sd 
[Eubacterium] 0.786 1.462 1.955 2.473 1.019 1.914 1.894 3.701 
[Prevotella] 0.803 2.163 0.713 1.714 0.594 1.324 0.030 0.096 
[Ruminococcus] 1.116 0.898 1.176 0.985 1.058 1.034 0.868 0.892 
Acidaminococcus 0.170 0.306 0.465 1.040 0.083 0.140 0.107 0.283 
Acinetobacter 0.000 0.000 0.000 0.000 0.003 0.006 0.000 0.000 
Actinobacillus 0.010 0.027 0.000 0.000 0.002 0.007 0.000 0.000 
Actinomyces 0.026 0.045 0.026 0.022 0.045 0.041 0.023 0.041 
Adlercreutzia 0.044 0.067 0.042 0.071 0.065 0.104 0.017 0.022 
Aeromicrobium 0.000 0.000 0.000 0.000 0.001 0.005 0.000 0.000 
Aggregatibacter 0.008 0.027 0.000 0.000 0.000 0.000 0.000 0.000 
Akkermansia 0.036 0.064 0.386 0.831 0.157 0.429 0.020 0.037 
Alistipes 0.001 0.005 0.000 0.000 0.000 0.000 0.000 0.000 
Anaerococcus 0.000 0.000 0.000 0.000 0.006 0.018 0.000 0.000 
Anaerofustis 0.001 0.004 0.000 0.000 0.000 0.000 0.003 0.010 
Anaerostipes 0.114 0.090 0.122 0.101 0.080 0.094 0.025 0.030 
Anaerotruncus 0.003 0.006 0.010 0.015 0.004 0.010 0.003 0.011 
Atopobium 0.004 0.008 0.003 0.010 0.005 0.009 0.004 0.009 
Bacteroides 38.40 17.79 29.04 17.04 34.58 16.386 28.178 10.973 
Bifidobacterium 4.152 4.175 4.693 3.170 6.911 12.093 9.586 13.458 
Bilophila 0.153 0.103 1.157 1.005 3.629 2.220 8.357 5.118 
Blautia 5.351 2.304 4.376 2.722 4.234 2.042 2.689 2.103 
Bulleidia 0.020 0.064 0.036 0.114 0.064 0.190 0.102 0.297 
Butyricimonas 0.110 0.139 0.088 0.102 0.068 0.080 0.053 0.068 
Campylobacter 0.002 0.007 0.003 0.007 0.019 0.044 0.011 0.034 
Cardiobacterium 0.002 0.007 0.000 0.000 0.000 0.000 0.000 0.000 
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Catenibacterium 0.055 0.172 0.139 0.433 0.150 0.475 0.000 0.000 
cc_115 0.047 0.108 0.107 0.240 0.020 0.034 0.007 0.016 
Christensenella 0.001 0.004 0.002 0.005 0.003 0.010 0.002 0.005 
Citrobacter 0.019 0.032 0.014 0.032 2.696 7.032 2.657 6.121 
Clostridium 0.098 0.108 0.110 0.158 1.975 5.718 0.977 2.892 
Clostridium 0.000 0.000 0.001 0.004 0.000 0.000 0.000 0.000 
Collinsella 0.494 0.424 0.678 0.596 0.404 0.342 0.496 0.802 
Coprobacillus 0.014 0.019 0.040 0.063 0.056 0.105 0.024 0.031 
Coprococcus 4.557 3.677 3.738 2.400 2.240 1.652 1.963 2.591 
Corynebacterium 0.003 0.006 0.002 0.005 0.002 0.005 0.000 0.000 
Dehalobacterium 0.000 0.000 0.001 0.004 0.002 0.005 0.000 0.000 
Delftia 0.000 0.000 0.000 0.000 0.001 0.004 0.000 0.000 
Desulfovibrio 0.183 0.351 0.172 0.538 0.278 0.563 0.231 0.395 
Dialister 0.359 0.755 0.883 1.192 0.616 1.018 0.742 2.079 
Dorea 0.920 0.647 0.901 0.750 0.739 0.588 1.109 1.389 
Eggerthella 0.052 0.081 0.016 0.019 0.036 0.053 0.149 0.377 
Enterobacter 0.004 0.011 0.002 0.008 0.004 0.009 0.013 0.037 
Enterococcus 0.505 1.153 0.397 1.043 0.692 1.183 1.513 2.926 
Epulopiscium 0.008 0.027 0.002 0.005 0.008 0.015 0.002 0.005 
Erwinia 0.000 0.000 0.003 0.010 0.007 0.011 0.003 0.006 
Escherichia 0.103 0.321 0.136 0.198 0.385 0.925 0.410 0.715 
Faecalibacterium 4.252 2.463 3.419 2.653 2.886 1.870 1.851 1.646 
Finegoldia 0.000 0.000 0.000 0.000 0.003 0.011 0.006 0.015 
Fusobacterium 0.078 0.214 3.981 12.525 2.340 6.027 4.789 11.705 
Granulicatella 0.017 0.023 0.009 0.016 0.008 0.009 0.010 0.017 
Haemophilus 0.157 0.450 0.022 0.045 0.045 0.132 0.039 0.080 
Helicobacter 0.003 0.010 0.002 0.005 0.005 0.015 0.000 0.000 
Holdemania 0.007 0.008 0.049 0.084 0.055 0.086 0.086 0.106 
Kaistobacter 0.000 0.000 0.000 0.000 0.001 0.005 0.000 0.000 
Klebsiella 0.053 0.165 0.106 0.335 0.131 0.406 0.001 0.004 
Lachnobacterium 0.084 0.257 0.119 0.208 0.072 0.176 0.006 0.020 
Lachnospira 1.510 1.315 0.959 1.309 1.092 1.055 0.766 1.009 
Lactobacillus 4.138 5.605 4.305 5.931 3.636 7.577 0.968 1.485 
Lactococcus 0.006 0.012 0.036 0.099 0.013 0.033 0.007 0.022 
Leuconostoc 0.001 0.004 0.005 0.013 0.012 0.037 0.005 0.015 
Megamonas 0.046 0.144 0.013 0.041 0.029 0.091 0.019 0.055 
Megasphaera 0.075 0.231 0.071 0.207 0.167 0.505 0.163 0.426 
Mesorhizobium 0.003 0.006 0.009 0.010 0.001 0.004 0.003 0.007 
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Methanobrevibacter 0.000 0.000 0.043 0.097 0.024 0.075 0.000 0.000 
Mogibacterium 0.001 0.004 0.000 0.000 0.000 0.000 0.000 0.000 
Morganella 0.005 0.012 0.000 0.000 0.067 0.212 0.250 0.790 
Odoribacter 0.286 0.239 0.380 0.319 0.354 0.321 0.187 0.130 
Oribacterium 0.000 0.000 0.000 0.000 0.003 0.006 0.003 0.008 
Oscillospira 0.656 0.297 2.348 1.975 6.037 5.236 5.489 5.221 
Other 0.000 0.000 0.001 0.004 0.000 0.000 0.000 0.000 
p-75-a5 0.000 0.000 0.000 0.000 0.000 0.000 0.014 0.044 
Parabacteroides 1.487 1.277 1.972 1.828 1.384 1.142 2.002 2.250 
Paraprevotella 0.138 0.279 0.460 0.730 0.297 0.579 0.021 0.062 
Parvimonas 0.001 0.004 0.002 0.005 0.000 0.000 0.000 0.000 
Pediococcus 0.000 0.000 0.001 0.004 0.001 0.004 0.000 0.000 
Peptococcus 0.000 0.000 0.000 0.000 0.000 0.000 0.001 0.004 
Peptoniphilus 0.000 0.000 0.000 0.000 0.001 0.004 0.002 0.005 
Peptostreptococcus 0.002 0.008 0.004 0.011 0.002 0.007 0.011 0.033 
ph2 0.000 0.000 0.000 0.000 0.002 0.005 0.000 0.000 
Phascolarctobacterium 1.770 1.694 1.175 1.618 1.030 1.237 0.713 0.892 
Plesiomonas 0.000 0.000 0.000 0.000 0.000 0.000 0.004 0.009 
Porphyromonas 0.001 0.004 0.000 0.000 0.000 0.000 0.000 0.000 
Prevotella 7.146 14.467 5.791 12.568 4.132 8.919 0.056 0.138 
Proteus 0.001 0.004 0.005 0.015 0.001 0.004 0.000 0.000 
PSB-M-3 0.000 0.000 0.001 0.004 0.002 0.007 0.001 0.004 
Pseudoramibacter_Eubacterium 0.000 0.000 0.000 0.000 0.001 0.004 0.001 0.004 
Pyramidobacter 0.000 0.000 0.012 0.028 0.009 0.028 0.000 0.000 
Ralstonia 0.001 0.005 0.003 0.009 0.004 0.009 0.004 0.009 
Roseburia 1.075 1.383 0.351 0.387 0.547 0.878 0.086 0.106 
Rothia 0.011 0.014 0.007 0.012 0.012 0.020 0.001 0.004 
Ruminococcus 3.164 3.243 3.646 3.432 3.705 3.715 2.625 3.365 
Scardovia 0.000 0.000 0.001 0.004 0.000 0.000 0.001 0.004 
Selenomonas 0.001 0.004 0.000 0.000 0.001 0.004 0.000 0.000 
Serratia 0.010 0.021 0.003 0.010 0.125 0.272 5.889 9.555 
Slackia 0.029 0.041 0.055 0.077 0.040 0.089 0.015 0.025 
SMB53 0.083 0.140 0.062 0.127 0.068 0.150 0.071 0.115 
Staphylococcus 0.000 0.000 0.005 0.011 0.003 0.010 0.000 0.000 
Streptococcus 12.560 12.610 16.192 22.119 4.316 4.325 6.851 8.978 
Sutterella 1.377 0.759 2.403 2.269 3.838 2.999 3.629 3.061 
TG5 0.002 0.007 0.001 0.004 0.000 0.000 0.000 0.000 
Trabulsiella 0.000 0.000 0.001 0.004 0.004 0.009 0.003 0.006 
	 170 
Turicibacter 0.076 0.108 0.098 0.171 0.104 0.209 0.108 0.187 
Veillonella 0.945 1.976 0.231 0.345 0.441 0.842 0.975 1.779 
 
 
Table A7. Mean relative abundance (%) ± standard deviation (SD) of bacterial taxa at the phylum, 
order, family and genus levels in Cirrhotic patients (CP) upon VSL#3 treatment, over time. 
 
 Time point 
Phylum T0 mean ± sd 
T5 
mean ± sd 
T10 
mean ± sd 
T24 
mean ± sd 
Actinobacteria 4.926 3.794 3.672 2.400 6.609 11.259 14.076 14.264 
Bacteroidetes 29.600 11.722 30.377 10.224 23.046 13.549 24.226 7.630 
Chloroflexi 0.001 0.004 0.000 0.000 0.000 0.000 0.000 0.000 
Cyanobacteria 0.011 0.024 0.009 0.029 0.009 0.025 0.001 0.003 
Euryarchaeota 0.009 0.025 0.004 0.013 0.009 0.019 0.005 0.016 
Firmicutes 62.897 7.610 54.142 12.439 52.691 12.577 49.669 11.586 
Fusobacteria 0.010 0.018 1.087 3.413 4.811 15.152 1.296 4.045 
Lentisphaerae 0.003 0.005 0.000 0.000 0.000 0.000 0.035 0.101 
Proteobacteria 2.467 2.794 10.633 11.836 12.744 12.626 10.608 9.037 
Synergistetes 0.003 0.007 0.004 0.010 0.010 0.029 0.024 0.077 
Tenericutes 0.014 0.039 0.001 0.003 0.000 0.000 0.000 0.000 
TM7 0.003 0.007 0.000 0.000 0.000 0.000 0.000 0.000 
Verrucomicrobia 0.057 0.111 0.072 0.188 0.072 0.205 0.061 0.178 
 
 Time point 
Order T0 mean ± sd 
T5 
mean ± sd 
T10 
mean ± sd 
T24 
mean ± sd 
Actinomycetales 0.021 0.011 0.009 0.013 0.008 0.013 0.013 0.019 
Aeromonadales 0.000 0.000 0.000 0.000 0.001 0.003 0.000 0.000 
Bacillales 0.000 0.000 0.000 0.000 0.001 0.003 0.003 0.007 
Bacteroidales 29.601 11.722 30.378 10.224 23.046 13.550 24.226 7.630 
Bifidobacteriales 4.400 3.944 3.047 2.441 6.138 11.277 11.946 12.365 
Burkholderiales 0.840 0.268 2.326 1.528 1.641 1.491 2.659 2.242 
Campylobacterales 0.009 0.015 0.002 0.004 0.001 0.003 0.007 0.022 
Clostridiales 33.945 11.952 29.440 10.636 22.812 15.440 36.398 10.338 
Coriobacteriales 0.505 0.299 0.616 0.431 0.463 0.433 2.117 3.053 
Desulfovibrionales 0.154 0.157 0.534 0.342 0.728 0.577 1.755 1.085 
Enterobacteriales 1.404 2.887 7.743 11.529 10.358 12.430 6.176 7.632 
Erysipelotrichales 0.962 0.854 9.470 16.751 16.533 18.154 2.467 3.006 
	 171 
Fusobacteriales 0.010 0.018 1.087 3.413 4.811 15.152 1.296 4.045 
Gemellales 0.005 0.008 0.001 0.003 0.001 0.003 0.001 0.003 
Lactobacillales 27.944 13.101 15.223 14.490 13.341 13.047 10.791 8.568 
Methanobacteriales 0.009 0.025 0.004 0.013 0.009 0.019 0.005 0.016 
ML615J-28 0.013 0.036 0.000 0.000 0.000 0.000 0.000 0.000 
Neisseriales 0.000 0.000 0.002 0.006 0.000 0.000 0.001 0.003 
Pasteurellales 0.045 0.077 0.019 0.042 0.012 0.024 0.007 0.015 
Pseudomonadales 0.000 0.000 0.000 0.000 0.001 0.003 0.000 0.000 
RF32 0.015 0.032 0.002 0.004 0.001 0.003 0.001 0.003 
RF39 0.001 0.004 0.001 0.003 0.000 0.000 0.000 0.000 
Rhizobiales 0.001 0.004 0.001 0.003 0.000 0.000 0.001 0.003 
SHA-98 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Synergistales 0.003 0.007 0.004 0.010 0.010 0.029 0.024 0.077 
Turicibacterales 0.042 0.098 0.009 0.020 0.003 0.010 0.010 0.019 
Verrucomicrobiales 0.057 0.111 0.072 0.188 0.072 0.205 0.061 0.178 
Victivallales 0.003 0.005 0.000 0.000 0.000 0.000 0.035 0.101 
YS2 0.011 0.024 0.009 0.029 0.008 0.026 0.000 0.000 
 
 Time point 
Family T0 mean ± sd 
T5 
mean ± sd 
T10 
mean ± sd 
T24 
mean ± sd 
[Barnesiellaceae] 0.238 0.224 0.243 0.298 0.146 0.221 0.353 0.583 
[Mogibacteriaceae] 0.049 0.070 0.033 0.047 0.042 0.099 0.202 0.311 
[Odoribacteraceae] 0.298 0.259 0.181 0.107 0.107 0.117 0.211 0.149 
[Paraprevotellaceae] 0.973 1.897 0.536 0.956 0.397 0.513 0.135 0.219 
[Tissierellaceae] 0.000 0.000 0.003 0.007 0.000 0.000 0.005 0.010 
Actinomycetaceae 0.016 0.014 0.005 0.007 0.006 0.013 0.009 0.016 
Aerococcaceae 0.000 0.000 0.000 0.000 0.000 0.000 0.001 0.003 
Alcaligenaceae 0.866 0.282 2.373 1.577 1.686 1.550 2.739 2.304 
Bacillaceae 0.000 0.000 0.000 0.000 0.001 0.003 0.001 0.003 
Bacteroidaceae 20.549 12.287 21.833 9.090 16.679 11.816 19.203 7.140 
Bifidobacteriaceae 4.518 4.034 3.092 2.446 6.227 11.371 12.459 12.928 
Campylobacteraceae 0.004 0.008 0.002 0.004 0.001 0.003 0.007 0.023 
Carnobacteriaceae 0.006 0.011 0.004 0.007 0.000 0.000 0.002 0.004 
Christensenellaceae 0.063 0.162 0.008 0.020 0.006 0.014 0.094 0.173 
Clostridiaceae 0.547 0.996 0.760 1.284 0.568 1.256 0.469 0.775 
Coriobacteriaceae 0.523 0.311 0.632 0.447 0.473 0.441 2.237 3.273 
Corynebacteriaceae 0.000 0.000 0.001 0.003 0.002 0.004 0.002 0.007 
	 172 
Dehalobacteriaceae 0.001 0.004 0.000 0.000 0.000 0.000 0.002 0.007 
Desulfovibrionaceae 0.159 0.162 0.548 0.355 0.743 0.592 1.809 1.108 
Dethiosulfovibrionaceae 0.003 0.007 0.003 0.010 0.010 0.030 0.025 0.079 
Enterobacteriaceae 1.424 2.911 7.820 11.547 10.527 12.597 6.326 7.669 
Enterococcaceae 0.318 0.657 0.558 0.914 0.550 0.913 1.075 1.314 
Erysipelotrichaceae 0.990 0.881 9.753 17.400 16.618 18.225 2.543 3.088 
Eubacteriaceae 0.003 0.005 0.000 0.000 0.001 0.003 0.004 0.007 
Fusobacteriaceae 0.010 0.018 1.092 3.429 4.831 15.216 1.317 4.110 
Gemellaceae 0.005 0.008 0.001 0.003 0.001 0.003 0.001 0.003 
Helicobacteraceae 0.005 0.015 0.000 0.000 0.000 0.000 0.000 0.000 
Lachnospiraceae 15.625 5.544 11.129 5.712 10.075 7.542 17.674 6.243 
Lactobacillaceae 5.403 3.287 3.187 3.503 3.011 3.536 2.561 4.086 
Leuconostocaceae 0.024 0.041 0.001 0.003 0.007 0.019 0.015 0.028 
Methanobacteriaceae 0.009 0.026 0.004 0.013 0.009 0.020 0.005 0.017 
Micrococcaceae 0.006 0.011 0.003 0.010 0.000 0.000 0.002 0.004 
Neisseriaceae 0.000 0.000 0.002 0.006 0.000 0.000 0.001 0.003 
Nocardioidaceae 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Oxalobacteraceae 0.001 0.004 0.002 0.004 0.000 0.000 0.000 0.000 
Pasteurellaceae 0.046 0.078 0.020 0.042 0.012 0.025 0.007 0.015 
Peptococcaceae 0.000 0.000 0.000 0.000 0.015 0.048 0.000 0.000 
Peptostreptococcaceae 0.014 0.022 0.002 0.007 0.015 0.033 0.014 0.028 
Phyllobacteriaceae 0.001 0.004 0.001 0.003 0.000 0.000 0.001 0.003 
Planococcaceae 0.000 0.000 0.000 0.000 0.000 0.000 0.001 0.003 
Porphyromonadaceae 0.803 0.694 1.272 0.959 1.402 1.525 2.099 2.214 
Prevotellaceae 6.191 12.442 4.038 9.180 4.003 8.172 0.310 0.954 
Pseudomonadaceae 0.000 0.000 0.000 0.000 0.001 0.003 0.000 0.000 
Rikenellaceae 1.223 1.266 0.709 0.597 0.580 0.756 1.884 1.805 
Ruminococcaceae 14.362 7.228 13.069 6.928 8.855 7.412 11.750 7.892 
S24-7 0.110 0.291 2.085 4.605 0.122 0.250 0.838 2.608 
Staphylococcaceae 0.000 0.000 0.000 0.000 0.000 0.000 0.001 0.003 
Streptococcaceae 22.891 11.800 11.668 13.250 10.026 11.578 7.425 7.214 
Succinivibrionaceae 0.000 0.000 0.000 0.000 0.001 0.003 0.000 0.000 
Synergistaceae 0.000 0.000 0.001 0.003 0.000 0.000 0.000 0.000 
Turicibacteraceae 0.043 0.101 0.009 0.021 0.003 0.010 0.010 0.019 
Veillonellaceae 1.617 1.382 3.243 2.422 2.165 2.170 4.067 5.267 
Verrucomicrobiaceae 0.059 0.114 0.073 0.192 0.074 0.213 0.063 0.184 




 Time point 
Genus T0 mean ± sd 
T5 
mean ± sd 
T10 
mean ± sd 
T24 
mean ± sd 
[Eubacterium] 0.374 0.870 1.670 3.669 1.649 2.228 0.317 0.579 
[Prevotella] 0.947 2.154 0.521 1.473 0.290 0.695 0.000 0.000 
[Ruminococcus] 0.916 0.495 0.711 0.496 1.617 3.667 1.251 0.859 
Acidaminococcus 0.251 0.340 0.559 0.977 0.802 1.177 3.534 7.346 
Actinobacillus 0.002 0.004 0.000 0.000 0.000 0.000 0.000 0.000 
Actinomyces 0.020 0.017 0.006 0.011 0.002 0.005 0.009 0.017 
Adlercreutzia 0.042 0.072 0.057 0.080 0.033 0.059 0.079 0.116 
Akkermansia 0.071 0.134 0.119 0.260 0.113 0.288 0.097 0.250 
Alistipes 0.002 0.005 0.000 0.000 0.000 0.000 0.000 0.000 
Anaerobacillus 0.000 0.000 0.000 0.000 0.002 0.006 0.002 0.005 
Anaerococcus 0.000 0.000 0.000 0.000 0.000 0.000 0.001 0.004 
Anaerofustis 0.003 0.006 0.000 0.000 0.000 0.000 0.004 0.007 
Anaerostipes 0.142 0.121 0.033 0.034 0.014 0.023 0.057 0.060 
Anaerotruncus 0.005 0.010 0.006 0.011 0.000 0.000 0.024 0.031 
Atopobium 0.000 0.000 0.000 0.000 0.000 0.000 0.002 0.005 
Bacteroides 25.528 15.032 37.395 10.619 31.893 20.803 27.708 6.211 
Bifidobacterium 5.559 4.887 5.656 4.178 9.193 14.627 18.073 19.059 
Bilophila 0.121 0.098 1.046 1.035 1.498 1.164 2.438 1.493 
Blautia 4.769 2.950 3.912 2.688 1.982 1.377 5.943 4.212 
Bulleidia 0.009 0.026 0.000 0.000 0.000 0.000 0.000 0.000 
Butyricimonas 0.087 0.128 0.078 0.125 0.044 0.060 0.063 0.068 
Campylobacter 0.005 0.009 0.002 0.005 0.000 0.000 0.013 0.036 
Cardiobacterium 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Catenibacterium 0.101 0.285 0.002 0.005 0.000 0.000 0.000 0.000 
cc_115 0.005 0.007 0.014 0.016 0.008 0.018 0.005 0.010 
Christensenella 0.000 0.000 0.000 0.000 0.000 0.000 0.004 0.007 
Chthoniobacter 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Citrobacter 0.017 0.031 0.003 0.006 6.228 17.412 0.003 0.006 
Clostridium 0.072 0.076 0.759 1.854 0.704 1.635 0.425 1.117 
Clostridium 0.000 0.000 0.000 0.000 0.006 0.017 0.000 0.000 
Clostridium 0.000 0.000 0.000 0.000 0.002 0.005 0.000 0.000 
Collinsella 0.350 0.347 0.638 0.579 0.600 0.663 2.900 4.660 
Coprobacillus 0.027 0.038 0.017 0.031 0.006 0.012 0.004 0.012 
Coprococcus 3.192 2.537 3.017 2.610 3.873 3.829 4.553 2.948 
	 174 
Corynebacterium 0.000 0.000 0.002 0.006 0.004 0.007 0.004 0.011 
Curvibacter 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Dehalobacterium 0.002 0.004 0.000 0.000 0.000 0.000 0.004 0.011 
Desulfovibrio 0.076 0.215 0.121 0.186 0.036 0.085 0.082 0.119 
Dialister 0.298 0.307 0.588 0.934 0.402 0.511 0.365 0.562 
Dorea 0.581 0.199 1.380 1.183 1.483 1.396 1.965 1.438 
Eggerthella 0.038 0.058 0.081 0.140 0.060 0.123 0.097 0.130 
Eikenella 0.000 0.000 0.002 0.005 0.000 0.000 0.002 0.005 
Enterobacter 0.002 0.004 0.000 0.000 0.000 0.000 0.000 0.000 
Enterococcus 0.435 0.944 0.614 1.064 0.592 1.173 1.237 1.865 
Epulopiscium 0.000 0.000 0.002 0.005 0.000 0.000 0.007 0.008 
Erwinia 0.002 0.004 0.000 0.000 0.007 0.021 0.002 0.005 
Escherichia 0.027 0.056 0.366 0.615 0.285 0.621 0.365 0.567 
Faecalibacterium 3.386 1.872 4.864 3.504 2.251 1.559 0.926 1.055 
Finegoldia 0.000 0.000 0.003 0.010 0.000 0.000 0.005 0.009 
Flavobacterium 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Fusobacterium 0.012 0.022 0.011 0.017 7.646 21.595 1.796 5.068 
Gemella 0.002 0.004 0.000 0.000 0.000 0.000 0.000 0.000 
Granulicatella 0.008 0.013 0.005 0.010 0.000 0.000 0.003 0.006 
Haemophilus 0.054 0.095 0.026 0.062 0.014 0.039 0.005 0.015 
Helicobacter 0.006 0.016 0.000 0.000 0.000 0.000 0.000 0.000 
Holdemania 0.011 0.024 0.017 0.016 0.019 0.027 0.015 0.022 
Klebsiella 0.057 0.162 0.011 0.032 0.009 0.020 0.000 0.000 
Lachnobacterium 0.143 0.250 0.061 0.138 0.070 0.146 0.017 0.029 
Lachnospira 0.988 0.660 0.500 0.547 0.240 0.277 0.416 0.335 
Lactobacillus 6.196 3.676 2.417 2.031 2.337 1.861 1.375 1.182 
Lactococcus 0.005 0.006 0.002 0.006 0.105 0.243 0.011 0.032 
Megamonas 0.000 0.000 0.002 0.004 0.008 0.023 0.016 0.044 
Megasphaera 0.011 0.017 0.010 0.024 0.014 0.041 0.282 0.741 
Mesorhizobium 0.002 0.005 0.002 0.006 0.000 0.000 0.002 0.005 
Methanobrevibacter 0.011 0.030 0.006 0.018 0.014 0.025 0.008 0.023 
Morganella 0.000 0.000 0.012 0.033 0.096 0.154 0.028 0.063 
Odoribacter 0.289 0.256 0.271 0.152 0.142 0.164 0.187 0.177 
Oribacterium 0.002 0.004 0.000 0.000 0.000 0.000 0.000 0.000 
Oscillospira 0.545 0.449 1.455 0.978 1.402 1.287 2.554 2.487 
Other 0.003 0.006 0.002 0.004 0.012 0.035 0.000 0.000 
Parabacteroides 0.995 0.845 2.315 1.695 2.166 2.034 2.835 2.781 
Paraprevotella 0.219 0.429 0.147 0.299 0.203 0.259 0.119 0.220 
	 175 
Pediococcus 0.009 0.017 0.002 0.005 0.007 0.010 0.000 0.000 
Peptococcus 0.000 0.000 0.000 0.000 0.022 0.062 0.000 0.000 
Peptostreptococcus 0.009 0.026 0.000 0.000 0.003 0.009 0.013 0.032 
Phascolarctobacterium 1.055 1.431 1.918 2.147 1.441 2.102 0.918 1.048 
Porphyromonas 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Prevotella 7.271 14.491 2.492 5.653 3.281 8.459 0.012 0.018 
Proteus 0.005 0.009 0.004 0.007 0.002 0.006 0.005 0.007 
PSB-M-3 0.000 0.000 0.000 0.000 0.002 0.005 0.001 0.004 
Pseudomonas 0.000 0.000 0.000 0.000 0.004 0.010 0.000 0.000 
Pyramidobacter 0.003 0.009 0.005 0.013 0.014 0.040 0.038 0.108 
Ralstonia 0.002 0.004 0.006 0.012 0.000 0.000 0.000 0.000 
Rikenella 0.000 0.000 0.000 0.000 0.000 0.000 0.002 0.005 
Roseburia 1.358 1.944 0.432 0.530 0.149 0.244 0.110 0.100 
Rothia 0.008 0.013 0.000 0.000 0.000 0.000 0.002 0.006 
Ruminococcus 3.715 3.478 1.865 1.378 2.050 1.942 2.285 2.575 
Scardovia 0.002 0.004 0.000 0.000 0.002 0.006 0.000 0.000 
Selenomonas 0.005 0.009 0.000 0.000 0.000 0.000 0.007 0.021 
Serratia 0.005 0.013 0.014 0.022 0.256 0.529 0.003 0.006 
SHD-231 0.002 0.004 0.000 0.000 0.000 0.000 0.000 0.000 
Slackia 0.040 0.048 0.065 0.149 0.035 0.053 0.081 0.154 
SMB53 0.025 0.046 0.022 0.046 0.015 0.018 0.015 0.021 
Staphylococcus 0.000 0.000 0.000 0.000 0.000 0.000 0.001 0.004 
Streptococcus 28.025 14.188 17.604 19.228 9.942 9.803 9.763 9.633 
Sutterella 1.056 0.329 3.356 2.466 2.201 2.304 3.580 3.000 
Trabulsiella 0.002 0.004 0.000 0.000 0.011 0.031 0.000 0.000 
Turicibacter 0.052 0.124 0.025 0.047 0.006 0.017 0.017 0.031 
Veillonella 0.322 0.469 0.675 1.347 0.385 0.846 0.884 1.393 
 
 
Table A8. Mean relative abundance (%) ± standard deviation (SD) of bacterial taxa at the phylum, 
order, family and genus levels in Cirrhotic patients (CP) upon VSL#3 + lactulose treatment, over 
time. 
 Time point 
Phylum T0 mean ± sd 
T5 
mean ± sd 
T10 
mean ± sd 
T24 
mean ± sd 
Actinobacteria 3.227 2.090 14.168 15.097 15.843 13.699 7.331 8.028 
Bacteroidetes 37.558 7.973 25.487 13.368 26.011 11.137 27.757 11.391 
Cyanobacteria 0.030 0.062 0.001 0.003 0.010 0.028 0.001 0.003 
Euryarchaeota 0.005 0.016 0.007 0.019 0.013 0.028 0.013 0.041 
	 176 
Firmicutes 57.634 8.265 51.535 11.514 52.300 6.715 48.621 11.271 
Fusobacteria 0.056 0.176 0.007 0.011 0.017 0.029 0.518 1.471 
Lentisphaerae 0.006 0.011 0.000 0.000 0.000 0.000 0.012 0.035 
Proteobacteria 1.392 0.677 8.760 8.002 5.770 6.154 15.614 11.100 
Synergistetes 0.001 0.003 0.001 0.003 0.000 0.000 0.021 0.060 
Tenericutes 0.018 0.043 0.001 0.003 0.000 0.000 0.001 0.003 
TM7 0.001 0.003 0.000 0.000 0.000 0.000 0.000 0.000 
Verrucomicrobia 0.070 0.129 0.033 0.082 0.036 0.091 0.110 0.245 
	




mean ± sd 
T5 
mean ± sd 
T10 
mean ± sd 
T24 
mean ± sd 
Actinomycetales 0.022 0.021 0.007 0.008 0.004 0.007 0.005 0.005 
Aeromonadales 0.001 0.003 0.000 0.000 0.000 0.000 0.000 0.000 
Bacillales 0.001 0.003 0.000 0.000 0.000 0.000 0.000 0.000 
Bacteroidales 37.559 7.972 25.488 13.368 26.012 11.138 27.757 11.391 
Bifidobacteriales 2.420 1.771 12.474 14.682 13.507 12.484 5.935 7.363 
Burkholderiales 0.835 0.357 1.401 0.964 0.724 0.459 2.248 2.258 
Campylobacterales 0.007 0.015 0.001 0.003 0.001 0.003 0.002 0.004 
Clostridiales 41.548 11.636 33.529 13.341 34.268 7.967 29.992 11.148 
Coriobacteriales 0.785 0.408 1.687 1.891 2.332 2.463 1.391 1.447 
Desulfovibrionales 0.222 0.172 0.179 0.173 0.514 0.559 1.668 0.758 
Enterobacteriales 0.294 0.574 7.154 7.532 4.501 5.875 11.667 10.829 
Erysipelotrichales 1.504 1.612 3.824 4.945 8.476 9.132 4.177 6.150 
Fusobacteriales 0.056 0.176 0.007 0.011 0.017 0.029 0.518 1.471 
Gemellales 0.004 0.009 0.000 0.000 0.002 0.004 0.002 0.004 
Lactobacillales 14.529 9.576 14.174 10.400 9.543 9.770 14.434 17.147 
Methanobacteriales 0.005 0.016 0.007 0.019 0.013 0.028 0.013 0.041 
ML615J-28 0.010 0.032 0.000 0.000 0.000 0.000 0.000 0.000 
Neisseriales 0.000 0.000 0.000 0.000 0.002 0.006 0.000 0.000 
Pasteurellales 0.020 0.034 0.018 0.032 0.021 0.030 0.023 0.031 
RF32 0.010 0.018 0.006 0.011 0.005 0.016 0.004 0.009 
RF39 0.008 0.018 0.001 0.003 0.000 0.000 0.001 0.003 
Rhizobiales 0.003 0.007 0.000 0.000 0.000 0.000 0.001 0.003 
SHA-98 0.003 0.007 0.000 0.000 0.000 0.000 0.000 0.000 
Synergistales 0.001 0.003 0.001 0.003 0.000 0.000 0.021 0.060 
Turicibacterales 0.045 0.095 0.007 0.011 0.011 0.023 0.017 0.028 
Verrucomicrobiales 0.070 0.129 0.033 0.082 0.035 0.091 0.110 0.245 
	 177 
Victivallales 0.006 0.011 0.000 0.000 0.000 0.000 0.012 0.035 
YS2 0.030 0.062 0.001 0.003 0.010 0.028 0.001 0.003 
	
 Time point 
Family T0 mean ± sd 
T5 
mean ± sd 
T10 
mean ± sd 
T24 
mean ± sd 
[Barnesiellaceae] 0.432 0.363 0.187 0.192 0.220 0.194 0.399 0.452 
[Cerasicoccaceae] 0.000 0.000 0.000 0.000 0.001 0.003 0.000 0.000 
[Mogibacteriaceae] 0.116 0.112 0.150 0.216 0.102 0.178 0.116 0.201 
[Odoribacteraceae] 0.387 0.180 0.197 0.213 0.159 0.168 0.252 0.192 
[Paraprevotellaceae] 0.809 1.464 0.168 0.306 0.237 0.500 0.170 0.343 
[Tissierellaceae] 0.000 0.000 0.003 0.005 0.013 0.028 0.034 0.069 
Actinomycetaceae 0.011 0.019 0.006 0.009 0.003 0.007 0.001 0.003 
Alcaligenaceae 0.866 0.374 1.436 0.977 0.753 0.484 2.291 2.294 
Bacteroidaceae 28.237 12.917 19.671 11.847 21.125 7.818 23.057 10.830 
Bifidobacteriaceae 2.539 1.861 12.832 14.859 14.070 13.052 6.090 7.689 
Campylobacteraceae 0.000 0.000 0.001 0.003 0.001 0.003 0.002 0.004 
Carnobacteriaceae 0.013 0.025 0.001 0.003 0.002 0.004 0.002 0.004 
Christensenellaceae 0.085 0.196 0.054 0.091 0.022 0.025 0.006 0.009 
Clostridiaceae 0.420 0.453 0.667 0.708 0.320 0.292 0.633 0.772 
Comamonadaceae 0.000 0.000 0.002 0.004 0.000 0.000 0.000 0.000 
Coriobacteriaceae 0.825 0.434 1.773 2.017 2.456 2.621 1.452 1.537 
Corynebacteriaceae 0.003 0.005 0.000 0.000 0.000 0.000 0.000 0.000 
Dehalobacteriaceae 0.002 0.007 0.001 0.003 0.001 0.003 0.000 0.000 
Desulfovibrionaceae 0.235 0.186 0.186 0.180 0.538 0.598 1.712 0.781 
Dethiosulfovibrionaceae 0.001 0.003 0.001 0.003 0.000 0.000 0.020 0.063 
Enterobacteriaceae 0.305 0.593 7.314 7.646 4.712 6.310 11.946 11.066 
Enterococcaceae 0.513 1.030 2.300 3.067 1.478 2.485 0.878 1.643 
Erysipelotrichaceae 1.600 1.772 3.893 5.005 8.672 9.362 4.237 6.171 
Eubacteriaceae 0.000 0.000 0.002 0.004 0.001 0.003 0.017 0.045 
Fusobacteriaceae 0.056 0.178 0.007 0.011 0.017 0.029 0.523 1.483 
Gemellaceae 0.004 0.009 0.000 0.000 0.002 0.004 0.002 0.004 
Helicobacteraceae 0.007 0.016 0.000 0.000 0.000 0.000 0.000 0.000 
Lachnospiraceae 18.923 4.676 14.724 7.082 17.146 4.648 12.119 6.542 
Lactobacillaceae 3.517 4.357 3.124 2.946 1.187 1.581 3.573 4.860 
Leuconostocaceae 0.024 0.047 0.014 0.026 0.004 0.010 0.024 0.058 
Methanobacteriaceae 0.005 0.017 0.007 0.020 0.014 0.029 0.014 0.043 
Microbacteriaceae 0.000 0.000 0.001 0.003 0.000 0.000 0.002 0.004 
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Micrococcaceae 0.007 0.010 0.000 0.000 0.001 0.003 0.002 0.004 
Oxalobacteraceae 0.002 0.005 0.000 0.000 0.000 0.000 0.002 0.007 
Pasteurellaceae 0.021 0.035 0.018 0.032 0.022 0.030 0.024 0.032 
Peptococcaceae 0.000 0.000 0.148 0.467 0.195 0.612 0.000 0.000 
Peptostreptococcaceae 0.020 0.032 0.013 0.015 0.003 0.010 0.023 0.035 
Phyllobacteriaceae 0.003 0.007 0.000 0.000 0.000 0.000 0.001 0.003 
Porphyromonadaceae 1.352 0.946 1.475 2.219 1.513 1.776 2.210 1.715 
Prevotellaceae 5.852 12.023 3.488 9.434 2.389 3.963 1.104 2.444 
Propionibacteriaceae 0.001 0.003 0.000 0.000 0.000 0.000 0.000 0.000 
Rikenellaceae 1.784 1.641 1.107 1.309 1.059 0.616 0.951 0.972 
Ruminococcaceae 17.688 8.001 14.094 7.321 11.955 5.859 10.616 6.088 
S24-7 0.263 0.578 0.002 0.007 0.188 0.337 0.260 0.431 
Staphylococcaceae 0.001 0.003 0.000 0.000 0.000 0.000 0.000 0.000 
Streptococcaceae 10.925 7.321 9.121 9.384 7.164 8.795 10.139 16.234 
Succinivibrionaceae 0.001 0.003 0.000 0.000 0.000 0.000 0.000 0.000 
Synergistaceae 0.000 0.000 0.000 0.000 0.000 0.000 0.002 0.004 
Turicibacteraceae 0.050 0.106 0.007 0.011 0.012 0.025 0.018 0.030 
Veillonellaceae 2.011 1.360 1.769 1.060 2.205 0.634 4.949 5.803 
Verrucomicrobiaceae 0.074 0.136 0.035 0.087 0.037 0.096 0.114 0.257 
Victivallaceae 0.006 0.011 0.000 0.000 0.000 0.000 0.013 0.036 
	
 Time point 
Genus T0 mean ± sd 
T5 
mean ± sd 
T10 
mean ± sd 
T24 
mean ± sd 
[Eubacterium] 0.945 1.929 1.536 3.407 1.355 1.766 1.792 2.597 
[Prevotella] 0.642 1.628 0.123 0.262 0.254 0.662 0.183 0.470 
[Ruminococcus] 1.126 0.680 1.297 0.853 0.894 0.695 0.675 0.429 
Acidaminococcus 0.285 0.498 0.116 0.209 0.162 0.256 1.824 4.521 
Acinetobacter 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Actinobacillus 0.000 0.000 0.001 0.004 0.007 0.022 0.001 0.004 
Actinomyces 0.014 0.022 0.009 0.013 0.003 0.008 0.001 0.004 
Adlercreutzia 0.068 0.107 0.073 0.120 0.008 0.014 0.003 0.006 
Akkermansia 0.097 0.178 0.041 0.102 0.045 0.111 0.156 0.348 
Anaerococcus 0.000 0.000 0.001 0.005 0.008 0.018 0.006 0.014 
Anaerofustis 0.000 0.000 0.003 0.006 0.001 0.004 0.003 0.011 
Anaerostipes 0.131 0.123 0.090 0.080 0.045 0.058 0.062 0.122 
Anaerotruncus 0.006 0.014 0.009 0.016 0.004 0.007 0.005 0.009 
Atopobium 0.001 0.004 0.000 0.000 0.000 0.000 0.000 0.000 
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Bacteroides 36.49 15.73 26.62 16.12 31.58 14.23 32.00 14.20 
Bifidobacterium 3.359 2.522 17.22 20.83 18.419 16.675 8.194 9.620 
Bilophila 0.230 0.124 0.215 0.216 0.819 1.083 2.300 1.273 
Blautia 6.059 2.833 5.651 3.182 5.038 3.083 2.202 1.716 
Bulleidia 0.014 0.045 0.035 0.110 0.000 0.000 0.026 0.083 
Butyricimonas 0.130 0.136 0.090 0.179 0.100 0.162 0.120 0.150 
Campylobacter 0.000 0.000 0.001 0.004 0.002 0.005 0.003 0.006 
Catenibacterium 0.099 0.314 0.776 2.455 0.002 0.005 0.156 0.482 
cc_115 0.096 0.218 0.005 0.013 0.003 0.005 0.009 0.023 
Christensenella 0.006 0.010 0.003 0.006 0.001 0.004 0.001 0.004 
Citrobacter 0.016 0.036 0.427 1.314 0.245 0.774 1.769 4.713 
Clostridium 0.047 0.044 0.345 0.809 0.132 0.216 0.429 1.084 
Collinsella 0.571 0.573 1.806 2.491 2.856 3.157 1.259 1.517 
Coprobacillus 0.015 0.022 0.004 0.007 0.001 0.004 0.005 0.008 
Coprococcus 5.147 2.746 4.599 3.354 5.701 3.654 4.336 4.030 
Corynebacterium 0.004 0.007 0.000 0.000 0.000 0.000 0.000 0.000 
Cryocola 0.000 0.000 0.001 0.005 0.000 0.000 0.001 0.004 
Dehalobacterium 0.003 0.009 0.002 0.006 0.001 0.004 0.000 0.000 
Delftia 0.000 0.000 0.001 0.004 0.000 0.000 0.000 0.000 
Desulfovibrio 0.067 0.212 0.033 0.076 0.015 0.036 0.133 0.257 
Dialister 0.578 0.819 0.570 0.752 0.838 1.133 0.335 0.735 
Dorea 0.854 0.400 0.897 0.539 1.388 1.377 1.885 2.210 
Eggerthella 0.011 0.016 0.043 0.070 0.051 0.066 0.109 0.145 
Eikenella 0.000 0.000 0.000 0.000 0.003 0.010 0.000 0.000 
Enterobacter 0.001 0.004 0.000 0.000 0.001 0.004 0.005 0.010 
Enterococcus 0.716 1.465 2.388 3.733 1.894 3.303 0.889 2.034 
Epulopiscium 0.000 0.000 0.004 0.011 0.004 0.012 0.008 0.020 
Erwinia 0.000 0.000 0.000 0.000 0.003 0.006 0.003 0.008 
Escherichia 0.008 0.011 0.322 0.476 0.225 0.394 0.389 0.503 
Faecalibacterium 3.665 1.651 2.716 2.012 2.108 1.881 0.976 1.265 
Finegoldia 0.000 0.000 0.001 0.004 0.006 0.009 0.023 0.046 
Fusobacterium 0.065 0.204 0.009 0.014 0.024 0.040 0.600 1.641 
Granulicatella 0.015 0.031 0.001 0.004 0.002 0.005 0.001 0.004 
Haemophilus 0.025 0.040 0.023 0.041 0.025 0.023 0.034 0.047 
Helicobacter 0.006 0.015 0.000 0.000 0.000 0.000 0.000 0.000 
Holdemania 0.023 0.042 0.018 0.028 0.015 0.017 0.053 0.096 
Klebsiella 0.059 0.185 0.075 0.219 0.011 0.035 0.172 0.513 
Lachnobacterium 0.228 0.298 0.057 0.106 0.040 0.084 0.030 0.090 
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Lachnospira 1.186 0.926 0.341 0.412 0.154 0.157 0.344 0.391 
Lactobacillus 4.145 4.957 3.629 3.467 1.321 1.779 4.555 6.545 
Lactococcus 0.010 0.023 0.003 0.008 0.001 0.004 0.040 0.119 
Leuconostoc 0.015 0.037 0.014 0.034 0.002 0.005 0.001 0.004 
Luteolibacter 0.000 0.000 0.001 0.004 0.000 0.000 0.000 0.000 
Megamonas 0.070 0.223 0.000 0.000 0.000 0.000 0.227 0.718 
Megasphaera 0.093 0.289 0.004 0.013 0.006 0.012 1.389 4.241 
Mesorhizobium 0.005 0.010 0.000 0.000 0.000 0.000 0.002 0.007 
Methanobrevibacter 0.007 0.022 0.009 0.025 0.017 0.036 0.018 0.058 
Microbacterium 0.000 0.000 0.000 0.000 0.000 0.000 0.001 0.004 
Mogibacterium 0.000 0.000 0.000 0.000 0.000 0.000 0.002 0.007 
Morganella 0.000 0.000 0.047 0.148 0.025 0.069 0.040 0.090 
Moryella 0.001 0.005 0.000 0.000 0.000 0.000 0.000 0.000 
Odoribacter 0.381 0.177 0.183 0.175 0.143 0.147 0.252 0.236 
Oscillospira 0.908 0.753 1.641 2.126 1.526 1.381 2.104 0.928 
Other 0.001 0.004 0.003 0.009 0.000 0.000 0.000 0.000 
Oxalobacter 0.000 0.000 0.000 0.000 0.000 0.000 0.004 0.013 
p-75-a5 0.002 0.005 0.000 0.000 0.000 0.000 0.000 0.000 
Parabacteroides 1.789 1.300 1.982 2.889 2.351 2.675 3.289 2.827 
Paraprevotella 0.310 0.585 0.082 0.175 0.091 0.160 0.077 0.138 
Pediococcus 0.000 0.000 0.000 0.000 0.000 0.000 0.001 0.004 
Peptococcus 0.000 0.000 0.188 0.596 0.256 0.803 0.000 0.000 
Peptoniphilus 0.000 0.000 0.001 0.004 0.006 0.019 0.018 0.034 
Peptostreptococcus 0.009 0.030 0.000 0.000 0.000 0.000 0.011 0.036 
Phascolarctobacterium 1.157 1.378 1.092 1.229 1.270 1.107 1.944 2.090 
Prevotella 6.956 13.907 4.153 11.110 4.120 6.870 1.714 3.882 
Proteus 0.000 0.000 0.004 0.007 0.000 0.000 0.004 0.009 
Pseudoramibacter_Eubacterium 0.000 0.000 0.000 0.000 0.000 0.000 0.018 0.057 
Pyramidobacter 0.001 0.004 0.001 0.004 0.000 0.000 0.027 0.085 
Ralstonia 0.003 0.006 0.000 0.000 0.000 0.000 0.000 0.000 
Rikenella 0.000 0.000 0.000 0.000 0.000 0.000 0.002 0.005 
Roseburia 1.168 2.025 0.206 0.196 0.107 0.115 0.086 0.139 
Rothia 0.009 0.012 0.000 0.000 0.001 0.004 0.003 0.006 
Ruminococcus 4.580 4.710 3.744 3.388 3.047 2.057 2.811 2.730 
Scardovia 0.001 0.004 0.000 0.000 0.000 0.000 0.001 0.005 
Selenomonas 0.000 0.000 0.001 0.004 0.006 0.015 0.001 0.004 
Serratia 0.006 0.016 0.017 0.055 0.005 0.013 0.802 2.507 
Slackia 0.074 0.101 0.063 0.132 0.015 0.024 0.019 0.053 
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SMB53 0.048 0.094 0.008 0.015 0.023 0.034 0.041 0.074 
Sphingobacterium 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Staphylococcus 0.002 0.005 0.000 0.000 0.000 0.000 0.000 0.000 
Streptococcus 13.69 8.903 11.819 12.074 9.194 11.084 12.917 20.793 
Sutterella 1.063 0.477 1.949 1.384 1.023 0.550 3.124 2.983 
Tetragenococcus 0.001 0.004 0.000 0.000 0.000 0.000 0.000 0.000 
Trabulsiella 0.000 0.000 0.001 0.004 0.000 0.000 0.008 0.025 
Turicibacter 0.068 0.148 0.010 0.015 0.018 0.040 0.029 0.051 
Veillonella 0.307 0.486 0.529 1.112 0.931 1.635 0.901 1.372 




Table A9. Mean relative abundance (%) ± standard deviation (SD) of bacterial taxa at the phylum, 
order, family and genus levels in Cirrhotic patients (CP) upon VSL#3 + lactulose + rifaximin 
treatment, over time. 
 Time point 
Phylum T0 mean ± sd 
T5 
mean ± sd 
T10 
mean ± sd 
T24 
mean ± sd 
Actinobacteria 4.249 3.335 3.324 3.473 5.362 5.697 4.838 8.990 
Bacteroidetes 34.848 13.123 31.679 11.952 20.894 14.725 14.264 16.806 
Chloroflexi 0.000 0.000 0.000 0.000 0.001 0.003 0.000 0.000 
Cyanobacteria 0.021 0.042 0.015 0.034 0.001 0.003 0.000 0.000 
Euryarchaeota 0.003 0.010 0.004 0.013 0.006 0.019 0.049 0.153 
Firmicutes 54.038 10.280 50.331 18.508 64.218 16.461 67.986 12.988 
Fusobacteria 0.010 0.013 1.363 4.263 1.186 3.227 1.465 3.197 
Lentisphaerae 0.001 0.003 0.002 0.004 0.000 0.000 0.003 0.010 
Proteobacteria 6.779 9.846 13.228 17.303 8.269 6.737 11.347 11.967 
Synergistetes 0.001 0.003 0.002 0.006 0.003 0.010 0.010 0.032 
Tenericutes 0.000 0.000 0.005 0.016 0.000 0.000 0.001 0.003 
TM7 0.002 0.004 0.002 0.004 0.000 0.000 0.000 0.000 
Verrucomicrobia 0.047 0.063 0.045 0.071 0.060 0.130 0.036 0.104 
 
 Time point 
Order T0 mean ± sd 
T5 
mean ± sd 
T10 
mean ± sd 
T24 
mean ± sd 
[Cerasicoccales] 0,0010 0,0032 0,0000 0,0000 0,0000 0,0000 0,0000 0,0000 
[Chthoniobacterales] 0,0000 0,0000 0,0000 0,0000 0,0000 0,0000 0,0010 0,0032 
Actinomycetales 0,0242 0,0203 0,0067 0,0116 0,0051 0,0072 0,0080 0,0148 
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Aeromonadales 0,0000 0,0000 0,0000 0,0000 0,0010 0,0032 0,0000 0,0000 
Anaerolineales 0,0000 0,0000 0,0000 0,0000 0,0010 0,0032 0,0000 0,0000 
Bacillales 0,0040 0,0070 0,0000 0,0000 0,0010 0,0032 0,0000 0,0000 
Bacteroidales 34,8493 13,1219 23,6641 4,9120 20,8944 14,7253 14,2635 16,8067 
Bifidobacteriales 3,6759 3,3896 2,7386 1,6089 4,7268 5,8875 4,6418 8,9814 
Burkholderiales 0,8106 0,4240 0,5110 0,6463 1,9035 1,4214 2,3558 1,5511 
Campylobacterales 0,0161 0,0273 0,0067 0,0116 0,0041 0,0098 0,0101 0,0178 
Clostridiales 33,4203 12,8815 27,8670 15,1197 27,7613 13,0436 17,8255 13,9702 
Coriobacteriales 0,5490 0,3713 0,5993 0,3059 0,6304 0,5194 0,1882 0,1928 
CW040 0,0010 0,0032 0,0000 0,0000 0,0000 0,0000 0,0000 0,0000 
Desulfovibrionales 0,1571 0,1221 1,6965 1,8621 1,1162 0,6943 1,3845 0,9219 
Enterobacteriales 5,6162 9,6830 16,9283 19,2348 5,2172 5,9691 7,5920 11,8735 
Erysipelotrichales 1,0828 0,6822 21,7571 18,4035 21,2751 23,5212 34,8289 19,1989 
Flavobacteriales 0,0000 0,0000 0,0000 0,0000 0,0000 0,0000 0,0010 0,0032 
Fusobacteriales 0,0101 0,0126 0,0000 0,0000 1,1856 3,2272 1,4649 3,1974 
Gemellales 0,0151 0,0219 0,0000 0,0000 0,0000 0,0000 0,0000 0,0000 
Lactobacillales 19,5100 19,0727 4,0766 1,5651 15,1668 12,7784 15,3209 11,3722 
Methanobacteriales 0,0030 0,0096 0,0439 0,0760 0,0061 0,0192 0,0494 0,1527 
Neisseriales 0,0020 0,0043 0,0000 0,0000 0,0010 0,0032 0,0000 0,0000 
Pasteurellales 0,1614 0,2697 0,0000 0,0000 0,0232 0,0735 0,0020 0,0043 
Pseudomonadales 0,0010 0,0032 0,0000 0,0000 0,0010 0,0032 0,0000 0,0000 
RF32 0,0091 0,0220 0,0101 0,0175 0,0020 0,0042 0,0000 0,0000 
RF39 0,0000 0,0000 0,0000 0,0000 0,0000 0,0000 0,0010 0,0032 
Rhizobiales 0,0030 0,0049 0,0067 0,0058 0,0000 0,0000 0,0000 0,0000 
SHA-98 0,0000 0,0000 0,0000 0,0000 0,0010 0,0032 0,0000 0,0000 
Synergistales 0,0010 0,0032 0,0000 0,0000 0,0030 0,0096 0,0101 0,0319 
Turicibacterales 0,0081 0,0149 0,0638 0,1106 0,0126 0,0332 0,0131 0,0345 
Verrucomicrobiales 0,0464 0,0605 0,0202 0,0202 0,0596 0,1299 0,0353 0,1047 
Victivallales 0,0010 0,0032 0,0000 0,0000 0,0000 0,0000 0,0030 0,0095 
YS2 0,0212 0,0415 0,0034 0,0058 0,0010 0,0032 0,0000 0,0000 
 
 Time point 
Family T0 mean ± sd 
T5 
mean ± sd 
T10 
mean ± sd 
T24 
mean ± sd 
[Barnesiellaceae] 0.356 0.390 0.255 0.299 0.085 0.076 0.134 0.330 
[Cerasicoccaceae] 0.001 0.003 0.001 0.003 0.000 0.000 0.000 0.000 
[Chthoniobacteraceae] 0.000 0.000 0.000 0.000 0.000 0.000 0.001 0.003 
[Mogibacteriaceae] 0.039 0.038 0.034 0.054 0.111 0.281 0.020 0.039 
[Odoribacteraceae] 0.287 0.242 0.264 0.201 0.110 0.122 0.038 0.059 
[Paraprevotellaceae] 0.963 1.880 0.689 1.099 0.116 0.180 0.037 0.101 
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[Tissierellaceae] 0.002 0.004 0.004 0.009 0.005 0.016 0.054 0.160 
Actinomycetaceae 0.013 0.017 0.013 0.020 0.002 0.004 0.005 0.011 
Aerococcaceae 0.003 0.005 0.001 0.003 0.001 0.003 0.000 0.000 
Alcaligenaceae 0.833 0.446 1.602 1.073 1.931 1.429 2.377 1.576 
Anaerolinaceae 0.000 0.000 0.000 0.000 0.001 0.003 0.000 0.000 
Bacillaceae 0.000 0.000 0.000 0.000 0.001 0.003 0.000 0.000 
Bacteroidaceae 27.366 11.476 23.173 11.289 15.179 10.934 11.504 14.893 
Bifidobacteriaceae 3.752 3.427 2.864 3.391 4.783 5.921 4.663 9.018 
Campylobacteraceae 0.003 0.005 0.005 0.009 0.004 0.010 0.010 0.018 
Carnobacteriaceae 0.020 0.034 0.009 0.009 0.003 0.005 0.004 0.007 
Christensenellaceae 0.009 0.012 0.010 0.024 0.035 0.099 0.025 0.060 
Clostridiaceae 0.363 0.347 0.413 0.355 0.817 1.278 0.252 0.398 
Comamonadaceae 0.000 0.000 0.000 0.000 0.000 0.000 0.001 0.003 
Coriobacteriaceae 0.566 0.385 0.518 0.358 0.648 0.539 0.191 0.199 
Corynebacteriaceae 0.000 0.000 0.001 0.003 0.000 0.000 0.001 0.003 
Dehalobacteriaceae 0.001 0.003 0.000 0.000 0.002 0.007 0.000 0.000 
Desulfovibrionaceae 0.162 0.127 1.038 0.738 1.137 0.712 1.403 0.963 
Dethiosulfovibrionaceae 0.001 0.003 0.002 0.006 0.003 0.010 0.010 0.032 
Enterobacteriaceae 5.713 9.869 10.724 17.151 5.328 6.054 7.634 11.906 
Enterococcaceae 0.581 0.790 0.299 0.538 0.250 0.335 1.830 4.770 
Erysipelotrichaceae 1.106 0.690 9.547 12.370 21.534 23.783 34.955 19.269 
Eubacteriaceae 0.001 0.003 0.000 0.000 0.003 0.010 0.000 0.000 
Flavobacteriaceae 0.000 0.000 0.000 0.000 0.000 0.000 0.001 0.003 
Fusobacteriaceae 0.009 0.011 1.378 4.312 1.194 3.252 1.469 3.207 
Gemellaceae 0.015 0.022 0.006 0.014 0.000 0.000 0.000 0.000 
Helicobacteraceae 0.014 0.030 0.000 0.000 0.000 0.000 0.000 0.000 
Lachnospiraceae 15.309 5.505 9.656 3.292 10.028 6.995 6.023 3.494 
Lactobacillaceae 4.047 4.629 2.659 3.131 3.375 3.486 6.097 8.248 
Leptotrichiaceae 0.001 0.003 0.000 0.000 0.000 0.000 0.000 0.000 
Leuconostocaceae 0.017 0.050 0.024 0.067 0.006 0.017 0.011 0.029 
Methanobacteriaceae 0.003 0.010 0.004 0.013 0.006 0.019 0.050 0.153 
Micrococcaceae 0.011 0.019 0.006 0.011 0.002 0.004 0.002 0.004 
Neisseriaceae 0.002 0.004 0.002 0.004 0.001 0.003 0.000 0.000 
Nocardioidaceae 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Oxalobacteraceae 0.001 0.003 0.001 0.003 0.000 0.000 0.000 0.000 
Pasteurellaceae 0.164 0.275 0.038 0.106 0.024 0.074 0.002 0.004 
Peptococcaceae 0.000 0.000 0.000 0.000 0.000 0.000 0.001 0.003 
Peptostreptococcaceae 0.003 0.007 0.007 0.016 0.008 0.016 0.025 0.073 
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Phyllobacteriaceae 0.003 0.005 0.000 0.000 0.000 0.000 0.000 0.000 
Porphyromonadaceae 0.933 0.759 1.258 1.204 0.713 0.820 1.164 3.322 
Prevotellaceae 3.587 7.500 4.599 6.918 2.447 5.250 1.224 3.853 
Propionibacteriaceae 0.000 0.000 0.000 0.000 0.001 0.003 0.000 0.000 
Pseudomonadaceae 0.001 0.003 0.001 0.003 0.001 0.003 0.000 0.000 
Rikenellaceae 1.074 0.823 0.813 0.869 0.874 1.280 0.256 0.502 
Ruminococcaceae 14.359 7.972 16.459 8.970 13.035 12.024 10.589 12.558 
S24-7 1.228 3.402 1.344 3.351 1.808 5.422 0.004 0.009 
Streptococcaceae 15.153 17.023 7.972 8.276 11.722 11.465 7.509 9.304 
Succinivibrionaceae 0.000 0.000 0.001 0.003 0.001 0.003 0.000 0.000 
Turicibacteraceae 0.008 0.015 0.027 0.083 0.013 0.033 0.013 0.036 
Veillonellaceae 1.859 1.123 2.232 1.370 2.591 4.262 0.372 0.359 
Verrucomicrobiaceae 0.048 0.062 0.045 0.073 0.061 0.132 0.035 0.105 
Victivallaceae 0.001 0.003 0.002 0.004 0.000 0.000 0.003 0.010 
 
 Time point 
Genus T0 mean ± sd 
T5 
mean ± sd 
T10 
mean ± sd 
T24 
mean ± sd 
[Eubacterium] 0.146 0.207 2.578 3.993 2.795 4.454 5.730 6.089 
[Prevotella] 0.976 2.100 0.823 1.626 0.086 0.247 0.002 0.007 
[Ruminococcus] 1.019 0.895 0.857 0.903 0.644 0.519 1.881 4.159 
Acidaminococcus 0.178 0.282 0.105 0.179 0.067 0.139 0.023 0.045 
Actinobacillus 0.005 0.008 0.005 0.017 0.000 0.000 0.000 0.000 
Actinomyces 0.022 0.031 0.026 0.048 0.003 0.006 0.007 0.015 
Adlercreutzia 0.042 0.073 0.038 0.068 0.062 0.096 0.032 0.072 
Aggregatibacter 0.004 0.008 0.000 0.000 0.000 0.000 0.000 0.000 
Akkermansia 0.062 0.080 0.067 0.101 0.106 0.205 0.052 0.148 
Anaerococcus 0.000 0.000 0.004 0.008 0.000 0.000 0.003 0.009 
Anaerostipes 0.076 0.073 0.054 0.052 0.046 0.057 0.018 0.031 
Anaerotruncus 0.006 0.008 0.003 0.006 0.011 0.029 0.000 0.000 
Arthrobacter 0.000 0.000 0.002 0.005 0.000 0.000 0.000 0.000 
Atopobium 0.003 0.007 0.001 0.004 0.000 0.000 0.000 0.000 
Bacteroides 38.93 17.231 35.150 15.486 24.601 15.297 18.871 22.734 
Bifidobacterium 5.043 3.999 4.586 5.013 8.678 9.764 7.968 12.824 
Bilophila 0.193 0.169 1.454 1.066 2.210 2.373 2.432 1.511 
Blautia 4.402 2.351 3.642 1.061 3.152 2.402 1.269 0.995 
Bulleidia 0.002 0.006 0.052 0.158 0.117 0.371 0.134 0.404 
Butyricimonas 0.070 0.099 0.130 0.166 0.040 0.057 0.010 0.017 
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Campylobacter 0.005 0.008 0.010 0.016 0.006 0.013 0.018 0.033 
Catenibacterium 0.000 0.000 2.744 8.659 5.675 17.94 5.979 18.88 
cc_115 0.015 0.035 0.024 0.062 0.034 0.072 0.024 0.052 
Christensenella 0.000 0.000 0.002 0.005 0.000 0.000 0.001 0.005 
Chthoniobacter 0.000 0.000 0.000 0.000 0.000 0.000 0.001 0.004 
Citrobacter 0.014 0.045 3.116 9.819 0.128 0.364 5.643 14.12 
Clostridium 0.069 0.060 0.165 0.216 0.744 1.762 0.328 0.782 
Clostridium 0.001 0.004 0.000 0.000 0.000 0.000 0.000 0.000 
Clostridium 0.000 0.000 0.003 0.006 0.006 0.015 0.005 0.009 
Collinsella 0.529 0.416 0.426 0.312 0.690 0.904 0.181 0.256 
Coprobacillus 0.007 0.012 0.019 0.024 0.033 0.045 0.057 0.106 
Coprococcus 4.035 2.927 1.932 1.310 2.578 2.296 0.647 0.578 
Corynebacterium 0.000 0.000 0.001 0.004 0.000 0.000 0.001 0.004 
Dehalobacterium 0.001 0.004 0.000 0.000 0.003 0.010 0.000 0.000 
Desulfovibrio 0.024 0.063 0.056 0.140 0.137 0.281 0.132 0.275 
Dialister 0.108 0.184 0.607 1.098 0.627 0.800 0.290 0.571 
Dorea 0.773 0.440 0.669 0.389 1.536 1.983 0.801 1.359 
Eggerthella 0.045 0.068 0.028 0.052 0.069 0.110 0.009 0.012 
Eikenella 0.001 0.004 0.004 0.009 0.001 0.004 0.000 0.000 
Enterobacter 0.000 0.000 0.005 0.011 0.001 0.004 0.010 0.027 
Enterococcus 0.895 1.212 0.648 1.254 0.636 1.257 4.146 10.56 
Epulopiscium 0.002 0.006 0.002 0.005 0.006 0.010 0.000 0.000 
Erwinia 0.002 0.006 0.004 0.009 0.000 0.000 0.002 0.008 
Escherichia 0.190 0.369 0.283 0.589 0.254 0.310 0.172 0.363 
Facklamia 0.002 0.005 0.000 0.000 0.000 0.000 0.000 0.000 
Faecalibacterium 3.522 2.394 4.501 2.691 2.702 2.604 0.756 1.101 
Finegoldia 0.004 0.008 0.000 0.000 0.002 0.007 0.000 0.000 
Flavobacterium 0.000 0.000 0.000 0.000 0.000 0.000 0.003 0.010 
Fusobacterium 0.014 0.018 1.554 4.834 1.456 3.651 2.439 5.145 
Gemella 0.006 0.008 0.004 0.009 0.000 0.000 0.000 0.000 
Granulicatella 0.025 0.043 0.014 0.013 0.004 0.006 0.006 0.010 
Haemophilus 0.277 0.513 0.086 0.256 0.031 0.098 0.004 0.009 
Helicobacter 0.019 0.040 0.000 0.000 0.000 0.000 0.000 0.000 
Holdemania 0.004 0.009 0.035 0.029 0.027 0.036 0.046 0.046 
Janthinobacterium 0.000 0.000 0.001 0.004 0.000 0.000 0.000 0.000 
Kingella 0.002 0.006 0.000 0.000 0.000 0.000 0.000 0.000 
Klebsiella 0.000 0.000 0.131 0.340 0.069 0.212 0.021 0.066 
Lachnobacterium 0.186 0.370 0.069 0.186 0.053 0.146 0.044 0.112 
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Lachnospira 0.721 0.561 0.549 0.417 0.347 0.280 0.413 0.731 
Lactobacillus 5.456 7.220 3.326 3.580 4.805 4.758 8.928 11.10 
Lactococcus 0.008 0.018 0.021 0.050 0.010 0.025 0.124 0.304 
Leptotrichia 0.002 0.006 0.000 0.000 0.000 0.000 0.000 0.000 
Leuconostoc 0.001 0.004 0.003 0.006 0.009 0.025 0.003 0.010 
Megamonas 0.000 0.000 0.048 0.153 0.182 0.576 0.004 0.013 
Megasphaera 0.013 0.023 0.319 0.971 1.072 3.346 0.006 0.011 
Melissococcus 0.000 0.000 0.000 0.000 0.000 0.000 0.005 0.015 
Mesorhizobium 0.005 0.008 0.000 0.000 0.000 0.000 0.000 0.000 
Methanobrevibacter 0.003 0.011 0.005 0.017 0.009 0.030 0.070 0.216 
Mogibacterium 0.000 0.000 0.000 0.000 0.001 0.004 0.000 0.000 
Morganella 0.002 0.005 0.034 0.094 0.000 0.000 0.413 1.144 
Odoribacter 0.312 0.285 0.272 0.188 0.130 0.160 0.050 0.074 
Oscillospira 0.509 0.264 2.157 1.303 2.515 2.483 4.656 4.496 
Other 0.001 0.004 0.000 0.000 0.002 0.005 0.000 0.000 
p-75-a5 0.000 0.000 0.003 0.006 0.000 0.000 0.000 0.000 
Parabacteroides 1.212 0.985 1.783 1.727 1.193 1.343 1.651 4.646 
Paraprevotella 0.208 0.339 0.172 0.262 0.090 0.177 0.051 0.142 
Pediococcus 0.001 0.004 0.001 0.004 0.002 0.005 0.014 0.032 
Peptoniphilus 0.000 0.000 0.002 0.005 0.003 0.011 0.164 0.514 
Peptostreptococcus 0.000 0.000 0.005 0.015 0.006 0.018 0.033 0.103 
Phascolarctobacterium 1.190 1.683 1.553 1.759 1.192 1.312 0.285 0.433 
Porphyromonas 0.000 0.000 0.003 0.010 0.000 0.000 0.000 0.000 
Prevotella 4.432 9.245 6.379 9.560 4.840 10.46 2.554 8.053 
Proteus 0.006 0.013 0.000 0.000 0.007 0.022 0.005 0.011 
PSB-M-3 0.000 0.000 0.001 0.004 0.003 0.011 0.001 0.004 
Pseudomonas 0.001 0.005 0.001 0.005 0.002 0.006 0.000 0.000 
Pseudoramibacter_Eubacterium 0.002 0.006 0.000 0.000 0.003 0.011 0.000 0.000 
Pyramidobacter 0.001 0.004 0.003 0.009 0.005 0.015 0.014 0.045 
Ralstonia 0.002 0.006 0.000 0.000 0.000 0.000 0.000 0.000 
Roseburia 0.452 0.450 0.155 0.248 0.234 0.349 0.024 0.040 
Rothia 0.015 0.024 0.007 0.014 0.003 0.005 0.005 0.011 
Ruminococcus 2.183 1.682 1.734 1.485 1.755 2.210 1.325 1.967 
Scardovia 0.000 0.000 0.002 0.008 0.000 0.000 0.002 0.007 
Selenomonas 0.004 0.008 0.003 0.008 0.001 0.004 0.006 0.018 
Serratia 0.004 0.009 0.031 0.071 0.074 0.212 0.877 2.560 
SHD-231 0.000 0.000 0.000 0.000 0.002 0.006 0.000 0.000 
Slackia 0.021 0.033 0.015 0.021 0.098 0.136 0.006 0.007 
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SMB53 0.008 0.014 0.024 0.053 0.006 0.012 0.016 0.037 
Staphylococcus 0.007 0.014 0.000 0.000 0.000 0.000 0.000 0.000 
Streptococcus 18.90 19.45 11.53 10.99 17.96 14.97 13.44 16.23 
Sutterella 1.153 0.600 2.497 2.445 2.835 2.001 4.595 3.971 
Tetragenococcus 0.003 0.006 0.000 0.000 0.000 0.000 0.000 0.000 
Trabulsiella 0.000 0.000 0.000 0.000 0.000 0.000 0.002 0.008 
Turicibacter 0.010 0.018 0.039 0.115 0.021 0.054 0.020 0.050 
Veillonella 1.190 2.077 0.604 1.418 0.451 0.952 0.033 0.047 
 
 
Table A10. Mean relative abundance (%) ± standard deviation (SD) of bacterial taxa at the phylum, 
order, family and genus levels in Cirrhotic patients (CP) upon VSL#3 + rifaximin treatment, over 
time. 
 Time point 
Phylum T0 mean ± sd 
T5 
mean ± sd 
T10 
mean ± sd 
T24 
mean ± sd 
Actinobacteria 5.867 4.093 4.364 5.183 5.336 5.661 10.160 11.321 
Bacteroidetes 33.537 14.661 25.386 11.472 24.852 11.057 18.090 12.357 
Cyanobacteria 0.025 0.069 0.000 0.000 0.011 0.019 0.001 0.003 
Euryarchaeota 0.013 0.035 0.005 0.016 0.004 0.013 0.047 0.083 
Firmicutes 57.973 10.553 60.962 13.406 57.555 10.059 61.102 14.474 
Fusobacteria 0.052 0.159 1.183 3.740 2.340 6.153 0.368 1.164 
Lentisphaerae 0.000 0.000 0.005 0.010 0.004 0.007 0.004 0.010 
Proteobacteria 2.479 3.093 8.082 9.112 9.825 6.540 10.154 15.033 
Synergistetes 0.006 0.019 0.000 0.000 0.004 0.013 0.018 0.058 
Tenericutes 0.007 0.022 0.002 0.006 0.005 0.010 0.005 0.011 
TM7 0.000 0.000 0.000 0.000 0.002 0.004 0.002 0.006 
Verrucomicrobia 0.040 0.114 0.011 0.020 0.063 0.173 0.048 0.151 
	
 Time points 
Order T0 mean ± sd 
T5 
mean ± sd 
T10 
mean ± sd 
T24 
mean ± sd 
[Cerasicoccales] 0.000 0.000 0.000 0.000 0.001 0.003 0.000 0.000 
Actinomycetales 0.022 0.022 0.030 0.023 0.017 0.013 0.015 0.033 
Aeromonadales 0.001 0.003 0.000 0.000 0.000 0.000 0.000 0.000 
Bacillales 0.002 0.006 0.001 0.003 0.001 0.003 0.001 0.003 
Bacteroidales 33.538 14.661 25.387 11.471 24.849 11.061 18.090 12.358 
Bifidobacteriales 5.012 4.279 3.796 5.316 4.909 5.779 9.634 11.444 
Burkholderiales 0.904 0.413 1.816 1.693 2.390 1.650 2.000 3.036 
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Campylobacterales 0.002 0.004 0.008 0.010 0.009 0.022 0.004 0.007 
Cardiobacteriales 0.000 0.000 0.001 0.003 0.000 0.000 0.000 0.000 
Clostridiales 36.308 12.091 34.322 13.525 27.886 12.107 34.626 17.494 
Coriobacteriales 0.833 0.755 0.537 0.363 0.410 0.217 0.511 0.391 
CW040 0.000 0.000 0.000 0.000 0.001 0.003 0.000 0.000 
Desulfovibrionales 0.202 0.188 0.553 0.466 2.068 1.499 2.259 2.580 
Enterobacteriales 1.306 3.180 5.652 8.483 5.326 7.415 5.880 12.120 
Erysipelotrichales 1.464 1.300 11.095 14.551 2.209 2.263 8.958 13.705 
Flavobacteriales 0.000 0.000 0.000 0.000 0.002 0.004 0.000 0.000 
Fusobacteriales 0.052 0.159 1.183 3.740 2.340 6.153 0.368 1.164 
Gemellales 0.005 0.010 0.002 0.004 0.002 0.004 0.002 0.004 
Lactobacillales 20.143 19.243 15.508 13.246 27.405 13.327 17.497 14.863 
Methanobacteriales 0.013 0.035 0.005 0.016 0.004 0.013 0.047 0.083 
ML615J-28 0.006 0.019 0.001 0.003 0.001 0.003 0.000 0.000 
Neisseriales 0.000 0.000 0.001 0.003 0.000 0.000 0.000 0.000 
Pasteurellales 0.052 0.128 0.037 0.108 0.016 0.028 0.006 0.016 
Pseudomonadales 0.002 0.006 0.000 0.000 0.002 0.004 0.000 0.000 
RF32 0.009 0.016 0.010 0.023 0.009 0.025 0.002 0.004 
RF39 0.001 0.003 0.001 0.003 0.004 0.007 0.005 0.011 
Rhizobiales 0.001 0.003 0.000 0.000 0.004 0.007 0.003 0.007 
SHA-98 0.001 0.003 0.000 0.000 0.000 0.000 0.000 0.000 
Sphingobacteriales 0.000 0.000 0.000 0.000 0.001 0.003 0.000 0.000 
Streptophyta 0.001 0.003 0.000 0.000 0.000 0.000 0.000 0.000 
Synergistales 0.006 0.019 0.000 0.000 0.004 0.013 0.018 0.058 
Turicibacterales 0.051 0.097 0.035 0.074 0.052 0.104 0.019 0.042 
Verrucomicrobiales 0.040 0.114 0.011 0.020 0.062 0.170 0.048 0.151 
Victivallales 0.000 0.000 0.005 0.010 0.004 0.007 0.004 0.010 
YS2 0.023 0.070 0.000 0.000 0.011 0.019 0.001 0.003 
	
 Time point 
Family T0 mean ± sd 
T5 
mean ± sd 
T10 
mean ± sd 
T24 
mean ± sd 
[Barnesiellaceae] 0.228 0.367 0.255 0.287 0.289 0.376 0.173 0.190 
[Cerasicoccaceae] 0.000 0.000 0.000 0.000 0.001 0.003 0.000 0.000 
[Mogibacteriaceae] 0.086 0.120 0.089 0.142 0.088 0.167 0.157 0.219 
[Odoribacteraceae] 0.294 0.288 0.287 0.242 0.271 0.253 0.209 0.228 
[Paraprevotellaceae] 1.015 1.709 0.232 0.446 0.579 1.043 0.099 0.149 
[Tissierellaceae] 0.000 0.000 0.004 0.010 0.010 0.021 0.004 0.010 
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[Weeksellaceae] 0.000 0.000 0.000 0.000 0.001 0.003 0.000 0.000 
Actinomycetaceae 0.015 0.019 0.025 0.024 0.011 0.012 0.009 0.017 
Aerococcaceae 0.001 0.003 0.000 0.000 0.000 0.000 0.000 0.000 
Alcaligenaceae 0.934 0.430 1.872 1.770 2.437 1.694 2.025 3.065 
Bacillaceae 0.000 0.000 0.000 0.000 0.001 0.003 0.000 0.000 
Bacteroidaceae 23.230 12.672 19.656 11.517 18.974 10.651 14.503 10.590 
Bifidobacteriaceae 5.182 4.400 3.867 5.351 4.978 5.807 9.761 11.591 
Campylobacteraceae 0.002 0.004 0.005 0.007 0.006 0.013 0.004 0.007 
Cardiobacteriaceae 0.000 0.000 0.001 0.003 0.000 0.000 0.000 0.000 
Carnobacteriaceae 0.011 0.015 0.009 0.013 0.012 0.016 0.004 0.007 
Christensenellaceae 0.050 0.132 0.046 0.103 0.040 0.103 0.126 0.256 
Clostridiaceae 0.940 1.162 1.236 2.592 1.139 2.682 0.804 1.451 
Coriobacteriaceae 0.869 0.796 0.553 0.374 0.420 0.224 0.524 0.406 
Corynebacteriaceae 0.000 0.000 0.001 0.003 0.002 0.006 0.000 0.000 
Dehalobacteriaceae 0.005 0.011 0.000 0.000 0.003 0.007 0.000 0.000 
Desulfovibrionaceae 0.210 0.196 0.570 0.486 2.115 1.541 2.295 2.601 
Dethiosulfovibrionaceae 0.006 0.020 0.000 0.000 0.004 0.013 0.018 0.058 
Enterobacteriaceae 1.324 3.207 5.784 8.592 5.421 7.520 5.926 12.159 
Enterococcaceae 0.041 0.051 0.297 0.481 0.552 0.992 0.409 0.697 
Erysipelotrichaceae 1.520 1.357 11.322 14.809 2.249 2.310 9.075 13.829 
Eubacteriaceae 0.001 0.003 0.000 0.000 0.002 0.006 0.001 0.003 
Flavobacteriaceae 0.000 0.000 0.000 0.000 0.001 0.003 0.000 0.000 
Fusobacteriaceae 0.052 0.161 1.197 3.786 2.361 6.212 0.369 1.167 
Gemellaceae 0.005 0.010 0.002 0.004 0.002 0.004 0.002 0.004 
Helicobacteraceae 0.000 0.000 0.003 0.010 0.003 0.010 0.000 0.000 
Lachnospiraceae 16.233 6.764 11.855 4.918 9.234 3.781 11.869 5.728 
Lactobacillaceae 5.070 5.064 5.616 6.792 5.857 5.219 5.463 7.667 
Leuconostocaceae 0.011 0.026 0.024 0.047 0.032 0.067 0.025 0.053 
Methanobacteriaceae 0.014 0.036 0.005 0.016 0.004 0.013 0.048 0.084 
Micrococcaceae 0.007 0.009 0.004 0.010 0.002 0.004 0.006 0.020 
Moraxellaceae 0.000 0.000 0.000 0.000 0.001 0.003 0.000 0.000 
Oxalobacteraceae 0.001 0.003 0.000 0.000 0.001 0.003 0.001 0.003 
Pasteurellaceae 0.052 0.129 0.038 0.109 0.016 0.028 0.006 0.016 
Peptococcaceae 0.050 0.158 0.025 0.072 0.002 0.007 0.102 0.225 
Peptostreptococcaceae 0.013 0.022 0.020 0.030 0.012 0.022 0.009 0.025 
Phyllobacteriaceae 0.001 0.003 0.000 0.000 0.004 0.007 0.003 0.007 
Planococcaceae 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Porphyromonadaceae 1.497 1.653 0.886 0.924 0.878 0.758 1.309 1.207 
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Prevotellaceae 5.672 11.893 2.247 6.169 3.190 7.123 0.538 1.190 
Propionibacteriaceae 0.001 0.003 0.001 0.003 0.002 0.006 0.000 0.000 
Pseudomonadaceae 0.002 0.007 0.000 0.000 0.001 0.003 0.000 0.000 
Rikenellaceae 1.246 1.445 0.964 1.220 1.095 1.450 1.546 1.706 
Ruminococcaceae 15.274 6.361 17.811 11.749 14.967 10.031 17.785 13.979 
S24-7 1.394 4.130 1.511 4.750 0.056 0.123 0.052 0.124 
Sphingobacteriaceae 0.000 0.000 0.000 0.000 0.001 0.003 0.000 0.000 
Staphylococcaceae 0.001 0.003 0.001 0.003 0.000 0.000 0.001 0.003 
Streptococcaceae 15.457 15.762 9.793 10.770 21.337 11.921 11.821 12.143 
Succinivibrionaceae 0.001 0.003 0.000 0.000 0.000 0.000 0.000 0.000 
Turicibacteraceae 0.053 0.100 0.036 0.076 0.054 0.107 0.019 0.043 
Veillonellaceae 1.885 1.143 1.834 1.173 1.213 0.935 2.844 3.817 
Verrucomicrobiaceae 0.042 0.119 0.011 0.021 0.062 0.173 0.048 0.152 
Victivallaceae 0.000 0.000 0.005 0.010 0.004 0.007 0.004 0.010 
	
 Time point 
Genus T0 mean ± sd 
T5 
mean ± sd 
T10 
mean ± sd 
T24 
mean ± sd 
[Eubacterium] 0.146 0.207 2.578 3.993 2.795 4.454 5.730 6.089 
[Prevotella] 0.976 2.100 0.823 1.626 0.086 0.247 0.002 0.007 
[Ruminococcus] 1.019 0.895 0.857 0.903 0.644 0.519 1.881 4.159 
Acidaminococcus 0.178 0.282 0.105 0.179 0.067 0.139 0.023 0.045 
Actinobacillus 0.005 0.008 0.005 0.017 0.000 0.000 0.000 0.000 
Actinomyces 0.022 0.031 0.026 0.048 0.003 0.006 0.007 0.015 
Adlercreutzia 0.042 0.073 0.038 0.068 0.062 0.096 0.032 0.072 
Aggregatibacter 0.004 0.008 0.000 0.000 0.000 0.000 0.000 0.000 
Akkermansia 0.062 0.080 0.067 0.101 0.106 0.205 0.052 0.148 
Anaerococcus 0.000 0.000 0.004 0.008 0.000 0.000 0.003 0.009 
Anaerostipes 0.076 0.073 0.054 0.052 0.046 0.057 0.018 0.031 
Anaerotruncus 0.006 0.008 0.003 0.006 0.011 0.029 0.000 0.000 
Arthrobacter 0.000 0.000 0.002 0.005 0.000 0.000 0.000 0.000 
Atopobium 0.003 0.007 0.001 0.004 0.000 0.000 0.000 0.000 
Bacteroides 38.93 17.23 35.15 15.48 24.60 15.29 18.87 22.73 
Bifidobacterium 5.043 3.999 4.586 5.013 8.678 9.764 7.968 12.82 
Bilophila 0.193 0.169 1.454 1.066 2.210 2.373 2.432 1.511 
Blautia 4.402 2.351 3.642 1.061 3.152 2.402 1.269 0.995 
Bulleidia 0.002 0.006 0.052 0.158 0.117 0.371 0.134 0.404 
Butyricimonas 0.070 0.099 0.130 0.166 0.040 0.057 0.010 0.017 
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Campylobacter 0.005 0.008 0.010 0.016 0.006 0.013 0.018 0.033 
Catenibacterium 0.000 0.000 2.744 8.659 5.675 17.94 5.979 18.88 
cc_115 0.015 0.035 0.024 0.062 0.034 0.072 0.024 0.052 
Christensenella 0.000 0.000 0.002 0.005 0.000 0.000 0.001 0.005 
Chryseobacterium 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Chthoniobacter 0.000 0.000 0.000 0.000 0.000 0.000 0.001 0.004 
Citrobacter 0.014 0.045 3.116 9.819 0.128 0.364 5.643 14.12 
Clostridium 0.069 0.060 0.165 0.216 0.744 1.762 0.328 0.782 
Clostridium 0.001 0.004 0.000 0.000 0.000 0.000 0.000 0.000 
Clostridium 0.000 0.000 0.003 0.006 0.006 0.015 0.005 0.009 
Collinsella 0.529 0.416 0.426 0.312 0.690 0.904 0.181 0.256 
Coprobacillus 0.007 0.012 0.019 0.024 0.033 0.045 0.057 0.106 
Coprococcus 4.035 2.927 1.932 1.310 2.578 2.296 0.647 0.578 
Corynebacterium 0.000 0.000 0.001 0.004 0.000 0.000 0.001 0.004 
Cryocola 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Dehalobacterium 0.001 0.004 0.000 0.000 0.003 0.010 0.000 0.000 
Desulfovibrio 0.024 0.063 0.056 0.140 0.137 0.281 0.132 0.275 
Dialister 0.108 0.184 0.607 1.098 0.627 0.800 0.290 0.571 
Dorea 0.773 0.440 0.669 0.389 1.536 1.983 0.801 1.359 
Eggerthella 0.045 0.068 0.028 0.052 0.069 0.110 0.009 0.012 
Eikenella 0.001 0.004 0.004 0.009 0.001 0.004 0.000 0.000 
Enterobacter 0.000 0.000 0.005 0.011 0.001 0.004 0.010 0.027 
Enterococcus 0.895 1.212 0.648 1.254 0.636 1.257 4.146 10.56 
Epulopiscium 0.002 0.006 0.002 0.005 0.006 0.010 0.000 0.000 
Erwinia 0.002 0.006 0.004 0.009 0.000 0.000 0.002 0.008 
Escherichia 0.190 0.369 0.283 0.589 0.254 0.310 0.172 0.363 
Facklamia 0.002 0.005 0.000 0.000 0.000 0.000 0.000 0.000 
Faecalibacterium 3.522 2.394 4.501 2.691 2.702 2.604 0.756 1.101 
Finegoldia 0.004 0.008 0.000 0.000 0.002 0.007 0.000 0.000 
Flavobacterium 0.000 0.000 0.000 0.000 0.000 0.000 0.003 0.010 
Fusobacterium 0.014 0.018 1.554 4.834 1.456 3.651 2.439 5.145 
Gemella 0.006 0.008 0.004 0.009 0.000 0.000 0.000 0.000 
Granulicatella 0.025 0.043 0.014 0.013 0.004 0.006 0.006 0.010 
Haemophilus 0.277 0.513 0.086 0.256 0.031 0.098 0.004 0.009 
Helicobacter 0.019 0.040 0.000 0.000 0.000 0.000 0.000 0.000 
Holdemania 0.004 0.009 0.035 0.029 0.027 0.036 0.046 0.046 
Janthinobacterium 0.000 0.000 0.001 0.004 0.000 0.000 0.000 0.000 
Kingella 0.002 0.006 0.000 0.000 0.000 0.000 0.000 0.000 
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Klebsiella 0.000 0.000 0.131 0.340 0.069 0.212 0.021 0.066 
Lachnobacterium 0.186 0.370 0.069 0.186 0.053 0.146 0.044 0.112 
Lachnospira 0.721 0.561 0.549 0.417 0.347 0.280 0.413 0.731 
Lactobacillus 5.456 7.220 3.326 3.580 4.805 4.758 8.928 11.10 
Lactococcus 0.008 0.018 0.021 0.050 0.010 0.025 0.124 0.304 
Leptotrichia 0.002 0.006 0.000 0.000 0.000 0.000 0.000 0.000 
Leuconostoc 0.001 0.004 0.003 0.006 0.009 0.025 0.003 0.010 
Megamonas 0.000 0.000 0.048 0.153 0.182 0.576 0.004 0.013 
Megasphaera 0.013 0.023 0.319 0.971 1.072 3.346 0.006 0.011 
Melissococcus 0.000 0.000 0.000 0.000 0.000 0.000 0.005 0.015 
Mesorhizobium 0.005 0.008 0.000 0.000 0.000 0.000 0.000 0.000 
Methanobrevibacter 0.003 0.011 0.005 0.017 0.009 0.030 0.070 0.216 
Mogibacterium 0.000 0.000 0.000 0.000 0.001 0.004 0.000 0.000 
Morganella 0.002 0.005 0.034 0.094 0.000 0.000 0.413 1.144 
Odoribacter 0.312 0.285 0.272 0.188 0.130 0.160 0.050 0.074 
Oscillospira 0.509 0.264 2.157 1.303 2.515 2.483 4.656 4.496 
Other 0.001 0.004 0.000 0.000 0.002 0.005 0.000 0.000 
p-75-a5 0.000 0.000 0.003 0.006 0.000 0.000 0.000 0.000 
Parabacteroides 1.212 0.985 1.783 1.727 1.193 1.343 1.651 4.646 
Paraprevotella 0.208 0.339 0.172 0.262 0.090 0.177 0.051 0.142 
Pediococcus 0.001 0.004 0.001 0.004 0.002 0.005 0.014 0.032 
Peptoniphilus 0.000 0.000 0.002 0.005 0.003 0.011 0.164 0.514 
Peptostreptococcus 0.000 0.000 0.005 0.015 0.006 0.018 0.033 0.103 
Phascolarctobacterium 1.190 1.683 1.553 1.759 1.192 1.312 0.285 0.433 
Prevotella 4.432 9.245 6.379 9.560 4.840 10.46 2.554 8.053 
Proteus 0.006 0.013 0.000 0.000 0.007 0.022 0.005 0.011 
PSB-M-3 0.000 0.000 0.001 0.004 0.003 0.011 0.001 0.004 
Pseudomonas 0.001 0.005 0.001 0.005 0.002 0.006 0.000 0.000 
Pseudoramibacter_Eubacterium 0.002 0.006 0.000 0.000 0.003 0.011 0.000 0.000 
Pyramidobacter 0.001 0.004 0.003 0.009 0.005 0.015 0.014 0.045 
Ralstonia 0.002 0.006 0.000 0.000 0.000 0.000 0.000 0.000 
Roseburia 0.452 0.450 0.155 0.248 0.234 0.349 0.024 0.040 
Rothia 0.015 0.024 0.007 0.014 0.003 0.005 0.005 0.011 
Ruminococcus 2.183 1.682 1.734 1.485 1.755 2.210 1.325 1.967 
Scardovia 0.000 0.000 0.002 0.008 0.000 0.000 0.002 0.007 
Selenomonas 0.004 0.008 0.003 0.008 0.001 0.004 0.006 0.018 
Serratia 0.004 0.009 0.031 0.071 0.074 0.212 0.877 2.560 
SHD-231 0.000 0.000 0.000 0.000 0.002 0.006 0.000 0.000 
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Slackia 0.021 0.033 0.015 0.021 0.098 0.136 0.006 0.007 
SMB53 0.008 0.014 0.024 0.053 0.006 0.012 0.016 0.037 
Staphylococcus 0.007 0.014 0.000 0.000 0.000 0.000 0.000 0.000 
Streptococcus 18.90 19.456 11.534 10.999 17.966 14.974 13.441 16.239 
Sutterella 1.153 0.600 2.497 2.445 2.835 2.001 4.595 3.971 
Tetragenococcus 0.003 0.006 0.000 0.000 0.000 0.000 0.000 0.000 
Turicibacter 0.010 0.018 0.039 0.115 0.021 0.054 0.020 0.050 
Veillonella 1.190 2.077 0.604 1.418 0.451 0.952 0.033 0.047 
 
 
Table A11. Mean relative abundance (%) ± standard deviation (SD) of bacterial taxa at the phylum, 
order, family and genus levels in Healthy subjects (HS) at the baseline, over time. 
 Time point 
Phylum T0 mean ± sd 
T5 
mean ± sd 
T10 
mean ± sd 
T24 
mean ± sd 
Actinobacteria 4.520 1.650 2.925 1.943 18.745 24.296 9.805 8.625 
Bacteroidetes 25.522 20.101 38.400 3.596 30.312 13.821 34.536 12.352 
Cyanobacteria 0.000 0.000 0.013 0.023 0.000 0.000 0.017 0.021 
Euryarchaeota 0.000 0.000 0.000 0.000 0.030 0.052 0.000 0.000 
Firmicutes 65.358 22.118 48.444 6.419 43.107 16.519 44.818 13.522 
Fusobacteria 0.000 0.000 0.010 0.017 0.003 0.006 0.118 0.102 
Proteobacteria 4.567 4.967 10.059 10.419 7.733 6.514 10.672 9.953 
Tenericutes 0.000 0.000 0.013 0.023 0.000 0.000 0.000 0.000 
Verrucomicrobia 0.034 0.041 0.135 0.216 0.071 0.123 0.034 0.050 
 
 Time point 
Order T0 mean ± sd 
T5 
mean ± sd 
T10 
mean ± sd 
T24 
mean ± sd 
[Cerasicoccales] 0.000 0.000 0.003 0.006 0.000 0.000 0.000 0.000 
Actinomycetales 0.013 0.006 0.000 0.000 0.000 0.000 0.000 0.000 
Bacillales 0.003 0.006 0.000 0.000 0.000 0.000 0.000 0.000 
Bacteroidales 25.522 20.101 38.402 3.593 30.312 13.821 34.541 12.358 
Bifidobacteriales 3.604 1.325 1.787 1.364 17.476 25.346 8.707 8.890 
Burkholderiales 1.992 2.132 1.021 1.260 1.151 0.730 1.482 0.802 
Campylobacterales 0.007 0.012 0.000 0.000 0.000 0.000 0.003 0.006 
Clostridiales 47.104 5.059 43.314 9.985 37.728 21.446 31.330 10.830 
Coriobacteriales 0.903 0.515 1.138 0.587 1.269 1.080 1.098 0.797 
CW040 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Desulfovibrionales 0.972 0.545 1.277 1.215 1.085 1.159 0.484 0.403 
Enterobacteriales 1.562 2.635 7.752 9.218 5.494 5.214 8.635 8.660 
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Erysipelotrichales 16.133 27.010 1.980 2.351 1.733 1.486 8.001 11.887 
Fusobacteriales 0.000 0.000 0.010 0.017 0.003 0.006 0.118 0.102 
Gemellales 0.000 0.000 0.000 0.000 0.000 0.000 0.003 0.006 
I025 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Lactobacillales 2.115 2.234 3.114 5.306 3.643 6.214 5.480 3.860 
Methanobacteriales 0.000 0.000 0.000 0.000 0.030 0.052 0.000 0.000 
Pasteurellales 0.030 0.044 0.000 0.000 0.000 0.000 0.047 0.073 
RF32 0.000 0.000 0.000 0.000 0.000 0.000 0.013 0.023 
RF39 0.000 0.000 0.013 0.023 0.000 0.000 0.000 0.000 
Rhizobiales 0.003 0.006 0.003 0.006 0.003 0.006 0.000 0.000 
SHA-98 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Turicibacterales 0.003 0.006 0.040 0.070 0.003 0.006 0.007 0.012 
Verrucomicrobiales 0.034 0.041 0.131 0.219 0.071 0.123 0.034 0.050 
YS2 0.000 0.000 0.013 0.023 0.000 0.000 0.017 0.021 
 
 Time point 
Family T0 mean ± sd T5 mean ± sd T10 mean ± sd T24 mean ± sd 
[Barnesiellaceae] 0.407 0.525 0.255 0.274 0.255 0.347 0.191 0.268 
[Mogibacteriaceae] 0.042 0.038 0.094 0.083 0.131 0.120 0.045 0.051 
[Odoribacteraceae] 0.288 0.253 0.386 0.180 0.231 0.118 0.208 0.112 
[Paraprevotellaceae] 0.000 0.000 0.816 1.155 0.395 0.683 0.205 0.356 
[Tissierellaceae] 0.010 0.010 0.004 0.006 0.017 0.029 0.000 0.000 
Actinomycetaceae 0.014 0.006 0.000 0.000 0.000 0.000 0.000 0.000 
Aerococcaceae 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Alcaligenaceae 2.054 2.191 1.035 1.252 1.183 0.748 1.501 0.809 
Bacillaceae 0.003 0.006 0.000 0.000 0.000 0.000 0.000 0.000 
Bacteroidaceae 19.480 15.218 27.666 6.019 21.982 6.817 29.814 13.577 
Bifidobacteriaceae 3.732 1.418 1.892 1.437 17.654 25.398 8.884 9.154 
Campylobacteraceae 0.000 0.000 0.000 0.000 0.000 0.000 0.003 0.006 
Carnobacteriaceae 0.000 0.000 0.003 0.006 0.000 0.000 0.000 0.000 
Christensenellaceae 0.007 0.006 0.033 0.040 0.007 0.012 0.024 0.033 
Clostridiaceae 0.453 0.624 0.607 0.305 0.668 0.275 0.333 0.365 
Coriobacteriaceae 0.941 0.558 1.207 0.627 1.334 1.142 1.108 0.794 
Dehalobacteriaceae 0.000 0.000 0.007 0.012 0.004 0.006 0.000 0.000 
Desulfovibrionaceae 0.996 0.544 1.339 1.279 1.116 1.206 0.490 0.407 
Enterobacteriaceae 1.607 2.712 7.876 9.232 5.590 5.254 8.756 8.759 
Enterococcaceae 1.042 1.020 0.031 0.027 2.003 3.434 0.984 0.865 
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Erysipelotrichaceae 16.328 27.299 2.156 2.629 1.814 1.597 8.044 11.913 
Eubacteriaceae 0.000 0.000 0.007 0.013 0.010 0.018 0.003 0.006 
Fusobacteriaceae 0.000 0.000 0.010 0.018 0.003 0.006 0.119 0.103 
Helicobacteraceae 0.007 0.012 0.000 0.000 0.000 0.000 0.000 0.000 
Lachnospiraceae 16.673 11.877 21.580 4.245 19.048 12.661 13.474 7.054 
Lactobacillaceae 0.180 0.189 0.324 0.552 0.618 1.062 1.291 1.120 
Leuconostocaceae 0.000 0.000 0.007 0.012 0.000 0.000 0.031 0.045 
Methanobacteriaceae 0.000 0.000 0.000 0.000 0.032 0.055 0.000 0.000 
Oxalobacteraceae 0.000 0.000 0.003 0.006 0.000 0.000 0.000 0.000 
Pasteurellaceae 0.031 0.046 0.000 0.000 0.000 0.000 0.048 0.074 
Peptococcaceae 0.000 0.000 0.000 0.000 0.160 0.277 0.000 0.000 
Peptostreptococcaceae 0.003 0.006 0.004 0.006 0.003 0.006 0.014 0.012 
Phyllobacteriaceae 0.003 0.006 0.004 0.006 0.004 0.006 0.000 0.000 
Porphyromonadaceae 1.147 0.914 2.599 0.488 1.582 1.733 2.085 1.571 
Prevotellaceae 0.003 0.006 4.046 3.695 1.247 2.152 1.051 1.820 
Rikenellaceae 0.958 1.012 1.159 0.979 0.938 0.880 0.887 0.746 
Ruminococcaceae 26.820 8.990 15.116 4.046 12.159 10.069 14.728 5.443 
S24-7 4.354 7.532 3.653 4.186 4.968 8.606 0.525 0.901 
Streptococcaceae 0.937 1.091 2.763 4.739 1.024 1.719 3.262 2.064 
Turicibacteraceae 0.004 0.006 0.044 0.077 0.003 0.006 0.007 0.012 
Veillonellaceae 1.441 1.244 3.130 0.547 3.740 2.842 1.850 1.982 
Verrucomicrobiaceae 0.035 0.043 0.138 0.230 0.074 0.127 0.034 0.050 
 
 Time point 
Genus T0 mean ± sd 
T5 
mean ± sd 
T0 
mean ± sd 
T24 
mean ± sd 
[Eubacterium] 0.397 0.674 1.906 2.995 1.338 2.252 2.248 3.464 
[Prevotella] 0.000 0.000 0.978 1.695 0.177 0.306 0.299 0.519 
[Ruminococcus] 1.444 0.439 1.332 1.215 0.988 1.055 1.206 1.580 
Acidaminococcus 1.203 1.562 0.109 0.189 2.384 4.129 0.113 0.196 
Actinomyces 0.037 0.023 0.000 0.000 0.000 0.000 0.000 0.000 
Adlercreutzia 0.220 0.151 0.042 0.073 0.071 0.112 0.045 0.079 
Akkermansia 0.072 0.063 0.205 0.343 0.128 0.221 0.045 0.064 
Anaerobacillus 0.005 0.009 0.000 0.000 0.000 0.000 0.000 0.000 
Anaerococcus 0.005 0.009 0.000 0.000 0.000 0.000 0.000 0.000 
Anaerofustis 0.000 0.000 0.010 0.018 0.000 0.000 0.005 0.008 
Anaerostipes 0.092 0.133 0.073 0.056 0.116 0.119 0.041 0.060 
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Anaerotruncus 0.000 0.000 0.021 0.024 0.012 0.021 0.010 0.009 
Bacteroides 33.499 18.319 40.506 6.861 32.176 13.340 41.822 16.138 
Bifidobacterium 11.862 10.855 2.785 2.147 22.740 31.674 12.516 11.890 
Bilophila 3.579 4.569 1.946 1.829 1.657 1.951 0.670 0.498 
Blautia 7.582 2.214 7.865 4.312 6.754 6.564 3.576 3.789 
Butyricimonas 0.057 0.055 0.228 0.200 0.150 0.179 0.041 0.036 
Catenibacterium 0.000 0.000 0.005 0.009 0.012 0.021 0.005 0.008 
cc_115 0.046 0.067 0.212 0.367 0.009 0.008 0.000 0.000 
Citrobacter 0.012 0.020 0.021 0.024 0.018 0.032 2.502 4.333 
Clostridium 0.100 0.074 0.380 0.563 0.253 0.291 0.073 0.072 
Clostridium 0.000 0.000 0.000 0.000 0.004 0.007 0.000 0.000 
Collinsella 1.522 0.696 0.942 0.594 1.408 1.212 1.400 1.595 
Coprobacillus 0.108 0.174 0.005 0.009 0.006 0.011 0.009 0.008 
Coprococcus 6.777 1.868 4.402 0.826 4.974 4.071 5.857 5.287 
Dehalobacterium 0.000 0.000 0.011 0.018 0.005 0.008 0.000 0.000 
Desulfovibrio 0.122 0.212 0.042 0.073 0.116 0.169 0.000 0.000 
Dialister 0.730 0.686 0.960 1.663 0.637 1.093 0.191 0.331 
Dorea 1.604 1.591 3.633 4.824 2.139 2.776 0.426 0.241 
Eggerthella 0.000 0.000 0.052 0.065 0.019 0.019 0.122 0.071 
Enterococcus 3.065 3.024 0.021 0.036 0.787 1.335 1.230 1.116 
Epulopiscium 0.005 0.009 0.000 0.000 0.006 0.011 0.005 0.008 
Escherichia 0.104 0.181 0.276 0.363 0.203 0.205 0.180 0.105 
Faecalibacterium 6.715 2.696 3.930 1.606 4.162 3.559 0.908 0.645 
Finegoldia 0.000 0.000 0.005 0.009 0.013 0.022 0.000 0.000 
Fusobacterium 0.000 0.000 0.016 0.027 0.004 0.007 0.176 0.158 
Gemella 0.000 0.000 0.000 0.000 0.000 0.000 0.004 0.008 
Granulicatella 0.000 0.000 0.005 0.009 0.000 0.000 0.000 0.000 
Haemophilus 0.048 0.068 0.000 0.000 0.000 0.000 0.058 0.087 
Helicobacter 0.005 0.009 0.000 0.000 0.000 0.000 0.000 0.000 
Holdemania 0.017 0.030 0.026 0.018 0.031 0.021 0.044 0.015 
Klebsiella 0.000 0.000 0.125 0.216 0.000 0.000 0.036 0.034 
Lachnobacterium 0.620 0.866 0.026 0.045 0.005 0.008 0.009 0.016 
Lachnospira 2.010 2.418 0.519 0.624 0.378 0.573 0.143 0.175 
Lactobacillus 0.518 0.497 0.453 0.771 0.563 0.964 1.538 1.333 
Lactococcus 0.000 0.000 0.005 0.009 0.005 0.008 0.000 0.000 
Leuconostoc 0.000 0.000 0.010 0.018 0.000 0.000 0.005 0.008 
Megasphaera 0.000 0.000 0.000 0.000 0.000 0.000 0.006 0.010 
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Mesorhizobium 0.005 0.009 0.005 0.009 0.005 0.008 0.000 0.000 
Methanobrevibacter 0.000 0.000 0.000 0.000 0.042 0.073 0.000 0.000 
Morganella 0.083 0.096 0.000 0.000 0.004 0.007 0.427 0.739 
Odoribacter 0.420 0.319 0.333 0.195 0.188 0.233 0.247 0.164 
Oribacterium 0.000 0.000 0.005 0.009 0.000 0.000 0.000 0.000 
Oscillospira 2.549 2.725 3.739 4.148 2.226 2.026 2.250 0.572 
Parabacteroides 1.936 1.204 3.832 0.751 2.258 2.248 3.206 2.878 
Paraprevotella 0.000 0.000 0.120 0.207 0.340 0.589 0.045 0.078 
Peptococcus 0.000 0.000 0.000 0.000 0.209 0.363 0.000 0.000 
Peptoniphilus 0.026 0.032 0.000 0.000 0.009 0.015 0.000 0.000 
Phascolarctobacterium 0.620 1.022 3.541 2.517 2.049 1.780 1.868 2.256 
Prevotella 0.005 0.009 5.998 5.631 1.633 2.818 1.763 3.054 
Ralstonia 0.000 0.000 0.005 0.009 0.000 0.000 0.000 0.000 
Rikenella 0.000 0.000 0.000 0.000 0.004 0.007 0.000 0.000 
Roseburia 1.068 1.647 0.172 0.096 0.312 0.329 0.072 0.093 
Ruminococcus 3.125 1.304 1.996 1.147 2.935 3.577 5.650 3.596 
Serratia 0.000 0.000 0.042 0.073 0.006 0.011 0.110 0.190 
Slackia 0.039 0.036 0.169 0.279 0.188 0.225 0.033 0.043 
SMB53 0.000 0.000 0.052 0.089 0.013 0.022 0.000 0.000 
Streptococcus 2.381 2.060 4.252 7.297 1.291 2.173 4.369 2.509 
Sutterella 3.324 2.850 1.580 1.941 1.777 1.363 2.091 0.956 
Turicibacter 0.006 0.010 0.062 0.107 0.004 0.007 0.009 0.015 
Veillonella 0.228 0.200 0.005 0.009 0.043 0.074 0.281 0.487 
 
 
Table A12. Mean relative abundance (%) ± standard deviation (SD) of bacterial taxa at the phylum, 
order, family and genus levels in Healthy subjects (HS) upon lactulose treatment, over time. 
 Time point 
Phylum T0 mean ± sd 
T5 
mean ± sd 
T10 
mean ± sd 
T24 
mean ± sd 
Actinobacteria 12.135 16.599 6.954 7.576 7.310 5.711 33.891 28.338 
Bacteroidetes 38.739 9.405 33.640 3.230 32.786 6.861 14.206 8.985 
Cyanobacteria 0.010 0.010 0.000 0.000 0.007 0.006 0.000 0.000 
Euryarchaeota 0.000 0.000 0.007 0.012 0.000 0.000 0.000 0.000 
Firmicutes 45.718 7.076 53.231 6.351 56.166 4.160 42.005 20.394 
Fusobacteria 0.013 0.012 0.000 0.000 0.003 0.006 0.003 0.006 
Lentisphaerae 0.000 0.000 0.007 0.012 0.003 0.006 0.003 0.006 
Proteobacteria 3.880 2.636 6.145 9.721 3.721 2.756 9.858 8.284 
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Tenericutes 0.003 0.006 0.013 0.023 0.003 0.006 0.000 0.000 
Verrucomicrobia 0.024 0.015 0.003 0.006 0.000 0.000 0.034 0.029 
 
 Time point 
Order T0 mean ± sd 
T5 
mean ± sd 
T10 
mean ± sd 
T24 
mean ± sd 
[Cerasicoccales] 0.003 0.006 0.003 0.006 0.000 0.000 0.000 0.000 
Actinomycetales 0.000 0.000 0.000 0.000 0.000 0.000 0.003 0.006 
Bacteroidales 38.561 9.498 33.640 3.230 32.788 6.862 14.206 8.985 
Bifidobacteriales 1.701 0.832 5.986 7.660 6.041 5.991 31.658 28.338 
Burkholderiales 0.487 0.294 1.097 1.271 1.177 0.674 2.217 2.558 
Campylobacterales 0.000 0.000 0.000 0.000 0.000 0.000 0.003 0.006 
Clostridiales 29.369 1.886 46.416 8.634 43.876 8.935 29.853 23.791 
Coriobacteriales 10.348 16.929 0.968 0.098 1.269 1.290 2.229 3.252 
Desulfovibrionales 0.319 0.088 0.943 1.463 0.221 0.156 2.565 4.304 
Enterobacteriales 2.988 2.836 4.101 7.016 2.312 1.959 5.073 7.764 
Erysipelotrichales 7.826 9.058 5.037 5.484 4.141 4.281 3.498 2.966 
Fusobacteriales 0.013 0.012 0.000 0.000 0.003 0.006 0.003 0.006 
Gemellales 0.000 0.000 0.000 0.000 0.014 0.023 0.003 0.006 
Lactobacillales 8.284 12.007 1.708 2.933 8.137 12.763 8.644 7.616 
Methanobacteriales 0.000 0.000 0.007 0.012 0.000 0.000 0.000 0.000 
RF32 0.030 0.020 0.003 0.006 0.010 0.018 0.000 0.000 
RF39 0.003 0.006 0.013 0.023 0.003 0.006 0.000 0.000 
Rhizobiales 0.003 0.006 0.000 0.000 0.000 0.000 0.000 0.000 
Turicibacterales 0.010 0.017 0.070 0.082 0.000 0.000 0.007 0.006 
Verrucomicrobiales 0.020 0.020 0.000 0.000 0.000 0.000 0.034 0.029 
Victivallales 0.000 0.000 0.007 0.012 0.003 0.006 0.003 0.006 
YS2 0.010 0.010 0.000 0.000 0.003 0.006 0.000 0.000 
 
 Time point 
Family T0 mean ± sd 
T5 
mean ± sd 
T10 
mean ± sd 
T24 
mean ± sd 
[Barnesiellaceae] 0,3794 0,1279 0,7490 0,510 0,0598 0,0539 0,2681 0,4644 
[Cerasicoccaceae] 0,0035 0,0060 0,0037 0,006 0,0000 0,0000 0,0000 0,0000 
[Mogibacteriaceae] 0,0347 0,0423 0,2573 0,059 0,0485 0,0659 0,0068 0,0118 
[Odoribacteraceae] 0,3164 0,2939 0,3761 0,104 0,2918 0,0613 0,1409 0,1673 
[Paraprevotellaceae] 0,0070 0,0121 0,2853 0,322 1,3218 2,2709 0,0000 0,0000 
[Tissierellaceae] 0,0035 0,0060 0,0073 0,006 0,0071 0,0123 0,5192 0,8906 
Actinomycetaceae 0,0000 0,0000 0,0000 0,000 0,0000 0,0000 0,0036 0,0062 
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Alcaligenaceae 0,5015 0,3066 1,1656 1,366 1,2262 0,7155 2,2333 2,5779 
Bacteroidaceae 36,640 9,5706 27,115 2,466 20,561 4,3966 12,216 7,1947 
Bifidobacteriaceae 1,7544 0,8710 6,1556 7,742 6,2762 6,1973 32,4419 28,4027 
Carnobacteriaceae 0,0035 0,0060 0,0036 0,006 0,0137 0,0238 0,0068 0,0118 
Christensenellaceae 0,0070 0,0060 0,0765 0,072 0,0834 0,1097 0,0068 0,0118 
Clostridiaceae 0,2501 0,1841 0,5574 0,251 0,1912 0,1880 0,2914 0,3775 
Coriobacteriaceae 10,490 17,140 1,0316 0,143 1,3318 1,3757 2,3708 3,4897 
Dehalobacteriaceae 0,0000 0,0000 0,0036 0,006 0,0000 0,0000 0,0000 0,0000 
Desulfovibrionaceae 0,3276 0,0899 1,0118 1,565 0,2317 0,1669 2,5987 4,3539 
Enterobacteriaceae 3,0763 2,9431 4,3929 7,517 2,4225 2,0631 5,0856 7,7679 
Enterococcaceae 0,2003 0,3199 0,0036 0,006 0,3981 0,6714 3,0137 3,6573 
Erysipelotrichaceae 8,0738 9,4085 5,2349 5,546 4,3500 4,5589 3,6623 3,2285 
Eubacteriaceae 0,0034 0,0059 0,0000 0,000 0,0036 0,0062 0,0000 0,0000 
Fusobacteriaceae 0,0138 0,0119 0,0000 0,000 0,0034 0,0059 0,0034 0,0058 
Gemellaceae 0,0000 0,0000 0,0000 0,000 0,0137 0,0238 0,0034 0,0059 
Helicobacteraceae 0,0000 0,0000 0,0000 0,000 0,0000 0,0000 0,0034 0,0059 
Lachnospiraceae 15,132 4,6100 20,257 7,052 26,899 7,7294 11,559 11,658 
Lactobacillaceae 1,7518 2,3337 0,2661 0,451 0,9887 1,6943 0,9608 0,9335 
Leptotrichiaceae 0,0000 0,0000 0,0000 0,000 0,0000 0,0000 0,0000 0,0000 
Leuconostocaceae 0,0311 0,0314 0,0000 0,000 0,0069 0,0120 0,0000 0,0000 
Methanobacteriaceae 0,0000 0,0000 0,0068 0,011 0,0000 0,0000 0,0000 0,0000 
Oxalobacteraceae 0,0000 0,0000 0,0000 0,000 0,0036 0,0062 0,0000 0,0000 
Pasteurellaceae 0,0243 0,0337 0,0000 0,000 0,0000 0,0000 0,0000 0,0000 
Peptococcaceae 0,0000 0,0000 0,1678 0,272 0,0000 0,0000 0,0000 0,0000 
Peptostreptococcaceae 0,0452 0,0783 0,0145 0,016 0,0036 0,0062 0,0000 0,0000 
Phyllobacteriaceae 0,0035 0,0060 0,0000 0,000 0,0000 0,0000 0,0000 0,0000 
Porphyromonadaceae 1,0973 1,2591 2,7411 0,920 2,1340 0,2874 0,4994 0,4637 
Prevotellaceae 0,8176 1,4071 2,1047 2,154 6,0392 8,0955 0,0108 0,0187 
Rikenellaceae 0,3755 0,5261 1,8692 1,294 1,3105 0,5568 0,6480 0,9676 
Ruminococcaceae 10,1368 4,8165 19,6850 1,324 12,792 1,7240 14,541 17,047 
S24-7 0,1009 0,1748 0,4838 0,811 2,1078 3,2152 0,8693 1,5058 
Streptococcaceae 6,5758 10,2467 1,5570 2,6777 6,8570 11,5589 4,6983 4,3347 
Turicibacteraceae 0,0104 0,0181 0,0767 0,0903 0,0000 0,0000 0,0068 0,0058 
Veillonellaceae 1,7885 0,5864 2,3319 0,9650 2,0175 0,5591 1,2904 0,4668 
Verrucomicrobiaceae 0,0207 0,0209 0,0000 0,0000 0,0000 0,0000 0,0349 0,0303 





 Time point 
Genus T0 
mean ± sd 
T5 
mean ± sd 
T10 
mean ± sd 
T24 
mean ± sd 
[Eubacterium] 0.042 0.074 4.884 5.083 0.621 0.313 0.042 0.074 
[Prevotella] 0.000 0.000 0.089 0.154 1.451 2.513 0.000 0.000 
[Ruminococcus] 0.477 0.406 1.161 1.028 1.797 2.971 0.477 0.406 
Acidaminococcus 0.054 0.048 0.369 0.639 0.024 0.025 0.054 0.048 
Actinomyces 0.005 0.009 0.000 0.000 0.000 0.000 0.005 0.009 
Adlercreutzia 0.063 0.064 0.074 0.128 0.030 0.042 0.063 0.064 
Akkermansia 0.049 0.043 0.000 0.000 0.000 0.000 0.049 0.043 
Alistipes 0.000 0.000 0.000 0.000 0.007 0.013 0.000 0.000 
Anaerococcus 0.000 0.000 0.000 0.000 0.007 0.013 0.000 0.000 
Anaerofustis 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Anaerostipes 0.056 0.073 0.058 0.055 0.062 0.035 0.056 0.073 
Anaerotruncus 0.000 0.000 0.034 0.059 0.004 0.008 0.000 0.000 
Bacteroides 16.965 10.303 38.386 6.330 32.238 16.332 16.965 10.303 
Bifidobacterium 43.329 36.488 7.955 9.326 9.007 7.473 43.329 36.488 
Bilophila 3.575 6.090 1.149 1.726 0.402 0.395 3.575 6.090 
Blautia 3.452 3.390 8.917 6.118 9.954 10.878 3.452 3.390 
Butyricimonas 0.014 0.025 0.205 0.138 0.171 0.044 0.014 0.025 
cc_115 0.023 0.030 0.188 0.325 0.015 0.026 0.023 0.030 
Christensenella 0.005 0.008 0.000 0.000 0.000 0.000 0.005 0.008 
Clostridium 0.227 0.317 0.121 0.103 0.021 0.036 0.227 0.317 
Collinsella 3.160 5.038 0.695 0.302 2.165 3.193 3.160 5.038 
Coprobacillus 0.004 0.007 0.000 0.000 0.004 0.007 0.004 0.007 
Coprococcus 2.680 3.411 5.203 1.630 6.004 3.719 2.680 3.411 
Desulfovibrio 0.030 0.041 0.397 0.688 0.000 0.000 0.030 0.041 
Dialister 0.274 0.474 1.095 1.261 0.815 0.811 0.274 0.474 
Dorea 0.195 0.258 2.088 1.387 0.772 0.683 0.195 0.258 
Eggerthella 0.052 0.089 0.034 0.045 0.016 0.014 0.052 0.089 
Enterococcus 1.774 1.523 0.006 0.010 0.491 0.851 1.774 1.523 
Escherichia 0.185 0.321 0.174 0.291 0.175 0.178 0.185 0.321 
Faecalibacterium 2.751 2.467 4.461 2.603 2.580 1.842 2.751 2.467 
Finegoldia 0.004 0.007 0.000 0.000 0.007 0.013 0.004 0.007 
Fusobacterium 0.004 0.007 0.000 0.000 0.004 0.007 0.004 0.007 
Gemella 0.000 0.000 0.000 0.000 0.004 0.007 0.000 0.000 
Granulicatella 0.009 0.016 0.000 0.000 0.017 0.029 0.009 0.016 
Helicobacter 0.005 0.008 0.000 0.000 0.000 0.000 0.005 0.008 
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Holdemania 0.039 0.023 0.004 0.007 0.004 0.008 0.039 0.023 
Lachnobacterium 0.024 0.041 0.037 0.063 0.026 0.045 0.024 0.041 
Lachnospira 0.536 0.486 0.798 1.062 0.165 0.083 0.536 0.486 
Lactobacillus 1.031 0.942 0.278 0.482 1.128 1.923 1.031 0.942 
Lactococcus 0.000 0.000 0.000 0.000 0.017 0.029 0.000 0.000 
Megasphaera 0.028 0.049 0.000 0.000 0.004 0.008 0.028 0.049 
Methanobrevibacter 0.000 0.000 0.008 0.015 0.000 0.000 0.000 0.000 
Morganella 0.019 0.033 0.000 0.000 0.000 0.000 0.019 0.033 
Odoribacter 0.183 0.209 0.336 0.243 0.252 0.032 0.183 0.209 
Oribacterium 0.000 0.000 0.000 0.000 0.004 0.007 0.000 0.000 
Oscillospira 5.479 9.093 2.530 2.454 1.300 0.729 5.479 9.093 
Parabacteroides 0.701 0.647 3.770 0.792 3.327 1.568 0.701 0.647 
Paraprevotella 0.000 0.000 0.173 0.300 0.132 0.229 0.000 0.000 
Parvimonas 0.000 0.000 0.006 0.010 0.000 0.000 0.000 0.000 
Peptococcus 0.000 0.000 0.199 0.344 0.000 0.000 0.000 0.000 
Peptoniphilus 0.703 1.218 0.005 0.009 0.000 0.000 0.703 1.218 
ph2 0.005 0.008 0.000 0.000 0.000 0.000 0.005 0.008 
Phascolarctobacterium 1.324 1.150 1.930 2.021 2.054 0.916 1.324 1.150 
Prevotella 0.015 0.027 2.870 3.079 8.115 9.356 0.015 0.027 
Proteus 0.009 0.008 0.000 0.000 0.000 0.000 0.009 0.008 
Roseburia 0.136 0.176 0.107 0.071 0.183 0.147 0.136 0.176 
Ruminococcus 1.555 2.294 4.800 1.909 3.992 1.848 1.555 2.294 
Serratia 0.071 0.123 0.000 0.000 0.000 0.000 0.071 0.123 
Slackia 0.005 0.008 0.016 0.017 0.064 0.065 0.005 0.008 
SMB53 0.004 0.007 0.075 0.071 0.000 0.000 0.004 0.007 
Streptococcus 6.327 5.973 2.457 4.228 8.286 13.854 6.327 5.973 
Sutterella 2.251 2.286 1.735 2.228 2.043 1.699 2.251 2.286 
Turicibacter 0.009 0.008 0.112 0.127 0.000 0.000 0.009 0.008 
Veillonella 0.071 0.066 0.000 0.000 0.012 0.011 0.071 0.066 
 
 
Table A13. Mean relative abundance (%) ± standard deviation (SD) of bacterial taxa at the phylum, 
order, family and genus levels in Healthy subjects (HS)  upon lactulose + rifaximin treatment, over 
time. 
 Time point 
Phylum T0 mean ± sd 
T5 
mean ± sd 
T10 
mean ± sd 
T24 
mean ± sd 
Actinobacteria 1.573 1.093 2.737 1.423 1.302 0.195 2.367 1.487 
Bacteroidetes 39.376 15.275 34.750 4.497 30.786 28.082 32.603 4.689 
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Cyanobacteria 0.017 0.015 0.000 0.000 0.003 0.006 0.000 0.000 
Euryarchaeota 0.000 0.000 0.000 0.000 0.003 0.006 0.253 0.358 
Firmicutes 44.601 10.202 55.352 6.925 58.763 17.964 62.871 5.754 
Fusobacteria 0.121 0.210 0.000 0.000 0.003 0.006 0.000 0.000 
Lentisphaerae 0.000 0.000 0.000 0.000 0.003 0.006 0.000 0.000 
Proteobacteria 14.292 11.116 7.097 9.466 9.119 11.852 1.891 0.086 
Tenericutes 0.007 0.006 0.023 0.041 0.000 0.000 0.000 0.000 
Verrucomicrobia 0.013 0.015 0.041 0.037 0.017 0.029 0.015 0.021 
 
 Time point 
Order T0 mean ± sd 
T5 
mean ± sd 
T10 
mean ± sd 
T24 
mean ± sd 
Actinomycetales 0.013 0.015 0.013 0.015 0.010 0.017 0.000 0.000 
Bacteroidales 39.379 15.275 34.750 4.497 30.786 28.082 32.603 4.689 
Bifidobacteriales 0.664 0.776 1.731 1.563 0.714 0.417 1.891 1.258 
Burkholderiales 2.093 1.388 0.598 0.904 2.297 2.763 1.517 0.258 
Campylobacterales 0.003 0.006 0.013 0.023 0.007 0.012 0.000 0.000 
Clostridiales 37.518 3.693 38.300 18.762 23.079 11.040 31.851 6.460 
Coriobacteriales 0.896 0.326 0.993 0.319 0.578 0.246 0.475 0.229 
Desulfovibrionales 0.800 1.055 1.242 1.003 1.139 0.839 0.238 0.336 
Enterobacteriales 11.336 9.534 5.244 9.004 5.616 8.705 0.137 0.165 
Erysipelotrichales 0.537 0.209 12.271 16.205 34.132 29.222 31.010 0.706 
Fusobacteriales 0.121 0.210 0.000 0.000 0.003 0.006 0.000 0.000 
Gemellales 0.000 0.000 0.000 0.000 0.003 0.006 0.000 0.000 
Lactobacillales 6.545 6.754 4.721 8.124 1.537 2.644 0.010 0.000 
Methanobacteriales 0.000 0.000 0.000 0.000 0.003 0.006 0.253 0.358 
Pasteurellales 0.020 0.027 0.000 0.000 0.023 0.041 0.000 0.000 
Pseudomonadales 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
RF32 0.030 0.030 0.000 0.000 0.020 0.035 0.000 0.000 
RF39 0.007 0.006 0.023 0.041 0.000 0.000 0.000 0.000 
Rhizobiales 0.003 0.006 0.000 0.000 0.003 0.006 0.000 0.000 
Turicibacterales 0.003 0.006 0.060 0.105 0.024 0.025 0.000 0.000 
Verrucomicrobiales 0.013 0.015 0.041 0.037 0.017 0.029 0.015 0.021 
Victivallales 0.000 0.000 0.000 0.000 0.003 0.006 0.000 0.000 






 Time point 
Family T0 mean ± sd 
T5 
mean ± sd 
T10 
mean ± sd 
T24 
mean ± sd 
[Barnesiellaceae] 0.314 0.414 0.558 0.161 0.351 0.497 0.021 0.029 
[Mogibacteriaceae] 0.383 0.483 0.196 0.146 0.037 0.052 0.127 0.180 
[Odoribacteraceae] 0.456 0.125 0.537 0.073 0.251 0.327 0.158 0.006 
[Paraprevotellaceae] 0.000 0.000 0.067 0.094 0.000 0.000 1.643 2.324 
[Tissierellaceae] 0.000 0.000 0.005 0.007 0.000 0.000 0.000 0.000 
[Weeksellaceae] 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Actinomycetaceae 0.021 0.015 0.011 0.001 0.016 0.022 0.000 0.000 
Alcaligenaceae 1.348 0.085 0.887 1.128 0.757 0.768 1.527 0.258 
Bacteroidaceae 37.099 25.025 29.444 1.704 45.500 17.433 26.887 5.831 
Bifidobacteriaceae 0.945 0.966 2.297 1.881 0.802 0.556 1.915 1.283 
Campylobacteraceae 0.005 0.007 0.000 0.000 0.010 0.015 0.000 0.000 
Carnobacteriaceae 0.000 0.000 0.005 0.007 0.010 0.015 0.000 0.000 
Christensenellaceae 0.173 0.230 0.105 0.119 0.016 0.008 0.010 0.000 
Clostridiaceae 0.588 0.268 0.547 0.672 0.245 0.246 0.332 0.106 
Coriobacteriaceae 1.002 0.455 1.148 0.498 0.598 0.370 0.481 0.234 
Corynebacteriaceae 0.000 0.000 0.005 0.007 0.000 0.000 0.000 0.000 
Dehalobacteriaceae 0.016 0.022 0.000 0.000 0.000 0.000 0.000 0.000 
Desulfovibrionaceae 0.199 0.015 0.783 0.778 0.891 1.008 0.241 0.341 
Dethiosulfovibrionaceae 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Enterobacteriaceae 8.530 11.515 0.048 0.005 0.604 0.099 0.137 0.165 
Enterococcaceae 0.452 0.550 0.982 1.388 0.026 0.037 0.000 0.000 
Erysipelotrichaceae 0.435 0.036 3.325 3.986 25.508 35.481 31.333 0.908 
Eubacteriaceae 0.005 0.007 0.000 0.000 0.000 0.000 0.000 0.000 
Fusobacteriaceae 0.000 0.000 0.000 0.000 0.005 0.007 0.000 0.000 
Gemellaceae 0.000 0.000 0.000 0.000 0.005 0.007 0.000 0.000 
Helicobacteraceae 0.000 0.000 0.021 0.029 0.000 0.000 0.000 0.000 
Lachnospiraceae 18.321 2.763 15.981 8.003 10.483 8.946 17.791 11.824 
Lactobacillaceae 2.091 0.669 0.852 1.206 1.190 1.683 0.000 0.000 
Leuconostocaceae 0.126 0.044 0.000 0.000 0.079 0.111 0.000 0.000 
Methanobacteriaceae 0.000 0.000 0.000 0.000 0.000 0.000 0.254 0.360 
Microbacteriaceae 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Micrococcaceae 0.000 0.000 0.005 0.007 0.000 0.000 0.000 0.000 
Oxalobacteraceae 0.000 0.000 0.006 0.008 0.000 0.000 0.005 0.007 
Pasteurellaceae 0.026 0.037 0.000 0.000 0.037 0.052 0.000 0.000 
Peptococcaceae 0.000 0.000 0.000 0.000 0.000 0.000 0.071 0.101 
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Peptostreptococcaceae 0.010 0.000 0.022 0.031 0.005 0.007 0.000 0.000 
Phyllobacteriaceae 0.005 0.007 0.000 0.000 0.000 0.000 0.000 0.000 
Porphyromonadaceae 1.175 0.745 1.809 1.448 0.313 0.298 0.532 0.307 
Prevotellaceae 0.011 0.015 2.499 3.520 0.000 0.000 1.369 1.921 
Rikenellaceae 1.807 2.407 2.228 0.023 0.115 0.105 0.271 0.096 
Ruminococcaceae 15.615 5.312 27.453 9.368 9.448 3.395 11.747 5.446 
S24-7 0.000 0.000 0.961 1.359 0.296 0.419 2.068 2.924 
Streptococcaceae 7.019 7.040 5.416 7.596 1.090 1.528 0.010 0.000 
Succinivibrionaceae 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Turicibacteraceae 0.005 0.007 0.100 0.141 0.010 0.015 0.000 0.000 
Veillonellaceae 1.802 0.959 1.673 1.781 1.272 1.582 1.052 0.182 
Verrucomicrobiaceae 0.016 0.022 0.026 0.037 0.026 0.037 0.015 0.022 
 
 Time point 
Genus T0 mean ± sd 
T5 
mean ± sd 
T10 
mean ± sd 
T24 
mean ± sd 
[Eubacterium] 0.152 0.110 2.557 3.535 1.665 2.853 7.946 11.238 
[Prevotella] 1.158 2.006 0.000 0.000 0.000 0.000 0.000 0.000 
[Ruminococcus] 0.905 0.666 0.780 0.581 0.758 0.330 0.597 0.438 
Acidaminococcus 0.810 1.403 0.072 0.126 0.000 0.000 0.000 0.000 
Actinobacillus 0.000 0.000 0.000 0.000 0.008 0.014 0.000 0.000 
Actinomyces 0.018 0.019 0.005 0.009 0.013 0.022 0.000 0.000 
Adlercreutzia 0.077 0.133 0.084 0.117 0.016 0.028 0.010 0.015 
Akkermansia 0.018 0.019 0.067 0.063 0.021 0.036 0.031 0.044 
Anaerofustis 0.006 0.010 0.000 0.000 0.000 0.000 0.000 0.000 
Anaerostipes 0.092 0.067 0.032 0.032 0.092 0.159 0.045 0.005 
Anaerotruncus 0.027 0.025 0.000 0.000 0.000 0.000 0.000 0.000 
Bacteroides 44.679 18.885 47.383 7.263 51.351 39.010 48.983 18.792 
Bifidobacterium 1.051 1.307 2.733 2.354 2.181 1.480 3.623 2.890 
Bilophila 1.211 1.616 2.047 1.735 4.455 4.669 0.381 0.539 
Blautia 6.583 2.051 5.395 5.562 3.176 2.425 6.707 1.181 
Bulleidia 0.004 0.007 0.000 0.000 0.077 0.133 0.000 0.000 
Butyricimonas 0.177 0.204 0.227 0.293 0.000 0.000 0.120 0.169 
Campylobacter 0.004 0.007 0.000 0.000 0.008 0.014 0.000 0.000 
Catenibacterium 0.000 0.000 0.005 0.009 0.000 0.000 0.000 0.000 
cc_115 0.000 0.000 0.233 0.326 0.000 0.000 0.000 0.000 
Citrobacter 0.025 0.044 2.990 5.178 0.156 0.031 0.191 0.271 
Clostridium 0.233 0.225 0.032 0.014 0.066 0.095 0.074 0.076 
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Collinsella 0.464 0.331 0.877 0.267 0.952 0.697 0.572 0.357 
Coprobacillus 0.011 0.009 0.010 0.018 0.235 0.396 0.000 0.000 
Coprococcus 4.110 1.954 4.014 2.077 1.370 0.646 11.585 14.081 
Corynebacterium 0.000 0.000 0.005 0.009 0.000 0.000 0.000 0.000 
Dehalobacterium 0.017 0.029 0.000 0.000 0.000 0.000 0.000 0.000 
Desulfovibrio 0.000 0.000 0.012 0.020 0.032 0.056 0.072 0.102 
Dialister 0.380 0.658 1.304 1.983 2.518 4.362 0.854 1.207 
Dorea 1.140 0.753 0.564 0.307 0.620 0.482 0.873 0.390 
Eggerthella 0.148 0.179 0.011 0.018 0.029 0.051 0.000 0.000 
Enterococcus 0.483 0.726 0.958 1.659 0.017 0.029 0.000 0.000 
Escherichia 0.590 0.511 0.005 0.009 1.000 1.731 0.000 0.000 
Faecalibacterium 2.531 1.661 3.405 2.628 1.672 1.355 4.809 6.779 
Finegoldia 0.000 0.000 0.000 0.000 0.019 0.033 0.000 0.000 
Fusobacterium 0.185 0.320 0.000 0.000 0.004 0.007 0.000 0.000 
Gemella 0.000 0.000 0.000 0.000 0.004 0.007 0.000 0.000 
Granulicatella 0.015 0.027 0.000 0.000 0.008 0.014 0.000 0.000 
Haemophilus 0.026 0.033 0.000 0.000 0.021 0.036 0.000 0.000 
Helicobacter 0.000 0.000 0.010 0.018 0.000 0.000 0.000 0.000 
Holdemania 0.091 0.091 0.069 0.079 0.072 0.067 0.018 0.003 
Klebsiella 0.072 0.124 0.000 0.000 0.000 0.000 0.000 0.000 
Lachnobacterium 0.011 0.019 0.213 0.256 0.000 0.000 0.000 0.000 
Lachnospira 0.867 1.027 0.734 0.514 1.019 0.684 0.824 1.166 
Lactobacillus 1.763 1.592 0.782 1.340 0.947 1.640 0.000 0.000 
Lactococcus 0.000 0.000 0.000 0.000 0.000 0.000 0.008 0.011 
Leuconostoc 0.050 0.086 0.000 0.000 0.004 0.007 0.000 0.000 
Megamonas 0.005 0.009 0.000 0.000 0.000 0.000 0.000 0.000 
Megasphaera 0.000 0.000 0.000 0.000 0.004 0.007 0.000 0.000 
Mesorhizobium 0.006 0.010 0.000 0.000 0.000 0.000 0.000 0.000 
Methanobrevibacter 0.000 0.000 0.000 0.000 0.019 0.033 0.399 0.564 
Morganella 0.000 0.000 0.005 0.009 0.004 0.007 0.000 0.000 
Odoribacter 0.460 0.190 0.309 0.286 0.246 0.287 0.163 0.207 
Oribacterium 0.004 0.007 0.000 0.000 0.000 0.000 0.000 0.000 
Oscillospira 3.869 3.132 2.704 0.958 8.943 13.234 1.694 0.560 
p-75-a5 0.000 0.000 0.000 0.000 0.346 0.599 0.000 0.000 
Parabacteroides 3.039 2.458 1.819 2.004 0.366 0.225 0.999 0.714 
Paraprevotella 0.113 0.195 0.000 0.000 0.000 0.000 2.577 3.644 
Peptococcus 0.000 0.000 0.000 0.000 0.000 0.000 0.112 0.158 
Peptoniphilus 0.000 0.000 0.005 0.009 0.000 0.000 0.000 0.000 
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Phascolarctobacterium 3.068 2.721 1.687 2.404 1.064 1.280 0.981 1.207 
Prevotella 3.409 5.877 2.391 4.128 0.038 0.067 2.148 3.009 
Ralstonia 0.000 0.000 0.005 0.009 0.019 0.033 0.010 0.015 
Roseburia 0.433 0.309 0.110 0.096 0.200 0.326 0.096 0.068 
Rothia 0.000 0.000 0.005 0.009 0.000 0.000 0.000 0.000 
Ruminococcus 4.388 2.739 2.746 2.277 1.567 1.626 0.776 0.573 
Serratia 0.013 0.022 4.623 8.007 0.391 0.644 0.000 0.000 
Slackia 0.213 0.317 0.071 0.064 0.000 0.000 0.018 0.003 
SMB53 0.008 0.015 0.021 0.037 0.062 0.096 0.000 0.000 
Streptococcus 7.536 9.819 5.421 9.334 0.891 1.472 0.010 0.015 
Sutterella 3.126 2.191 0.332 0.372 11.009 17.293 1.685 1.435 
Turicibacter 0.004 0.007 0.096 0.166 0.104 0.160 0.000 0.000 
Varibaculum 0.000 0.000 0.005 0.009 0.000 0.000 0.000 0.000 
Veillonella 0.123 0.200 0.026 0.045 0.100 0.173 0.008 0.011 
 
 
Table A14. Mean relative abundance (%) ± standard deviation (SD) of bacterial taxa at the phylum, 
order, family and genus levels in Healthy subjects (HS) upon rifaximin treatment, over time. 
 
 Time point 
Phylum T0 mean ± sd 
T5 
mean ± sd 
T10 
mean ± sd 
T24 
mean ± sd 
Actinobacteria 10.870 11.999 4.543 2.015 4.875 1.362 3.294 2.957 
Bacteroidetes 33.474 2.480 35.162 9.343 32.021 9.560 34.833 9.869 
Cyanobacteria 0.174 0.199 0.003 0.006 0.003 0.006 0.007 0.012 
Euryarchaeota 0.610 1.056 0.121 0.132 0.024 0.041 0.000 0.000 
Firmicutes 51.749 11.493 55.019 15.698 52.510 10.243 41.104 6.062 
Fusobacteria 0.000 0.000 0.000 0.000 0.000 0.000 8.555 14.818 
Lentisphaerae 0.044 0.075 0.003 0.006 0.000 0.000 0.000 0.000 
Proteobacteria 3.814 3.630 4.469 6.365 10.536 9.206 12.176 8.172 
Synergistetes 0.000 0.000 0.239 0.413 0.000 0.000 0.000 0.000 
Tenericutes 0.000 0.000 0.003 0.006 0.000 0.000 0.003 0.006 
Verrucomicrobia 0.000 0.000 0.437 0.757 0.030 0.044 0.027 0.025 
 
 
 Time point 
Order T0 mean ± sd 
T5 
mean ± sd 
T10 
mean ± sd 
T24 
mean ± sd 
[Cerasicoccales] 0.000 0.000 0.003 0.006 0.000 0.000 0.000 0.000 
Actinomycetales 0.007 0.012 0.010 0.010 0.013 0.006 0.013 0.012 
Bacillales 0.000 0.000 0.003 0.006 0.000 0.000 0.000 0.000 
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Bacteroidales 25.751 19.086 35.163 9.344 32.023 9.561 34.833 9.869 
Bifidobacteriales 7.618 9.730 3.486 1.823 3.549 0.293 2.500 2.509 
Burkholderiales 1.525 1.151 0.809 0.348 3.133 2.498 2.720 2.742 
Campylobacterales 0.000 0.000 0.000 0.000 0.010 0.017 0.000 0.000 
Clostridiales 42.357 25.222 45.726 5.212 48.319 6.889 32.170 13.179 
Coriobacteriales 0.744 0.753 1.047 0.718 1.313 1.108 0.781 0.448 
Desulfovibrionales 0.458 0.404 1.391 2.306 3.822 3.317 4.294 2.240 
Enterobacteriales 0.945 1.506 2.252 3.718 3.560 4.808 5.156 8.720 
Erysipelotrichales 9.773 13.481 1.353 1.178 1.911 1.563 3.554 3.899 
Fusobacteriales 0.000 0.000 0.000 0.000 0.000 0.000 8.555 14.818 
Lactobacillales 10.672 17.466 7.919 13.472 2.282 3.848 5.282 9.079 
Methanobacteriales 0.047 0.081 0.121 0.132 0.024 0.041 0.000 0.000 
ML615J-28 0.000 0.000 0.003 0.006 0.000 0.000 0.000 0.000 
Pseudomonadales 0.000 0.000 0.000 0.000 0.003 0.006 0.000 0.000 
RF32 0.000 0.000 0.013 0.023 0.000 0.000 0.003 0.006 
RF39 0.000 0.000 0.000 0.000 0.000 0.000 0.003 0.006 
Rhizobiales 0.003 0.006 0.000 0.000 0.007 0.006 0.003 0.006 
SHA-98 0.000 0.000 0.007 0.012 0.000 0.000 0.000 0.000 
Synergistales 0.000 0.000 0.239 0.413 0.000 0.000 0.000 0.000 
Turicibacterales 0.084 0.051 0.013 0.023 0.000 0.000 0.098 0.160 
Verrucomicrobiales 0.000 0.000 0.434 0.751 0.030 0.044 0.027 0.025 
Victivallales 0.003 0.006 0.003 0.006 0.000 0.000 0.000 0.000 
YS2 0.010 0.017 0.003 0.006 0.000 0.000 0.007 0.012 
 
 Time point 
Family T0 mean ± sd 
T5 
mean ± sd 
T10 
mean ± sd 
T24 
mean ± sd 
[Barnesiellaceae] 0.681 0.697 0.565 0.478 0.447 0.369 0.193 0.196 
[Cerasicoccaceae] 0.000 0.000 0.003 0.006 0.000 0.000 0.000 0.000 
[Mogibacteriaceae] 0.272 0.332 0.204 0.141 0.110 0.137 0.032 0.028 
[Odoribacteraceae] 0.411 0.358 0.609 0.145 0.421 0.190 0.371 0.189 
[Paraprevotellaceae] 0.253 0.438 0.838 0.800 0.417 0.723 0.220 0.371 
[Tissierellaceae] 0.000 0.000 0.000 0.000 0.007 0.006 0.004 0.006 
Actinomycetaceae 0.003 0.006 0.010 0.011 0.010 0.011 0.007 0.012 
Alcaligenaceae 1.575 1.124 0.827 0.353 3.222 2.549 2.765 2.743 
Bacteroidaceae 21.764 15.356 28.000 6.523 25.051 6.558 26.925 3.668 
Bifidobacteriaceae 7.760 9.725 3.605 1.825 3.707 0.380 2.616 2.638 
Burkholderiaceae 0.000 0.000 0.004 0.006 0.000 0.000 0.000 0.000 
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Carnobacteriaceae 0.015 0.025 0.000 0.000 0.007 0.012 0.007 0.012 
Christensenellaceae 0.022 0.029 0.207 0.277 0.036 0.062 0.039 0.059 
Clostridiaceae 2.796 2.259 0.381 0.392 0.542 0.553 0.482 0.283 
Comamonadaceae 0.000 0.000 0.004 0.006 0.003 0.006 0.000 0.000 
Coriobacteriaceae 0.795 0.802 1.091 0.758 1.381 1.186 0.817 0.476 
Corynebacteriaceae 0.000 0.000 0.000 0.000 0.004 0.006 0.000 0.000 
Desulfovibrionaceae 0.482 0.432 1.421 2.352 3.956 3.439 4.445 2.270 
Dethiosulfovibrionaceae 0.000 0.000 0.243 0.422 0.000 0.000 0.000 0.000 
Enterobacteriaceae 0.955 1.514 2.299 3.792 3.719 5.055 5.503 9.315 
Enterococcaceae 0.024 0.026 0.063 0.110 1.056 1.819 0.014 0.012 
Erysipelotrichaceae 9.925 13.512 1.411 1.243 2.008 1.674 3.758 4.196 
Eubacteriaceae 0.000 0.000 0.000 0.000 0.003 0.006 0.000 0.000 
Fusobacteriaceae 0.000 0.000 0.000 0.000 0.000 0.000 8.584 14.868 
Helicobacteraceae 0.000 0.000 0.000 0.000 0.010 0.018 0.000 0.000 
Lachnospiraceae 16.348 13.348 15.980 8.158 16.078 5.442 9.833 5.278 
Lactobacillaceae 2.104 3.568 1.274 2.032 0.130 0.216 0.409 0.699 
Leuconostocaceae 0.000 0.000 0.011 0.018 0.000 0.000 0.007 0.012 
Methanobacteriaceae 0.050 0.086 0.124 0.135 0.025 0.043 0.000 0.000 
Microbacteriaceae 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Micrococcaceae 0.000 0.000 0.000 0.000 0.000 0.000 0.007 0.012 
Moraxellaceae 0.000 0.000 0.000 0.000 0.004 0.006 0.000 0.000 
Oxalobacteraceae 0.000 0.000 0.004 0.006 0.007 0.012 0.004 0.006 
Pasteurellaceae 0.004 0.006 0.000 0.000 0.000 0.000 0.000 0.000 
Peptococcaceae 0.150 0.232 0.113 0.195 0.189 0.328 0.000 0.000 
Peptostreptococcaceae 0.018 0.032 0.007 0.006 0.004 0.006 0.004 0.006 
Phyllobacteriaceae 0.004 0.006 0.000 0.000 0.007 0.006 0.004 0.006 
Porphyromonadaceae 1.684 1.764 2.679 1.393 2.111 1.856 2.026 0.602 
Prevotellaceae 1.318 2.275 1.266 2.165 1.680 2.901 0.339 0.502 
Propionibacteriaceae 0.003 0.006 0.000 0.000 0.000 0.000 0.000 0.000 
Rikenellaceae 1.483 0.985 2.462 0.780 1.667 1.094 0.984 0.617 
Ruminococcaceae 18.760 12.961 24.669 2.963 27.820 9.429 17.392 9.364 
S24-7 0.000 0.000 0.113 0.187 1.750 3.031 5.191 7.723 
Streptococcaceae 8.630 13.972 6.855 11.800 1.125 1.866 4.855 8.363 
Turicibacteraceae 0.089 0.057 0.014 0.024 0.000 0.000 0.104 0.171 
Veillonellaceae 1.615 1.238 2.195 1.336 1.254 0.617 2.034 0.680 
Verrucomicrobiaceae 0.000 0.000 0.442 0.766 0.032 0.046 0.028 0.027 
Victivallaceae 0.004 0.006 0.004 0.006 0.000 0.000 0.000 0.000 
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 Time point 
Genus T0 mean ± sd 
T5 
mean ± sd 
T10 
mean ± sd 
T24 
mean ± sd 
[Eubacterium] 1.442 2.458 1.087 1.757 1.532 2.383 3.237 5.311 
[Prevotella] 0.009 0.016 0.036 0.063 0.254 0.440 0.231 0.384 
[Ruminococcus] 0.560 0.463 0.751 0.431 0.948 0.089 0.658 0.548 
Acidaminococcus 0.066 0.089 0.318 0.550 0.046 0.080 0.004 0.006 
Acinetobacter 0.000 0.000 0.000 0.000 0.005 0.008 0.000 0.000 
Actinomyces 0.005 0.009 0.014 0.013 0.015 0.015 0.011 0.019 
Adlercreutzia 0.005 0.009 0.032 0.034 0.086 0.089 0.044 0.077 
Akkermansia 0.000 0.000 0.612 1.059 0.044 0.063 0.039 0.042 
Anaerofustis 0.000 0.000 0.000 0.000 0.005 0.009 0.000 0.000 
Anaerostipes 0.158 0.152 0.131 0.065 0.113 0.089 0.071 0.070 
Anaerotruncus 0.015 0.015 0.022 0.028 0.018 0.032 0.006 0.010 
Atopobium 0.000 0.000 0.000 0.000 0.005 0.009 0.000 0.000 
Bacteroides 29.714 20.404 36.800 9.190 34.484 7.478 39.557 11.796 
Bifidobacterium 11.411 14.746 4.795 2.673 5.132 0.150 4.019 4.249 
Bilophila 0.132 0.130 1.959 3.256 5.587 4.840 5.966 3.598 
Blautia 4.589 2.529 6.416 4.302 5.530 2.504 3.873 2.023 
Butyricimonas 0.282 0.400 0.369 0.429 0.230 0.299 0.164 0.195 
cc_115 0.014 0.025 0.038 0.054 0.087 0.151 0.000 0.000 
Christensenella 0.000 0.000 0.009 0.008 0.005 0.008 0.000 0.000 
Citrobacter 0.030 0.041 0.000 0.000 0.616 1.053 0.009 0.008 
Clostridium 2.541 3.350 0.078 0.081 0.052 0.041 0.112 0.112 
Clostridium 0.000 0.000 0.004 0.008 0.000 0.000 0.006 0.010 
Collinsella 0.666 0.889 0.856 0.911 1.309 1.295 0.639 0.492 
Coprobacillus 0.026 0.044 0.009 0.016 0.000 0.000 0.066 0.115 
Coprococcus 5.756 6.039 3.918 1.912 4.223 2.830 1.845 1.582 
Corynebacterium 0.000 0.000 0.000 0.000 0.005 0.008 0.000 0.000 
Curvibacter 0.000 0.000 0.000 0.000 0.005 0.009 0.000 0.000 
Desulfovibrio 0.529 0.477 0.000 0.000 0.073 0.126 0.233 0.404 
Dialister 1.155 1.895 2.326 1.415 0.987 0.866 1.372 2.376 
Dorea 0.596 0.494 0.536 0.213 0.440 0.351 0.523 0.141 
Eggerthella 0.041 0.071 0.004 0.008 0.000 0.000 0.006 0.010 
Enterococcus 0.010 0.018 0.080 0.139 1.575 2.728 0.007 0.013 
Epulopiscium 0.000 0.000 0.005 0.008 0.000 0.000 0.006 0.010 
Escherichia 0.041 0.071 0.099 0.149 0.015 0.027 0.319 0.552 
Faecalibacterium 4.183 3.056 3.632 2.027 6.924 1.241 5.181 3.764 
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Fusobacterium 0.000 0.000 0.000 0.000 0.000 0.000 9.519 16.487 
Granulicatella 0.005 0.009 0.000 0.000 0.010 0.018 0.007 0.013 
Haemophilus 0.005 0.009 0.000 0.000 0.000 0.000 0.000 0.000 
Helicobacter 0.000 0.000 0.000 0.000 0.010 0.018 0.000 0.000 
Holdemania 0.035 0.017 0.070 0.071 0.080 0.070 0.094 0.047 
Lachnobacterium 0.000 0.000 0.104 0.102 0.102 0.165 0.018 0.031 
Lachnospira 1.777 2.614 0.607 0.812 1.039 0.784 0.600 0.714 
Lactobacillus 3.001 5.158 1.563 2.464 0.194 0.325 0.395 0.670 
Lactococcus 0.005 0.009 0.000 0.000 0.000 0.000 0.000 0.000 
Leuconostoc 0.000 0.000 0.013 0.023 0.000 0.000 0.007 0.013 
Megasphaera 0.000 0.000 0.000 0.000 0.010 0.018 0.000 0.000 
Mesorhizobium 0.005 0.008 0.000 0.000 0.009 0.008 0.006 0.010 
Methanobrevibacter 0.066 0.115 0.168 0.187 0.032 0.056 0.000 0.000 
Morganella 0.000 0.000 0.000 0.000 0.021 0.036 0.000 0.000 
Odoribacter 0.276 0.372 0.423 0.276 0.349 0.121 0.411 0.278 
Oscillospira 2.107 2.325 4.636 3.809 8.152 6.949 3.962 3.183 
Other 0.005 0.009 0.000 0.000 0.000 0.000 0.000 0.000 
p-75-a5 0.000 0.000 0.000 0.000 0.000 0.000 0.006 0.010 
Parabacteroides 2.268 2.343 3.538 1.872 2.826 2.321 3.035 1.410 
Paraprevotella 0.327 0.567 1.091 1.102 0.286 0.496 0.015 0.026 
Peptococcus 0.185 0.320 0.144 0.250 0.245 0.424 0.000 0.000 
Phascolarctobacterium 0.948 0.956 0.272 0.339 0.640 0.545 1.598 0.994 
Prevotella 1.755 3.026 1.620 2.771 2.177 3.757 0.549 0.855 
Pyramidobacter 0.000 0.000 0.337 0.583 0.000 0.000 0.000 0.000 
Ralstonia 0.000 0.000 0.005 0.008 0.009 0.016 0.006 0.010 
Roseburia 1.559 1.363 1.413 2.196 0.464 0.593 0.536 0.919 
Rothia 0.000 0.000 0.000 0.000 0.000 0.000 0.007 0.013 
Ruminococcus 6.383 5.277 9.175 1.666 4.993 3.658 1.835 1.683 
Serratia 0.000 0.000 0.000 0.000 2.754 4.441 0.055 0.096 
Slackia 0.019 0.033 0.113 0.075 0.072 0.025 0.048 0.074 
SMB53 0.147 0.204 0.000 0.000 0.000 0.000 0.042 0.073 
Staphylococcus 0.000 0.000 0.005 0.008 0.000 0.000 0.000 0.000 
Streptococcus 12.852 20.921 8.700 14.974 1.684 2.806 5.393 9.266 
Sutterella 2.147 1.860 1.040 0.580 3.440 2.534 3.471 2.991 
Trabulsiella 0.000 0.000 0.000 0.000 0.005 0.008 0.000 0.000 
Turicibacter 0.126 0.079 0.019 0.033 0.000 0.000 0.172 0.289 




Table A15. Mean relative abundance (%) ± standard deviation (SD) of bacterial taxa at the phylum, 
order, family and genus levels in Healthy subjects (HS) upon VSL#3 treatment over time. 
 
 Time point 
Phylum T0 mean ± sd 
T5 
mean ± sd 
T10 
mean ± sd 
T24 
mean ± sd 
Actinobacteria 17.827 17.686 11.415 13.823 3.370 1.263 2.983 1.014 
Bacteroidetes 23.357 16.702 35.603 4.084 27.133 15.619 32.408 5.739 
Cyanobacteria 0.000 0.000 0.000 0.000 0.000 0.000 0.003 0.006 
Euryarchaeota 0.000 0.000 0.037 0.064 0.017 0.029 0.074 0.119 
Firmicutes 57.651 1.517 51.218 12.256 53.219 6.930 54.093 7.871 
Fusobacteria 0.005 0.007 0.000 0.000 0.003 0.006 0.000 0.000 
Lentisphaerae 0.000 0.000 0.000 0.000 0.013 0.015 0.010 0.017 
Proteobacteria 1.139 0.554 1.700 1.773 16.235 14.171 10.424 8.040 
Tenericutes 0.000 0.000 0.007 0.012 0.010 0.017 0.000 0.000 
TM7 0.000 0.000 0.000 0.000 0.000 0.000 0.003 0.006 
Verrucomicrobia 0.020 0.029 0.020 0.027 0.000 0.000 0.000 0.000 
 
 Time point 
Order T0 mean ± sd 
T5 
mean ± sd 
T10 
mean ± sd 
T24 
mean ± sd 
Actinomycetales 0.005 0.007 0.000 0.000 0.010 0.010 0.003 0.006 
Bacteroidales 23.357 16.702 35.603 4.084 27.133 15.619 32.411 5.738 
Bifidobacteriales 15.374 15.545 1.996 0.325 2.093 0.995 2.036 1.104 
Burkholderiales 0.630 0.177 0.362 0.318 1.286 1.609 1.559 1.869 
Clostridiales 42.416 0.501 39.858 6.650 40.887 8.826 41.709 4.663 
Coriobacteriales 2.448 2.148 9.419 14.090 1.267 0.732 0.944 0.484 
Desulfovibrionales 0.428 0.263 0.214 0.199 1.532 1.364 1.069 0.954 
Enterobacteriales 0.076 0.107 1.116 1.340 13.404 11.817 7.791 8.112 
Erysipelotrichales 1.340 1.223 2.811 0.773 6.642 6.442 1.599 1.041 
Fusobacteriales 0.005 0.007 0.000 0.000 0.003 0.006 0.000 0.000 
Lactobacillales 13.896 2.239 8.503 5.363 5.614 5.447 10.663 6.907 
Methanobacteriales 0.000 0.000 0.037 0.064 0.017 0.029 0.074 0.119 
Pasteurellales 0.005 0.007 0.003 0.006 0.010 0.017 0.003 0.006 
RF39 0.000 0.000 0.007 0.012 0.010 0.017 0.000 0.000 
Rhizobiales 0.000 0.000 0.003 0.006 0.000 0.000 0.000 0.000 
Turicibacterales 0.000 0.000 0.047 0.065 0.077 0.061 0.128 0.150 
Verrucomicrobiales 0.020 0.029 0.017 0.029 0.000 0.000 0.000 0.000 
Victivallales 0.000 0.000 0.000 0.000 0.013 0.015 0.010 0.017 
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 Time point 
Family T0 mean ± sd 
T5 
mean ± sd 
T10 
mean ± sd 
T24 
mean ± sd 
[Barnesiellaceae] 0.130 0.125 0.593 0.305 0.402 0.099 0.623 0.344 
[Cerasicoccaceae] 0.000 0.000 0.004 0.006 0.000 0.000 0.000 0.000 
[Mogibacteriaceae] 0.058 0.023 0.190 0.154 0.150 0.105 0.346 0.306 
[Odoribacteraceae] 0.168 0.164 0.348 0.187 0.487 0.277 0.504 0.152 
[Paraprevotellaceae] 0.000 0.000 0.359 0.478 0.381 0.660 0.045 0.078 
[Tissierellaceae] 0.005 0.007 0.000 0.000 0.055 0.087 0.019 0.032 
Actinomycetaceae 0.005 0.007 0.000 0.000 0.011 0.011 0.004 0.006 
Alcaligenaceae 0.653 0.180 0.373 0.322 1.341 1.663 1.665 2.012 
Bacteroidaceae 17.217 9.750 28.011 1.973 21.561 11.269 26.304 2.464 
Bifidobacteriaceae 15.894 16.024 2.097 0.358 2.218 1.038 2.166 1.167 
Carnobacteriaceae 0.000 0.000 0.000 0.000 0.000 0.000 0.011 0.019 
Christensenellaceae 0.010 0.015 0.050 0.051 0.043 0.023 0.044 0.049 
Clostridiaceae 0.336 0.432 0.620 0.466 0.600 0.192 0.970 0.500 
Coriobacteriaceae 2.532 2.212 9.645 14.360 1.361 0.798 1.004 0.493 
Dehalobacteriaceae 0.000 0.000 0.000 0.000 0.004 0.006 0.000 0.000 
Desulfovibrionaceae 0.443 0.270 0.225 0.205 1.640 1.477 1.165 1.045 
Enterobacteriaceae 0.078 0.110 1.145 1.365 14.248 12.463 8.493 9.016 
Enterococcaceae 4.803 6.762 0.250 0.432 0.011 0.010 0.007 0.013 
Erysipelotrichaceae 1.385 1.260 2.965 0.910 6.969 6.607 1.711 1.122 
Eubacteriaceae 0.000 0.000 0.027 0.047 0.000 0.000 0.000 0.000 
Fusobacteriaceae 0.005 0.007 0.000 0.000 0.003 0.006 0.000 0.000 
Lachnospiraceae 21.848 1.929 17.831 2.749 15.312 8.411 14.342 2.104 
Lactobacillaceae 1.852 1.678 1.201 0.743 0.893 0.865 1.117 0.673 
Leuconostocaceae 0.000 0.000 0.007 0.012 0.000 0.000 0.000 0.000 
Methanobacteriaceae 0.000 0.000 0.038 0.067 0.018 0.031 0.077 0.123 
Oxalobacteraceae 0.000 0.000 0.000 0.000 0.004 0.006 0.000 0.000 
Pasteurellaceae 0.005 0.007 0.003 0.006 0.011 0.019 0.004 0.006 
Peptococcaceae 0.000 0.000 0.581 1.005 0.178 0.299 0.699 1.182 
Peptostreptococcaceae 0.000 0.000 0.004 0.006 0.114 0.171 0.244 0.377 
Phyllobacteriaceae 0.000 0.000 0.004 0.006 0.000 0.000 0.000 0.000 
Porphyromonadaceae 0.892 0.939 3.088 3.026 2.710 2.156 3.366 2.819 
Prevotellaceae 0.005 0.007 3.034 2.642 1.402 2.314 1.463 1.283 
Rikenellaceae 0.788 0.430 1.524 1.008 1.776 0.880 1.960 0.149 
Ruminococcaceae 16.939 1.860 15.455 6.477 19.432 4.093 18.577 6.105 
S24-7 5.074 7.175 0.390 0.676 0.343 0.594 0.304 0.516 
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Streptococcaceae 7.731 7.522 7.579 5.655 5.025 4.776 10.285 6.778 
Turicibacteraceae 0.000 0.000 0.051 0.070 0.082 0.063 0.138 0.160 
Veillonellaceae 1.123 0.235 2.292 0.229 1.201 0.384 2.336 1.075 
Verrucomicrobiaceae 0.021 0.030 0.017 0.030 0.000 0.000 0.000 0.000 
Victivallaceae 0.000 0.000 0.000 0.000 0.014 0.016 0.011 0.019 
 
 Time point 
Genus T0 mean ± sd 
T5 
mean ± sd 
T10 
mean ± sd 
T24 
mean ± sd 
[Eubacterium] 0.014 0.019 3.228 1.028 1.956 2.072 1.229 1.895 
[Prevotella] 0.000 0.000 0.323 0.456 0.294 0.416 0.214 0.370 
[Ruminococcus] 1.079 0.159 1.017 1.191 0.856 0.244 1.604 1.600 
Acidaminococcus 0.366 0.517 0.000 0.000 0.105 0.149 0.000 0.000 
Actinomyces 0.008 0.011 0.000 0.000 0.025 0.003 0.015 0.026 
Adlercreutzia 0.070 0.055 0.000 0.000 0.023 0.033 0.284 0.418 
Akkermansia 0.031 0.043 0.000 0.000 0.000 0.000 0.005 0.009 
Anaerofustis 0.000 0.000 0.000 0.000 0.000 0.000 0.010 0.018 
Anaerostipes 0.076 0.088 0.048 0.027 0.107 0.119 0.085 0.061 
Anaerotruncus 0.000 0.000 0.000 0.000 0.019 0.007 0.041 0.071 
Atopobium 0.000 0.000 0.000 0.000 0.000 0.000 0.005 0.008 
Bacteroides 24.321 15.372 35.504 2.740 29.779 13.677 31.992 9.016 
Bifidobacterium 21.069 20.377 3.007 0.141 4.570 0.580 14.084 19.444 
Bilophila 0.521 0.432 0.184 0.261 1.824 2.579 1.453 1.577 
Blautia 7.382 1.476 7.145 1.813 7.249 1.920 8.079 1.918 
Butyricimonas 0.007 0.010 0.376 0.115 0.313 0.409 0.236 0.232 
cc_115 0.000 0.000 0.227 0.284 0.007 0.010 0.009 0.016 
Christensenella 0.007 0.010 0.007 0.010 0.000 0.000 0.005 0.009 
Citrobacter 0.007 0.010 0.000 0.000 0.035 0.050 0.000 0.000 
Clostridium 0.015 0.022 0.333 0.366 0.146 0.091 0.075 0.077 
Clostridium 0.000 0.000 0.000 0.000 0.012 0.017 0.000 0.000 
Collinsella 3.018 3.031 1.081 1.362 1.027 1.122 3.617 4.524 
Coprobacillus 0.000 0.000 0.000 0.000 0.035 0.050 0.005 0.009 
Coprococcus 7.836 3.095 4.157 0.174 5.556 3.559 7.967 1.612 
Dehalobacterium 0.000 0.000 0.000 0.000 0.007 0.010 0.009 0.016 
Desulfovibrio 0.061 0.087 0.000 0.000 0.409 0.579 0.025 0.043 
Dialister 0.224 0.316 2.348 0.065 0.780 1.103 0.614 0.747 
Dorea 0.951 0.455 1.093 0.585 0.848 0.504 1.707 0.745 
Enterococcus 6.192 8.735 0.000 0.000 0.012 0.017 1.237 2.142 
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Escherichia 0.007 0.010 0.007 0.010 0.327 0.463 0.045 0.055 
Faecalibacterium 4.656 4.593 3.847 0.703 5.271 2.164 3.302 3.076 
Fusobacterium 0.007 0.010 0.000 0.000 0.012 0.017 0.000 0.000 
Holdemania 0.000 0.000 0.007 0.010 0.035 0.050 0.036 0.062 
Lachnobacterium 0.102 0.144 0.044 0.043 0.007 0.010 0.005 0.008 
Lachnospira 1.548 1.826 0.207 0.292 1.156 1.539 0.392 0.211 
Lactobacillus 2.516 2.389 1.750 1.011 1.760 2.470 0.222 0.359 
Lactococcus 0.000 0.000 0.000 0.000 0.012 0.017 0.000 0.000 
Leuconostoc 0.000 0.000 0.000 0.000 0.000 0.000 0.046 0.079 
Megamonas 0.007 0.010 0.000 0.000 0.000 0.000 0.000 0.000 
Megasphaera 0.014 0.019 0.007 0.010 0.000 0.000 0.000 0.000 
Mesorhizobium 0.000 0.000 0.007 0.010 0.000 0.000 0.000 0.000 
Methanobrevibacter 0.000 0.000 0.074 0.105 0.034 0.048 0.009 0.016 
Odoribacter 0.234 0.255 0.224 0.164 0.292 0.084 0.220 0.139 
Oscillospira 0.631 0.046 2.280 1.701 3.975 3.339 4.373 5.519 
Parabacteroides 1.285 1.395 5.687 3.597 2.912 3.390 3.624 2.367 
Paraprevotella 0.000 0.000 0.256 0.361 0.438 0.619 0.341 0.591 
Parvimonas 0.000 0.000 0.000 0.000 0.007 0.010 0.000 0.000 
Pediococcus 0.008 0.011 0.000 0.000 0.000 0.000 0.000 0.000 
Peptococcus 0.000 0.000 1.116 1.579 0.335 0.474 0.136 0.236 
Peptoniphilus 0.007 0.010 0.000 0.000 0.000 0.000 0.005 0.009 
Phascolarctobacterium 0.698 0.988 0.703 0.222 1.076 0.825 0.873 0.391 
Prevotella 0.007 0.010 5.978 0.294 2.607 3.686 1.551 2.686 
Pseudomonas 0.000 0.000 0.000 0.000 0.000 0.000 0.005 0.009 
Ralstonia 0.000 0.000 0.000 0.000 0.007 0.010 0.000 0.000 
Roseburia 1.186 1.600 0.115 0.067 0.210 0.032 0.171 0.101 
Ruminococcus 1.582 0.522 3.111 1.248 8.643 1.929 5.593 4.659 
Serratia 0.007 0.010 0.000 0.000 0.094 0.132 0.000 0.000 
Slackia 0.037 0.034 0.027 0.038 0.048 0.068 0.242 0.373 
SMB53 0.000 0.000 0.066 0.094 0.035 0.050 0.005 0.008 
Streptococcus 11.094 11.245 14.102 3.892 10.708 15.046 1.905 2.316 
Sutterella 0.871 0.147 0.206 0.166 3.827 4.871 2.237 3.353 
Turicibacter 0.000 0.000 0.102 0.106 0.177 0.212 0.000 0.000 






Table A16. Mean relative abundance (%) ± standard deviation (SD) of bacterial taxa at the phylum, 
order, family and genus levels in Healthy subjects (HS) upon VSL#3 + lactulose treatment, over 
time. 
 Time point 
Phylum T0 mean ± sd 
T5 
mean ± sd 
T10 
mean ± sd 
T24 
mean ± sd 
Actinobacteria 3.866 2.553 18.398 9.928 13.158 15.403 23.039 19.096 
Bacteroidetes 35.434 1.796 26.316 6.300 30.532 10.158 22.240 10.424 
Chloroflexi 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Cyanobacteria 0.003 0.006 0.003 0.006 0.003 0.006 0.000 0.000 
Euryarchaeota 0.000 0.000 0.010 0.017 0.007 0.012 0.077 0.134 
Firmicutes 52.158 5.312 53.081 10.787 53.076 5.978 53.809 9.923 
Fusobacteria 0.101 0.175 0.000 0.000 0.000 0.000 0.000 0.000 
Lentisphaerae 0.000 0.000 0.000 0.000 0.007 0.006 0.000 0.000 
Proteobacteria 8.414 9.318 2.192 1.510 3.211 4.189 0.821 0.464 
Tenericutes 0.003 0.006 0.000 0.000 0.000 0.000 0.000 0.000 
TM7 0.000 0.000 0.000 0.000 0.003 0.006 0.000 0.000 
Verrucomicrobia 0.020 0.017 0.000 0.000 0.003 0.006 0.013 0.023 
 
 Time point 
Order T0 mean ± sd 
T5 
mean ± sd 
T10 
mean ± sd 
T24 
mean ± sd 
Actinomycetales 0.010 0.010 0.007 0.012 0.010 0.017 0.000 0.000 
Bacteroidales 35.436 1.792 26.317 6.300 30.533 10.160 22.240 10.424 
Bifidobacteriales 2.953 2.459 16.506 7.525 9.655 13.207 20.633 17.665 
Burkholderiales 1.123 1.394 1.320 1.093 1.506 2.225 0.484 0.674 
Clostridiales 35.821 3.087 45.137 12.374 47.443 9.566 31.223 12.562 
Coriobacteriales 0.903 0.090 1.886 2.572 3.492 2.254 2.406 3.670 
Desulfovibrionales 0.756 0.804 0.584 0.497 0.983 1.035 0.239 0.266 
Enterobacteriales 6.520 7.246 0.288 0.207 0.718 0.985 0.097 0.061 
Erysipelotrichales 6.302 9.807 5.143 3.766 3.282 3.084 18.353 21.061 
Fusobacteriales 0.101 0.175 0.000 0.000 0.000 0.000 0.000 0.000 
Gemellales 0.007 0.012 0.000 0.000 0.000 0.000 0.000 0.000 
Lactobacillales 10.028 6.516 2.622 0.990 2.350 2.010 4.233 1.974 
Methanobacteriales 0.000 0.000 0.010 0.017 0.007 0.012 0.077 0.134 
Pseudomonadales 0.003 0.006 0.000 0.000 0.003 0.006 0.000 0.000 
RF32 0.007 0.006 0.000 0.000 0.000 0.000 0.000 0.000 
RF39 0.003 0.006 0.000 0.000 0.000 0.000 0.000 0.000 
Turicibacterales 0.003 0.006 0.181 0.313 0.000 0.000 0.000 0.000 
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Verrucomicrobiales 0.020 0.017 0.000 0.000 0.003 0.006 0.013 0.023 
Victivallales 0.000 0.000 0.000 0.000 0.007 0.006 0.000 0.000 
YS2 0.003 0.006 0.000 0.000 0.003 0.006 0.000 0.000 
 
 Time point 
Family T0 mean ± sd 
T5 
mean ± sd 
T10 
mean ± sd 
T24 
mean ± sd 
[Barnesiellaceae] 0.115 0.139 0.086 0.106 0.237 0.375 0.248 0.413 
[Mogibacteriaceae] 0.017 0.016 0.052 0.018 0.553 0.850 0.071 0.071 
[Odoribacteraceae] 0.319 0.166 0.114 0.104 0.335 0.240 0.089 0.067 
[Paraprevotellaceae] 0.745 1.290 0.187 0.324 0.432 0.749 0.058 0.100 
[Tissierellaceae] 0.007 0.012 0.000 0.000 0.003 0.006 0.000 0.000 
Actinomycetaceae 0.007 0.006 0.004 0.006 0.010 0.018 0.000 0.000 
Alcaligenaceae 1.137 1.397 1.385 1.178 1.573 2.319 0.493 0.680 
Bacteroidaceae 25.669 5.534 20.762 2.098 23.452 7.543 18.528 12.865 
Bifidobacteriaceae 3.067 2.567 17.337 8.075 10.202 13.972 21.494 18.209 
Carnobacteriaceae 0.007 0.006 0.000 0.000 0.000 0.000 0.000 0.000 
Christensenellaceae 0.014 0.016 0.017 0.029 0.259 0.430 0.037 0.056 
Clostridiaceae 0.522 0.314 1.999 3.042 0.715 0.526 0.130 0.096 
Coriobacteriaceae 0.931 0.109 1.983 2.713 3.679 2.392 2.590 3.984 
Dehalobacteriaceae 0.000 0.000 0.003 0.006 0.007 0.012 0.000 0.000 
Desulfovibrionaceae 0.768 0.804 0.619 0.527 1.030 1.079 0.245 0.266 
Enterobacteriaceae 6.623 7.275 0.305 0.222 0.750 1.027 0.102 0.067 
Enterococcaceae 0.024 0.026 0.036 0.053 0.875 1.496 0.040 0.060 
Erysipelotrichaceae 6.561 10.227 5.318 3.809 3.466 3.263 18.645 21.000 
Fusobacteriaceae 0.102 0.176 0.000 0.000 0.000 0.000 0.000 0.000 
Gemellaceae 0.007 0.012 0.000 0.000 0.000 0.000 0.000 0.000 
Lachnospiraceae 17.336 4.166 19.366 1.324 22.532 0.900 16.919 8.628 
Lactobacillaceae 1.545 0.749 0.572 0.043 0.174 0.283 0.557 0.337 
Leuconostocaceae 0.000 0.000 0.000 0.000 0.031 0.055 0.000 0.000 
Methanobacteriaceae 0.000 0.000 0.010 0.018 0.007 0.012 0.078 0.136 
Microbacteriaceae 0.003 0.006 0.000 0.000 0.000 0.000 0.000 0.000 
Oxalobacteraceae 0.000 0.000 0.004 0.006 0.000 0.000 0.000 0.000 
Pasteurellaceae 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Peptococcaceae 0.000 0.000 0.109 0.189 0.106 0.184 0.126 0.218 
Peptostreptococcaceae 0.028 0.048 0.011 0.019 0.014 0.016 0.003 0.006 
Porphyromonadaceae 2.144 0.531 1.924 2.281 2.666 1.805 1.587 2.229 
Prevotellaceae 3.014 3.134 0.753 1.303 1.208 2.093 0.565 0.960 
Pseudomonadaceae 0.003 0.006 0.000 0.000 0.003 0.006 0.000 0.000 
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Rikenellaceae 0.762 0.219 0.928 0.226 2.081 1.798 0.788 0.735 
Ruminococcaceae 13.597 2.429 19.738 10.352 19.418 8.552 10.755 2.311 
S24-7 3.732 5.530 2.673 4.629 1.705 2.954 0.889 1.532 
Streptococcaceae 8.743 6.085 2.118 1.054 1.360 1.674 3.802 1.764 
Turicibacteraceae 0.003 0.006 0.193 0.334 0.000 0.000 0.000 0.000 
Veillonellaceae 2.428 2.117 1.391 0.903 1.094 0.382 1.144 0.960 
Verrucomicrobiaceae 0.021 0.018 0.000 0.000 0.004 0.006 0.015 0.025 
Victivallaceae 0.000 0.000 0.000 0.000 0.007 0.006 0.000 0.000 
 
 Time point 
Genus T0 mean ± sd 
T5 
mean ± sd 
T10 
mean ± sd 
T24 
mean ± sd 
[Eubacterium] 3.207 5.438 2.749 4.749 1.229 1.895 3.418 3.124 
[Prevotella] 0.997 1.726 0.116 0.200 0.214 0.370 0.060 0.104 
[Ruminococcus] 0.680 0.500 0.596 0.283 1.604 1.600 1.685 2.061 
Acidaminococcus 0.636 1.102 0.351 0.608 0.000 0.000 0.000 0.000 
Actinomyces 0.005 0.009 0.005 0.009 0.015 0.026 0.000 0.000 
Adlercreutzia 0.030 0.039 0.015 0.026 0.284 0.418 0.042 0.049 
Akkermansia 0.030 0.026 0.000 0.000 0.005 0.009 0.020 0.035 
Anaerofustis 0.000 0.000 0.000 0.000 0.010 0.018 0.000 0.000 
Anaerostipes 0.101 0.120 0.128 0.100 0.085 0.061 0.031 0.053 
Anaerotruncus 0.005 0.009 0.000 0.000 0.041 0.071 0.013 0.022 
Atopobium 0.000 0.000 0.000 0.000 0.005 0.008 0.000 0.000 
Bacteroides 38.511 9.860 27.521 0.558 31.992 9.016 31.065 28.115 
Bifidobacterium 4.528 3.642 23.569 12.160 14.084 19.444 28.647 23.559 
Bilophila 1.072 1.243 0.420 0.642 1.453 1.577 0.417 0.524 
Blautia 4.815 1.517 6.137 1.994 8.079 1.918 5.294 1.925 
Butyricimonas 0.163 0.203 0.054 0.093 0.236 0.232 0.032 0.040 
cc_115 0.011 0.019 0.005 0.009 0.009 0.016 0.000 0.000 
Christensenella 0.000 0.000 0.004 0.007 0.005 0.009 0.004 0.007 
Citrobacter 0.005 0.010 0.010 0.017 0.000 0.000 0.000 0.000 
Clostridium 0.281 0.446 0.307 0.378 0.075 0.077 0.009 0.008 
Clostridium 0.000 0.000 0.000 0.000 0.000 0.000 0.013 0.022 
Collinsella 0.974 0.143 2.467 3.872 3.617 4.524 3.436 5.561 
Coprobacillus 0.005 0.009 0.044 0.077 0.005 0.009 0.097 0.167 
Coprococcus 3.625 0.495 4.466 1.257 7.967 1.612 3.979 2.058 
Cryocola 0.005 0.010 0.000 0.000 0.000 0.000 0.000 0.000 
Dehalobacterium 0.000 0.000 0.004 0.007 0.009 0.016 0.000 0.000 
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Desulfovibrio 0.060 0.103 0.440 0.674 0.025 0.043 0.015 0.027 
Dialister 0.638 1.105 0.428 0.434 0.614 0.747 0.309 0.270 
Dorea 0.807 0.521 1.624 1.299 1.707 0.745 1.297 1.222 
Eggerthella 0.075 0.130 0.168 0.291 0.056 0.097 0.000 0.000 
Enterococcus 0.025 0.043 0.000 0.000 1.237 2.142 0.012 0.010 
Epulopiscium 0.005 0.009 0.000 0.000 0.000 0.000 0.000 0.000 
Escherichia 0.324 0.339 0.010 0.017 0.045 0.055 0.000 0.000 
Faecalibacterium 5.182 0.966 6.782 4.556 3.302 3.076 2.469 1.687 
Finegoldia 0.011 0.019 0.000 0.000 0.000 0.000 0.000 0.000 
Fusobacterium 0.150 0.260 0.000 0.000 0.000 0.000 0.000 0.000 
Granulicatella 0.010 0.009 0.000 0.000 0.000 0.000 0.000 0.000 
Holdemania 0.016 0.015 0.030 0.026 0.036 0.062 0.090 0.156 
Klebsiella 0.095 0.165 0.000 0.000 0.000 0.000 0.000 0.000 
Lachnobacterium 0.011 0.019 0.000 0.000 0.005 0.008 0.019 0.033 
Lachnospira 1.064 1.566 0.949 1.189 0.392 0.211 0.319 0.357 
Lactobacillus 2.060 0.997 0.696 0.153 0.222 0.359 0.763 0.594 
Leuconostoc 0.000 0.000 0.000 0.000 0.046 0.079 0.000 0.000 
Methanobrevibacter 0.000 0.000 0.012 0.021 0.009 0.016 0.099 0.171 
Odoribacter 0.310 0.130 0.093 0.097 0.220 0.139 0.097 0.044 
Oscillospira 1.870 1.768 1.117 0.769 4.373 5.519 2.267 2.341 
Parabacteroides 3.208 0.829 2.417 2.740 3.624 2.367 2.039 2.775 
Paraprevotella 0.105 0.182 0.112 0.193 0.341 0.591 0.013 0.022 
Peptococcus 0.000 0.000 0.132 0.229 0.136 0.236 0.159 0.275 
Peptoniphilus 0.000 0.000 0.000 0.000 0.005 0.009 0.000 0.000 
Peptostreptococcus 0.000 0.000 0.005 0.009 0.000 0.000 0.000 0.000 
Phascolarctobacterium 2.332 2.537 1.025 0.528 0.873 0.391 1.291 1.578 
Prevotella 4.547 4.631 0.913 1.582 1.551 2.686 0.713 1.209 
Pseudomonas 0.005 0.009 0.000 0.000 0.005 0.009 0.000 0.000 
Roseburia 0.784 1.261 2.510 4.094 0.171 0.101 0.335 0.457 
Ruminococcus 2.140 1.352 6.553 5.429 5.593 4.659 2.844 2.168 
Scardovia 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Slackia 0.015 0.026 0.032 0.030 0.242 0.373 0.056 0.049 
SMB53 0.005 0.010 0.088 0.142 0.005 0.008 0.000 0.000 
Streptococcus 12.757 8.472 2.762 1.202 1.905 2.316 5.970 3.193 
Sutterella 1.680 2.068 1.801 1.700 2.237 3.353 0.562 0.707 
Turicibacter 0.005 0.010 0.267 0.462 0.000 0.000 0.000 0.000 
Varibaculum 0.005 0.010 0.000 0.000 0.000 0.000 0.000 0.000 
Veillonella 0.010 0.009 0.054 0.094 0.000 0.000 0.000 0.000 
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Table A17. Mean relative abundance (%) ± standard deviation (SD) of bacterial taxa at the phylum, 
order, family and genus levels in Healthy subjects (HS) upon VSL#3 + lactulose + rifaximin 
treatment. over time. 
 Time point 
Phylum T0 mean ± sd 
T5 
mean ± sd 
T10 
mean ± sd 
T24 
mean ± sd 
Actinobacteria 2.719 0.991 3.345 1.506 2.604 2.108 3.188 3.461 
Bacteroidetes 25.768 10.080 23.664 4.912 28.718 24.674 21.806 3.715 
Chloroflexi 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Cyanobacteria 0.000 0.000 0.003 0.006 0.007 0.012 0.003 0.006 
Euryarchaeota 0.013 0.023 0.044 0.076 0.020 0.035 0.132 0.228 
Firmicutes 70.680 11.251 53.765 21.836 61.251 30.984 50.611 25.571 
Fusobacteria 0.000 0.000 0.000 0.000 0.194 0.337 0.000 0.000 
Lentisphaerae 0.010 0.010 0.000 0.000 0.003 0.006 0.000 0.000 
Proteobacteria 0.779 0.450 19.159 21.691 7.129 9.822 24.252 20.676 
Tenericutes 0.030 0.052 0.000 0.000 0.000 0.000 0.000 0.000 
Verrucomicrobia 0.000 0.000 0.020 0.020 0.074 0.128 0.007 0.006 
 
 Time point 
Order T0 mean ± sd 
T5 
mean ± sd 
T10 
mean ± sd 
T24 
mean ± sd 
Actinomycetales 1.904 0.655 0.007 0.012 0.010 0.017 0.000 0.000 
Bacteroidales 0.000 0.000 23.664 4.912 28.718 24.674 21.808 3.713 
Bifidobacteriales 0.788 0.472 2.739 1.609 1.443 1.150 2.919 3.535 
Burkholderiales 0.000 0.000 0.511 0.646 0.958 1.249 2.447 2.441 
Campylobacterales 0.000 0.000 0.007 0.012 0.000 0.000 0.000 0.000 
Cardiobacteriales 0.138 0.111 0.000 0.000 0.000 0.000 0.000 0.000 
Clostridiales 0.003 0.006 27.867 15.120 28.988 17.750 26.637 12.833 
Coriobacteriales 25.768 10.080 0.599 0.306 1.151 0.983 0.270 0.092 
Desulfovibrionales 0.000 0.000 1.697 1.862 1.170 1.020 0.437 0.394 
Enterobacteriales 0.000 0.000 16.928 19.235 4.924 7.995 21.354 18.663 
Erysipelotrichales 0.000 0.000 21.757 18.404 28.557 46.104 18.249 15.883 
Fusobacteriales 0.010 0.010 0.000 0.000 0.194 0.337 0.000 0.000 
Gemellales 10.210 12.016 0.000 0.000 0.000 0.000 0.000 0.000 
I025 0.003 0.006 0.000 0.000 0.000 0.000 0.000 0.000 
Lactobacillales 0.000 0.000 4.077 1.565 3.699 3.823 5.724 3.899 
Methanobacteriales 0.027 0.046 0.044 0.076 0.020 0.035 0.132 0.228 
Neisseriales 0.228 0.319 0.000 0.000 0.023 0.041 0.000 0.000 
Pasteurellales 0.000 0.000 0.000 0.000 0.047 0.081 0.003 0.006 
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RF32 0.000 0.000 0.010 0.017 0.003 0.006 0.003 0.006 
RF39 0.027 0.047 0.000 0.000 0.000 0.000 0.000 0.000 
Rhizobiales 0.000 0.000 0.007 0.006 0.003 0.006 0.000 0.000 
SHA-98 15.576 25.180 0.000 0.000 0.000 0.000 0.000 0.000 
Sphingomonadales 0.397 0.305 0.000 0.000 0.000 0.000 0.000 0.000 
Turicibacterales 44.890 10.460 0.064 0.111 0.013 0.015 0.007 0.012 
Verrucomicrobiales 0.000 0.000 0.020 0.020 0.074 0.128 0.007 0.006 
Victivallales 0.017 0.021 0.000 0.000 0.003 0.006 0.000 0.000 
YS2 0.000 0.000 0.003 0.006 0.000 0.000 0.003 0.006 
 
 Time point 
Family T0 mean ± sd 
T5 
mean ± sd 
T10 
mean ± sd 
T24 
mean ± sd 
[Barnesiellaceae] 0.052 0.021 0.191 0.167 0.314 0.379 0.157 0.222 
[Mogibacteriaceae] 0.350 0.228 0.059 0.093 0.098 0.152 0.061 0.081 
[Odoribacteraceae] 0.583 0.481 0.132 0.110 0.311 0.383 0.127 0.078 
[Paraprevotellaceae] 0.293 0.508 0.236 0.400 0.415 0.719 0.276 0.478 
Actinomycetaceae 0.025 0.043 0.007 0.012 0.007 0.012 0.000 0.000 
Alcaligenaceae 0.413 0.322 0.527 0.668 0.977 1.263 2.512 2.534 
Bacteroidaceae 21.011 8.417 21.569 6.902 24.638 21.457 20.255 4.684 
Bifidobacteriaceae 1.981 0.709 2.813 1.679 1.499 1.212 3.002 3.661 
Carnobacteriaceae 0.000 0.000 0.003 0.006 0.000 0.000 0.000 0.000 
Christensenellaceae 0.351 0.295 0.003 0.006 0.011 0.018 0.003 0.006 
Clostridiaceae 0.199 0.236 0.683 0.668 0.539 0.471 1.539 2.242 
Coriobacteriaceae 0.822 0.500 0.612 0.315 1.192 1.029 0.274 0.091 
Corynebacteriaceae 0.000 0.000 0.000 0.000 0.004 0.006 0.000 0.000 
Dehalobacteriaceae 0.000 0.000 0.003 0.006 0.007 0.012 0.000 0.000 
Desulfovibrionaceae 0.239 0.334 1.739 1.927 1.203 1.052 0.448 0.406 
Enterobacteriaceae 0.144 0.116 17.362 19.908 4.998 8.100 21.869 19.175 
Enterococcaceae 0.109 0.123 0.042 0.072 0.335 0.391 0.938 1.476 
Erysipelotrichaceae 15.800 25.481 22.071 18.538 29.747 48.028 18.459 16.038 
Eubacteriaceae 0.000 0.000 0.000 0.000 0.000 0.000 0.007 0.012 
Fusobacteriaceae 0.000 0.000 0.000 0.000 0.197 0.341 0.000 0.000 
Gemellaceae 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Helicobacteraceae 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Lachnospiraceae 20.032 1.973 10.386 8.472 11.867 7.436 13.474 15.012 
Lactobacillaceae 1.140 1.551 1.019 0.177 0.490 0.742 1.322 1.570 
Leuconostocaceae 0.046 0.040 0.038 0.066 0.020 0.035 0.051 0.089 
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Methanobacteriaceae 0.014 0.024 0.045 0.078 0.021 0.037 0.133 0.230 
Neisseriaceae 0.000 0.000 0.000 0.000 0.024 0.041 0.000 0.000 
Pasteurellaceae 0.000 0.000 0.000 0.000 0.048 0.082 0.003 0.006 
Peptococcaceae 0.027 0.047 0.073 0.126 0.120 0.207 0.041 0.071 
Peptostreptococcaceae 0.000 0.000 0.003 0.006 0.024 0.021 0.038 0.066 
Phyllobacteriaceae 0.000 0.000 0.007 0.006 0.004 0.006 0.000 0.000 
Porphyromonadaceae 0.926 0.639 0.575 0.699 1.908 2.514 0.184 0.181 
Prevotellaceae 0.583 1.001 0.885 1.523 1.273 2.205 0.702 1.208 
Rikenellaceae 3.364 2.763 0.412 0.482 0.744 1.137 0.542 0.588 
Ruminococcaceae 21.219 11.593 13.879 5.347 11.986 9.428 6.819 4.329 
S24-7 0.000 0.000 0.128 0.222 0.003 0.006 0.000 0.000 
Streptococcaceae 9.237 11.089 3.053 1.856 2.936 2.784 3.491 3.091 
Turicibacteraceae 0.000 0.000 0.066 0.114 0.014 0.016 0.007 0.012 
Veillonellaceae 1.028 0.202 1.350 0.526 1.947 1.896 3.256 4.311 
Verrucomicrobiaceae 0.000 0.000 0.020 0.020 0.075 0.129 0.007 0.006 
Victivallaceae 0.010 0.011 0.000 0.000 0.004 0.006 0.000 0.000 
 
 Time point 
Genus T0 mean ± sd 
T5 
mean ± sd 
T10 
mean ± sd 
T24 
mean ± sd 
[Eubacterium] 7.166 11.752 3.138 4.505 5.471 6.398 3.418 3.124 
[Prevotella] 0.000 0.000 0.034 0.046 0.183 0.316 0.060 0.104 
[Ruminococcus] 1.003 0.580 0.483 0.025 0.970 0.871 1.685 2.061 
Acidaminococcus 0.005 0.008 0.065 0.112 0.000 0.000 0.000 0.000 
Actinomyces 0.034 0.060 0.010 0.017 0.009 0.015 0.000 0.000 
Adlercreutzia 0.145 0.165 0.006 0.011 0.000 0.000 0.042 0.049 
Akkermansia 0.000 0.000 0.035 0.038 0.095 0.164 0.020 0.035 
Anaerostipes 0.130 0.095 0.041 0.056 0.101 0.100 0.031 0.053 
Anaerotruncus 0.020 0.034 0.006 0.010 0.004 0.008 0.013 0.022 
Atopobium 0.000 0.000 0.000 0.000 0.031 0.054 0.000 0.000 
Bacteroides 31.250 9.128 36.392 15.648 31.738 26.326 31.065 28.115 
Bifidobacterium 2.915 0.507 4.418 2.139 3.623 2.416 28.647 23.559 
Bilophila 0.331 0.470 2.646 2.665 6.535 9.553 0.417 0.524 
Blautia 7.798 1.388 4.239 4.040 4.612 2.267 5.294 1.925 
Butyricimonas 0.248 0.163 0.098 0.171 0.254 0.440 0.032 0.040 
Campylobacter 0.000 0.000 0.010 0.017 0.000 0.000 0.000 0.000 
cc_115 0.000 0.000 0.015 0.026 0.063 0.109 0.000 0.000 
Christensenella 0.007 0.012 0.000 0.000 0.004 0.008 0.004 0.007 
	 222 
Citrobacter 0.010 0.017 12.981 14.427 2.020 3.498 0.000 0.000 
Clostridium 0.104 0.155 0.186 0.157 0.035 0.030 0.009 0.008 
Clostridium 0.000 0.000 0.000 0.000 0.031 0.054 0.013 0.022 
Collinsella 0.155 0.182 0.801 0.567 1.231 0.827 3.436 5.561 
Coprobacillus 0.098 0.170 0.015 0.026 0.887 1.513 0.097 0.167 
Coprococcus 10.149 9.057 5.877 8.220 3.663 2.730 3.979 2.058 
Corynebacterium 0.000 0.000 0.000 0.000 0.004 0.008 0.000 0.000 
Dehalobacterium 0.000 0.000 0.006 0.010 0.009 0.015 0.000 0.000 
Desulfovibrio 0.000 0.000 0.052 0.061 0.000 0.000 0.015 0.027 
Dialister 1.411 0.598 0.986 1.644 0.866 0.875 0.309 0.270 
Dorea 0.586 0.466 0.434 0.292 0.541 0.457 1.297 1.222 
Eggerthella 0.009 0.008 0.035 0.060 0.082 0.142 0.000 0.000 
Enterococcus 0.140 0.166 0.025 0.043 1.010 1.089 0.012 0.010 
Erwinia 0.000 0.000 0.005 0.009 0.004 0.007 0.000 0.000 
Escherichia 0.000 0.000 0.000 0.000 0.164 0.193 0.000 0.000 
Faecalibacterium 1.598 0.165 3.282 3.129 2.811 3.372 2.469 1.687 
Fusobacterium 0.000 0.000 0.000 0.000 0.250 0.433 0.000 0.000 
Granulicatella 0.000 0.000 0.005 0.009 0.000 0.000 0.000 0.000 
Haemophilus 0.000 0.000 0.000 0.000 0.060 0.104 0.000 0.000 
Holdemania 0.123 0.138 0.155 0.228 0.730 1.242 0.090 0.156 
Klebsiella 0.000 0.000 0.000 0.000 0.013 0.022 0.000 0.000 
Lachnobacterium 0.139 0.171 0.012 0.020 0.000 0.000 0.019 0.033 
Lachnospira 0.673 0.583 0.599 0.534 0.131 0.129 0.319 0.357 
Lactobacillus 1.459 1.813 1.544 0.172 0.735 0.821 0.763 0.594 
Lactococcus 0.000 0.000 0.005 0.009 0.004 0.007 0.000 0.000 
Leuconostoc 0.062 0.055 0.000 0.000 0.000 0.000 0.000 0.000 
Megasphaera 0.000 0.000 0.000 0.000 0.009 0.015 0.000 0.000 
Mesorhizobium 0.000 0.000 0.012 0.011 0.004 0.008 0.000 0.000 
Methanobrevibacter 0.027 0.047 0.075 0.130 0.027 0.046 0.099 0.171 
Morganella 0.000 0.000 0.447 0.774 0.267 0.462 0.000 0.000 
Odoribacter 0.557 0.500 0.112 0.078 0.140 0.126 0.097 0.044 
Oscillospira 4.451 4.578 2.912 0.598 5.296 5.370 2.267 2.341 
Parabacteroides 1.293 0.808 0.943 1.177 2.417 3.184 2.039 2.775 
Paraprevotella 0.579 1.003 0.359 0.622 0.343 0.594 0.013 0.022 
Peptococcus 0.054 0.093 0.122 0.211 0.151 0.262 0.159 0.275 
Phascolarctobacterium 0.210 0.081 1.134 0.760 1.584 2.126 1.291 1.578 
Prevotella 1.150 1.979 1.476 2.544 1.612 2.792 0.713 1.209 
Proteus 0.000 0.000 0.000 0.000 0.004 0.007 0.000 0.000 
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Roseburia 1.606 1.681 0.632 1.065 0.053 0.053 0.335 0.457 
Rothia 0.005 0.009 0.000 0.000 0.000 0.000 0.000 0.000 
Ruminococcus 8.898 5.914 2.941 2.152 5.248 2.867 2.844 2.168 
Serratia 0.000 0.000 4.048 5.547 0.090 0.157 0.000 0.000 
Slackia 0.194 0.182 0.012 0.011 0.027 0.046 0.056 0.049 
SMB53 0.000 0.000 0.020 0.034 0.157 0.272 0.000 0.000 
Streptococcus 12.744 13.779 5.234 3.315 11.690 14.427 5.970 3.193 
Sutterella 0.448 0.494 0.717 0.980 1.481 1.404 0.562 0.707 
Trabulsiella 0.000 0.000 0.010 0.017 0.000 0.000 0.000 0.000 
Turicibacter 0.000 0.000 0.094 0.163 0.099 0.159 0.000 0.000 
Veillonella 0.016 0.014 0.055 0.095 0.297 0.515 0.000 0.000 
 
 
Table A18. Mean relative abundance (%) ± standard deviation (SD) of bacterial taxa at the phylum, 
order, family and genus levels in Healthy subjects (HS) upon VSL#3 + rifaximin treatment over 
time. 
 Time point 
Phylum T0 mean ± sd 
T5 
mean ± sd 
T10 
mean ± sd 
T24 
mean ± sd 
Actinobacteria 3.548 1.395 2.571 2.268 4.093 1.558 3.060 0.677 
Bacteroidetes 35.957 2.121 34.111 11.109 32.075 8.075 33.183 0.274 
Cyanobacteria 0.010 0.017 0.017 0.021 0.000 0.000 0.010 0.010 
Euryarchaeota 0.050 0.087 0.000 0.000 0.003 0.006 0.000 0.000 
Firmicutes 58.993 2.428 48.425 15.816 51.750 8.207 52.445 5.015 
Fusobacteria 0.000 0.000 0.054 0.093 0.000 0.000 0.007 0.012 
Lentisphaerae 0.017 0.021 0.000 0.000 0.000 0.000 0.010 0.017 
Proteobacteria 1.418 0.882 14.755 23.114 11.991 12.262 11.265 4.691 
Synergistetes 0.003 0.006 0.000 0.000 0.000 0.000 0.000 0.000 
Tenericutes 0.003 0.006 0.003 0.006 0.007 0.012 0.007 0.006 
TM7 0.000 0.000 0.000 0.000 0.000 0.000 0.003 0.006 
Verrucomicrobia 0.000 0.000 0.064 0.086 0.081 0.073 0.010 0.000 
 
 Time point 
Order T0 mean ± sd 
T5 
mean ± sd 
T10 
mean ± sd 
T24 
mean ± sd 
[Cerasicoccales] 0.000 0.000 0.000 0.000 0.000 0.000 0.003 0.006 
Actinomycetales 0.007 0.006 0.003 0.006 0.007 0.012 0.003 0.006 
Bacteroidales 35.957 2.121 34.111 11.109 32.076 8.074 33.187 0.275 
Bifidobacteriales 2.693 1.112 2.174 2.153 3.197 1.391 2.157 0.175 
Burkholderiales 0.466 0.465 0.885 0.759 0.584 0.455 2.709 3.088 
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Campylobacterales 0.000 0.000 0.010 0.017 0.017 0.029 0.003 0.006 
Clostridiales 46.626 11.299 30.118 12.732 39.591 12.685 41.018 3.872 
Coriobacteriales 0.848 0.320 0.393 0.304 0.890 0.327 0.900 0.553 
Desulfovibrionales 0.835 0.761 1.570 1.838 2.609 2.394 2.445 1.645 
Enterobacteriales 0.114 0.082 12.284 20.997 8.762 10.323 6.095 5.190 
Erysipelotrichales 2.764 2.136 12.499 16.971 2.881 3.760 2.118 3.259 
Fusobacteriales 0.000 0.000 0.054 0.093 0.000 0.000 0.007 0.012 
Lactobacillales 9.479 6.976 5.717 6.726 9.246 2.759 9.254 4.437 
Methanobacteriales 0.050 0.087 0.000 0.000 0.003 0.006 0.000 0.000 
Pasteurellales 0.003 0.006 0.000 0.000 0.007 0.012 0.013 0.006 
Pseudomonadales 0.000 0.000 0.000 0.000 0.007 0.012 0.000 0.000 
RF32 0.000 0.000 0.007 0.006 0.000 0.000 0.000 0.000 
RF39 0.003 0.006 0.003 0.006 0.007 0.012 0.007 0.006 
Rhizobiales 0.000 0.000 0.000 0.000 0.003 0.006 0.000 0.000 
Synergistales 0.003 0.006 0.000 0.000 0.000 0.000 0.000 0.000 
Turicibacterales 0.124 0.156 0.091 0.086 0.034 0.058 0.060 0.056 
Verrucomicrobiales 0.000 0.000 0.064 0.086 0.081 0.073 0.007 0.006 
Victivallales 0.017 0.021 0.000 0.000 0.000 0.000 0.010 0.017 
YS2 0.010 0.017 0.017 0.021 0.000 0.000 0.003 0.006 
 
 Time point 
Family T0 mean ± sd 
T5 
mean ± sd 
T10 
mean ± sd 
T24 
mean ± sd 
[Barnesiellaceae] 0.727 0.436 0.205 0.150 0.457 0.360 0.955 0.357 
[Cerasicoccaceae] 0.000 0.000 0.000 0.000 0.000 0.000 0.004 0.006 
[Mogibacteriaceae] 0.306 0.253 0.048 0.066 0.052 0.019 0.198 0.103 
[Odoribacteraceae] 0.574 0.108 0.256 0.127 0.353 0.042 0.468 0.043 
[Paraprevotellaceae] 0.247 0.329 0.846 1.341 0.000 0.000 0.007 0.006 
[Tissierellaceae] 0.000 0.000 0.007 0.013 0.007 0.006 0.018 0.016 
Actinomycetaceae 0.007 0.006 0.000 0.000 0.000 0.000 0.004 0.006 
Alcaligenaceae 0.500 0.512 0.895 0.774 0.601 0.464 2.821 3.180 
Bacteroidaceae 29.979 2.263 23.724 3.583 26.964 7.292 28.173 1.969 
Bifidobacteriaceae 2.902 1.167 2.286 2.212 3.317 1.430 2.275 0.154 
Carnobacteriaceae 0.011 0.019 0.000 0.000 0.000 0.000 0.011 0.010 
Christensenellaceae 0.066 0.050 0.019 0.032 0.021 0.021 0.086 0.075 
Clostridiaceae 1.252 0.190 0.841 0.620 0.396 0.408 0.644 0.470 
Comamonadaceae 0.000 0.000 0.004 0.006 0.000 0.000 0.000 0.000 
Coriobacteriaceae 0.914 0.331 0.422 0.344 0.927 0.350 0.944 0.562 
Corynebacteriaceae 0.000 0.000 0.000 0.000 0.004 0.006 0.000 0.000 
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Dehalobacteriaceae 0.000 0.000 0.000 0.000 0.004 0.006 0.003 0.006 
Desulfovibrionaceae 0.910 0.830 1.613 1.892 2.704 2.494 2.582 1.754 
Dethiosulfovibrionaceae 0.004 0.006 0.000 0.000 0.000 0.000 0.000 0.000 
Enterobacteriaceae 0.124 0.090 12.646 21.622 9.098 10.775 6.454 5.566 
Enterococcaceae 0.011 0.019 0.035 0.060 1.095 1.870 0.769 1.303 
Erysipelotrichaceae 2.990 2.332 12.701 16.916 2.999 3.923 2.253 3.472 
Fusobacteriaceae 0.000 0.000 0.054 0.094 0.000 0.000 0.007 0.012 
Helicobacteraceae 0.000 0.000 0.000 0.000 0.018 0.030 0.003 0.006 
Lachnospiraceae 16.717 9.071 11.809 6.690 12.364 9.052 14.220 6.869 
Lactobacillaceae 1.193 1.006 1.221 1.073 1.052 0.656 1.094 0.618 
Leuconostocaceae 0.000 0.000 0.052 0.090 0.000 0.000 0.000 0.000 
Methanobacteriaceae 0.053 0.093 0.000 0.000 0.004 0.006 0.000 0.000 
Micrococcaceae 0.000 0.000 0.003 0.006 0.004 0.006 0.000 0.000 
Oxalobacteraceae 0.004 0.006 0.000 0.000 0.003 0.006 0.003 0.006 
Pasteurellaceae 0.004 0.006 0.000 0.000 0.007 0.012 0.014 0.006 
Peptococcaceae 0.114 0.198 0.000 0.000 0.000 0.000 0.004 0.006 
Peptostreptococcaceae 0.007 0.006 0.007 0.013 0.007 0.006 0.007 0.006 
Phyllobacteriaceae 0.000 0.000 0.000 0.000 0.003 0.006 0.000 0.000 
Porphyromonadaceae 2.140 0.686 1.200 1.266 1.753 0.850 1.998 0.314 
Prevotellaceae 2.531 2.186 7.926 10.446 0.109 0.171 0.711 1.204 
Pseudomonadaceae 0.000 0.000 0.000 0.000 0.007 0.012 0.000 0.000 
Rikenellaceae 2.145 0.292 0.907 1.054 1.553 1.328 2.282 0.781 
Ruminococcaceae 21.641 3.622 13.048 3.685 23.063 5.380 19.451 4.345 
S24-7 0.476 0.824 0.526 0.688 2.068 3.075 0.379 0.656 
Streptococcaceae 8.995 6.550 4.909 6.736 7.435 4.002 7.944 5.506 
Turicibacteraceae 0.135 0.170 0.098 0.095 0.035 0.061 0.064 0.060 
Veillonellaceae 2.302 0.540 1.619 0.475 1.434 1.020 3.132 0.810 
Verrucomicrobiaceae 0.000 0.000 0.065 0.088 0.084 0.076 0.007 0.006 
Victivallaceae 0.018 0.023 0.000 0.000 0.000 0.000 0.011 0.019 
 
 Time point 
Genus T0 mean ± sd 
T5 
mean ± sd 
T10 
mean ± sd 
T24 
mean ± sd 
[Eubacterium] 2.891 2.672 3.337 2.805 2.634 4.312 1.764 3.030 
[Prevotella] 0.005 0.008 1.189 2.060 0.000 0.000 0.000 0.000 
[Ruminococcus] 0.860 0.365 0.584 0.700 0.753 0.428 0.936 0.473 
Acidaminococcus 0.069 0.120 0.092 0.159 0.216 0.373 1.694 2.308 
Actinomyces 0.009 0.008 0.000 0.000 0.000 0.000 0.005 0.009 
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Adlercreutzia 0.034 0.048 0.000 0.000 0.107 0.130 0.175 0.177 
Akkermansia 0.000 0.000 0.094 0.123 0.120 0.112 0.010 0.009 
Anaerococcus 0.000 0.000 0.005 0.009 0.005 0.009 0.005 0.008 
Anaerostipes 0.183 0.159 0.061 0.028 0.065 0.041 0.040 0.033 
Anaerotruncus 0.000 0.000 0.000 0.000 0.000 0.000 0.020 0.017 
Bacteroides 39.285 4.112 33.975 3.012 40.074 6.642 39.646 3.751 
Bifidobacterium 3.759 1.424 3.170 3.090 4.867 1.710 3.196 0.179 
Bilophila 0.761 1.168 2.248 2.519 4.190 4.342 3.279 2.793 
Blautia 5.194 0.680 5.871 2.686 4.192 3.579 5.046 1.697 
Bulleidia 0.000 0.000 0.000 0.000 0.437 0.757 0.000 0.000 
Butyricimonas 0.321 0.208 0.098 0.072 0.092 0.091 0.207 0.123 
Campylobacter 0.000 0.000 0.015 0.025 0.000 0.000 0.000 0.000 
cc_115 0.023 0.022 0.169 0.294 0.032 0.055 0.010 0.017 
Christensenella 0.000 0.000 0.000 0.000 0.000 0.000 0.005 0.009 
Citrobacter 0.000 0.000 8.937 15.479 0.613 0.968 0.010 0.009 
Clostridium 0.310 0.475 0.201 0.163 0.043 0.012 0.035 0.022 
Collinsella 0.607 0.562 0.249 0.114 0.661 0.601 0.738 0.758 
Coprobacillus 0.019 0.033 0.010 0.017 0.005 0.009 0.068 0.106 
Coprococcus 5.349 5.488 2.541 2.363 4.164 4.637 3.322 2.540 
Corynebacterium 0.000 0.000 0.000 0.000 0.005 0.009 0.000 0.000 
Dehalobacterium 0.000 0.000 0.000 0.000 0.005 0.009 0.005 0.009 
Delftia 0.000 0.000 0.005 0.009 0.000 0.000 0.000 0.000 
Desulfovibrio 0.386 0.669 0.063 0.109 0.103 0.121 0.289 0.501 
Dialister 1.940 1.719 0.707 1.137 1.586 2.199 1.353 1.577 
Dorea 0.570 0.062 0.666 0.317 0.351 0.240 2.163 1.894 
Eggerthella 0.005 0.009 0.019 0.034 0.000 0.000 0.005 0.009 
Enterobacter 0.000 0.000 0.000 0.000 0.000 0.000 0.005 0.009 
Enterococcus 0.015 0.026 0.019 0.034 1.631 2.781 1.083 1.848 
Epulopiscium 0.000 0.000 0.000 0.000 0.000 0.000 0.020 0.022 
Erwinia 0.000 0.000 0.024 0.042 0.006 0.011 0.000 0.000 
Escherichia 0.000 0.000 0.000 0.000 0.328 0.568 0.223 0.182 
Faecalibacterium 4.294 1.990 3.150 0.792 3.810 1.869 3.206 0.336 
Finegoldia 0.000 0.000 0.000 0.000 0.000 0.000 0.010 0.017 
Flavobacterium 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Fusobacterium 0.000 0.000 0.086 0.148 0.000 0.000 0.010 0.018 
Granulicatella 0.000 0.000 0.000 0.000 0.000 0.000 0.005 0.009 
Haemophilus 0.005 0.009 0.000 0.000 0.011 0.018 0.020 0.008 
Helicobacter 0.000 0.000 0.000 0.000 0.016 0.027 0.005 0.009 
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Holdemania 0.019 0.022 0.065 0.051 0.062 0.075 0.024 0.042 
Klebsiella 0.000 0.000 0.019 0.034 0.006 0.011 0.000 0.000 
Lachnobacterium 0.014 0.025 0.045 0.078 0.310 0.537 0.015 0.026 
Lachnospira 1.304 1.957 0.374 0.310 0.933 0.414 1.042 0.779 
Lactobacillus 1.372 1.183 1.595 1.367 1.351 0.757 1.363 0.706 
Lactococcus 0.000 0.000 0.020 0.023 0.011 0.010 0.000 0.000 
Megasphaera 0.000 0.000 0.005 0.008 0.010 0.009 0.010 0.008 
Mesorhizobium 0.000 0.000 0.000 0.000 0.005 0.008 0.000 0.000 
Methanobrevibacter 0.068 0.118 0.000 0.000 0.006 0.011 0.000 0.000 
Morganella 0.000 0.000 0.485 0.839 0.000 0.000 0.025 0.043 
Odoribacter 0.432 0.345 0.269 0.107 0.443 0.061 0.452 0.194 
Oscillospira 2.474 1.681 2.002 1.166 4.451 3.702 3.894 2.109 
p-75-a5 0.000 0.000 0.005 0.009 0.006 0.011 0.015 0.025 
Parabacteroides 2.781 0.813 1.672 1.660 2.738 1.628 2.795 0.352 
Paraprevotella 0.259 0.448 0.075 0.130 0.000 0.000 0.005 0.009 
Peptococcus 0.145 0.252 0.000 0.000 0.000 0.000 0.005 0.009 
Peptoniphilus 0.000 0.000 0.000 0.000 0.000 0.000 0.005 0.009 
Phascolarctobacterium 0.994 1.084 1.465 1.492 0.398 0.417 1.192 1.597 
Plesiomonas 0.000 0.000 0.000 0.000 0.005 0.008 0.000 0.000 
Porphyromonas 0.000 0.000 0.000 0.000 0.000 0.000 0.005 0.008 
Prevotella 3.251 2.805 12.241 16.758 0.186 0.296 0.971 1.641 
PSB-M-3 0.000 0.000 0.005 0.008 0.000 0.000 0.000 0.000 
Pseudomonas 0.000 0.000 0.000 0.000 0.009 0.016 0.000 0.000 
Roseburia 0.847 1.298 0.686 0.974 0.317 0.282 0.215 0.300 
Rothia 0.000 0.000 0.005 0.008 0.005 0.009 0.000 0.000 
Ruminococcus 6.533 3.877 2.474 1.601 3.314 2.790 3.907 0.555 
Serratia 0.005 0.009 0.635 1.087 1.925 3.335 0.000 0.000 
Slackia 0.018 0.031 0.005 0.009 0.057 0.075 0.055 0.052 
SMB53 0.186 0.211 0.059 0.051 0.042 0.074 0.127 0.151 
Streptococcus 11.595 8.374 6.646 8.938 11.282 6.145 11.118 7.632 
Sutterella 0.616 0.714 1.343 1.186 0.839 0.615 3.893 4.309 
Trabulsiella 0.000 0.000 0.005 0.008 0.000 0.000 0.005 0.009 
Turicibacter 0.177 0.220 0.133 0.128 0.061 0.105 0.090 0.082 















































Supplementary Tables Chapter 3 
 
Table A1. Wilcoxon rank-sum test results for each alpha-diversity calculated on the number of 
observed OTUs, the Chao1 index and the Shannon entropy index 
 
 Metric p value* 
Placebo A vs Placebo B Observed 0.5167 
 Chao1 0.7209 
 Shannon 0.7065 
Placebo A vs VSL#3 A Observed 0.5167 
 Chao1 0.7209 
 Shannon 0.3427 
Placebo A vs VSL#3 B Observed 0.7546 
 Chao1 0.7209 
 Shannon 0.3427 
Placebo B vs VSL#3 A Observed 0.5167 
 Chao1 0.7209 
 Shannon 0.3427 
Placebo B vs VSL#3 B Observed 0.5167 
 Chao1 0.7209 
 Shannon 0.3427 
VSL#3 A vs VSL#3 B Observed 0.5167 
 Chao1 0.7209 
 Shannon 1.000 
*Bonferroni corrected p-values 
 
 
Table A2. Mean relative abundance (%) ± standard deviation (SD) of bacterial OTUs in placebo 
subjects at time zero (Placebo A) and after treatment (Placebo B). 
 
Species Placebo A mean ±  sd 
Placebo B 
mean ±  sd 
Ruminococcu bromii 25.3692 15.8105 18.8758 12.2916 
Bifidobacterium bifidum 19.0553 26.7762 11.0522 9.1910 
Bacteroides gadei 10.3927 10.0760 9.7545 10.1620 
Bifidobacterium pseudolongum 10.3860 7.3847 9.7613 6.3789 
Akkermansia  9.5480 10.5999 6.8879 11.5825 
Collinsella stercoris 6.4283 6.6761 5.6622 2.7985 
Bacteroides plebeius 4.5248 5.3153 2.9789 3.7003 
Bacteroides eggerthii 1.8163 0.9764 1.5760 0.8545 
Veillonella parvula 1.5848 2.1582 1.7724 1.7600 
Prevotella aureus 1.5302 2.6181 1.7761 3.7807 
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Blautia producta 1.3357 0.7530 1.2331 0.7553 
Faecalibacterium prausnitzii 1.2856 1.6195 0.1996 0.2595 
[Eubacterium] adhaesivum 1.2142 1.5265 0.5007 0.9200 
Eggerthella caccae 1.0751 1.5655 0.3553 0.3230 
Haemophilus johnsonii 0.9612 1.9224 0.0716 0.1317 
Coprococcus formicigenerans 0.9335 1.0997 6.7445 11.3838 
Parabacteroides copri 0.6916 0.4843 0.5158 0.1747 
Blautia eutactus 0.6084 0.6283 0.2746 0.2125 
Bacteroides fragilis 0.3062 0.6303 2.4452 5.6226 
Bacteroides ovatus 0.2601 0.1971 0.4260 0.5797 
[Eubacterium] dolichum 0.1795 0.3714 0.0127 0.0293 
Ruminococcus noxia 0.1389 0.1176 0.5152 0.6238 
[Eubacterium] cylindroides 0.1313 0.2717 0.4121 0.9487 
Streptococcus sobrinus 0.1183 0.2411 0.0319 0.0576 
Roseburia gnavus 0.0255 0.0203 0.0290 0.0219 
Aggregatibacter parainfluenzae 0.0211 0.0437 0.0000 0.0000 
Staphylococcus equorum 0.0170 0.0214 0.0360 0.0302 
Clostridium obeum 0.0142 0.0181 0.0051 0.0087 
Rothia adolescentis 0.0106 0.0097 0.0156 0.0223 
Oxalobacter coli 0.0080 0.0165 0.0125 0.0288 
Lactobacillus acidilactici 0.0057 0.0092 1.3403 2.6811 
Pyramidobacter muciniphila 0.0045 0.0094 0.0322 0.0675 
Pediococcus garvieae 0.0039 0.0054 0.0850 0.1909 
Staphylococcus mucosae 0.0036 0.0048 0.0161 0.0372 
Pseudomonas anthropi 0.0015 0.0032 0.0017 0.0039 
Selenomonas dispar 0.0015 0.0031 0.0000 0.0000 
Veillonella biforme 0.0015 0.0031 0.0021 0.0031 
Rothia mucilaginosa 0.0012 0.0025 0.0096 0.0196 
Lactococcus anginosus 0.0012 0.0025 0.0057 0.0089 
Methylobacterium formigenes 0.0012 0.0025 0.0011 0.0026 
Escherichia morganii 0.0012 0.0025 0.0073 0.0114 
Dorea faecis 0.0012 0.0024 0.0000 0.0000 
 
 
Table A3. Mean relative abundance (%) ± standard deviation (SD) of bacterial OTUs in VSL#3 
treated subjects at time zero (VSL#3 A) and after treatment (VSL#3 B). 
 
Species VSL#3 A mean ±  sd 
VSL#3 B 
mean ±  sd 
Ruminococcus bromii 24.9425 18.3981 10.5788 9.6048 
Bifidobacterium bifidum 11.6391 9.0232 16.1874 13.9684 
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Bifidobacterium pseudolongum 11.5582 6.6043 34.5783 31.3134 
Akkermansia  9.3796 16.1058 0.0057 0.0033 
Veillonella parvula 8.1652 8.5054 2.2412 2.2050 
Collinsella stercoris 7.7141 6.5915 8.3773 7.1389 
Bacteroides gadei 7.5445 8.9452 3.1893 4.7841 
[Eubacterium] cylindroides 3.9125 6.7265 0.0000 0.0000 
Bacteroides plebeius 2.7361 3.2363 0.8699 0.7481 
Bacteroides fragilis 2.1284 3.6592 2.5390 4.0624 
Bacteroides eggerthii 1.6310 2.1336 1.0557 1.0652 
Lactobacillus acidilactici 1.4687 1.6012 0.7183 0.9687 
Parabacteroides copri 1.4445 1.2669 0.4160 0.4234 
Blautia eutactus 0.9905 1.1008 2.4534 3.4143 
Ruminococcus noxia 0.9781 1.1510 2.1578 2.3750 
[Eubacterium] adhaesivum 0.8083 1.1220 4.0055 2.9539 
Eggerthella caccae 0.6680 0.7203 0.6634 0.6062 
Bacteroides ovatus 0.5681 0.8540 2.2723 2.9588 
Blautia producta 0.5325 0.5243 0.3440 0.2657 
Pediococcus garvieae 0.4457 0.7610 3.3620 5.0775 
Faecalibacterium prausnitzii 0.2422 0.2082 0.4714 0.4936 
Clostridium obeum 0.1735 0.2853 0.0012 0.0019 
Coprococcus formicigenerans 0.0499 0.0798 0.0000 0.0000 
Lactobacillus ruminis 0.0466 0.0801 0.0070 0.0094 
Roseburia gnavus 0.0359 0.0235 0.0114 0.0092 
Morganella segnis 0.0331 0.0569 0.0020 0.0032 
Haemophilus johnsonii 0.0310 0.0441 0.0317 0.0508 
Bifidobacterium aerofaciens 0.0268 0.0405 0.9886 1.5825 
Streptococcus sobrinus 0.0226 0.0280 0.0250 0.0251 
Rothia adolescentis 0.0215 0.0232 0.0126 0.0092 
Dysgonomonas distasonis 0.0101 0.0173 0.0000 0.0000 
Escherichia morganii 0.0086 0.0149 0.0217 0.0214 
Dorea faecis 0.0075 0.0108 0.0000 0.0000 
Veillonella biforme 0.0053 0.0092 0.0000 0.0000 
Aggregatibacter parainfluenzae 0.0053 0.0092 0.0000 0.0000 
Staphylococcus equorum 0.0043 0.0051 0.0165 0.0248 
[Eubacterium] dolichum 0.0033 0.0057 0.0137 0.0220 
Lactobacillus reuteri 0.0029 0.0050 0.0000 0.0000 
Jonquetella piscolens 0.0028 0.0049 0.0000 0.0000 
Clostridium perfringens 0.0027 0.0046 0.0018 0.0019 
Rothia mucilaginosa 0.0025 0.0028 0.0062 0.0071 
Streptococcus hiranonis 0.0022 0.0038 0.0120 0.0192 
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Acinetobacter veronii 0.0015 0.0025 0.0009 0.0014 
Selenomonas dispar 0.0013 0.0023 0.0000 0.0000 
Prevotella aureus 0.0011 0.0019 0.0011 0.0018 
 
 
Table A4. Mean relative abundance (%) ± standard deviation (SD) of bacterial OTUs at phylum 
and genus levels in placebo subjects at time zero (Placebo A) and after treatment (Placebo B). 
 
Phylum Placebo A mean ±  sd 
Placebo B  
mean ±  sd 
Firmicutes 62.8911 31.3035 66.3142 28.2484 
Bacteroidetes 18.5002 27.3994 15.6216 32.4831 
Actinobacteria 13.7728 26.2122 14.9279 21.7833 
Verrucomicrobia 2.7280 7.3946 1.6947 10.7678 
Proteobacteria 2.0865 7.6064 1.4003 6.4096 
Euryarchaeota 0.0091 0.0457 0.0179 0.1559 
TM7 0.0044 0.0122 0.0021 0.0128 
Cyanobacteria 0.0031 0.0048 0.0013 0.0038 
[Thermi] 0.0014 0.0036 0.0029 0.0142 
Synergistetes 0.0013 0.0065 0.0079 0.0627 
Lentisphaerae 0.0010 0.0051 0.0000 0.0000 
Fusobacteria 0.0009 0.0046 0.0045 0.0390 
FBP 0.0003 0.0015 0.0000 0.0000 
Tenericutes 0.0000 0.0000 0.0047 0.0195 
 
Genus Placebo A mean ±  sd 
Placebo B 
mean ±  sd 
Bacteroides 18.8303 18.0160 16.2303 15.2853 
Bifidobacterium 15.5980 16.9148 17.8382 12.6348 
Coprococcus 12.2004 7.6454 10.7919 9.4874 
Blautia 11.3537 6.3178 12.1481 6.4445 
Faecalibacterium 10.2037 8.6650 6.5619 6.4149 
Streptococcus 6.1190 12.5240 9.9395 12.5188 
Ruminococcus 6.0894 2.2079 6.1898 2.9898 
Akkermansia 3.8415 5.8101 2.3945 6.0448 
Collinsella 2.5879 3.6585 1.9904 1.4659 
Dialister 2.2178 3.2700 2.8713 4.1196 
[Ruminococcus] 2.1559 1.9275 1.3356 1.5271 
Dorea 1.3217 1.0927 2.0435 1.0270 
Oscillospira 1.0387 0.9176 1.0612 0.4872 
Parabacteroides 0.9147 0.8331 0.6094 0.6688 
[Eubacterium] 0.7956 1.3935 0.6138 1.0550 
Veillonella 0.6385 1.1843 0.6169 0.9180 
	 233 
Prevotella 0.6171 1.4337 0.6202 1.9786 
Eggerthella 0.4324 0.8580 0.1235 0.1686 
Haemophilus 0.4090 1.1169 0.0252 0.0699 
Clostridium 0.3792 0.3548 0.4747 0.5994 
Odoribacter 0.2923 0.4962 0.1514 0.1573 
Sutterella 0.2560 0.4379 0.0472 0.0852 
Turicibacter 0.2248 0.3364 0.1508 0.2677 
Adlercreutzia 0.1857 0.3732 0.1212 0.2495 
Lachnospira 0.1625 0.1622 0.1868 0.2939 
Anaerostipes 0.1332 0.1416 0.2979 0.2259 
Megamonas 0.1044 0.2944 0.1193 0.4122 
Paraprevotella 0.0941 0.1700 0.2078 0.5878 
Bilophila 0.0929 0.1802 0.0328 0.0430 
Desulfovibrio 0.0891 0.1829 0.0941 0.3177 
Roseburia 0.0798 0.0828 0.0772 0.1068 
Phascolarctobacterium 0.0695 0.0999 0.0757 0.1967 
Coprobacillus 0.0501 0.0647 0.0330 0.0467 
Granulicatella 0.0369 0.0746 0.0198 0.0155 
Actinomyces 0.0347 0.0398 0.0506 0.0766 
Enterococcus 0.0314 0.0475 0.5229 1.6517 
Lactobacillus 0.0275 0.0552 1.9360 4.9056 
Megasphaera 0.0275 0.0761 0.0007 0.0023 
Lachnobacterium 0.0225 0.0506 1.0043 3.4488 
Anaerotruncus 0.0223 0.0385 0.0048 0.0074 
Aggregatibacter 0.0200 0.0565 0.0000 0.0000 
Anaerofustis 0.0193 0.0286 0.0664 0.1793 
Holdemania 0.0160 0.0109 0.0084 0.0068 
Citrobacter 0.0152 0.0428 0.0000 0.0000 
Lactococcus 0.0135 0.0340 0.0040 0.0073 
Corynebacterium 0.0131 0.0292 0.0079 0.0106 
Methanobrevibacter 0.0128 0.0359 0.0253 0.0875 
SMB53 0.0123 0.0189 0.0091 0.0130 
Hymenobacter 0.0114 0.0116 0.0127 0.0217 
Slackia 0.0109 0.0308 0.0087 0.0299 
Staphylococcus 0.0083 0.0128 0.0193 0.0236 
cc_115 0.0071 0.0144 0.0013 0.0045 
Leuconostoc 0.0059 0.0166 0.0071 0.0112 
Acidaminococcus 0.0050 0.0140 0.0564 0.1324 
Rothia 0.0048 0.0065 0.0088 0.0217 
Sphingomonas 0.0035 0.0038 0.0008 0.0027 
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Oxalobacter 0.0032 0.0090 0.0043 0.0150 
Butyricimonas 0.0031 0.0056 0.0203 0.0599 
Bulleidia 0.0029 0.0039 0.0003 0.0010 
Dehalobacterium 0.0026 0.0040 0.0062 0.0134 
Deinococcus 0.0020 0.0028 0.0041 0.0080 
Pyramidobacter 0.0018 0.0051 0.0112 0.0352 
Pediococcus 0.0016 0.0029 0.0301 0.0993 
Serratia 0.0015 0.0041 0.0000 0.0000 
Peptostreptococcus 0.0014 0.0028 0.0023 0.0024 
Mesorhizobium 0.0014 0.0026 0.0013 0.0022 
Peptoniphilus 0.0014 0.0027 0.0057 0.0196 
Atopobium 0.0013 0.0025 0.0048 0.0081 
Fusobacterium 0.0013 0.0036 0.0063 0.0219 
Anaerococcus 0.0012 0.0035 0.0032 0.0089 
Acinetobacter 0.0011 0.0020 0.0009 0.0030 
Mogibacterium 0.0011 0.0020 0.0000 0.0000 
Kineococcus 0.0011 0.0020 0.0026 0.0063 
 
 
Table A5. Mean relative abundance (%) ± standard deviation (SD) of bacterial OTUs at phylum 
and genus levels in VSL#3 treated subjects at time zero (VSL#3 A) and after treatment (VSL#3 B). 
 
Phylum VSL#3 A mean ±  sd 
VSL#3 B 
mean ±  sd 
Firmicutes 61.4592 32.2273 59.9439 38.9242 
Bacteroidetes 17.8785 29.7245 6.0176 12.9508 
Actinobacteria 16.2091 19.8766 29.4074 29.1935 
Verrucomicrobia 2.3289 12.4278 0.0020 0.0045 
Proteobacteria 2.0811 5.5745 4.5922 18.7261 
Fusobacteria 0.0302 0.1365 0.0240 0.1431 
TM7 0.0068 0.0134 0.0020 0.0073 
Cyanobacteria 0.0037 0.0083 0.0009 0.0025 
[Thermi] 0.0017 0.0073 0.0038 0.0125 
Synergistetes 0.0007 0.0037 0.0000 0.0000 
Euryarchaeota 0.0000 0.0000 0.0054 0.0323 
FBP 0.0000 0.0000 0.0008 0.0030 
 
Genus VSL#3 A mean ±  sd 
VSL#3 B  
mean ±  sd 
Bifidobacterium 21.9571 13.0528 34.8223 17.1220 
Bacteroides 15.8570 11.4011 6.7008 5.5927 
Streptococcus 9.4927 11.6893 10.2088 17.8602 
Lactobacillus 8.8494 9.4110 2.0448 1.6432 
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Blautia 7.4817 7.7956 6.0312 5.5939 
Coprococcus 5.4913 4.4630 5.3584 4.9365 
Veillonella 4.7068 4.2111 1.9613 2.3610 
Faecalibacterium 4.5059 5.2907 8.8974 12.4892 
Ruminococcus 3.2100 3.9937 8.0558 8.7221 
Akkermansia 2.8756 5.9429 0.0026 0.0025 
Pediococcus 2.6784 5.2091 1.6204 3.7394 
Collinsella 2.2235 2.4764 3.5048 5.3968 
[Eubacterium] 1.6743 2.3412 2.6431 2.1426 
Dorea 1.3677 1.1853 0.8406 0.7507 
Peptostreptococcus 1.0984 2.2216 0.0014 0.0035 
Sutterella 0.9078 1.4260 0.1860 0.1751 
Acidaminococcus 0.8273 1.4828 0.2388 0.3900 
[Ruminococcus] 0.7645 0.6234 1.1600 1.8281 
Parabacteroides 0.6570 0.7987 0.6016 0.7170 
Coprobacillus 0.4512 0.9252 0.5170 0.8028 
Dialister 0.3793 0.3824 0.2858 0.6954 
Phascolarctobacterium 0.3259 0.4857 0.3534 0.5515 
Lactococcus 0.3205 0.6327 0.6061 1.4816 
Oscillospira 0.3186 0.2884 0.4435 0.5043 
Enterococcus 0.2912 0.4141 1.0913 1.5490 
Clostridium 0.2337 0.3742 0.2889 0.4247 
Eggerthella 0.2133 0.2649 0.3241 0.4444 
Anaerostipes 0.1709 0.2383 0.2586 0.3751 
Roseburia 0.0951 0.0859 0.0832 0.0678 
Adlercreutzia 0.0703 0.1313 0.0928 0.1577 
Actinomyces 0.0633 0.0604 0.0373 0.0242 
Fusobacterium 0.0383 0.0648 0.0318 0.0778 
Bilophila 0.0355 0.0702 0.0523 0.0748 
Megasphaera 0.0352 0.0637 0.0037 0.0091 
Granulicatella 0.0334 0.0231 0.0524 0.0628 
Anaerotruncus 0.0303 0.0627 0.0000 0.0000 
Leuconostoc 0.0291 0.0404 0.0015 0.0026 
Turicibacter 0.0262 0.0541 0.0395 0.0539 
Atopobium 0.0218 0.0407 0.0527 0.1151 
Lachnospira 0.0186 0.0236 0.0961 0.2006 
Odoribacter 0.0142 0.0293 0.0064 0.0109 
Anaerofustis 0.0134 0.0136 0.0197 0.0298 
Finegoldia 0.0127 0.0139 0.0069 0.0107 
Rothia 0.0110 0.0094 0.0091 0.0108 
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Morganella 0.0102 0.0210 0.0010 0.0024 
Prevotella 0.0092 0.0092 0.0038 0.0092 
Peptoniphilus 0.0077 0.0097 0.0048 0.0080 
Citrobacter 0.0076 0.0100 0.0112 0.0127 
SMB53 0.0075 0.0116 0.0059 0.0070 
Anaerococcus 0.0066 0.0080 0.0038 0.0052 
Corynebacterium 0.0065 0.0064 0.0045 0.0075 
Lachnobacterium 0.0061 0.0101 0.0004 0.0010 
Selenomonas 0.0057 0.0108 0.0000 0.0000 
Mesorhizobium 0.0049 0.0080 0.0008 0.0013 
Staphylococcus 0.0045 0.0064 0.0083 0.0181 
Porphyromonas 0.0039 0.0070 0.0000 0.0000 
Dysgonomonas 0.0031 0.0064 0.0000 0.0000 
Butyricimonas 0.0030 0.0063 0.0484 0.1062 
Escherichia 0.0026 0.0055 0.0104 0.0158 
Mogibacterium 0.0025 0.0035 0.0000 0.0000 
Pseudoramibacter_Eubacterium 0.0022 0.0030 0.1648 0.4019 
Hymenobacter 0.0022 0.0030 0.0083 0.0067 
Comamonas 0.0022 0.0045 0.0000 0.0000 
Deinococcus 0.0021 0.0035 0.0050 0.0068 
Peptococcus 0.0020 0.0041 0.0013 0.0031 
Slackia 0.0016 0.0034 0.0009 0.0022 
Aggregatibacter 0.0016 0.0034 0.0000 0.0000 
Campylobacter 0.0016 0.0017 0.0005 0.0013 
Haemophilus 0.0014 0.0021 0.0156 0.0373 
Kineococcus 0.0011 0.0015 0.0009 0.0014 
Parvimonas 0.0011 0.0015 0.0011 0.0016 
Christensenella 0.0010 0.0021 0.0003 0.0008 









Well, as for all the things, also this journey is going to finish.  
There are a lot of people, situation and occasions to thank, but of course I will try to write about the 
most important. 
As first, thanks a lot to Kieran, for gave me the opportunity to start this PhD at the Fondazione 
Edmund Mach three years ago: it has been a great honor and luck having you as internal supervisor. 
Your experience, knowledge and scientific passion have represented a new and mature way to look 
at the research world. 
Thanks to Francesca, for the time in the lab, the shared experience, the precious time in teaching 
and helping. 
Thanks to Lorenza, I will keep our scientific, and not only, talk in the lab, as a nice remembrance of 
these years. 
Thanks to Elena, for the time in the lab and the help. 
Many thanks to Benedetta: even if we know each other since a long time, it was great being your 
PhD student. 
Thanks to Francesca Campagna and Professor Piero Amodio, for the shared experience. 
Of course thanks to the companions of these years: Ilaria, Athanasios, Florencia and Francesco. 
Being PhD student is a strange experience, sometimes funny, sometimes frustrating, like when you 
feel as in the middle of …nowhere? When you start screaming, “I don’t know what to do now!” 
“..oh no, I’ve to repeat all!” “..damn, I didn’t want this!!”- and etc, etc... Thanks a lot to you all the 
funny moment ant life sharing. 
Many thanks to the Fondazione Edmund Mach to support and finance this research project. 
A big thank is for my parents and my grandparents. Even if distant, they’ve always trusted in me 
and supported my decisions and work. Being a parent is a strange adventure, and now I know this 
clearly. But is funny too! 
A giant thanks to my half, Lisa. There are not enough words to tell you how big have been your 
presence, support and help: half of the apple, no more words. 
To finish, an enormous thanks to Elia, our little-big precious one. As you arrived, everything 
changed, as a new perfume, almost saying “no one will delete this time, but a new one is going to 
came”. 
Then, here I am. Last but not the least, the main thank goes to my self. For my tenacity, for 
believing in this journey and for the strength for reaching this goal. Now it’s finishing, the line is 




Maso Sette Fontane 
Giovo (TN) 
Italy 
09 December 2016 

